

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 September 2001 (20.09.2001)

PCT

(10) International Publication Number  
**WO 01/068848 A3**

- (51) International Patent Classification<sup>7</sup>: **C12N 15/12**,  
15/62, C07K 14/47, 14/705, 16/18, G01N 33/53, C12Q  
1/68
- (21) International Application Number: PCT/US01/06520
- (22) International Filing Date: 28 February 2001 (28.02.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- |                |                             |    |
|----------------|-----------------------------|----|
| PCT/US00/05601 | 1 March 2000 (01.03.2000)   | US |
| PCT/US00/05841 | 2 March 2000 (02.03.2000)   | US |
| 60/187,202     | 3 March 2000 (03.03.2000)   | US |
| 60/186,968     | 6 March 2000 (06.03.2000)   | US |
| 60/189,328     | 14 March 2000 (14.03.2000)  | US |
| 60/189,320     | 14 March 2000 (14.03.2000)  | US |
| PCT/US00/06884 | 15 March 2000 (15.03.2000)  | US |
| 60/191,048     | 21 March 2000 (21.03.2000)  | US |
| 60/190,828     | 21 March 2000 (21.03.2000)  | US |
| 60/191,314     | 21 March 2000 (21.03.2000)  | US |
| 60/191,007     | 21 March 2000 (21.03.2000)  | US |
| 60/192,655     | 28 March 2000 (28.03.2000)  | US |
| 60/193,032     | 29 March 2000 (29.03.2000)  | US |
| 60/193,053     | 29 March 2000 (29.03.2000)  | US |
| PCT/US00/08439 | 30 March 2000 (30.03.2000)  | US |
| 60/194,647     | 4 April 2000 (04.04.2000)   | US |
| 60/194,449     | 4 April 2000 (04.04.2000)   | US |
| 60/196,820     | 11 April 2000 (11.04.2000)  | US |
| 60/195,975     | 11 April 2000 (11.04.2000)  | US |
| 60/196,000     | 11 April 2000 (11.04.2000)  | US |
| 60/196,187     | 11 April 2000 (11.04.2000)  | US |
| 60/196,690     | 11 April 2000 (11.04.2000)  | US |
| 60/198,121     | 18 April 2000 (18.04.2000)  | US |
| 60/198,585     | 18 April 2000 (18.04.2000)  | US |
| 60/199,654     | 25 April 2000 (25.04.2000)  | US |
| 60/199,397     | 25 April 2000 (25.04.2000)  | US |
| 60/199,550     | 25 April 2000 (25.04.2000)  | US |
| 60/201,516     | 3 May 2000 (03.05.2000)     | US |
| PCT/US00/13705 | 17 May 2000 (17.05.2000)    | US |
| PCT/US00/14042 | 22 May 2000 (22.05.2000)    | US |
| PCT/US00/14941 | 30 May 2000 (30.05.2000)    | US |
| PCT/US00/15264 | 2 June 2000 (02.06.2000)    | US |
| 60/209,832     | 5 June 2000 (05.06.2000)    | US |
| PCT/US00/20710 | 28 July 2000 (28.07.2000)   | US |
| 09/644,848     | 22 August 2000 (22.08.2000) | US |
| PCT/US00/23328 | 24 August 2000 (24.08.2000) | US |
- (60/000,000 15 September 2000 (15.09.2000) US  
PCT/US00/30952  
8 November 2000 (08.11.2000) US  
PCT/US00/32678  
1 December 2000 (01.12.2000) US  
PCT/US00/34956  
20 December 2000 (20.12.2000) US
- (71) Applicant (for all designated States except US): **GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).
- (72) Inventors; and
- (73) Inventors/Applicants (for US only): **BAKER, Kevin, P.** [GB/US]; 14006 Indian Run Drive, Darnestown, MD 20878 (US). **CHEN, Jian** [US/US]; 121 York Drive, Princeton, NJ 08540 (US). **DESNOYERS, Luc** [CA/US]; 2050 Stockton Street, San Francisco, CA 94133 (US). **GODDARD, Audrey** [CA/US]; 110 Congo Street, San Francisco, CA 94131 (US). **GODOWSKI, Paul, J.** [US/US]; 2627 Easton Drive, Burlingame, CA 94010 (US). **GURNEY, Austin, L.** [US/US]; 1 Debbie Lane, Belmont, CA 94002 (US). **PAN, James** [CA/US]; 2705 Coronet Boulevard, Belmont, CA 94002 (US). **SMITH, Victoria** [AU/US]; 19 Dwight Road, Burlingame, CA 94010 (US). **WATANABE, Colin, K.** [US/US]; 128 Corliss Drive, Moraga, CA 94556 (US). **WOOD, William, I.** [US/US]; 35 Southdown Court, Hillsborough, CA 94010 (US). **ZHANG, Zemin** [CN/US]; 876 Taurus Drive, Foster City, CA 94404 (US).
- (74) Agents: **BARNES, Elizabeth, M.** et al.; c/o Genentech, Inc., MS49, 1 DNA Way, South San Francisco, CA 94080-4990 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

(57) Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

WO 01/068848 A3

**WO 01/068848 A3**



**Published:**

— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**(88) Date of publication of the international search report:**

29 August 2002

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/06520

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N15/62 C07K14/47 C07K14/705 C07K16/18  
G01N33/53 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, SEQUENCE SEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 63088 A (BAKER KEVIN ;CHEN JIAN (US); GENENTECH INC (US); YUAN JEAN (US); G) 9 December 1999 (1999-12-09) page 1 -page 2; claims 1-26; figures 3,4; examples 1-3,5,139-147 page 281 -page 284 page 305 -page 314 page 345 -page 373 ---	1-24
X	WO 99 54461 A (SCHMITT ARMIN ;SPECHT THOMAS (DE); DAHL EDGAR (DE); HINZMANN BERND) 28 October 1999 (1999-10-28) page 1 -page 7; claims 1-38; figures 1-5; examples 1-4 see SEQ ID NO: 53 (pp.215 and 216), SEQ ID NO: 300 (pp. 350 and 351) page 163 --- -/--	1-24

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

28 February 2002

Date of mailing of the international search report

06.06.2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Oderwald, H

## INTERNATIONAL SEARCH REPORT

Internatic..... Application No

PCT/US 01/06520

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X, L	WO 00 73454 A (GENENTECH INC) 7 December 2000 (2000-12-07) page 1 -page 2; claims 1-118; figures 3,4; examples 1-3,5,139-172 page 43 -page 44 page 283 -page 288 page 304 -page 316 page 338 page 371 -page 398 ---	1-24
P,X	WO 00 58473 A (CURAGEN CORP ;LEACH MARTIN (US); SHIMKETS RICHARD A (US)) 5 October 2000 (2000-10-05) see SEQ ID NOs: 3231 and 3232 (pp. 2436 and 2437) page 1 -page 4; claims 1-32 ---	1-24
E	WO 01 57190 A (CAO YICHENG ;CHEN RUI HONG (US); GOODRICH RYLE (US); HYSEQ INC (US) 9 August 2001 (2001-08-09) page 1 -page 97; claims 1-28; examples 1-9 -& DATABASE EM GSN [Online] EBI, Hinxton, UK; AC/ID AAK52618, "SEQ ID NO: 2147" XP002191775 abstract -& DATABASE EM GSP [Online] EBI, Hinxton, UK; AC/ID AAM78501, "SEQ ID NO: 1163" XP002191776 abstract -----	1-24



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/06520

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  

Although claims 20 and 21 are directed to a method of treatment of the human/animal body (in so far as in vivo methods are concerned), the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  

1-24 (all partially)

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1: claims 1-24 partially

An isolated nucleic acid SEQ ID NO: 1 which encodes amino acid sequence SEQ ID NO: 2. A vector, a host cell, a process for producing a polypeptide, an isolated polypeptide encoded by said nucleic acid. A chimeric molecule, an antibody, methods for stimulating the release of TNF-alpha, for stimulating the proliferation or differentiation, for detecting the presence of tumor, an oligonucleotide probe.

Inventions 2-305: claims 1-24 partially

same as invention 1 but comprising the polynucleotide and amino acid sequence in the order given in claims 1 and 2 (invention 2 is limited to SEQ ID NO: 3 and 4 and invention 305 is limited to SEQ ID NO: 609 and 610).

## INTERNATIONAL SEARCH REPORT

Information on patent family members

Internatic... Application No

PCT/US 01/06520

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9963088	A	09-12-1999	AU 4328699 A	20-12-1999
			CA 2328895 A1	09-12-1999
			WO 9963088 A2	09-12-1999
			AU 2212299 A	26-07-1999
			WO 9935170 A2	15-07-1999
-----				
WO 9954461	A	28-10-1999	DE 19817948 A1	21-10-1999
			WO 9954461 A2	28-10-1999
			EP 1071775 A2	31-01-2001
-----				
WO 0073454	A	07-12-2000	AU 1748200 A	19-06-2000
			AU 1932000 A	03-07-2000
			AU 2192800 A	12-07-2000
			AU 2215300 A	28-12-2000
			AU 2495200 A	28-09-2000
			AU 2600800 A	28-09-2000
			AU 2879400 A	31-07-2001
			AU 3246100 A	28-12-2000
			AU 3381600 A	28-09-2000
			AU 3514400 A	28-09-2000
			AU 3774300 A	18-12-2000
			AU 4328699 A	20-12-1999
			AU 5441200 A	18-12-2000
			AU 5460100 A	18-12-2000
			AU 5591100 A	18-12-2000
			EP 1173563 A1	23-01-2002
			EP 1159419 A1	05-12-2001
			EP 1185648 A2	13-03-2002
			EP 1135485 A2	26-09-2001
			EP 1141285 A2	10-10-2001
			EP 1141289 A2	10-10-2001
			WO 0053753 A2	14-09-2000
			WO 0053755 A2	14-09-2000
			WO 0153486 A1	26-07-2001
			WO 0075327 A1	14-12-2000
			WO 0053757 A2	14-09-2000
			WO 0053758 A2	14-09-2000
			WO 0073454 A1	07-12-2000
			WO 0073445 A2	07-12-2000
			WO 0073348 A2	07-12-2000
			WO 0073452 A2	07-12-2000
			WO 0032221 A2	08-06-2000
			WO 0036102 A2	22-06-2000
			WO 0037640 A2	29-06-2000
			WO 0075316 A1	14-12-2000
			US 2002058309 A1	16-05-2002
			AU 2883600 A	28-09-2000
			AU 2883700 A	09-01-2001
			WO 0053756 A2	14-09-2000
			WO 0078961 A1	28-12-2000
			AU 2883900 A	30-01-2001
			WO 0104311 A1	18-01-2001
			AU 1749800 A	04-10-2000
			AU 1749900 A	12-07-2000
			AU 2390700 A	05-02-2001
			AU 2399300 A	28-09-2000
			AU 3107000 A	19-06-2000
			AU 4011300 A	05-02-2001

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/06520

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0058473	A	05-10-2000	AU 3774500 A EP 1165784 A2 WO 0058473 A2	16-10-2000 02-01-2002 05-10-2000
WO 0157190	A	09-08-2001	AU 2591801 A AU 3128801 A AU 3297101 A AU 3300301 A AU 3329301 A AU 3484701 A AU 3484801 A AU 3486501 A AU 3494401 A AU 3665801 A AU 3666001 A AU 3666301 A AU 3672101 A AU 4314201 A WO 0153326 A1 WO 0155334 A2 WO 0155335 A2 WO 0157255 A1 WO 0157260 A1 WO 0157175 A2 WO 0157261 A1 WO 0157262 A1 WO 0157187 A2 WO 0157265 A1 WO 0157188 A2 WO 0157266 A1 WO 0157267 A1 WO 0157190 A2	31-07-2001 14-08-2001 07-08-2001 07-08-2001 14-08-2001 14-08-2001 14-08-2001 14-08-2001 14-08-2001 14-08-2001 14-08-2001 14-08-2001 14-08-2001 14-08-2001 26-07-2001 02-08-2001 02-08-2001 09-08-2001 09-08-2001 09-08-2001 09-08-2001 09-08-2001 09-08-2001 09-08-2001 09-08-2001 09-08-2001 09-08-2001 09-08-2001 09-08-2001

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 September 2001 (20.09.2001)

PCT

(10) International Publication Number  
**WO 01/68848 A2**

(51) International Patent Classification<sup>7</sup>: **C12N 15/12**,  
15/62, C07K 14/47, 14/705, 16/18, G01N 33/53, C12Q  
1/68

60/000,000 15 September 2000 (15.09.2000) US  
PCT/US00/30952

8 November 2000 (08.11.2000) US  
PCT/US00/32678

(21) International Application Number: PCT/US01/06520

1 December 2000 (01.12.2000) US  
PCT/US00/34956

(22) International Filing Date: 28 February 2001 (28.02.2001)

20 December 2000 (20.12.2000) US

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): **GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).

(30) Priority Data:

PCT/US00/05601	1 March 2000 (01.03.2000)	US
PCT/US00/05841	2 March 2000 (02.03.2000)	US
60/187,202	3 March 2000 (03.03.2000)	US
60/186,968	6 March 2000 (06.03.2000)	US
60/189,328	14 March 2000 (14.03.2000)	US
60/189,320	14 March 2000 (14.03.2000)	US
PCT/US00/06884	15 March 2000 (15.03.2000)	US
60/191,048	21 March 2000 (21.03.2000)	US
60/190,828	21 March 2000 (21.03.2000)	US
60/191,314	21 March 2000 (21.03.2000)	US
60/191,007	21 March 2000 (21.03.2000)	US
60/192,655	28 March 2000 (28.03.2000)	US
60/193,032	29 March 2000 (29.03.2000)	US
60/193,053	29 March 2000 (29.03.2000)	US
PCT/US00/08439	30 March 2000 (30.03.2000)	US
60/194,647	4 April 2000 (04.04.2000)	US
60/194,449	4 April 2000 (04.04.2000)	US
60/196,820	11 April 2000 (11.04.2000)	US
60/195,975	11 April 2000 (11.04.2000)	US
60/196,000	11 April 2000 (11.04.2000)	US
60/196,187	11 April 2000 (11.04.2000)	US
60/196,690	11 April 2000 (11.04.2000)	US
60/198,121	18 April 2000 (18.04.2000)	US
60/198,585	18 April 2000 (18.04.2000)	US
60/199,654	25 April 2000 (25.04.2000)	US
60/199,397	25 April 2000 (25.04.2000)	US
60/199,550	25 April 2000 (25.04.2000)	US
60/201,516	3 May 2000 (03.05.2000)	US
PCT/US00/13705	17 May 2000 (17.05.2000)	US
PCT/US00/14042	22 May 2000 (22.05.2000)	US
PCT/US00/14941	30 May 2000 (30.05.2000)	US
PCT/US00/15264	2 June 2000 (02.06.2000)	US
60/209,832	5 June 2000 (05.06.2000)	US
PCT/US00/20710	28 July 2000 (28.07.2000)	US
09/644,848	22 August 2000 (22.08.2000)	US
PCT/US00/23328	24 August 2000 (24.08.2000)	US

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAKER, Kevin, P.** [GB/US]; 14006 Indian Run Drive, Darnestown, MD 20878 (US). **CHEN, Jian** [CN/US]; 121 York Drive, Princeton, NJ 08540 (US). **DESNOYERS, Luc** [CA/US]; 2050 Stockton Street, San Francisco, CA 94133 (US). **GODDARD, Audrey** [CA/US]; 110 Congo Street, San Francisco, CA 94131 (US). **GODOWSKI, Paul, J.** [US/US]; 2627 Easton Drive, Burlingame, CA 94010 (US). **GURNEY, Austin, L.** [US/US]; 1 Debbie Lane, Belmont, CA 94002 (US). **PAN, James** [CA/US]; 2705 Coronet Boulevard, Belmont, CA 94002 (US). **SMITH, Victoria** [AU/US]; 19 Dwight Road, Burlingame, CA 94010 (US). **WATANABE, Colin, K.** [US/US]; 128 Corliss Drive, Moraga, CA 94556 (US). **WOOD, William, I.** [US/US]; 35 Southdown Court, Hillsborough, CA 94010 (US). **ZHANG, Zemin** [CN/US]; 876 Taurus Drive, Foster City, CA 94404 (US).

(74) Agents: **BARNES, Elizabeth, M.** et al.; c/o Genentech, Inc., MS49, 1 DNA Way, South San Francisco, CA 94080-4990 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

(57) Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.



WO 01/68848 A2



**Published:**

— without international search report and to be republished  
upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE  
SAME**

**FIELD OF THE INVENTION**

5 The present invention relates generally to the identification and isolation of novel DNA and to the recombinant production of novel polypeptides.

**BACKGROUND OF THE INVENTION**

10 Extracellular proteins play important roles in, among other things, the formation, differentiation and maintenance of multicellular organisms. The fate of many individual cells, e.g., proliferation, migration, differentiation, or interaction with other cells, is typically governed by information received from other cells and/or the immediate environment. This information is often transmitted by secreted polypeptides (for instance, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and hormones) which are, in turn, received and interpreted by diverse cell receptors or membrane-bound proteins. These secreted polypeptides or signaling molecules normally pass through the cellular secretory pathway to reach their site of  
15 action in the extracellular environment.

Secreted proteins have various industrial applications, including as pharmaceuticals, diagnostics, biosensors and bioreactors. Most protein drugs available at present, such as thrombolytic agents, interferons, interleukins, erythropoietins, colony stimulating factors, and various other cytokines, are secretory proteins. Their receptors, which are membrane proteins, also have potential as therapeutic or diagnostic agents. Efforts  
20 are being undertaken by both industry and academia to identify new, native secreted proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted proteins. Examples of screening methods and techniques are described in the literature [see, for example, Klein et al., *Proc. Natl. Acad. Sci.* 93:7108-7113 (1996); U.S. Patent No. 5,536,637].

Membrane-bound proteins and receptors can play important roles in, among other things, the formation,  
25 differentiation and maintenance of multicellular organisms. The fate of many individual cells, e.g., proliferation, migration, differentiation, or interaction with other cells, is typically governed by information received from other cells and/or the immediate environment. This information is often transmitted by secreted polypeptides (for instance, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and hormones) which are, in turn, received and interpreted by diverse cell receptors or membrane-bound proteins.  
30 Such membrane-bound proteins and cell receptors include, but are not limited to, cytokine receptors, receptor kinases, receptor phosphatases, receptors involved in cell-cell interactions, and cellular adhesion molecules like selectins and integrins. For instance, transduction of signals that regulate cell growth and differentiation is regulated in part by phosphorylation of various cellular proteins. Protein tyrosine kinases, enzymes that catalyze that process, can also act as growth factor receptors. Examples include fibroblast growth factor receptor and

nerve growth factor receptor.

Membrane-bound proteins and receptor molecules have various industrial applications, including as pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance, can be employed as therapeutic agents to block receptor-ligand interactions. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction.

Efforts are being undertaken by both industry and academia to identify new, native receptor or membrane-bound proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel receptor or membrane-bound proteins.

#### SUMMARY OF THE INVENTION

In one embodiment, the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a PRO polypeptide.

In one aspect, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule encoding a PRO polypeptide having a full-length amino acid sequence as disclosed herein, an amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of the full-length amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a).

In other aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94%



nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule comprising the coding sequence of a full-length PRO polypeptide cDNA as disclosed herein, the coding sequence of a PRO polypeptide lacking the signal peptide as disclosed herein, the coding sequence of an extracellular domain of a transmembrane PRO polypeptide, with or without the signal peptide, as disclosed herein or the coding sequence of any other specifically defined fragment of the full-length amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a).

In a further aspect, the invention concerns an isolated nucleic acid molecule comprising a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule that encodes the same mature polypeptide encoded by any of the human protein cDNAs deposited with the ATCC as disclosed herein, or (b) the complement of the DNA molecule of (a).

Another aspect the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated, or is complementary to such encoding nucleotide sequence, wherein the transmembrane domain(s) of such polypeptide are disclosed herein. Therefore, soluble extracellular domains of the herein described PRO polypeptides are contemplated.

Another embodiment is directed to fragments of a PRO polypeptide coding sequence, or the complement thereof, that may find use as, for example, hybridization probes, for encoding fragments of a PRO polypeptide that may optionally encode a polypeptide comprising a binding site for an anti-PRO antibody or as antisense oligonucleotide probes. Such nucleic acid fragments are usually at least about 10 nucleotides in length, alternatively at least about 15 nucleotides in length, alternatively at least about 20 nucleotides in length, alternatively at least about 30 nucleotides in length, alternatively at least about 40 nucleotides in length, alternatively at least about 50 nucleotides in length, alternatively at least about 60 nucleotides in length, alternatively at least about 70 nucleotides in length, alternatively at least about 80 nucleotides in length, alternatively at least about 90 nucleotides in length, alternatively at least about 100 nucleotides in length, alternatively at least about 110 nucleotides in length, alternatively at least about 120 nucleotides in length,

alternatively at least about 130 nucleotides in length, alternatively at least about 140 nucleotides in length, alternatively at least about 150 nucleotides in length, alternatively at least about 160 nucleotides in length, alternatively at least about 170 nucleotides in length, alternatively at least about 180 nucleotides in length, alternatively at least about 190 nucleotides in length, alternatively at least about 200 nucleotides in length, alternatively at least about 250 nucleotides in length, alternatively at least about 300 nucleotides in length, alternatively at least about 350 nucleotides in length, alternatively at least about 400 nucleotides in length, alternatively at least about 450 nucleotides in length, alternatively at least about 500 nucleotides in length, alternatively at least about 600 nucleotides in length, alternatively at least about 700 nucleotides in length, alternatively at least about 800 nucleotides in length, alternatively at least about 900 nucleotides in length and alternatively at least about 1000 nucleotides in length, wherein in this context the term "about" means the referenced nucleotide sequence length plus or minus 10% of that referenced length. It is noted that novel fragments of a PRO polypeptide-encoding nucleotide sequence may be determined in a routine manner by aligning the PRO polypeptide-encoding nucleotide sequence with other known nucleotide sequences using any of a number of well known sequence alignment programs and determining which PRO polypeptide-encoding nucleotide sequence fragment(s) are novel. All of such PRO polypeptide-encoding nucleotide sequences are contemplated herein. Also contemplated are the PRO polypeptide fragments encoded by these nucleotide molecule fragments, preferably those PRO polypeptide fragments that comprise a binding site for an anti-PRO antibody.

In another embodiment, the invention provides isolated PRO polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.

In a certain aspect, the invention concerns an isolated PRO polypeptide, comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81% amino acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91% amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to a PRO polypeptide having a full-length amino acid sequence as disclosed herein, an amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of the full-length amino acid sequence as disclosed herein.

In a further aspect, the invention concerns an isolated PRO polypeptide comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81% amino acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83%

amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91% amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to an amino acid sequence encoded by any of the human protein cDNAs deposited with the ATCC as disclosed herein.

In a specific aspect, the invention provides an isolated PRO polypeptide without the N-terminal signal sequence and/or the initiating methionine and is encoded by a nucleotide sequence that encodes such an amino acid sequence as hereinbefore described. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.

Another aspect the invention provides an isolated PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.

In yet another embodiment, the invention concerns agonists and antagonists of a native PRO polypeptide as defined herein. In a particular embodiment, the agonist or antagonist is an anti-PRO antibody or a small molecule.

In a further embodiment, the invention concerns a method of identifying agonists or antagonists to a PRO polypeptide which comprise contacting the PRO polypeptide with a candidate molecule and monitoring a biological activity mediated by said PRO polypeptide. Preferably, the PRO polypeptide is a native PRO polypeptide.

In a still further embodiment, the invention concerns a composition of matter comprising a PRO polypeptide, or an agonist or antagonist of a PRO polypeptide as herein described, or an anti-PRO antibody, in combination with a carrier. Optionally, the carrier is a pharmaceutically acceptable carrier.

Another embodiment of the present invention is directed to the use of a PRO polypeptide, or an agonist or antagonist thereof as hereinbefore described, or an anti-PRO antibody, for the preparation of a medicament useful in the treatment of a condition which is responsive to the PRO polypeptide, an agonist or antagonist thereof or an anti-PRO antibody.

In other embodiments of the present invention, the invention provides vectors comprising DNA encoding any of the herein described polypeptides. Host cell comprising any such vector are also provided. By way of example, the host cells may be CHO cells, *E. coli*, or yeast. A process for producing any of the herein described

polypeptides is further provided and comprises culturing host cells under conditions suitable for expression of the desired polypeptide and recovering the desired polypeptide from the cell culture.

In other embodiments, the invention provides chimeric molecules comprising any of the herein described polypeptides fused to a heterologous polypeptide or amino acid sequence. Example of such chimeric molecules comprise any of the herein described polypeptides fused to an epitope tag sequence or a Fc region of an immunoglobulin.

In another embodiment, the invention provides an antibody which binds, preferably specifically, to any of the above or below described polypeptides. Optionally, the antibody is a monoclonal antibody, humanized antibody, antibody fragment or single-chain antibody.

In yet other embodiments, the invention provides oligonucleotide probes which may be useful for isolating genomic and cDNA nucleotide sequences, measuring or detecting expression of an associated gene or as antisense probes, wherein those probes may be derived from any of the above or below described nucleotide sequences. Preferred probe lengths are described above.

In yet other embodiments, the present invention is directed to methods of using the PRO polypeptides of the present invention for a variety of uses based upon the functional biological assay data presented in the Examples below.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a nucleotide sequence (SEQ ID NO:1) of a native sequence PRO276 cDNA, wherein SEQ ID NO:1 is a clone designated herein as "DNA16435-1208".

Figure 2 shows the amino acid sequence (SEQ ID NO:2) derived from the coding sequence of SEQ ID NO:1 shown in Figure 1.

Figure 3 shows a nucleotide sequence (SEQ ID NO:3) of a native sequence PRO284 cDNA, wherein SEQ ID NO:3 is a clone designated herein as "DNA23318-1211".

Figure 4 shows the amino acid sequence (SEQ ID NO:4) derived from the coding sequence of SEQ ID NO:3 shown in Figure 3.

Figure 5 shows a nucleotide sequence (SEQ ID NO:5) of a native sequence PRO193 cDNA, wherein SEQ ID NO:5 is a clone designated herein as "DNA23322-1393".

Figure 6 shows the amino acid sequence (SEQ ID NO:6) derived from the coding sequence of SEQ ID NO:5 shown in Figure 5.

Figure 7 shows a nucleotide sequence (SEQ ID NO:7) of a native sequence PRO190 cDNA, wherein SEQ ID NO:7 is a clone designated herein as "DNA23334-1392".

Figure 8 shows the amino acid sequence (SEQ ID NO:8) derived from the coding sequence of SEQ ID NO:7 shown in Figure 7.

Figure 9 shows a nucleotide sequence (SEQ ID NO:9) of a native sequence PRO180 cDNA, wherein SEQ ID NO:9 is a clone designated herein as "DNA26843-1389".

Figure 10 shows the amino acid sequence (SEQ ID NO:10) derived from the coding sequence of SEQ ID NO:9 shown in Figure 9.

Figure 11 shows a nucleotide sequence (SEQ ID NO:11) of a native sequence PRO194 cDNA, wherein SEQ ID NO:11 is a clone designated herein as "DNA26844-1394".

Figure 12 shows the amino acid sequence (SEQ ID NO:12) derived from the coding sequence of SEQ ID NO:11 shown in Figure 11.

5 Figure 13 shows a nucleotide sequence (SEQ ID NO:13) of a native sequence PRO218 cDNA, wherein SEQ ID NO:13 is a clone designated herein as "DNA30867-1335".

Figure 14 shows the amino acid sequence (SEQ ID NO:14) derived from the coding sequence of SEQ ID NO:13 shown in Figure 13.

Figure 15 shows a nucleotide sequence (SEQ ID NO:15) of a native sequence PRO260 cDNA, wherein SEQ ID NO:15 is a clone designated herein as "DNA33470-1175".

10 Figure 16 shows the amino acid sequence (SEQ ID NO:16) derived from the coding sequence of SEQ ID NO:15 shown in Figure 15.

Figure 17 shows a nucleotide sequence (SEQ ID NO:17) of a native sequence PRO233 cDNA, wherein SEQ ID NO:17 is a clone designated herein as "DNA34436-1238".

15 Figure 18 shows the amino acid sequence (SEQ ID NO:18) derived from the coding sequence of SEQ ID NO:17 shown in Figure 17.

Figure 19 shows a nucleotide sequence (SEQ ID NO:19) of a native sequence PRO234 cDNA, wherein SEQ ID NO:19 is a clone designated herein as "DNA35557-1137".

Figure 20 shows the amino acid sequence (SEQ ID NO:20) derived from the coding sequence of SEQ ID NO:19 shown in Figure 19.

20 Figure 21 shows a nucleotide sequence (SEQ ID NO:21) of a native sequence PRO236 cDNA, wherein SEQ ID NO:21 is a clone designated herein as "DNA35599-1168".

Figure 22 shows the amino acid sequence (SEQ ID NO:22) derived from the coding sequence of SEQ ID NO:21 shown in Figure 21.

25 Figure 23 shows a nucleotide sequence (SEQ ID NO:23) of a native sequence PRO244 cDNA, wherein SEQ ID NO:23 is a clone designated herein as "DNA35668-1171".

Figure 24 shows the amino acid sequence (SEQ ID NO:24) derived from the coding sequence of SEQ ID NO:23 shown in Figure 23.

Figure 25 shows a nucleotide sequence (SEQ ID NO:25) of a native sequence PRO262 cDNA, wherein SEQ ID NO:25 is a clone designated herein as "DNA36992-1168".

30 Figure 26 shows the amino acid sequence (SEQ ID NO:26) derived from the coding sequence of SEQ ID NO:25 shown in Figure 25.

Figure 27 shows a nucleotide sequence (SEQ ID NO:27) of a native sequence PRO271 cDNA, wherein SEQ ID NO:27 is a clone designated herein as "DNA39423-1182".

35 Figure 28 shows the amino acid sequence (SEQ ID NO:28) derived from the coding sequence of SEQ ID NO:27 shown in Figure 27.

Figure 29 shows a nucleotide sequence (SEQ ID NO:29) of a native sequence PRO268 cDNA, wherein SEQ ID NO:29 is a clone designated herein as "DNA39427-1179".

Figure 30 shows the amino acid sequence (SEQ ID NO:30) derived from the coding sequence of SEQ ID NO:29 shown in Figure 29.

Figure 31 shows a nucleotide sequence (SEQ ID NO:31) of a native sequence PRO270 cDNA, wherein SEQ ID NO:31 is a clone designated herein as "DNA39510-1181".

5 Figure 32 shows the amino acid sequence (SEQ ID NO:32) derived from the coding sequence of SEQ ID NO:31 shown in Figure 31.

Figure 33 shows a nucleotide sequence (SEQ ID NO:33) of a native sequence PRO355 cDNA, wherein SEQ ID NO:33 is a clone designated herein as "DNA39518-1247".

Figure 34 shows the amino acid sequence (SEQ ID NO:34) derived from the coding sequence of SEQ ID NO:33 shown in Figure 33.

10 Figure 35 shows a nucleotide sequence (SEQ ID NO:35) of a native sequence PRO298 cDNA, wherein SEQ ID NO:35 is a clone designated herein as "DNA39975-1210".

Figure 36 shows the amino acid sequence (SEQ ID NO:36) derived from the coding sequence of SEQ ID NO:35 shown in Figure 35.

15 Figure 37 shows a nucleotide sequence (SEQ ID NO:37) of a native sequence PRO299 cDNA, wherein SEQ ID NO:37 is a clone designated herein as "DNA39976-1215".

Figure 38 shows the amino acid sequence (SEQ ID NO:38) derived from the coding sequence of SEQ ID NO:37 shown in Figure 37.

Figure 39 shows a nucleotide sequence (SEQ ID NO:39) of a native sequence PRO296 cDNA, wherein SEQ ID NO:39 is a clone designated herein as "DNA39979-1213".

20 Figure 40 shows the amino acid sequence (SEQ ID NO:40) derived from the coding sequence of SEQ ID NO:39 shown in Figure 39.

Figure 41 shows a nucleotide sequence (SEQ ID NO:41) of a native sequence PRO329 cDNA, wherein SEQ ID NO:41 is a clone designated herein as "DNA40594-1233".

25 Figure 42 shows the amino acid sequence (SEQ ID NO:42) derived from the coding sequence of SEQ ID NO:41 shown in Figure 41.

Figure 43 shows a nucleotide sequence (SEQ ID NO:43) of a native sequence PRO330 cDNA, wherein SEQ ID NO:43 is a clone designated herein as "DNA40603-1232".

Figure 44 shows the amino acid sequence (SEQ ID NO:44) derived from the coding sequence of SEQ ID NO:43 shown in Figure 43.

30 Figure 45 shows a nucleotide sequence (SEQ ID NO:45) of a native sequence PRO294 cDNA, wherein SEQ ID NO:45 is a clone designated herein as "DNA40604-1187".

Figure 46 shows the amino acid sequence (SEQ ID NO:46) derived from the coding sequence of SEQ ID NO:45 shown in Figure 45.

35 Figure 47 shows a nucleotide sequence (SEQ ID NO:47) of a native sequence PRO300 cDNA, wherein SEQ ID NO:47 is a clone designated herein as "DNA40625-1189".

Figure 48 shows the amino acid sequence (SEQ ID NO:48) derived from the coding sequence of SEQ ID NO:47 shown in Figure 47.

Figure 49 shows a nucleotide sequence (SEQ ID NO:49) of a native sequence PRO307 cDNA, wherein SEQ ID NO:49 is a clone designated herein as "DNA41225-1217".

Figure 50 shows the amino acid sequence (SEQ ID NO:50) derived from the coding sequence of SEQ ID NO:49 shown in Figure 49.

5 Figure 51 shows a nucleotide sequence (SEQ ID NO:51) of a native sequence PRO334 cDNA, wherein SEQ ID NO:51 is a clone designated herein as "DNA41379-1236".

Figure 52 shows the amino acid sequence (SEQ ID NO:52) derived from the coding sequence of SEQ ID NO:51 shown in Figure 51.

Figure 53 shows a nucleotide sequence (SEQ ID NO:53) of a native sequence PRO352 cDNA, wherein SEQ ID NO:53 is a clone designated herein as "DNA41386-1316".

10 Figure 54 shows the amino acid sequence (SEQ ID NO:54) derived from the coding sequence of SEQ ID NO:53 shown in Figure 53.

Figure 55 shows a nucleotide sequence (SEQ ID NO:55) of a native sequence PRO710 cDNA, wherein SEQ ID NO:55 is a clone designated herein as "DNA44161-1434".

15 Figure 56 shows the amino acid sequence (SEQ ID NO:56) derived from the coding sequence of SEQ ID NO:55 shown in Figure 55.

Figure 57 shows a nucleotide sequence (SEQ ID NO:57) of a native sequence PRO873 cDNA, wherein SEQ ID NO:57 is a clone designated herein as "DNA44179-1362".

Figure 58 shows the amino acid sequence (SEQ ID NO:58) derived from the coding sequence of SEQ ID NO:57 shown in Figure 57.

20 Figure 59 shows a nucleotide sequence (SEQ ID NO:59) of a native sequence PRO354 cDNA, wherein SEQ ID NO:59 is a clone designated herein as "DNA44192-1246".

Figure 60 shows the amino acid sequence (SEQ ID NO:60) derived from the coding sequence of SEQ ID NO:59 shown in Figure 59.

25 Figure 61 shows a nucleotide sequence (SEQ ID NO:61) of a native sequence PRO1151 cDNA, wherein SEQ ID NO:61 is a clone designated herein as "DNA44694-1500".

Figure 62 shows the amino acid sequence (SEQ ID NO:62) derived from the coding sequence of SEQ ID NO:61 shown in Figure 61.

Figure 63 shows a nucleotide sequence (SEQ ID NO:63) of a native sequence PRO382 cDNA, wherein SEQ ID NO:63 is a clone designated herein as "DNA45234-1277".

30 Figure 64 shows the amino acid sequence (SEQ ID NO:64) derived from the coding sequence of SEQ ID NO:63 shown in Figure 63.

Figure 65 shows a nucleotide sequence (SEQ ID NO:65) of a native sequence PRO1864 cDNA, wherein SEQ ID NO:65 is a clone designated herein as "DNA45409-2511".

35 Figure 66 shows the amino acid sequence (SEQ ID NO:66) derived from the coding sequence of SEQ ID NO:65 shown in Figure 65.

Figure 67 shows a nucleotide sequence (SEQ ID NO:67) of a native sequence PRO386 cDNA, wherein SEQ ID NO:67 is a clone designated herein as "DNA45415-1318".

Figure 68 shows the amino acid sequence (SEQ ID NO:68) derived from the coding sequence of SEQ ID NO:67 shown in Figure 67.

Figure 69 shows a nucleotide sequence (SEQ ID NO:69) of a native sequence PRO541 cDNA, wherein SEQ ID NO:69 is a clone designated herein as "DNA45417-1432".

5 Figure 70 shows the amino acid sequence (SEQ ID NO:70) derived from the coding sequence of SEQ ID NO:69 shown in Figure 69.

Figure 71 shows a nucleotide sequence (SEQ ID NO:71) of a native sequence PRO852 cDNA, wherein SEQ ID NO:71 is a clone designated herein as "DNA45493-1349".

Figure 72 shows the amino acid sequence (SEQ ID NO:72) derived from the coding sequence of SEQ ID NO:71 shown in Figure 71.

10 Figure 73 shows a nucleotide sequence (SEQ ID NO:73) of a native sequence PRO700 cDNA, wherein SEQ ID NO:73 is a clone designated herein as "DNA46776-1284".

Figure 74 shows the amino acid sequence (SEQ ID NO:74) derived from the coding sequence of SEQ ID NO:73 shown in Figure 73.

15 Figures 75A-75B show a nucleotide sequence (SEQ ID NO:75) of a native sequence PRO708 cDNA, wherein SEQ ID NO:75 is a clone designated herein as "DNA48296-1292".

Figure 76 shows the amino acid sequence (SEQ ID NO:76) derived from the coding sequence of SEQ ID NO:75 shown in Figures 75A-75B.

Figure 77 shows a nucleotide sequence (SEQ ID NO:77) of a native sequence PRO707 cDNA, wherein SEQ ID NO:77 is a clone designated herein as "DNA48306-1291".

20 Figure 78 shows the amino acid sequence (SEQ ID NO:78) derived from the coding sequence of SEQ ID NO:77 shown in Figure 77.

Figure 79 shows a nucleotide sequence (SEQ ID NO:79) of a native sequence PRO864 cDNA, wherein SEQ ID NO:79 is a clone designated herein as "DNA48328-1355".

25 Figure 80 shows the amino acid sequence (SEQ ID NO:80) derived from the coding sequence of SEQ ID NO:79 shown in Figure 79.

Figure 81 shows a nucleotide sequence (SEQ ID NO:81) of a native sequence PRO706 cDNA, wherein SEQ ID NO:81 is a clone designated herein as "DNA48329-1290".

Figure 82 shows the amino acid sequence (SEQ ID NO:82) derived from the coding sequence of SEQ ID NO:81 shown in Figure 81.

30 Figure 83 shows a nucleotide sequence (SEQ ID NO:83) of a native sequence PRO732 cDNA, wherein SEQ ID NO:83 is a clone designated herein as "DNA48334-1435".

Figure 84 shows the amino acid sequence (SEQ ID NO:84) derived from the coding sequence of SEQ ID NO:83 shown in Figure 83.

35 Figure 85 shows a nucleotide sequence (SEQ ID NO:85) of a native sequence PRO537 cDNA, wherein SEQ ID NO:85 is a clone designated herein as "DNA49141-1431".

Figure 86 shows the amino acid sequence (SEQ ID NO:86) derived from the coding sequence of SEQ ID NO:85 shown in Figure 85.



Figure 87 shows a nucleotide sequence (SEQ ID NO:87) of a native sequence PRO545 cDNA, wherein SEQ ID NO:87 is a clone designated herein as "DNA49624-1279".

Figure 88 shows the amino acid sequence (SEQ ID NO:88) derived from the coding sequence of SEQ ID NO:87 shown in Figure 87.

5 Figure 89 shows a nucleotide sequence (SEQ ID NO:89) of a native sequence PRO718 cDNA, wherein SEQ ID NO:89 is a clone designated herein as "DNA49647-1398".

Figure 90 shows the amino acid sequence (SEQ ID NO:90) derived from the coding sequence of SEQ ID NO:89 shown in Figure 89.

Figure 91 shows a nucleotide sequence (SEQ ID NO:91) of a native sequence PRO872 cDNA, wherein SEQ ID NO:91 is a clone designated herein as "DNA49819-1439".

10 Figure 92 shows the amino acid sequence (SEQ ID NO:92) derived from the coding sequence of SEQ ID NO:91 shown in Figure 91.

Figure 93 shows a nucleotide sequence (SEQ ID NO:93) of a native sequence PRO704 cDNA, wherein SEQ ID NO:93 is a clone designated herein as "DNA50911-1288".

15 Figure 94 shows the amino acid sequence (SEQ ID NO:94) derived from the coding sequence of SEQ ID NO:93 shown in Figure 93.

Figure 95 shows a nucleotide sequence (SEQ ID NO:95) of a native sequence PRO705 cDNA, wherein SEQ ID NO:95 is a clone designated herein as "DNA50914-1289".

Figure 96 shows the amino acid sequence (SEQ ID NO:96) derived from the coding sequence of SEQ ID NO:95 shown in Figure 95.

20 Figure 97 shows a nucleotide sequence (SEQ ID NO:97) of a native sequence PRO871 cDNA, wherein SEQ ID NO:97 is a clone designated herein as "DNA50919-1361".

Figure 98 shows the amino acid sequence (SEQ ID NO:98) derived from the coding sequence of SEQ ID NO:97 shown in Figure 97.

25 Figure 99 shows a nucleotide sequence (SEQ ID NO:99) of a native sequence PRO702 cDNA, wherein SEQ ID NO:99 is a clone designated herein as "DNA50980-1286".

Figure 100 shows the amino acid sequence (SEQ ID NO:100) derived from the coding sequence of SEQ ID NO:99 shown in Figure 99.

Figure 101 shows a nucleotide sequence (SEQ ID NO:101) of a native sequence PRO944 cDNA, wherein SEQ ID NO:101 is a clone designated herein as "DNA52185-1370".

30 Figure 102 shows the amino acid sequence (SEQ ID NO:102) derived from the coding sequence of SEQ ID NO:101 shown in Figure 101.

Figure 103 shows a nucleotide sequence (SEQ ID NO:103) of a native sequence PRO739 cDNA, wherein SEQ ID NO:103 is a clone designated herein as "DNA52756".

35 Figure 104 shows the amino acid sequence (SEQ ID NO:104) derived from the coding sequence of SEQ ID NO:103 shown in Figure 103.

Figure 105 shows a nucleotide sequence (SEQ ID NO:105) of a native sequence PRO941 cDNA, wherein SEQ ID NO:105 is a clone designated herein as "DNA53906-1368".

Figure 106 shows the amino acid sequence (SEQ ID NO:106) derived from the coding sequence of SEQ ID NO:105 shown in Figure 105.

Figure 107 shows a nucleotide sequence (SEQ ID NO:107) of a native sequence PRO1082 cDNA, wherein SEQ ID NO:107 is a clone designated herein as "DNA53912-1457".

5 Figure 108 shows the amino acid sequence (SEQ ID NO:108) derived from the coding sequence of SEQ ID NO:107 shown in Figure 107.

Figure 109 shows a nucleotide sequence (SEQ ID NO:109) of a native sequence PRO1133 cDNA, wherein SEQ ID NO:109 is a clone designated herein as "DNA53913-1490".

Figure 110 shows the amino acid sequence (SEQ ID NO:110) derived from the coding sequence of SEQ ID NO:109 shown in Figure 109.

10 Figure 111 shows a nucleotide sequence (SEQ ID NO:111) of a native sequence PRO983 cDNA, wherein SEQ ID NO:111 is a clone designated herein as "DNA53977-1371".

Figure 112 shows the amino acid sequence (SEQ ID NO:112) derived from the coding sequence of SEQ ID NO:111 shown in Figure 111.

15 Figure 113 shows a nucleotide sequence (SEQ ID NO:113) of a native sequence PRO784 cDNA, wherein SEQ ID NO:113 is a clone designated herein as "DNA53978-1443".

Figure 114 shows the amino acid sequence (SEQ ID NO:114) derived from the coding sequence of SEQ ID NO:113 shown in Figure 113.

Figure 115 shows a nucleotide sequence (SEQ ID NO:115) of a native sequence PRO783 cDNA, wherein SEQ ID NO:115 is a clone designated herein as "DNA53996-1442".

20 Figure 116 shows the amino acid sequence (SEQ ID NO:116) derived from the coding sequence of SEQ ID NO:115 shown in Figure 115.

Figure 117 shows a nucleotide sequence (SEQ ID NO:117) of a native sequence PRO940 cDNA, wherein SEQ ID NO:117 is a clone designated herein as "DNA54002-1367".

25 Figure 118 shows the amino acid sequence (SEQ ID NO:118) derived from the coding sequence of SEQ ID NO:117 shown in Figure 117.

Figure 119 shows a nucleotide sequence (SEQ ID NO:119) of a native sequence PRO768 cDNA, wherein SEQ ID NO:119 is a clone designated herein as "DNA55737-1345".

Figure 120 shows the amino acid sequence (SEQ ID NO:120) derived from the coding sequence of SEQ ID NO:119 shown in Figure 119.

30 Figure 121 shows a nucleotide sequence (SEQ ID NO:121) of a native sequence PRO1079 cDNA, wherein SEQ ID NO:121 is a clone designated herein as "DNA56050-1455".

Figure 122 shows the amino acid sequence (SEQ ID NO:122) derived from the coding sequence of SEQ ID NO:121 shown in Figure 121.

35 Figure 123 shows a nucleotide sequence (SEQ ID NO:123) of a native sequence PRO1078 cDNA, wherein SEQ ID NO:123 is a clone designated herein as "DNA56052-1454".

Figure 124 shows the amino acid sequence (SEQ ID NO:124) derived from the coding sequence of SEQ ID NO:123 shown in Figure 123.

Figure 125 shows a nucleotide sequence (SEQ ID NO:125) of a native sequence PRO1018 cDNA, wherein SEQ ID NO:125 is a clone designated herein as "DNA56107-1415".

Figure 126 shows the amino acid sequence (SEQ ID NO:126) derived from the coding sequence of SEQ ID NO:125 shown in Figure 125.

5 Figure 127 shows a nucleotide sequence (SEQ ID NO:127) of a native sequence PRO793 cDNA, wherein SEQ ID NO:127 is a clone designated herein as "DNA56110-1437".

Figure 128 shows the amino acid sequence (SEQ ID NO:128) derived from the coding sequence of SEQ ID NO:127 shown in Figure 127.

Figure 129 shows a nucleotide sequence (SEQ ID NO:129) of a native sequence PRO1773 cDNA, wherein SEQ ID NO:129 is a clone designated herein as "DNA56406-1704".

10 Figure 130 shows the amino acid sequence (SEQ ID NO:130) derived from the coding sequence of SEQ ID NO:129 shown in Figure 129.

Figure 131 shows a nucleotide sequence (SEQ ID NO:131) of a native sequence PRO1014 cDNA, wherein SEQ ID NO:131 is a clone designated herein as "DNA56409-1377".

15 Figure 132 shows the amino acid sequence (SEQ ID NO:132) derived from the coding sequence of SEQ ID NO:131 shown in Figure 131.

Figure 133 shows a nucleotide sequence (SEQ ID NO:133) of a native sequence PRO1013 cDNA, wherein SEQ ID NO:133 is a clone designated herein as "DNA56410-1414".

Figure 134 shows the amino acid sequence (SEQ ID NO:134) derived from the coding sequence of SEQ ID NO:133 shown in Figure 133.

20 Figure 135 shows a nucleotide sequence (SEQ ID NO:135) of a native sequence PRO937 cDNA, wherein SEQ ID NO:135 is a clone designated herein as "DNA56436-1448".

Figure 136 shows the amino acid sequence (SEQ ID NO:136) derived from the coding sequence of SEQ ID NO:135 shown in Figure 135.

25 Figure 137 shows a nucleotide sequence (SEQ ID NO:137) of a native sequence PRO1477 cDNA, wherein SEQ ID NO:137 is a clone designated herein as "DNA56529-1647".

Figure 138 shows the amino acid sequence (SEQ ID NO:138) derived from the coding sequence of SEQ ID NO:137 shown in Figure 137.

Figure 139 shows a nucleotide sequence (SEQ ID NO:139) of a native sequence PRO842 cDNA, wherein SEQ ID NO:139 is a clone designated herein as "DNA56855-1447".

30 Figure 140 shows the amino acid sequence (SEQ ID NO:140) derived from the coding sequence of SEQ ID NO:139 shown in Figure 139.

Figure 141 shows a nucleotide sequence (SEQ ID NO:141) of a native sequence PRO839 cDNA, wherein SEQ ID NO:141 is a clone designated herein as "DNA56859-1445".

35 Figure 142 shows the amino acid sequence (SEQ ID NO:142) derived from the coding sequence of SEQ ID NO:141 shown in Figure 141.

Figure 143 shows a nucleotide sequence (SEQ ID NO:143) of a native sequence PRO1180 cDNA, wherein SEQ ID NO:143 is a clone designated herein as "DNA56860-1510".

Figure 144 shows the amino acid sequence (SEQ ID NO:144) derived from the coding sequence of SEQ ID NO:143 shown in Figure 143.

Figure 145 shows a nucleotide sequence (SEQ ID NO:145) of a native sequence PRO1134 cDNA, wherein SEQ ID NO:145 is a clone designated herein as "DNA56865-1491".

5 Figure 146 shows the amino acid sequence (SEQ ID NO:146) derived from the coding sequence of SEQ ID NO:145 shown in Figure 145.

Figure 147 shows a nucleotide sequence (SEQ ID NO:147) of a native sequence PRO1115 cDNA, wherein SEQ ID NO:147 is a clone designated herein as "DNA56868-1478".

Figure 148 shows the amino acid sequence (SEQ ID NO:148) derived from the coding sequence of SEQ ID NO:147 shown in Figure 147.

10 Figure 149 shows a nucleotide sequence (SEQ ID NO:149) of a native sequence PRO1277 cDNA, wherein SEQ ID NO:149 is a clone designated herein as "DNA56869-1545".

Figure 150 shows the amino acid sequence (SEQ ID NO:150) derived from the coding sequence of SEQ ID NO:149 shown in Figure 149.

15 Figure 151 shows a nucleotide sequence (SEQ ID NO:151) of a native sequence PRO1135 cDNA, wherein SEQ ID NO:151 is a clone designated herein as "DNA56870-1492".

Figure 152 shows the amino acid sequence (SEQ ID NO:152) derived from the coding sequence of SEQ ID NO:151 shown in Figure 151.

Figure 153 shows a nucleotide sequence (SEQ ID NO:153) of a native sequence PRO827 cDNA, wherein SEQ ID NO:153 is a clone designated herein as "DNA57039-1402".

20 Figure 154 shows the amino acid sequence (SEQ ID NO:154) derived from the coding sequence of SEQ ID NO:153 shown in Figure 153.

Figure 155 shows a nucleotide sequence (SEQ ID NO:155) of a native sequence PRO1057 cDNA, wherein SEQ ID NO:155 is a clone designated herein as "DNA57253-1382".

25 Figure 156 shows the amino acid sequence (SEQ ID NO:156) derived from the coding sequence of SEQ ID NO:155 shown in Figure 155.

Figure 157 shows a nucleotide sequence (SEQ ID NO:157) of a native sequence PRO1113 cDNA, wherein SEQ ID NO:157 is a clone designated herein as "DNA57254-1477".

Figure 158 shows the amino acid sequence (SEQ ID NO:158) derived from the coding sequence of SEQ ID NO:157 shown in Figure 157.

30 Figure 159 shows a nucleotide sequence (SEQ ID NO:159) of a native sequence PRO1006 cDNA, wherein SEQ ID NO:159 is a clone designated herein as "DNA57699-1412".

Figure 160 shows the amino acid sequence (SEQ ID NO:160) derived from the coding sequence of SEQ ID NO:159 shown in Figure 159.

35 Figure 161 shows a nucleotide sequence (SEQ ID NO:161) of a native sequence PRO1074 cDNA, wherein SEQ ID NO:161 is a clone designated herein as "DNA57704-1452".

Figure 162 shows the amino acid sequence (SEQ ID NO:162) derived from the coding sequence of SEQ ID NO:161 shown in Figure 161.

Figure 163 shows a nucleotide sequence (SEQ ID NO:163) of a native sequence PRO1073 cDNA, wherein SEQ ID NO:163 is a clone designated herein as "DNA57710-1451".

Figure 164 shows the amino acid sequence (SEQ ID NO:164) derived from the coding sequence of SEQ ID NO:163 shown in Figure 163.

5 Figure 165 shows a nucleotide sequence (SEQ ID NO:165) of a native sequence PRO1136 cDNA, wherein SEQ ID NO:165 is a clone designated herein as "DNA57827-1493".

Figure 166 shows the amino acid sequence (SEQ ID NO:166) derived from the coding sequence of SEQ ID NO:165 shown in Figure 165.

Figure 167 shows a nucleotide sequence (SEQ ID NO:167) of a native sequence PRO1004 cDNA, wherein SEQ ID NO:167 is a clone designated herein as "DNA57844-1410".

10 Figure 168 shows the amino acid sequence (SEQ ID NO:168) derived from the coding sequence of SEQ ID NO:167 shown in Figure 167.

Figure 169 shows a nucleotide sequence (SEQ ID NO:169) of a native sequence PRO1344 cDNA, wherein SEQ ID NO:169 is a clone designated herein as "DNA58723-1588".

15 Figure 170 shows the amino acid sequence (SEQ ID NO:170) derived from the coding sequence of SEQ ID NO:169 shown in Figure 169.

Figure 171 shows a nucleotide sequence (SEQ ID NO:171) of a native sequence PRO1110 cDNA, wherein SEQ ID NO:171 is a clone designated herein as "DNA58727-1474".

Figure 172 shows the amino acid sequence (SEQ ID NO:172) derived from the coding sequence of SEQ ID NO:171 shown in Figure 171.

20 Figure 173 shows a nucleotide sequence (SEQ ID NO:173) of a native sequence PRO1378 cDNA, wherein SEQ ID NO:173 is a clone designated herein as "DNA58730-1607".

Figure 174 shows the amino acid sequence (SEQ ID NO:174) derived from the coding sequence of SEQ ID NO:173 shown in Figure 173.

25 Figure 175 shows a nucleotide sequence (SEQ ID NO:175) of a native sequence PRO1481 cDNA, wherein SEQ ID NO:175 is a clone designated herein as "DNA58732-1650".

Figure 176 shows the amino acid sequence (SEQ ID NO:176) derived from the coding sequence of SEQ ID NO:175 shown in Figure 175.

Figure 177 shows a nucleotide sequence (SEQ ID NO:177) of a native sequence PRO1109 cDNA, wherein SEQ ID NO:177 is a clone designated herein as "DNA58737-1473".

30 Figure 178 shows the amino acid sequence (SEQ ID NO:178) derived from the coding sequence of SEQ ID NO:177 shown in Figure 177.

Figure 179 shows a nucleotide sequence (SEQ ID NO:179) of a native sequence PRO1383 cDNA, wherein SEQ ID NO:179 is a clone designated herein as "DNA58743-1609".

35 Figure 180 shows the amino acid sequence (SEQ ID NO:180) derived from the coding sequence of SEQ ID NO:179 shown in Figure 179.

Figure 181 shows a nucleotide sequence (SEQ ID NO:181) of a native sequence PRO1072 cDNA, wherein SEQ ID NO:181 is a clone designated herein as "DNA58747-1384".

Figure 182 shows the amino acid sequence (SEQ ID NO:182) derived from the coding sequence of SEQ ID NO:181 shown in Figure 181.

Figure 183 shows a nucleotide sequence (SEQ ID NO:183) of a native sequence PRO1189 cDNA, wherein SEQ ID NO:183 is a clone designated herein as "DNA58828-1519".

5 Figure 184 shows the amino acid sequence (SEQ ID NO:184) derived from the coding sequence of SEQ ID NO:183 shown in Figure 183.

Figure 185 shows a nucleotide sequence (SEQ ID NO:185) of a native sequence PRO1003 cDNA, wherein SEQ ID NO:185 is a clone designated herein as "DNA58846-1409".

Figure 186 shows the amino acid sequence (SEQ ID NO:186) derived from the coding sequence of SEQ ID NO:185 shown in Figure 185.

10 Figure 187 shows a nucleotide sequence (SEQ ID NO:187) of a native sequence PRO1108 cDNA, wherein SEQ ID NO:187 is a clone designated herein as "DNA58848-1472".

Figure 188 shows the amino acid sequence (SEQ ID NO:188) derived from the coding sequence of SEQ ID NO:187 shown in Figure 187.

15 Figure 189 shows a nucleotide sequence (SEQ ID NO:189) of a native sequence PRO1137 cDNA, wherein SEQ ID NO:189 is a clone designated herein as "DNA58849-1494".

Figure 190 shows the amino acid sequence (SEQ ID NO:190) derived from the coding sequence of SEQ ID NO:189 shown in Figure 189.

Figure 191 shows a nucleotide sequence (SEQ ID NO:191) of a native sequence PRO1138 cDNA, wherein SEQ ID NO:191 is a clone designated herein as "DNA58850-1495".

20 Figure 192 shows the amino acid sequence (SEQ ID NO:192) derived from the coding sequence of SEQ ID NO:191 shown in Figure 191.

Figure 193 shows a nucleotide sequence (SEQ ID NO:193) of a native sequence PRO1415 cDNA, wherein SEQ ID NO:193 is a clone designated herein as "DNA58852-1637".

25 Figure 194 shows the amino acid sequence (SEQ ID NO:194) derived from the coding sequence of SEQ ID NO:193 shown in Figure 193.

Figure 195 shows a nucleotide sequence (SEQ ID NO:195) of a native sequence PRO1054 cDNA, wherein SEQ ID NO:195 is a clone designated herein as "DNA58853-1423".

Figure 196 shows the amino acid sequence (SEQ ID NO:196) derived from the coding sequence of SEQ ID NO:195 shown in Figure 195.

30 Figure 197 shows a nucleotide sequence (SEQ ID NO:197) of a native sequence PRO994 cDNA, wherein SEQ ID NO:197 is a clone designated herein as "DNA58855-1422".

Figure 198 shows the amino acid sequence (SEQ ID NO:198) derived from the coding sequence of SEQ ID NO:197 shown in Figure 197.

35 Figure 199 shows a nucleotide sequence (SEQ ID NO:199) of a native sequence PRO1069 cDNA, wherein SEQ ID NO:199 is a clone designated herein as "DNA59211-1450".

Figure 200 shows the amino acid sequence (SEQ ID NO:200) derived from the coding sequence of SEQ ID NO:199 shown in Figure 199.

Figure 201 shows a nucleotide sequence (SEQ ID NO:201) of a native sequence PRO1411 cDNA, wherein SEQ ID NO:201 is a clone designated herein as "DNA59212-1627".

Figure 202 shows the amino acid sequence (SEQ ID NO:202) derived from the coding sequence of SEQ ID NO:201 shown in Figure 201.

5 Figure 203 shows a nucleotide sequence (SEQ ID NO:203) of a native sequence PRO1129 cDNA, wherein SEQ ID NO:203 is a clone designated herein as "DNA59213-1487".

Figure 204 shows the amino acid sequence (SEQ ID NO:204) derived from the coding sequence of SEQ ID NO:203 shown in Figure 203.

Figure 205 shows a nucleotide sequence (SEQ ID NO:205) of a native sequence PRO1359 cDNA, wherein SEQ ID NO:205 is a clone designated herein as "DNA59219-1613".

10 Figure 206 shows the amino acid sequence (SEQ ID NO:206) derived from the coding sequence of SEQ ID NO:205 shown in Figure 205.

Figure 207 shows a nucleotide sequence (SEQ ID NO:207) of a native sequence PRO1139 cDNA, wherein SEQ ID NO:207 is a clone designated herein as "DNA59497-1496".

15 Figure 208 shows the amino acid sequence (SEQ ID NO:208) derived from the coding sequence of SEQ ID NO:207 shown in Figure 207.

Figure 209 shows a nucleotide sequence (SEQ ID NO:209) of a native sequence PRO1065 cDNA, wherein SEQ ID NO:209 is a clone designated herein as "DNA59602-1436".

Figure 210 shows the amino acid sequence (SEQ ID NO:210) derived from the coding sequence of SEQ ID NO:209 shown in Figure 209.

20 Figure 211 shows a nucleotide sequence (SEQ ID NO:211) of a native sequence PRO1028 cDNA, wherein SEQ ID NO:211 is a clone designated herein as "DNA59603-1419".

Figure 212 shows the amino acid sequence (SEQ ID NO:212) derived from the coding sequence of SEQ ID NO:211 shown in Figure 211.

25 Figure 213 shows a nucleotide sequence (SEQ ID NO:213) of a native sequence PRO1027 cDNA, wherein SEQ ID NO:213 is a clone designated herein as "DNA59605-1418".

Figure 214 shows the amino acid sequence (SEQ ID NO:214) derived from the coding sequence of SEQ ID NO:213 shown in Figure 213.

Figure 215 shows a nucleotide sequence (SEQ ID NO:215) of a native sequence PRO1140 cDNA, wherein SEQ ID NO:215 is a clone designated herein as "DNA59607-1497".

30 Figure 216 shows the amino acid sequence (SEQ ID NO:216) derived from the coding sequence of SEQ ID NO:215 shown in Figure 215.

Figure 217 shows a nucleotide sequence (SEQ ID NO:217) of a native sequence PRO1291 cDNA, wherein SEQ ID NO:217 is a clone designated herein as "DNA59610-1556".

35 Figure 218 shows the amino acid sequence (SEQ ID NO:218) derived from the coding sequence of SEQ ID NO:217 shown in Figure 217.

Figure 219 shows a nucleotide sequence (SEQ ID NO:219) of a native sequence PRO1105 cDNA, wherein SEQ ID NO:219 is a clone designated herein as "DNA59612-1466".

Figure 220 shows the amino acid sequence (SEQ ID NO:220) derived from the coding sequence of SEQ ID NO:219 shown in Figure 219.

Figure 221 shows a nucleotide sequence (SEQ ID NO:221) of a native sequence PRO1026 cDNA, wherein SEQ ID NO:221 is a clone designated herein as "DNA59613-1417".

5 Figure 222 shows the amino acid sequence (SEQ ID NO:222) derived from the coding sequence of SEQ ID NO:221 shown in Figure 221.

Figure 223 shows a nucleotide sequence (SEQ ID NO:223) of a native sequence PRO1104 cDNA, wherein SEQ ID NO:223 is a clone designated herein as "DNA59616-1465".

Figure 224 shows the amino acid sequence (SEQ ID NO:224) derived from the coding sequence of SEQ ID NO:223 shown in Figure 223.

10 Figure 225 shows a nucleotide sequence (SEQ ID NO:225) of a native sequence PRO1100 cDNA, wherein SEQ ID NO:225 is a clone designated herein as "DNA59619-1464".

Figure 226 shows the amino acid sequence (SEQ ID NO:226) derived from the coding sequence of SEQ ID NO:225 shown in Figure 225.

15 Figure 227 shows a nucleotide sequence (SEQ ID NO:227) of a native sequence PRO1141 cDNA, wherein SEQ ID NO:227 is a clone designated herein as "DNA59625-1498".

Figure 228 shows the amino acid sequence (SEQ ID NO:228) derived from the coding sequence of SEQ ID NO:227 shown in Figure 227.

Figure 229 shows a nucleotide sequence (SEQ ID NO:229) of a native sequence PRO1772 cDNA, wherein SEQ ID NO:229 is a clone designated herein as "DNA59817-1703".

20 Figure 230 shows the amino acid sequence (SEQ ID NO:230) derived from the coding sequence of SEQ ID NO:229 shown in Figure 229.

Figure 231 shows a nucleotide sequence (SEQ ID NO:231) of a native sequence PRO1064 cDNA, wherein SEQ ID NO:231 is a clone designated herein as "DNA59827-1426".

25 Figure 232 shows the amino acid sequence (SEQ ID NO:232) derived from the coding sequence of SEQ ID NO:231 shown in Figure 231.

Figure 233 shows a nucleotide sequence (SEQ ID NO:233) of a native sequence PRO1379 cDNA, wherein SEQ ID NO:233 is a clone designated herein as "DNA59828-1608".

Figure 234 shows the amino acid sequence (SEQ ID NO:234) derived from the coding sequence of SEQ ID NO:233 shown in Figure 233.

30 Figure 235 shows a nucleotide sequence (SEQ ID NO:235) of a native sequence PRO3573 cDNA, wherein SEQ ID NO:235 is a clone designated herein as "DNA59837-2545".

Figure 236 shows the amino acid sequence (SEQ ID NO:236) derived from the coding sequence of SEQ ID NO:235 shown in Figure 235.

35 Figure 237 shows a nucleotide sequence (SEQ ID NO:237) of a native sequence PRO3566 cDNA, wherein SEQ ID NO:237 is a clone designated herein as "DNA59844-2542".

Figure 238 shows the amino acid sequence (SEQ ID NO:238) derived from the coding sequence of SEQ ID NO:237 shown in Figure 237.



Figure 239 shows a nucleotide sequence (SEQ ID NO:239) of a native sequence PRO1156 cDNA, wherein SEQ ID NO:239 is a clone designated herein as "DNA59853-1505".

Figure 240 shows the amino acid sequence (SEQ ID NO:240) derived from the coding sequence of SEQ ID NO:239 shown in Figure 239.

5 Figure 241 shows a nucleotide sequence (SEQ ID NO:241) of a native sequence PRO1098 cDNA, wherein SEQ ID NO:241 is a clone designated herein as "DNA59854-1459".

Figure 242 shows the amino acid sequence (SEQ ID NO:242) derived from the coding sequence of SEQ ID NO:241 shown in Figure 241.

Figure 243 shows a nucleotide sequence (SEQ ID NO:243) of a native sequence PRO1128 cDNA, wherein SEQ ID NO:243 is a clone designated herein as "DNA59855-1485".

10 Figure 244 shows the amino acid sequence (SEQ ID NO:244) derived from the coding sequence of SEQ ID NO:243 shown in Figure 243.

Figure 245 shows a nucleotide sequence (SEQ ID NO:245) of a native sequence PRO1248 cDNA, wherein SEQ ID NO:245 is a clone designated herein as "DNA60278-1530".

15 Figure 246 shows the amino acid sequence (SEQ ID NO:246) derived from the coding sequence of SEQ ID NO:245 shown in Figure 245.

Figure 247 shows a nucleotide sequence (SEQ ID NO:247) of a native sequence PRO1127 cDNA, wherein SEQ ID NO:247 is a clone designated herein as "DNA60283-1484".

Figure 248 shows the amino acid sequence (SEQ ID NO:248) derived from the coding sequence of SEQ ID NO:247 shown in Figure 247.

20 Figure 249 shows a nucleotide sequence (SEQ ID NO:249) of a native sequence PRO1316 cDNA, wherein SEQ ID NO:249 is a clone designated herein as "DNA60608-1577".

Figure 250 shows the amino acid sequence (SEQ ID NO:250) derived from the coding sequence of SEQ ID NO:249 shown in Figure 249.

25 Figure 251 shows a nucleotide sequence (SEQ ID NO:251) of a native sequence PRO1197 cDNA, wherein SEQ ID NO:251 is a clone designated herein as "DNA60611-1524".

Figure 252 shows the amino acid sequence (SEQ ID NO:252) derived from the coding sequence of SEQ ID NO:251 shown in Figure 251.

Figure 253 shows a nucleotide sequence (SEQ ID NO:253) of a native sequence PRO1125 cDNA, wherein SEQ ID NO:253 is a clone designated herein as "DNA60619-1482".

30 Figure 254 shows the amino acid sequence (SEQ ID NO:254) derived from the coding sequence of SEQ ID NO:253 shown in Figure 253.

Figure 255 shows a nucleotide sequence (SEQ ID NO:255) of a native sequence PRO1158 cDNA, wherein SEQ ID NO:255 is a clone designated herein as "DNA60625-1507".

35 Figure 256 shows the amino acid sequence (SEQ ID NO:256) derived from the coding sequence of SEQ ID NO:255 shown in Figure 255.

Figure 257 shows a nucleotide sequence (SEQ ID NO:257) of a native sequence PRO1124 cDNA, wherein SEQ ID NO:257 is a clone designated herein as "DNA60629-1481".

Figure 258 shows the amino acid sequence (SEQ ID NO:258) derived from the coding sequence of SEQ ID NO:257 shown in Figure 257.

Figure 259 shows a nucleotide sequence (SEQ ID NO:259) of a native sequence PRO1380 cDNA, wherein SEQ ID NO:259 is a clone designated herein as "DNA60740-1615".

5 Figure 260 shows the amino acid sequence (SEQ ID NO:260) derived from the coding sequence of SEQ ID NO:259 shown in Figure 259.

Figure 261 shows a nucleotide sequence (SEQ ID NO:261) of a native sequence PRO1377 cDNA, wherein SEQ ID NO:261 is a clone designated herein as "DNA61608-1606".

Figure 262 shows the amino acid sequence (SEQ ID NO:262) derived from the coding sequence of SEQ ID NO:261 shown in Figure 261.

10 Figure 263 shows a nucleotide sequence (SEQ ID NO:263) of a native sequence PRO1287 cDNA, wherein SEQ ID NO:263 is a clone designated herein as "DNA61755-1554".

Figure 264 shows the amino acid sequence (SEQ ID NO:264) derived from the coding sequence of SEQ ID NO:263 shown in Figure 263.

15 Figure 265 shows a nucleotide sequence (SEQ ID NO:265) of a native sequence PRO1249 cDNA, wherein SEQ ID NO:265 is a clone designated herein as "DNA62809-1531".

Figure 266 shows the amino acid sequence (SEQ ID NO:266) derived from the coding sequence of SEQ ID NO:265 shown in Figure 265.

Figure 267 shows a nucleotide sequence (SEQ ID NO:267) of a native sequence PRO1335 cDNA, wherein SEQ ID NO:267 is a clone designated herein as "DNA62812-1594".

20 Figure 268 shows the amino acid sequence (SEQ ID NO:268) derived from the coding sequence of SEQ ID NO:267 shown in Figure 267.

Figure 269 shows a nucleotide sequence (SEQ ID NO:269) of a native sequence PRO3572 cDNA, wherein SEQ ID NO:269 is a clone designated herein as "DNA62813-2544".

25 Figure 270 shows the amino acid sequence (SEQ ID NO:270) derived from the coding sequence of SEQ ID NO:269 shown in Figure 269.

Figure 271 shows a nucleotide sequence (SEQ ID NO:271) of a native sequence PRO1599 cDNA, wherein SEQ ID NO:271 is a clone designated herein as "DNA62845-1684".

Figure 272 shows the amino acid sequence (SEQ ID NO:272) derived from the coding sequence of SEQ ID NO:271 shown in Figure 271.

30 Figure 273 shows a nucleotide sequence (SEQ ID NO:273) of a native sequence PRO1374 cDNA, wherein SEQ ID NO:273 is a clone designated herein as "DNA64849-1604".

Figure 274 shows the amino acid sequence (SEQ ID NO:274) derived from the coding sequence of SEQ ID NO:273 shown in Figure 273.

35 Figure 275 shows a nucleotide sequence (SEQ ID NO:275) of a native sequence PRO1345 cDNA, wherein SEQ ID NO:275 is a clone designated herein as "DNA64852-1589".

Figure 276 shows the amino acid sequence (SEQ ID NO:276) derived from the coding sequence of SEQ ID NO:275 shown in Figure 275.

Figure 277 shows a nucleotide sequence (SEQ ID NO:277) of a native sequence PRO1311 cDNA, wherein SEQ ID NO:277 is a clone designated herein as "DNA64863-1573".

Figure 278 shows the amino acid sequence (SEQ ID NO:278) derived from the coding sequence of SEQ ID NO:277 shown in Figure 277.

5 Figure 279 shows a nucleotide sequence (SEQ ID NO:279) of a native sequence PRO1357 cDNA, wherein SEQ ID NO:279 is a clone designated herein as "DNA64881-1602".

Figure 280 shows the amino acid sequence (SEQ ID NO:280) derived from the coding sequence of SEQ ID NO:279 shown in Figure 279.

Figure 281 shows a nucleotide sequence (SEQ ID NO:281) of a native sequence PRO1557 cDNA, wherein SEQ ID NO:281 is a clone designated herein as "DNA64902-1667".

10 Figure 282 shows the amino acid sequence (SEQ ID NO:282) derived from the coding sequence of SEQ ID NO:281 shown in Figure 281.

Figure 283 shows a nucleotide sequence (SEQ ID NO:283) of a native sequence PRO1305 cDNA, wherein SEQ ID NO:283 is a clone designated herein as "DNA64952-1568".

15 Figure 284 shows the amino acid sequence (SEQ ID NO:284) derived from the coding sequence of SEQ ID NO:283 shown in Figure 283.

Figure 285 shows a nucleotide sequence (SEQ ID NO:285) of a native sequence PRO1302 cDNA, wherein SEQ ID NO:285 is a clone designated herein as "DNA65403-1565".

Figure 286 shows the amino acid sequence (SEQ ID NO:286) derived from the coding sequence of SEQ ID NO:285 shown in Figure 285.

20 Figure 287 shows a nucleotide sequence (SEQ ID NO:287) of a native sequence PRO1266 cDNA, wherein SEQ ID NO:287 is a clone designated herein as "DNA65413-1534".

Figure 288 shows the amino acid sequence (SEQ ID NO:288) derived from the coding sequence of SEQ ID NO:287 shown in Figure 287.

25 Figures 289A-289B show a nucleotide sequence (SEQ ID NO:289) of a native sequence PRO1336 cDNA, wherein SEQ ID NO:289 is a clone designated herein as "DNA65423-1595".

Figure 290 shows the amino acid sequence (SEQ ID NO:290) derived from the coding sequence of SEQ ID NO:289 shown in Figures 289A-289B.

Figure 291 shows a nucleotide sequence (SEQ ID NO:291) of a native sequence PRO1278 cDNA, wherein SEQ ID NO:291 is a clone designated herein as "DNA66304-1546".

30 Figure 292 shows the amino acid sequence (SEQ ID NO:292) derived from the coding sequence of SEQ ID NO:291 shown in Figure 291.

Figure 293 shows a nucleotide sequence (SEQ ID NO:293) of a native sequence PRO1270 cDNA, wherein SEQ ID NO:293 is a clone designated herein as "DNA66308-1537".

35 Figure 294 shows the amino acid sequence (SEQ ID NO:294) derived from the coding sequence of SEQ ID NO:293 shown in Figure 293.

Figure 295 shows a nucleotide sequence (SEQ ID NO:295) of a native sequence PRO1298 cDNA, wherein SEQ ID NO:295 is a clone designated herein as "DNA66511-1563".

Figure 296 shows the amino acid sequence (SEQ ID NO:296) derived from the coding sequence of SEQ ID NO:295 shown in Figure 295.

Figure 297 shows a nucleotide sequence (SEQ ID NO:297) of a native sequence PRO1301 cDNA, wherein SEQ ID NO:297 is a clone designated herein as "DNA66512-1564".

5 Figure 298 shows the amino acid sequence (SEQ ID NO:298) derived from the coding sequence of SEQ ID NO:297 shown in Figure 297.

Figure 299 shows a nucleotide sequence (SEQ ID NO:299) of a native sequence PRO1268 cDNA, wherein SEQ ID NO:299 is a clone designated herein as "DNA66519-1535".

Figure 300 shows the amino acid sequence (SEQ ID NO:300) derived from the coding sequence of SEQ ID NO:299 shown in Figure 299.

10 Figure 301 shows a nucleotide sequence (SEQ ID NO:301) of a native sequence PRO1327 cDNA, wherein SEQ ID NO:301 is a clone designated herein as "DNA66521-1583".

Figure 302 shows the amino acid sequence (SEQ ID NO:302) derived from the coding sequence of SEQ ID NO:301 shown in Figure 301.

15 Figure 303 shows a nucleotide sequence (SEQ ID NO:303) of a native sequence PRO1328 cDNA, wherein SEQ ID NO:303 is a clone designated herein as "DNA66658-1584".

Figure 304 shows the amino acid sequence (SEQ ID NO:304) derived from the coding sequence of SEQ ID NO:303 shown in Figure 303.

Figure 305 shows a nucleotide sequence (SEQ ID NO:305) of a native sequence PRO1329 cDNA, wherein SEQ ID NO:305 is a clone designated herein as "DNA66660-1585".

20 Figure 306 shows the amino acid sequence (SEQ ID NO:306) derived from the coding sequence of SEQ ID NO:305 shown in Figure 305.

Figure 307 shows a nucleotide sequence (SEQ ID NO:307) of a native sequence PRO1339 cDNA, wherein SEQ ID NO:307 is a clone designated herein as "DNA66669-1597".

25 Figure 308 shows the amino acid sequence (SEQ ID NO:308) derived from the coding sequence of SEQ ID NO:307 shown in Figure 307.

Figure 309 shows a nucleotide sequence (SEQ ID NO:309) of a native sequence PRO1342 cDNA, wherein SEQ ID NO:309 is a clone designated herein as "DNA66674-1599".

Figure 310 shows the amino acid sequence (SEQ ID NO:310) derived from the coding sequence of SEQ ID NO:309 shown in Figure 309.

30 Figures 311A-311B show a nucleotide sequence (SEQ ID NO:311) of a native sequence PRO1487 cDNA, wherein SEQ ID NO:311 is a clone designated herein as "DNA68836-1656".

Figure 312 shows the amino acid sequence (SEQ ID NO:312) derived from the coding sequence of SEQ ID NO:311 shown in Figures 311A-311B.

35 Figure 313 shows a nucleotide sequence (SEQ ID NO:313) of a native sequence PRO3579 cDNA, wherein SEQ ID NO:313 is a clone designated herein as "DNA68862-2546".

Figure 314 shows the amino acid sequence (SEQ ID NO:314) derived from the coding sequence of SEQ ID NO:313 shown in Figure 313.

Figure 315 shows a nucleotide sequence (SEQ ID NO:315) of a native sequence PRO1472 cDNA, wherein SEQ ID NO:315 is a clone designated herein as "DNA68866-1644".

Figure 316 shows the amino acid sequence (SEQ ID NO:316) derived from the coding sequence of SEQ ID NO:315 shown in Figure 315.

5 Figure 317 shows a nucleotide sequence (SEQ ID NO:317) of a native sequence PRO1385 cDNA, wherein SEQ ID NO:317 is a clone designated herein as "DNA68869-1610".

Figure 318 shows the amino acid sequence (SEQ ID NO:318) derived from the coding sequence of SEQ ID NO:317 shown in Figure 317.

Figure 319 shows a nucleotide sequence (SEQ ID NO:319) of a native sequence PRO1461 cDNA, wherein SEQ ID NO:319 is a clone designated herein as "DNA68871-1638".

10 Figure 320 shows the amino acid sequence (SEQ ID NO:320) derived from the coding sequence of SEQ ID NO:319 shown in Figure 319.

Figure 321 shows a nucleotide sequence (SEQ ID NO:321) of a native sequence PRO1429 cDNA, wherein SEQ ID NO:321 is a clone designated herein as "DNA68879-1631".

15 Figure 322 shows the amino acid sequence (SEQ ID NO:322) derived from the coding sequence of SEQ ID NO:321 shown in Figure 321.

Figure 323 shows a nucleotide sequence (SEQ ID NO:323) of a native sequence PRO1568 cDNA, wherein SEQ ID NO:323 is a clone designated herein as "DNA68880-1676".

Figure 324 shows the amino acid sequence (SEQ ID NO:324) derived from the coding sequence of SEQ ID NO:323 shown in Figure 323.

20 Figure 325 shows a nucleotide sequence (SEQ ID NO:325) of a native sequence PRO1569 cDNA, wherein SEQ ID NO:325 is a clone designated herein as "DNA68882-1677".

Figure 326 shows the amino acid sequence (SEQ ID NO:326) derived from the coding sequence of SEQ ID NO:325 shown in Figure 325.

25 Figure 327 shows a nucleotide sequence (SEQ ID NO:327) of a native sequence PRO1753 cDNA, wherein SEQ ID NO:327 is a clone designated herein as "DNA68883-1691".

Figure 328 shows the amino acid sequence (SEQ ID NO:328) derived from the coding sequence of SEQ ID NO:327 shown in Figure 327.

Figure 329 shows a nucleotide sequence (SEQ ID NO:329) of a native sequence PRO1570 cDNA, wherein SEQ ID NO:329 is a clone designated herein as "DNA68885-1678".

30 Figure 330 shows the amino acid sequence (SEQ ID NO:330) derived from the coding sequence of SEQ ID NO:329 shown in Figure 329.

Figure 331 shows a nucleotide sequence (SEQ ID NO:331) of a native sequence PRO1559 cDNA, wherein SEQ ID NO:331 is a clone designated herein as "DNA68886".

35 Figure 332 shows the amino acid sequence (SEQ ID NO:332) derived from the coding sequence of SEQ ID NO:331 shown in Figure 331.

Figure 333 shows a nucleotide sequence (SEQ ID NO:333) of a native sequence PRO1486 cDNA, wherein SEQ ID NO:333 is a clone designated herein as "DNA71180-1655".

Figure 334 shows the amino acid sequence (SEQ ID NO:334) derived from the coding sequence of SEQ ID NO:333 shown in Figure 333.

Figure 335 shows a nucleotide sequence (SEQ ID NO:335) of a native sequence PRO1433 cDNA, wherein SEQ ID NO:335 is a clone designated herein as "DNA71184-1634".

5 Figure 336 shows the amino acid sequence (SEQ ID NO:336) derived from the coding sequence of SEQ ID NO:335 shown in Figure 335.

Figure 337 shows a nucleotide sequence (SEQ ID NO:337) of a native sequence PRO1490 cDNA, wherein SEQ ID NO:337 is a clone designated herein as "DNA71213-1659".

Figure 338 shows the amino acid sequence (SEQ ID NO:338) derived from the coding sequence of SEQ ID NO:337 shown in Figure 337.

10 Figure 339 shows a nucleotide sequence (SEQ ID NO:339) of a native sequence PRO1482 cDNA, wherein SEQ ID NO:339 is a clone designated herein as "DNA71234-1651".

Figure 340 shows the amino acid sequence (SEQ ID NO:340) derived from the coding sequence of SEQ ID NO:339 shown in Figure 339.

15 Figure 341 shows a nucleotide sequence (SEQ ID NO:341) of a native sequence PRO1409 cDNA, wherein SEQ ID NO:341 is a clone designated herein as "DNA71269-1621".

Figure 342 shows the amino acid sequence (SEQ ID NO:342) derived from the coding sequence of SEQ ID NO:341 shown in Figure 341.

Figure 343 shows a nucleotide sequence (SEQ ID NO:343) of a native sequence PRO1446 cDNA, wherein SEQ ID NO:343 is a clone designated herein as "DNA71277-1636".

20 Figure 344 shows the amino acid sequence (SEQ ID NO:344) derived from the coding sequence of SEQ ID NO:343 shown in Figure 343.

Figure 345 shows a nucleotide sequence (SEQ ID NO:345) of a native sequence PRO1604 cDNA, wherein SEQ ID NO:345 is a clone designated herein as "DNA71286-1687".

25 Figure 346 shows the amino acid sequence (SEQ ID NO:346) derived from the coding sequence of SEQ ID NO:345 shown in Figure 345.

Figure 347 shows a nucleotide sequence (SEQ ID NO:347) of a native sequence PRO1491 cDNA, wherein SEQ ID NO:347 is a clone designated herein as "DNA71883-1660".

Figure 348 shows the amino acid sequence (SEQ ID NO:348) derived from the coding sequence of SEQ ID NO:347 shown in Figure 347.

30 Figure 349 shows a nucleotide sequence (SEQ ID NO:349) of a native sequence PRO1431 cDNA, wherein SEQ ID NO:349 is a clone designated herein as "DNA73401-1633".

Figure 350 shows the amino acid sequence (SEQ ID NO:350) derived from the coding sequence of SEQ ID NO:349 shown in Figure 349.

35 Figures 351A-351B show a nucleotide sequence (SEQ ID NO:351) of a native sequence PRO1563 cDNA, wherein SEQ ID NO:351 is a clone designated herein as "DNA73492-1671".

Figure 352 shows the amino acid sequence (SEQ ID NO:352) derived from the coding sequence of SEQ ID NO:351 shown in Figures 351A-351B.

Figure 353 shows a nucleotide sequence (SEQ ID NO:353) of a native sequence PRO1571 cDNA, wherein SEQ ID NO:353 is a clone designated herein as "DNA73730-1679".

Figure 354 shows the amino acid sequence (SEQ ID NO:354) derived from the coding sequence of SEQ ID NO:353 shown in Figure 353.

5 Figure 355 shows a nucleotide sequence (SEQ ID NO:355) of a native sequence PRO1572 cDNA, wherein SEQ ID NO:355 is a clone designated herein as "DNA73734-1680".

Figure 356 shows the amino acid sequence (SEQ ID NO:356) derived from the coding sequence of SEQ ID NO:355 shown in Figure 355.

Figure 357 shows a nucleotide sequence (SEQ ID NO:357) of a native sequence PRO1573 cDNA, wherein SEQ ID NO:357 is a clone designated herein as "DNA73735-1681".

10 Figure 358 shows the amino acid sequence (SEQ ID NO:358) derived from the coding sequence of SEQ ID NO:357 shown in Figure 357.

Figure 359 shows a nucleotide sequence (SEQ ID NO:359) of a native sequence PRO1508 cDNA, wherein SEQ ID NO:359 is a clone designated herein as "DNA73742-1662".

15 Figure 360 shows the amino acid sequence (SEQ ID NO:360) derived from the coding sequence of SEQ ID NO:359 shown in Figure 359.

Figure 361 shows a nucleotide sequence (SEQ ID NO:361) of a native sequence PRO1485 cDNA, wherein SEQ ID NO:361 is a clone designated herein as "DNA73746-1654".

Figure 362 shows the amino acid sequence (SEQ ID NO:362) derived from the coding sequence of SEQ ID NO:361 shown in Figure 361.

20 Figure 363 shows a nucleotide sequence (SEQ ID NO:363) of a native sequence PRO1564 cDNA, wherein SEQ ID NO:363 is a clone designated herein as "DNA73760-1672".

Figure 364 shows the amino acid sequence (SEQ ID NO:364) derived from the coding sequence of SEQ ID NO:363 shown in Figure 363.

25 Figure 365 shows a nucleotide sequence (SEQ ID NO:365) of a native sequence PRO1550 cDNA, wherein SEQ ID NO:365 is a clone designated herein as "DNA76393-1664".

Figure 366 shows the amino acid sequence (SEQ ID NO:366) derived from the coding sequence of SEQ ID NO:365 shown in Figure 365.

Figure 367 shows a nucleotide sequence (SEQ ID NO:367) of a native sequence PRO1757 cDNA, wherein SEQ ID NO:367 is a clone designated herein as "DNA76398-1699".

30 Figure 368 shows the amino acid sequence (SEQ ID NO:368) derived from the coding sequence of SEQ ID NO:367 shown in Figure 367.

Figure 369 shows a nucleotide sequence (SEQ ID NO:369) of a native sequence PRO1758 cDNA, wherein SEQ ID NO:369 is a clone designated herein as "DNA76399-1700".

35 Figure 370 shows the amino acid sequence (SEQ ID NO:370) derived from the coding sequence of SEQ ID NO:369 shown in Figure 369.

Figure 371 shows a nucleotide sequence (SEQ ID NO:371) of a native sequence PRO1781 cDNA, wherein SEQ ID NO:371 is a clone designated herein as "DNA76522-2500".

Figure 372 shows the amino acid sequence (SEQ ID NO:372) derived from the coding sequence of SEQ ID NO:371 shown in Figure 371.

Figure 373 shows a nucleotide sequence (SEQ ID NO:373) of a native sequence PRO1606 cDNA, wherein SEQ ID NO:373 is a clone designated herein as "DNA76533-1689".

5 Figure 374 shows the amino acid sequence (SEQ ID NO:374) derived from the coding sequence of SEQ ID NO:373 shown in Figure 373.

Figure 375 shows a nucleotide sequence (SEQ ID NO:375) of a native sequence PRO1784 cDNA, wherein SEQ ID NO:375 is a clone designated herein as "DNA77303-2502".

Figure 376 shows the amino acid sequence (SEQ ID NO:376) derived from the coding sequence of SEQ ID NO:375 shown in Figure 375.

10 Figure 377 shows a nucleotide sequence (SEQ ID NO:377) of a native sequence PRO1774 cDNA, wherein SEQ ID NO:377 is a clone designated herein as "DNA77626-1705".

Figure 378 shows the amino acid sequence (SEQ ID NO:378) derived from the coding sequence of SEQ ID NO:377 shown in Figure 377.

15 Figure 379 shows a nucleotide sequence (SEQ ID NO:379) of a native sequence PRO1605 cDNA, wherein SEQ ID NO:379 is a clone designated herein as "DNA77648-1688".

Figure 380 shows the amino acid sequence (SEQ ID NO:380) derived from the coding sequence of SEQ ID NO:379 shown in Figure 379.

Figure 381 shows a nucleotide sequence (SEQ ID NO:381) of a native sequence PRO1928 cDNA, wherein SEQ ID NO:381 is a clone designated herein as "DNA81754-2532".

20 Figure 382 shows the amino acid sequence (SEQ ID NO:382) derived from the coding sequence of SEQ ID NO:381 shown in Figure 381.

Figure 383 shows a nucleotide sequence (SEQ ID NO:383) of a native sequence PRO1865 cDNA, wherein SEQ ID NO:383 is a clone designated herein as "DNA81757-2512".

25 Figure 384 shows the amino acid sequence (SEQ ID NO:384) derived from the coding sequence of SEQ ID NO:383 shown in Figure 383.

Figure 385 shows a nucleotide sequence (SEQ ID NO:385) of a native sequence PRO1925 cDNA, wherein SEQ ID NO:385 is a clone designated herein as "DNA82302-2529".

Figure 386 shows the amino acid sequence (SEQ ID NO:386) derived from the coding sequence of SEQ ID NO:385 shown in Figure 385.

30 Figure 387 shows a nucleotide sequence (SEQ ID NO:387) of a native sequence PRO1926 cDNA, wherein SEQ ID NO:387 is a clone designated herein as "DNA82340-2530".

Figure 388 shows the amino acid sequence (SEQ ID NO:388) derived from the coding sequence of SEQ ID NO:387 shown in Figure 387.

35 Figure 389 shows a nucleotide sequence (SEQ ID NO:389) of a native sequence PRO2630 cDNA, wherein SEQ ID NO:389 is a clone designated herein as "DNA83551".

Figure 390 shows the amino acid sequence (SEQ ID NO:390) derived from the coding sequence of SEQ ID NO:389 shown in Figure 389.



Figure 391 shows a nucleotide sequence (SEQ ID NO:391) of a native sequence PRO3443 cDNA, wherein SEQ ID NO:391 is a clone designated herein as "DNA87991-2540".

Figure 392 shows the amino acid sequence (SEQ ID NO:392) derived from the coding sequence of SEQ ID NO:391 shown in Figure 391.

5 Figure 393 shows a nucleotide sequence (SEQ ID NO:393) of a native sequence PRO3301 cDNA, wherein SEQ ID NO:393 is a clone designated herein as "DNA88002".

Figure 394 shows the amino acid sequence (SEQ ID NO:394) derived from the coding sequence of SEQ ID NO:393 shown in Figure 393.

Figure 395 shows a nucleotide sequence (SEQ ID NO:395) of a native sequence PRO3442 cDNA, wherein SEQ ID NO:395 is a clone designated herein as "DNA92238-2539".

10 Figure 396 shows the amino acid sequence (SEQ ID NO:396) derived from the coding sequence of SEQ ID NO:395 shown in Figure 395.

Figure 397 shows a nucleotide sequence (SEQ ID NO:397) of a native sequence PRO4978 cDNA, wherein SEQ ID NO:397 is a clone designated herein as "DNA95930".

15 Figure 398 shows the amino acid sequence (SEQ ID NO:398) derived from the coding sequence of SEQ ID NO:397 shown in Figure 397.

Figure 399 shows a nucleotide sequence (SEQ ID NO:399) of a native sequence PRO5801 cDNA, wherein SEQ ID NO:399 is a clone designated herein as "DNA115291-2681".

Figure 400 shows the amino acid sequence (SEQ ID NO:400) derived from the coding sequence of SEQ ID NO:399 shown in Figure 399.

20 Figure 401 shows a nucleotide sequence (SEQ ID NO:401) of a native sequence PRO19630 cDNA, wherein SEQ ID NO:401 is a clone designated herein as "DNA23336-2861".

Figure 402 shows the amino acid sequence (SEQ ID NO:402) derived from the coding sequence of SEQ ID NO:401 shown in Figure 401.

25 Figure 403 shows a nucleotide sequence (SEQ ID NO:403) of a native sequence PRO203 cDNA, wherein SEQ ID NO:403 is a clone designated herein as "DNA30862-1396".

Figure 404 shows the amino acid sequence (SEQ ID NO:404) derived from the coding sequence of SEQ ID NO:403 shown in Figure 403.

Figure 405 shows a nucleotide sequence (SEQ ID NO:405) of a native sequence PRO204 cDNA, wherein SEQ ID NO:405 is a clone designated herein as "DNA30871-1157".

30 Figure 406 shows the amino acid sequence (SEQ ID NO:406) derived from the coding sequence of SEQ ID NO:405 shown in Figure 405.

Figure 407 shows a nucleotide sequence (SEQ ID NO:407) of a native sequence PRO210 cDNA, wherein SEQ ID NO:407 is a clone designated herein as "DNA32279-1131".

35 Figure 408 shows the amino acid sequence (SEQ ID NO:408) derived from the coding sequence of SEQ ID NO:407 shown in Figure 407.

Figure 409 shows a nucleotide sequence (SEQ ID NO:409) of a native sequence PRO223 cDNA, wherein SEQ ID NO:409 is a clone designated herein as "DNA33206-1165".

Figure 410 shows the amino acid sequence (SEQ ID NO:410) derived from the coding sequence of SEQ ID NO:409 shown in Figure 409.

Figure 411 shows a nucleotide sequence (SEQ ID NO:411) of a native sequence PRO247 cDNA, wherein SEQ ID NO:411 is a clone designated herein as "DNA35673-1201".

5 Figure 412 shows the amino acid sequence (SEQ ID NO:412) derived from the coding sequence of SEQ ID NO:411 shown in Figure 411.

Figure 413 shows a nucleotide sequence (SEQ ID NO:413) of a native sequence PRO358 cDNA, wherein SEQ ID NO:413 is a clone designated herein as "DNA47361-1154-2".

Figure 414 shows the amino acid sequence (SEQ ID NO:414) derived from the coding sequence of SEQ ID NO:413 shown in Figure 413.

10 Figure 415 shows a nucleotide sequence (SEQ ID NO:415) of a native sequence PRO724 cDNA, wherein SEQ ID NO:415 is a clone designated herein as "DNA49631-1328".

Figure 416 shows the amino acid sequence (SEQ ID NO:416) derived from the coding sequence of SEQ ID NO:415 shown in Figure 415.

15 Figure 417 shows a nucleotide sequence (SEQ ID NO:417) of a native sequence PRO868 cDNA, wherein SEQ ID NO:417 is a clone designated herein as "DNA52594-1270".

Figure 418 shows the amino acid sequence (SEQ ID NO:418) derived from the coding sequence of SEQ ID NO:417 shown in Figure 417.

Figure 419 shows a nucleotide sequence (SEQ ID NO:419) of a native sequence PRO740 cDNA, wherein SEQ ID NO:419 is a clone designated herein as "DNA55800-1263".

20 Figure 420 shows the amino acid sequence (SEQ ID NO:420) derived from the coding sequence of SEQ ID NO:419 shown in Figure 419.

Figure 421 shows a nucleotide sequence (SEQ ID NO:421) of a native sequence PRO1478 cDNA, wherein SEQ ID NO:421 is a clone designated herein as "DNA56531-1648".

25 Figure 422 shows the amino acid sequence (SEQ ID NO:422) derived from the coding sequence of SEQ ID NO:421 shown in Figure 421.

Figure 423 shows a nucleotide sequence (SEQ ID NO:423) of a native sequence PRO162 cDNA, wherein SEQ ID NO:423 is a clone designated herein as "DNA56965-1356".

Figure 424 shows the amino acid sequence (SEQ ID NO:424) derived from the coding sequence of SEQ ID NO:423 shown in Figure 423.

30 Figure 425 shows a nucleotide sequence (SEQ ID NO:425) of a native sequence PRO828 cDNA, wherein SEQ ID NO:425 is a clone designated herein as "DNA57037-1444".

Figure 426 shows the amino acid sequence (SEQ ID NO:426) derived from the coding sequence of SEQ ID NO:425 shown in Figure 425.

35 Figure 427 shows a nucleotide sequence (SEQ ID NO:427) of a native sequence PRO819 cDNA, wherein SEQ ID NO:427 is a clone designated herein as "DNA57695-1340".

Figure 428 shows the amino acid sequence (SEQ ID NO:428) derived from the coding sequence of SEQ ID NO:427 shown in Figure 427.

Figure 429 shows a nucleotide sequence (SEQ ID NO:429) of a native sequence PRO813 cDNA, wherein SEQ ID NO:429 is a clone designated herein as "DNA57834-1339".

Figure 430 shows the amino acid sequence (SEQ ID NO:430) derived from the coding sequence of SEQ ID NO:429 shown in Figure 429.

5 Figure 431 shows a nucleotide sequence (SEQ ID NO:431) of a native sequence PRO1194 cDNA, wherein SEQ ID NO:431 is a clone designated herein as "DNA57841-1522".

Figure 432 shows the amino acid sequence (SEQ ID NO:432) derived from the coding sequence of SEQ ID NO:431 shown in Figure 431.

Figure 433 shows a nucleotide sequence (SEQ ID NO:433) of a native sequence PRO887 cDNA, wherein SEQ ID NO:433 is a clone designated herein as "DNA58130".

10 Figure 434 shows the amino acid sequence (SEQ ID NO:434) derived from the coding sequence of SEQ ID NO:433 shown in Figure 433.

Figure 435 shows a nucleotide sequence (SEQ ID NO:435) of a native sequence PRO1071 cDNA, wherein SEQ ID NO:435 is a clone designated herein as "DNA58847-1383".

15 Figure 436 shows the amino acid sequence (SEQ ID NO:436) derived from the coding sequence of SEQ ID NO:435 shown in Figure 435.

Figure 437 shows a nucleotide sequence (SEQ ID NO:437) of a native sequence PRO1029 cDNA, wherein SEQ ID NO:437 is a clone designated herein as "DNA59493-1420".

Figure 438 shows the amino acid sequence (SEQ ID NO:438) derived from the coding sequence of SEQ ID NO:437 shown in Figure 437.

20 Figure 439 shows a nucleotide sequence (SEQ ID NO:439) of a native sequence PRO1190 cDNA, wherein SEQ ID NO:439 is a clone designated herein as "DNA59586-1520".

Figure 440 shows the amino acid sequence (SEQ ID NO:440) derived from the coding sequence of SEQ ID NO:439 shown in Figure 439.

25 Figure 441 shows a nucleotide sequence (SEQ ID NO:441) of a native sequence PRO4334 cDNA, wherein SEQ ID NO:441 is a clone designated herein as "DNA59608-2577".

Figure 442 shows the amino acid sequence (SEQ ID NO:442) derived from the coding sequence of SEQ ID NO:441 shown in Figure 441.

Figure 443 shows a nucleotide sequence (SEQ ID NO:443) of a native sequence PRO1155 cDNA, wherein SEQ ID NO:443 is a clone designated herein as "DNA59849-1504".

30 Figure 444 shows the amino acid sequence (SEQ ID NO:444) derived from the coding sequence of SEQ ID NO:443 shown in Figure 443.

Figure 445 shows a nucleotide sequence (SEQ ID NO:445) of a native sequence PRO1157 cDNA, wherein SEQ ID NO:445 is a clone designated herein as "DNA60292-1506".

35 Figure 446 shows the amino acid sequence (SEQ ID NO:446) derived from the coding sequence of SEQ ID NO:445 shown in Figure 445.

Figure 447 shows a nucleotide sequence (SEQ ID NO:447) of a native sequence PRO1122 cDNA, wherein SEQ ID NO:447 is a clone designated herein as "DNA62377-1381-1".

Figure 448 shows the amino acid sequence (SEQ ID NO:448) derived from the coding sequence of SEQ ID NO:447 shown in Figure 447.

Figure 449 shows a nucleotide sequence (SEQ ID NO:449) of a native sequence PRO1183 cDNA, wherein SEQ ID NO:449 is a clone designated herein as "DNA62880-1513".

5 Figure 450 shows the amino acid sequence (SEQ ID NO:450) derived from the coding sequence of SEQ ID NO:449 shown in Figure 449.

Figure 451 shows a nucleotide sequence (SEQ ID NO:451) of a native sequence PRO1337 cDNA, wherein SEQ ID NO:451 is a clone designated herein as "DNA66672-1586".

Figure 452 shows the amino acid sequence (SEQ ID NO:452) derived from the coding sequence of SEQ ID NO:451 shown in Figure 451.

10 Figure 453 shows a nucleotide sequence (SEQ ID NO:453) of a native sequence PRO1480 cDNA, wherein SEQ ID NO:453 is a clone designated herein as "DNA67962-1649".

Figure 454 shows the amino acid sequence (SEQ ID NO:454) derived from the coding sequence of SEQ ID NO:453 shown in Figure 453.

15 Figure 455 shows a nucleotide sequence (SEQ ID NO:455) of a native sequence PRO19645 cDNA, wherein SEQ ID NO:455 is a clone designated herein as "DNA69555-2867".

Figure 456 shows the amino acid sequence (SEQ ID NO:456) derived from the coding sequence of SEQ ID NO:455 shown in Figure 455.

Figure 457 shows a nucleotide sequence (SEQ ID NO:457) of a native sequence PRO9782 cDNA, wherein SEQ ID NO:457 is a clone designated herein as "DNA71162-2764".

20 Figure 458 shows the amino acid sequence (SEQ ID NO:458) derived from the coding sequence of SEQ ID NO:457 shown in Figure 457.

Figure 459 shows a nucleotide sequence (SEQ ID NO:459) of a native sequence PRO1419 cDNA, wherein SEQ ID NO:459 is a clone designated herein as "DNA71290-1630".

25 Figure 460 shows the amino acid sequence (SEQ ID NO:460) derived from the coding sequence of SEQ ID NO:459 shown in Figure 459.

Figure 461 shows a nucleotide sequence (SEQ ID NO:461) of a native sequence PRO1575 cDNA, wherein SEQ ID NO:461 is a clone designated herein as "DNA76401-1683".

Figure 462 shows the amino acid sequence (SEQ ID NO:462) derived from the coding sequence of SEQ ID NO:461 shown in Figure 461.

30 Figure 463 shows a nucleotide sequence (SEQ ID NO:463) of a native sequence PRO1567 cDNA, wherein SEQ ID NO:463 is a clone designated herein as "DNA76541-1675".

Figure 464 shows the amino acid sequence (SEQ ID NO:464) derived from the coding sequence of SEQ ID NO:463 shown in Figure 463.

35 Figure 465 shows a nucleotide sequence (SEQ ID NO:465) of a native sequence PRO1891 cDNA, wherein SEQ ID NO:465 is a clone designated herein as "DNA76788-2526".

Figure 466 shows the amino acid sequence (SEQ ID NO:466) derived from the coding sequence of SEQ ID NO:465 shown in Figure 465.

Figure 467 shows a nucleotide sequence (SEQ ID NO:467) of a native sequence PRO1889 cDNA, wherein SEQ ID NO:467 is a clone designated herein as "DNA77623-2524".

Figure 468 shows the amino acid sequence (SEQ ID NO:468) derived from the coding sequence of SEQ ID NO:467 shown in Figure 467.

5 Figure 469 shows a nucleotide sequence (SEQ ID NO:469) of a native sequence PRO1785 cDNA, wherein SEQ ID NO:469 is a clone designated herein as "DNA80136-2503".

Figure 470 shows the amino acid sequence (SEQ ID NO:470) derived from the coding sequence of SEQ ID NO:469 shown in Figure 469.

Figure 471 shows a nucleotide sequence (SEQ ID NO:471) of a native sequence PRO6003 cDNA, wherein SEQ ID NO:471 is a clone designated herein as "DNA83568-2692".

10 Figure 472 shows the amino acid sequence (SEQ ID NO:472) derived from the coding sequence of SEQ ID NO:471 shown in Figure 471.

Figure 473 shows a nucleotide sequence (SEQ ID NO:473) of a native sequence PRO4333 cDNA, wherein SEQ ID NO:473 is a clone designated herein as "DNA84210-2576".

15 Figure 474 shows the amino acid sequence (SEQ ID NO:474) derived from the coding sequence of SEQ ID NO:473 shown in Figure 473.

Figure 475 shows a nucleotide sequence (SEQ ID NO:475) of a native sequence PRO4356 cDNA, wherein SEQ ID NO:475 is a clone designated herein as "DNA86576-2595".

Figure 476 shows the amino acid sequence (SEQ ID NO:476) derived from the coding sequence of SEQ ID NO:475 shown in Figure 475.

20 Figure 477 shows a nucleotide sequence (SEQ ID NO:477) of a native sequence PRO4352 cDNA, wherein SEQ ID NO:477 is a clone designated herein as "DNA87976-2593".

Figure 478 shows the amino acid sequence (SEQ ID NO:478) derived from the coding sequence of SEQ ID NO:477 shown in Figure 477.

25 Figure 479 shows a nucleotide sequence (SEQ ID NO:479) of a native sequence PRO4354 cDNA, wherein SEQ ID NO:479 is a clone designated herein as "DNA92256-2596".

Figure 480 shows the amino acid sequence (SEQ ID NO:480) derived from the coding sequence of SEQ ID NO:479 shown in Figure 479.

Figure 481 shows a nucleotide sequence (SEQ ID NO:481) of a native sequence PRO4369 cDNA, wherein SEQ ID NO:481 is a clone designated herein as "DNA92289-2598".

30 Figure 482 shows the amino acid sequence (SEQ ID NO:482) derived from the coding sequence of SEQ ID NO:481 shown in Figure 481.

Figure 483 shows a nucleotide sequence (SEQ ID NO:483) of a native sequence PRO6030 cDNA, wherein SEQ ID NO:483 is a clone designated herein as "DNA96850-2705".

35 Figure 484 shows the amino acid sequence (SEQ ID NO:484) derived from the coding sequence of SEQ ID NO:483 shown in Figure 483.

Figure 485 shows a nucleotide sequence (SEQ ID NO:485) of a native sequence PRO4433 cDNA, wherein SEQ ID NO:485 is a clone designated herein as "DNA96855-2629".

Figure 486 shows the amino acid sequence (SEQ ID NO:486) derived from the coding sequence of SEQ ID NO:485 shown in Figure 485.

Figure 487 shows a nucleotide sequence (SEQ ID NO:487) of a native sequence PRO4424 cDNA, wherein SEQ ID NO:487 is a clone designated herein as "DNA96857-2636".

5 Figure 488 shows the amino acid sequence (SEQ ID NO:488) derived from the coding sequence of SEQ ID NO:487 shown in Figure 487.

Figure 489 shows a nucleotide sequence (SEQ ID NO:489) of a native sequence PRO6017 cDNA, wherein SEQ ID NO:489 is a clone designated herein as "DNA96860-2700".

Figure 490 shows the amino acid sequence (SEQ ID NO:490) derived from the coding sequence of SEQ ID NO:489 shown in Figure 489.

10 Figure 491 shows a nucleotide sequence (SEQ ID NO:491) of a native sequence PRO19563 cDNA, wherein SEQ ID NO:491 is a clone designated herein as "DNA96861-2844".

Figure 492 shows the amino acid sequence (SEQ ID NO:492) derived from the coding sequence of SEQ ID NO:491 shown in Figure 491.

15 Figure 493 shows a nucleotide sequence (SEQ ID NO:493) of a native sequence PRO6015 cDNA, wherein SEQ ID NO:493 is a clone designated herein as "DNA96866-2698".

Figure 494 shows the amino acid sequence (SEQ ID NO:494) derived from the coding sequence of SEQ ID NO:493 shown in Figure 493.

Figure 495 shows a nucleotide sequence (SEQ ID NO:495) of a native sequence PRO5779 cDNA, wherein SEQ ID NO:495 is a clone designated herein as "DNA96870-2676".

20 Figure 496 shows the amino acid sequence (SEQ ID NO:496) derived from the coding sequence of SEQ ID NO:495 shown in Figure 495.

Figure 497 shows a nucleotide sequence (SEQ ID NO:497) of a native sequence PRO5776 cDNA, wherein SEQ ID NO:497 is a clone designated herein as "DNA96872-2674".

25 Figure 498 shows the amino acid sequence (SEQ ID NO:498) derived from the coding sequence of SEQ ID NO:497 shown in Figure 497.

Figure 499 shows a nucleotide sequence (SEQ ID NO:499) of a native sequence PRO4430 cDNA, wherein SEQ ID NO:499 is a clone designated herein as "DNA96878-2626".

Figure 500 shows the amino acid sequence (SEQ ID NO:500) derived from the coding sequence of SEQ ID NO:499 shown in Figure 499.

30 Figure 501 shows a nucleotide sequence (SEQ ID NO:501) of a native sequence PRO4421 cDNA, wherein SEQ ID NO:501 is a clone designated herein as "DNA96879-2619".

Figure 502 shows the amino acid sequence (SEQ ID NO:502) derived from the coding sequence of SEQ ID NO:501 shown in Figure 501.

35 Figure 503 shows a nucleotide sequence (SEQ ID NO:503) of a native sequence PRO4499 cDNA, wherein SEQ ID NO:503 is a clone designated herein as "DNA96889-2641".

Figure 504 shows the amino acid sequence (SEQ ID NO:504) derived from the coding sequence of SEQ ID NO:503 shown in Figure 503.

Figure 505 shows a nucleotide sequence (SEQ ID NO:505) of a native sequence PRO4423 cDNA, wherein SEQ ID NO:505 is a clone designated herein as "DNA96893-2621".

Figure 506 shows the amino acid sequence (SEQ ID NO:506) derived from the coding sequence of SEQ ID NO:505 shown in Figure 505.

5 Figure 507 shows a nucleotide sequence (SEQ ID NO:507) of a native sequence PRO5998 cDNA, wherein SEQ ID NO:507 is a clone designated herein as "DNA96897-2688".

Figure 508 shows the amino acid sequence (SEQ ID NO:508) derived from the coding sequence of SEQ ID NO:507 shown in Figure 507.

Figure 509 shows a nucleotide sequence (SEQ ID NO:509) of a native sequence PRO4501 cDNA, wherein SEQ ID NO:509 is a clone designated herein as "DNA98564-2643".

10 Figure 510 shows the amino acid sequence (SEQ ID NO:510) derived from the coding sequence of SEQ ID NO:509 shown in Figure 509.

Figure 511 shows a nucleotide sequence (SEQ ID NO:511) of a native sequence PRO6240 cDNA, wherein SEQ ID NO:511 is a clone designated herein as "DNA107443-2718".

15 Figure 512 shows the amino acid sequence (SEQ ID NO:512) derived from the coding sequence of SEQ ID NO:511 shown in Figure 511.

Figure 513 shows a nucleotide sequence (SEQ ID NO:513) of a native sequence PRO6245 cDNA, wherein SEQ ID NO:513 is a clone designated herein as "DNA107786-2723".

Figure 514 shows the amino acid sequence (SEQ ID NO:514) derived from the coding sequence of SEQ ID NO:513 shown in Figure 513.

20 Figure 515 shows a nucleotide sequence (SEQ ID NO:515) of a native sequence PRO6175 cDNA, wherein SEQ ID NO:515 is a clone designated herein as "DNA108682-2712".

Figure 516 shows the amino acid sequence (SEQ ID NO:516) derived from the coding sequence of SEQ ID NO:515 shown in Figure 515.

25 Figure 517 shows a nucleotide sequence (SEQ ID NO:517) of a native sequence PRO9742 cDNA, wherein SEQ ID NO:517 is a clone designated herein as "DNA108684-2761".

Figure 518 shows the amino acid sequence (SEQ ID NO:518) derived from the coding sequence of SEQ ID NO:517 shown in Figure 517.

Figure 519 shows a nucleotide sequence (SEQ ID NO:519) of a native sequence PRO7179 cDNA, wherein SEQ ID NO:519 is a clone designated herein as "DNA108701-2749".

30 Figure 520 shows the amino acid sequence (SEQ ID NO:520) derived from the coding sequence of SEQ ID NO:519 shown in Figure 519.

Figure 521 shows a nucleotide sequence (SEQ ID NO:521) of a native sequence PRO6239 cDNA, wherein SEQ ID NO:521 is a clone designated herein as "DNA108720-2717".

35 Figure 522 shows the amino acid sequence (SEQ ID NO:522) derived from the coding sequence of SEQ ID NO:521 shown in Figure 521.

Figure 523 shows a nucleotide sequence (SEQ ID NO:523) of a native sequence PRO6493 cDNA, wherein SEQ ID NO:523 is a clone designated herein as "DNA108726-2729".

Figure 524 shows the amino acid sequence (SEQ ID NO:524) derived from the coding sequence of SEQ ID NO:523 shown in Figure 523.

Figures 525A-525B show a nucleotide sequence (SEQ ID NO:525) of a native sequence PRO9741 cDNA, wherein SEQ ID NO:525 is a clone designated herein as "DNA108728-2760".

5 Figure 526 shows the amino acid sequence (SEQ ID NO:526) derived from the coding sequence of SEQ ID NO:525 shown in Figures 525A-525B.

Figure 527 shows a nucleotide sequence (SEQ ID NO:527) of a native sequence PRO9822 cDNA, wherein SEQ ID NO:527 is a clone designated herein as "DNA108738-2767".

Figure 528 shows the amino acid sequence (SEQ ID NO:528) derived from the coding sequence of SEQ ID NO:527 shown in Figure 527.

10 Figure 529 shows a nucleotide sequence (SEQ ID NO:529) of a native sequence PRO6244 cDNA, wherein SEQ ID NO:529 is a clone designated herein as "DNA108743-2722".

Figure 530 shows the amino acid sequence (SEQ ID NO:530) derived from the coding sequence of SEQ ID NO:529 shown in Figure 529.

15 Figure 531 shows a nucleotide sequence (SEQ ID NO:531) of a native sequence PRO9740 cDNA, wherein SEQ ID NO:531 is a clone designated herein as "DNA108758-2759".

Figure 532 shows the amino acid sequence (SEQ ID NO:532) derived from the coding sequence of SEQ ID NO:531 shown in Figure 531.

Figure 533 shows a nucleotide sequence (SEQ ID NO:533) of a native sequence PRO9739 cDNA, wherein SEQ ID NO:533 is a clone designated herein as "DNA108765-2758".

20 Figure 534 shows the amino acid sequence (SEQ ID NO:534) derived from the coding sequence of SEQ ID NO:533 shown in Figure 533.

Figure 535 shows a nucleotide sequence (SEQ ID NO:535) of a native sequence PRO7177 cDNA, wherein SEQ ID NO:535 is a clone designated herein as "DNA108783-2747".

25 Figure 536 shows the amino acid sequence (SEQ ID NO:536) derived from the coding sequence of SEQ ID NO:535 shown in Figure 535.

Figure 537 shows a nucleotide sequence (SEQ ID NO:537) of a native sequence PRO7178 cDNA, wherein SEQ ID NO:537 is a clone designated herein as "DNA108789-2748".

Figure 538 shows the amino acid sequence (SEQ ID NO:538) derived from the coding sequence of SEQ ID NO:537 shown in Figure 537.

30 Figure 539 shows a nucleotide sequence (SEQ ID NO:539) of a native sequence PRO6246 cDNA, wherein SEQ ID NO:539 is a clone designated herein as "DNA108806-2724".

Figure 540 shows the amino acid sequence (SEQ ID NO:540) derived from the coding sequence of SEQ ID NO:539 shown in Figure 539.

35 Figure 541 shows a nucleotide sequence (SEQ ID NO:541) of a native sequence PRO6241 cDNA, wherein SEQ ID NO:541 is a clone designated herein as "DNA108936-2719".

Figure 542 shows the amino acid sequence (SEQ ID NO:542) derived from the coding sequence of SEQ ID NO:541 shown in Figure 541.



Figure 543 shows a nucleotide sequence (SEQ ID NO:543) of a native sequence PRO9835 cDNA, wherein SEQ ID NO:543 is a clone designated herein as "DNA119510-2771".

Figure 544 shows the amino acid sequence (SEQ ID NO:544) derived from the coding sequence of SEQ ID NO:543 shown in Figure 543.

5 Figure 545 shows a nucleotide sequence (SEQ ID NO:545) of a native sequence PRO9857 cDNA, wherein SEQ ID NO:545 is a clone designated herein as "DNA119517-2778".

Figure 546 shows the amino acid sequence (SEQ ID NO:546) derived from the coding sequence of SEQ ID NO:545 shown in Figure 545.

Figure 547 shows a nucleotide sequence (SEQ ID NO:547) of a native sequence PRO7436 cDNA, wherein SEQ ID NO:547 is a clone designated herein as "DNA119535-2756".

10 Figure 548 shows the amino acid sequence (SEQ ID NO:548) derived from the coding sequence of SEQ ID NO:547 shown in Figure 547.

Figure 549 shows a nucleotide sequence (SEQ ID NO:549) of a native sequence PRO9856 cDNA, wherein SEQ ID NO:549 is a clone designated herein as "DNA119537-2777".

15 Figure 550 shows the amino acid sequence (SEQ ID NO:550) derived from the coding sequence of SEQ ID NO:549 shown in Figure 549.

Figure 551 shows a nucleotide sequence (SEQ ID NO:551) of a native sequence PRO19605 cDNA, wherein SEQ ID NO:551 is a clone designated herein as "DNA119714-2851".

Figure 552 shows the amino acid sequence (SEQ ID NO:552) derived from the coding sequence of SEQ ID NO:551 shown in Figure 551.

20 Figure 553 shows a nucleotide sequence (SEQ ID NO:553) of a native sequence PRO9859 cDNA, wherein SEQ ID NO:553 is a clone designated herein as "DNA125170-2780".

Figure 554 shows the amino acid sequence (SEQ ID NO:554) derived from the coding sequence of SEQ ID NO:553 shown in Figure 553.

25 Figure 555 shows a nucleotide sequence (SEQ ID NO:555) of a native sequence PRO12970 cDNA, wherein SEQ ID NO:555 is a clone designated herein as "DNA129594-2841".

Figure 556 shows the amino acid sequence (SEQ ID NO:556) derived from the coding sequence of SEQ ID NO:555 shown in Figure 555.

Figure 557 shows a nucleotide sequence (SEQ ID NO:557) of a native sequence PRO19626 cDNA, wherein SEQ ID NO:557 is a clone designated herein as "DNA129793-2857".

30 Figure 558 shows the amino acid sequence (SEQ ID NO:558) derived from the coding sequence of SEQ ID NO:557 shown in Figure 557.

Figure 559 shows a nucleotide sequence (SEQ ID NO:559) of a native sequence PRO9833 cDNA, wherein SEQ ID NO:559 is a clone designated herein as "DNA130809-2769".

35 Figure 560 shows the amino acid sequence (SEQ ID NO:560) derived from the coding sequence of SEQ ID NO:559 shown in Figure 559.

Figure 561 shows a nucleotide sequence (SEQ ID NO:561) of a native sequence PRO19670 cDNA, wherein SEQ ID NO:561 is a clone designated herein as "DNA131639-2874".

Figure 562 shows the amino acid sequence (SEQ ID NO:562) derived from the coding sequence of SEQ ID NO:561 shown in Figure 561.

Figure 563 shows a nucleotide sequence (SEQ ID NO:563) of a native sequence PRO19624 cDNA, wherein SEQ ID NO:563 is a clone designated herein as "DNA131649-2855".

5 Figure 564 shows the amino acid sequence (SEQ ID NO:564) derived from the coding sequence of SEQ ID NO:563 shown in Figure 563.

Figure 565 shows a nucleotide sequence (SEQ ID NO:565) of a native sequence PRO19680 cDNA, wherein SEQ ID NO:565 is a clone designated herein as "DNA131652-2876".

Figure 566 shows the amino acid sequence (SEQ ID NO:566) derived from the coding sequence of SEQ ID NO:565 shown in Figure 565.

10 Figure 567 shows a nucleotide sequence (SEQ ID NO:567) of a native sequence PRO19675 cDNA, wherein SEQ ID NO:567 is a clone designated herein as "DNA131658-2875".

Figure 568 shows the amino acid sequence (SEQ ID NO:568) derived from the coding sequence of SEQ ID NO:567 shown in Figure 567.

15 Figure 569 shows a nucleotide sequence (SEQ ID NO:569) of a native sequence PRO9834 cDNA, wherein SEQ ID NO:569 is a clone designated herein as "DNA132162-2770".

Figure 570 shows the amino acid sequence (SEQ ID NO:570) derived from the coding sequence of SEQ ID NO:569 shown in Figure 569.

Figure 571 shows a nucleotide sequence (SEQ ID NO:571) of a native sequence PRO9744 cDNA, wherein SEQ ID NO:571 is a clone designated herein as "DNA136110-2763".

20 Figure 572 shows the amino acid sequence (SEQ ID NO:572) derived from the coding sequence of SEQ ID NO:571 shown in Figure 571.

Figure 573 shows a nucleotide sequence (SEQ ID NO:573) of a native sequence PRO19644 cDNA, wherein SEQ ID NO:573 is a clone designated herein as "DNA139592-2866".

25 Figure 574 shows the amino acid sequence (SEQ ID NO:574) derived from the coding sequence of SEQ ID NO:573 shown in Figure 573.

Figure 575 shows a nucleotide sequence (SEQ ID NO:575) of a native sequence PRO19625 cDNA, wherein SEQ ID NO:575 is a clone designated herein as "DNA139608-2856".

Figure 576 shows the amino acid sequence (SEQ ID NO:576) derived from the coding sequence of SEQ ID NO:575 shown in Figure 575.

30 Figure 577 shows a nucleotide sequence (SEQ ID NO:577) of a native sequence PRO19597 cDNA, wherein SEQ ID NO:577 is a clone designated herein as "DNA143292-2848".

Figure 578 shows the amino acid sequence (SEQ ID NO:578) derived from the coding sequence of SEQ ID NO:577 shown in Figure 577.

35 Figure 579 shows a nucleotide sequence (SEQ ID NO:579) of a native sequence PRO16090 cDNA, wherein SEQ ID NO:579 is a clone designated herein as "DNA144844-2843".

Figure 580 shows the amino acid sequence (SEQ ID NO:580) derived from the coding sequence of SEQ ID NO:579 shown in Figure 579.

Figure 581 shows a nucleotide sequence (SEQ ID NO:581) of a native sequence PRO19576 cDNA, wherein SEQ ID NO:581 is a clone designated herein as "DNA144857-2845".

Figure 582 shows the amino acid sequence (SEQ ID NO:582) derived from the coding sequence of SEQ ID NO:581 shown in Figure 581.

5 Figure 583 shows a nucleotide sequence (SEQ ID NO:583) of a native sequence PRO19646 cDNA, wherein SEQ ID NO:583 is a clone designated herein as "DNA145841-2868".

Figure 584 shows the amino acid sequence (SEQ ID NO:584) derived from the coding sequence of SEQ ID NO:583 shown in Figure 583.

Figure 585 shows a nucleotide sequence (SEQ ID NO:585) of a native sequence PRO19814 cDNA, wherein SEQ ID NO:585 is a clone designated herein as "DNA148004-2882".

10 Figure 586 shows the amino acid sequence (SEQ ID NO:586) derived from the coding sequence of SEQ ID NO:585 shown in Figure 585.

Figure 587 shows a nucleotide sequence (SEQ ID NO:587) of a native sequence PRO19669 cDNA, wherein SEQ ID NO:587 is a clone designated herein as "DNA149893-2873".

15 Figure 588 shows the amino acid sequence (SEQ ID NO:588) derived from the coding sequence of SEQ ID NO:587 shown in Figure 587.

Figure 589 shows a nucleotide sequence (SEQ ID NO:589) of a native sequence PRO19818 cDNA, wherein SEQ ID NO:589 is a clone designated herein as "DNA149930-2884".

Figure 590 shows the amino acid sequence (SEQ ID NO:590) derived from the coding sequence of SEQ ID NO:589 shown in Figure 589.

20 Figure 591 shows a nucleotide sequence (SEQ ID NO:591) of a native sequence PRO20088 cDNA, wherein SEQ ID NO:591 is a clone designated herein as "DNA150157-2898".

Figure 592 shows the amino acid sequence (SEQ ID NO:592) derived from the coding sequence of SEQ ID NO:591 shown in Figure 591.

25 Figure 593 shows a nucleotide sequence (SEQ ID NO:593) of a native sequence PRO16089 cDNA, wherein SEQ ID NO:593 is a clone designated herein as "DNA150163-2842".

Figure 594 shows the amino acid sequence (SEQ ID NO:594) derived from the coding sequence of SEQ ID NO:593 shown in Figure 593.

Figure 595 shows a nucleotide sequence (SEQ ID NO:595) of a native sequence PRO20025 cDNA, wherein SEQ ID NO:595 is a clone designated herein as "DNA153579-2894".

30 Figure 596 shows the amino acid sequence (SEQ ID NO:596) derived from the coding sequence of SEQ ID NO:595 shown in Figure 595.

Figure 597 shows a nucleotide sequence (SEQ ID NO:597) of a native sequence PRO20040 cDNA, wherein SEQ ID NO:597 is a clone designated herein as "DNA164625-2890".

35 Figure 598 shows the amino acid sequence (SEQ ID NO:598) derived from the coding sequence of SEQ ID NO:597 shown in Figure 597.

Figure 599 shows a nucleotide sequence (SEQ ID NO:599) of a native sequence PRO791 cDNA, wherein SEQ ID NO:599 is a clone designated herein as "DNA57838-1337".

Figure 600 shows the amino acid sequence (SEQ ID NO:600) derived from the coding sequence of SEQ ID NO:599 shown in Figure 599.

Figure 601 shows a nucleotide sequence (SEQ ID NO:601) of a native sequence PRO1131 cDNA, wherein SEQ ID NO:601 is a clone designated herein as "DNA59777-1480".

5 Figure 602 shows the amino acid sequence (SEQ ID NO:602) derived from the coding sequence of SEQ ID NO:601 shown in Figure 601.

Figure 603 shows a nucleotide sequence (SEQ ID NO:603) of a native sequence PRO1343 cDNA, wherein SEQ ID NO:603 is a clone designated herein as "DNA66675-1587".

Figure 604 shows the amino acid sequence (SEQ ID NO:604) derived from the coding sequence of SEQ ID NO:603 shown in Figure 603.

10 Figure 605 shows a nucleotide sequence (SEQ ID NO:605) of a native sequence PRO1760 cDNA, wherein SEQ ID NO:605 is a clone designated herein as "DNA76532-1702".

Figure 606 shows the amino acid sequence (SEQ ID NO:606) derived from the coding sequence of SEQ ID NO:605 shown in Figure 605.

15 Figure 607 shows a nucleotide sequence (SEQ ID NO:607) of a native sequence PRO6029 cDNA, wherein SEQ ID NO:607 is a clone designated herein as "DNA105849-2704".

Figure 608 shows the amino acid sequence (SEQ ID NO:608) derived from the coding sequence of SEQ ID NO:607 shown in Figure 607.

Figure 609 shows a nucleotide sequence (SEQ ID NO:609) of a native sequence PRO1801 cDNA, wherein SEQ ID NO:609 is a clone designated herein as "DNA83500-2506".

20 Figure 610 shows the amino acid sequence (SEQ ID NO:610) derived from the coding sequence of SEQ ID NO:609 shown in Figure 609.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

##### I. Definitions

25 The terms "PRO polypeptide" and "PRO" as used herein and when immediately followed by a numerical designation refer to various polypeptides, wherein the complete designation (i.e., PRO/number) refers to specific polypeptide sequences as described herein. The terms "PRO/number polypeptide" and "PRO/number" wherein the term "number" is provided as an actual numerical designation as used herein encompass native sequence polypeptides and polypeptide variants (which are further defined herein). The PRO polypeptides described herein  
30 may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods. The term "PRO polypeptide" refers to each individual PRO/number polypeptide disclosed herein. All disclosures in this specification which refer to the "PRO polypeptide" refer to each of the polypeptides individually as well as jointly. For example, descriptions of the preparation of, purification of, derivation of, formation of antibodies to or against, administration of, compositions containing,  
35 treatment of a disease with, etc., pertain to each polypeptide of the invention individually. The term "PRO polypeptide" also includes variants of the PRO/number polypeptides disclosed herein.

A "native sequence PRO polypeptide" comprises a polypeptide having the same amino acid sequence as

the corresponding PRO polypeptide derived from nature. Such native sequence PRO polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term "native sequence PRO polypeptide" specifically encompasses naturally-occurring truncated or secreted forms of the specific PRO polypeptide (*e.g.*, an extracellular domain sequence), naturally-occurring variant forms (*e.g.*, alternatively spliced forms) and naturally-occurring allelic variants of the polypeptide. In various embodiments of the invention, the native sequence PRO polypeptides disclosed herein are mature or full-length native sequence polypeptides comprising the full-length amino acids sequences shown in the accompanying figures. Start and stop codons are shown in bold font and underlined in the figures. However, while the PRO polypeptide disclosed in the accompanying figures are shown to begin with methionine residues designated herein as amino acid position 1 in the figures, it is conceivable and possible that other methionine residues located either upstream or downstream from the amino acid position 1 in the figures may be employed as the starting amino acid residue for the PRO polypeptides.

The PRO polypeptide "extracellular domain" or "ECD" refers to a form of the PRO polypeptide which is essentially free of the transmembrane and cytoplasmic domains. Ordinarily, a PRO polypeptide ECD will have less than 1 % of such transmembrane and/or cytoplasmic domains and preferably, will have less than 0.5 % of such domains. It will be understood that any transmembrane domains identified for the PRO polypeptides of the present invention are identified pursuant to criteria routinely employed in the art for identifying that type of hydrophobic domain. The exact boundaries of a transmembrane domain may vary but most likely by no more than about 5 amino acids at either end of the domain as initially identified herein. Optionally, therefore, an extracellular domain of a PRO polypeptide may contain from about 5 or fewer amino acids on either side of the transmembrane domain/extracellular domain boundary as identified in the Examples or specification and such polypeptides, with or without the associated signal peptide, and nucleic acid encoding them, are contemplated by the present invention.

The approximate location of the "signal peptides" of the various PRO polypeptides disclosed herein are shown in the present specification and/or the accompanying figures. It is noted, however, that the C-terminal boundary of a signal peptide may vary, but most likely by no more than about 5 amino acids on either side of the signal peptide C-terminal boundary as initially identified herein, wherein the C-terminal boundary of the signal peptide may be identified pursuant to criteria routinely employed in the art for identifying that type of amino acid sequence element (*e.g.*, Nielsen et al., Prot. Eng. 10:1-6 (1997) and von Heinje et al., Nucl. Acids. Res. 14:4683-4690 (1986)). Moreover, it is also recognized that, in some cases, cleavage of a signal sequence from a secreted polypeptide is not entirely uniform, resulting in more than one secreted species. These mature polypeptides, where the signal peptide is cleaved within no more than about 5 amino acids on either side of the C-terminal boundary of the signal peptide as identified herein, and the polynucleotides encoding them, are contemplated by the present invention.

"PRO polypeptide variant" means an active PRO polypeptide as defined above or below having at least about 80% amino acid sequence identity with a full-length native sequence PRO polypeptide sequence as disclosed herein, a PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein. Such PRO polypeptide variants include, for instance, PRO

polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C-terminus of the full-length native amino acid sequence. Ordinarily, a PRO polypeptide variant will have at least about 80% amino acid sequence identity, alternatively at least about 81% amino acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91% amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to a full-length native sequence PRO polypeptide sequence as disclosed herein, a PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of a full-length PRO polypeptide sequence as disclosed herein. Ordinarily, PRO variant polypeptides are at least about 10 amino acids in length, alternatively at least about 20 amino acids in length, alternatively at least about 30 amino acids in length, alternatively at least about 40 amino acids in length, alternatively at least about 50 amino acids in length, alternatively at least about 60 amino acids in length, alternatively at least about 70 amino acids in length, alternatively at least about 80 amino acids in length, alternatively at least about 90 amino acids in length, alternatively at least about 100 amino acids in length, alternatively at least about 150 amino acids in length, alternatively at least about 200 amino acids in length, alternatively at least about 300 amino acids in length, or more.

"Percent (%) amino acid sequence identity" with respect to the PRO polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific PRO polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through

Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

$$100 \text{ times the fraction } X/Y$$

where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. As examples of % amino acid sequence identity calculations using this method, Tables 2 and 3 demonstrate how to calculate the % amino acid sequence identity of the amino acid sequence designated "Comparison Protein" to the amino acid sequence designated "PRO", wherein "PRO" represents the amino acid sequence of a hypothetical PRO polypeptide of interest, "Comparison Protein" represents the amino acid sequence of a polypeptide against which the "PRO" polypeptide of interest is being compared, and "X", "Y" and "Z" each represent different hypothetical amino acid residues.

Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program. However, % amino acid sequence identity values may also be obtained as described below by using the WU-BLAST-2 computer program (Altschul et al., Methods in Enzymology 266:460-480 (1996)). Most of the WU-BLAST-2 search parameters are set to the default values. Those not set to default values, i.e., the adjustable parameters, are set with the following values: overlap span = 1, overlap fraction = 0.125, word threshold (T) = 11, and scoring matrix = BLOSUM62. When WU-BLAST-2 is employed, a % amino acid sequence identity value is determined by dividing (a) the number of matching identical amino acid residues between the amino acid sequence of the PRO polypeptide of interest having a sequence derived from the native PRO polypeptide and the comparison amino acid sequence of interest (i.e., the sequence against which the PRO polypeptide of interest is being compared which may be a PRO variant polypeptide) as determined by WU-BLAST-2 by (b) the total number of amino acid residues of the PRO polypeptide of interest. For example, in the statement "a polypeptide comprising an the amino acid sequence A which has or having at least 80% amino acid sequence identity to the amino acid sequence B", the amino acid sequence A is the comparison amino acid sequence of interest and the amino acid sequence B is the amino acid sequence of the PRO polypeptide of interest.

Percent amino acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program may be downloaded from <http://www.ncbi.nlm.nih.gov> or otherwise obtained from the

National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several search parameters, wherein all of those search parameters are set to default values including, for example, unmask = yes, strand = all, expected occurrences = 10, minimum low complexity length = 15/5, multi-pass e-value = 0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.

In situations where NCBI-BLAST2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

$$100 \text{ times the fraction } X/Y$$

where X is the number of amino acid residues scored as identical matches by the sequence alignment program NCBI-BLAST2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A.

"PRO variant polynucleotide" or "PRO variant nucleic acid sequence" means a nucleic acid molecule which encodes an active PRO polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with a nucleotide acid sequence encoding a full-length native sequence PRO polypeptide sequence as disclosed herein, a full-length native sequence PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein. Ordinarily, a PRO variant polynucleotide will have at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity with a nucleic acid sequence encoding a full-length native sequence PRO polypeptide sequence as disclosed herein, a full-length native sequence PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal sequence, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein. Variants do not encompass the native nucleotide sequence.



Ordinarily, PRO variant polynucleotides are at least about 30 nucleotides in length, alternatively at least about 60 nucleotides in length, alternatively at least about 90 nucleotides in length, alternatively at least about 120 nucleotides in length, alternatively at least about 150 nucleotides in length, alternatively at least about 180 nucleotides in length, alternatively at least about 210 nucleotides in length, alternatively at least about 240 nucleotides in length, alternatively at least about 270 nucleotides in length, alternatively at least about 300 nucleotides in length, alternatively at least about 450 nucleotides in length, alternatively at least about 600 nucleotides in length, alternatively at least about 900 nucleotides in length, or more.

"Percent (%) nucleic acid sequence identity" with respect to PRO-encoding nucleic acid sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in the PRO nucleic acid sequence of interest, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. For purposes herein, however, % nucleic acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

In situations where ALIGN-2 is employed for nucleic acid sequence comparisons, the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain % nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:

$$100 \text{ times the fraction } W/Z$$

where W is the number of nucleotides scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C. As examples of % nucleic acid sequence identity calculations, Tables 4 and 5, demonstrate how to calculate the % nucleic acid sequence identity of the nucleic acid sequence designated "Comparison DNA" to the nucleic acid sequence designated "PRO-DNA", wherein "PRO-DNA" represents a hypothetical PRO-encoding nucleic acid sequence of interest, "Comparison DNA" represents the nucleotide sequence of a nucleic acid molecule against which the "PRO-DNA" nucleic acid molecule of interest is being compared, and "N", "L" and "V" each represent

different hypothetical nucleotides.

Unless specifically stated otherwise, all % nucleic acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program. However, % nucleic acid sequence identity values may also be obtained as described below by using the WU-BLAST-2 computer program (Altschul et al., Methods in Enzymology 266:460-480 (1996)). Most of the WU-BLAST-2 search parameters are set to the default values. Those not set to default values, i.e., the adjustable parameters, are set with the following values: overlap span = 1, overlap fraction = 0.125, word threshold (T) = 11, and scoring matrix = BLOSUM62. When WU-BLAST-2 is employed, a % nucleic acid sequence identity value is determined by dividing (a) the number of matching identical nucleotides between the nucleic acid sequence of the PRO polypeptide-encoding nucleic acid molecule of interest having a sequence derived from the native sequence PRO polypeptide-encoding nucleic acid and the comparison nucleic acid molecule of interest (i.e., the sequence against which the PRO polypeptide-encoding nucleic acid molecule of interest is being compared which may be a variant PRO polynucleotide) as determined by WU-BLAST-2 by (b) the total number of nucleotides of the PRO polypeptide-encoding nucleic acid molecule of interest. For example, in the statement "an isolated nucleic acid molecule comprising a nucleic acid sequence A which has or having at least 80% nucleic acid sequence identity to the nucleic acid sequence B", the nucleic acid sequence A is the comparison nucleic acid molecule of interest and the nucleic acid sequence B is the nucleic acid sequence of the PRO polypeptide-encoding nucleic acid molecule of interest.

Percent nucleic acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program may be downloaded from <http://www.ncbi.nlm.nih.gov> or otherwise obtained from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several search parameters, wherein all of those search parameters are set to default values including, for example, unmask = yes, strand = all, expected occurrences = 10, minimum low complexity length = 15/5, multi-pass e-value = 0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.

In situations where NCBI-BLAST2 is employed for sequence comparisons, the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain % nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:

$$100 \text{ times the fraction } W/Z$$

where W is the number of nucleotides scored as identical matches by the sequence alignment program NCBI-BLAST2 in that program's alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C.

In other embodiments, PRO variant polynucleotides are nucleic acid molecules that encode an active PRO polypeptide and which are capable of hybridizing, preferably under stringent hybridization and wash conditions,

to nucleotide sequences encoding a full-length PRO polypeptide as disclosed herein. PRO variant polypeptides may be those that are encoded by a PRO variant polynucleotide.

"Isolated," when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic  
5 uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide *in situ* within recombinant cells, since at least one  
10 component of the PRO polypeptide natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.

An "isolated" PRO polypeptide-encoding nucleic acid or other polypeptide-encoding nucleic acid is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the polypeptide-encoding nucleic acid. An isolated  
15 polypeptide-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated polypeptide-encoding nucleic acid molecules therefore are distinguished from the specific polypeptide-encoding nucleic acid molecule as it exists in natural cells. However, an isolated polypeptide-encoding nucleic acid molecule includes polypeptide-encoding nucleic acid molecules contained in cells that ordinarily express the polypeptide where, for example, the nucleic acid molecule is in a chromosomal location different from that of  
20 natural cells.

The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid  
25 sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and  
30 in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

The term "antibody" is used in the broadest sense and specifically covers, for example, single anti-PRO  
35 monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies), anti-PRO antibody compositions with polyepitopic specificity, single chain anti-PRO antibodies, and fragments of anti-PRO antibodies (see below). The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially

homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts.

"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).

"Stringent conditions" or "high stringency conditions", as defined herein, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1 % sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1 % sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1 % SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

"Moderately stringent conditions" may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent than those described above. An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

The term "epitope tagged" when used herein refers to a chimeric polypeptide comprising a PRO polypeptide fused to a "tag polypeptide". The tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused. The tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes. Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues).

As used herein, the term "immunoadhesin" designates antibody-like molecules which combine the binding specificity of a heterologous protein (an "adhesin") with the effector functions of immunoglobulin constant domains. Structurally, the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding

specificity which is other than the antigen recognition and binding site of an antibody (i.e., is "heterologous"), and an immunoglobulin constant domain sequence. The adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand. The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM.

5 "Active" or "activity" for the purposes herein refers to form(s) of a PRO polypeptide which retain a biological and/or an immunological activity of native or naturally-occurring PRO, wherein "biological" activity refers to a biological function (either inhibitory or stimulatory) caused by a native or naturally-occurring PRO other than the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring PRO and an "immunological" activity refers to the ability to induce the production of an  
10 antibody against an antigenic epitope possessed by a native or naturally-occurring PRO.

The term "antagonist" is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a native PRO polypeptide disclosed herein. In a similar manner, the term "agonist" is used in the broadest sense and includes any molecule that mimics a biological activity of a native PRO polypeptide disclosed herein. Suitable agonist or antagonist molecules specifically  
15 include agonist or antagonist antibodies or antibody fragments, fragments or amino acid sequence variants of native PRO polypeptides, peptides, antisense oligonucleotides, small organic molecules, etc. Methods for identifying agonists or antagonists of a PRO polypeptide may comprise contacting a PRO polypeptide with a candidate agonist or antagonist molecule and measuring a detectable change in one or more biological activities normally associated with the PRO polypeptide.

20 "Treatment" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.

"Chronic" administration refers to administration of the agent(s) in a continuous mode as opposed to an  
25 acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time. "Intermittent" administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature.

"Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc. Preferably, the mammal is human.

30 Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.

"Carriers" as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution. Examples of physiologically acceptable  
35 carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine,

asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN™, polyethylene glycol (PEG), and PLURONICS™.

5 "Antibody fragments" comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')<sub>2</sub>, and Fv fragments; diabodies; linear antibodies (Zapata et al., Protein Eng. 8(10): 1057-1062 [1995]); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

10 Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, a designation reflecting the ability to crystallize readily. Pepsin treatment yields an F(ab')<sub>2</sub> fragment that has two antigen-combining sites and is still capable of cross-linking antigen.

15 "Fv" is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the V<sub>H</sub>-V<sub>L</sub> dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

20 The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab fragments differ from Fab' fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')<sub>2</sub> antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

25 The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains.

30 Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2.

35 "Single-chain Fv" or "sFv" antibody fragments comprise the V<sub>H</sub> and V<sub>L</sub> domains of antibody, wherein these domains are present in a single polypeptide chain. Preferably, the Fv polypeptide further comprises a polypeptide linker between the V<sub>H</sub> and V<sub>L</sub> domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv, see Pluckhun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenberg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).

The term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (V<sub>H</sub>) connected to a light-chain variable domain (V<sub>L</sub>) in the same

polypeptide chain ( $V_H$ - $V_L$ ). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).

5 An "isolated" antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence  
10 by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.

15 An antibody that "specifically binds to" or is "specific for" a particular polypeptide or an epitope on a particular polypeptide is one that binds to that particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope.

The word "label" when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody. The label may be detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical  
20 alteration of a substrate compound or composition which is detectable.

By "solid phase" is meant a non-aqueous matrix to which the antibody of the present invention can adhere. Examples of solid phases encompassed herein include those formed partially or entirely of glass (e.g., controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones. In certain embodiments, depending on the context, the solid phase can comprise the well of an assay  
25 plate; in others it is a purification column (e.g., an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275,149.

A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as a PRO polypeptide or antibody thereto) to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of  
30 biological membranes.

A "small molecule" is defined herein to have a molecular weight below about 500 Daltons.

An "effective amount" of a polypeptide disclosed herein or an agonist or antagonist thereof is an amount sufficient to carry out a specifically stated purpose. An "effective amount" may be determined empirically and in a routine manner, in relation to the stated purpose.  
35

**Table 1**

```

/*
 *
 * C-C increased from 12 to 15
 * Z is average of EQ
 * B is average of ND
5  * match with stop is _M; stop-stop = 0; J (joker) match = 0
 */
#define _M      -8      /* value of a match with a stop */

10 int _day[26][26] = {
/*
/* A */  { 2, 0, -2, 0, 0, -4, 1, -1, -1, 0, -1, -2, -1, 0, _M, 1, 0, -2, 1, 1, 0, 0, -6, 0, -3, 0},
/* B */  { 0, 3, -4, 3, 2, -5, 0, 1, -2, 0, 0, -3, -2, 2, _M, -1, 1, 0, 0, 0, 0, -2, -5, 0, -3, 1},
/* C */  {-2, -4, 15, -5, -5, -4, -3, -3, -2, 0, -5, -6, -5, -4, _M, -3, -5, -4, 0, -2, 0, -2, -8, 0, 0, -5},
15 /* D */  { 0, 3, -5, 4, 3, -6, 1, 1, -2, 0, 0, -4, -3, 2, _M, -1, 2, -1, 0, 0, 0, -2, -7, 0, -4, 2},
/* E */  { 0, 2, -5, 3, 4, -5, 0, 1, -2, 0, 0, -3, -2, 1, _M, -1, 2, -1, 0, 0, 0, -2, -7, 0, -4, 3},
/* F */  {-4, -5, -4, -6, -5, 9, -5, -2, 1, 0, -5, 2, 0, -4, _M, -5, -5, -4, -3, -3, 0, -1, 0, 0, 7, -5},
/* G */  { 1, 0, -3, 1, 0, -5, 5, -2, -3, 0, -2, -4, -3, 0, _M, -1, -1, -3, 1, 0, 0, -1, -7, 0, -5, 0},
/* H */  {-1, 1, -3, 1, 1, -2, -2, 6, -2, 0, 0, -2, -2, 2, _M, 0, 3, 2, -1, -1, 0, -2, -3, 0, 0, 2},
20 /* I */  {-1, -2, -2, -2, -2, 1, -3, -2, 5, 0, -2, 2, 2, -2, _M, -2, -2, -2, -1, 0, 0, 4, -5, 0, -1, -2},
/* J */  { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* K */  {-1, 0, -5, 0, 0, -5, -2, 0, -2, 0, 5, -3, 0, 1, _M, -1, 1, 3, 0, 0, 0, -2, -3, 0, -4, 0},
/* L */  {-2, -3, -6, -4, -3, 2, -4, -2, 2, 0, -3, 6, 4, -3, _M, -3, -2, -3, -3, -1, 0, 2, -2, 0, -1, -2},
/* M */  {-1, -2, -5, -3, -2, 0, -3, -2, 2, 0, 0, 4, 6, -2, _M, -2, -1, 0, -2, -1, 0, 2, -4, 0, -2, -1},
25 /* N */  { 0, 2, -4, 2, 1, -4, 0, 2, -2, 0, 1, -3, -2, 2, _M, -1, 1, 0, 1, 0, 0, -2, -4, 0, -2, 1},
/* O */  { _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, 0, _M, _M, _M, _M, _M, _M, _M, _M, _M},
/* P */  { 1, -1, -3, -1, -1, -5, -1, 0, -2, 0, -1, -3, -2, -1, _M, 6, 0, 0, 1, 0, 0, -1, -6, 0, -5, 0},
/* Q */  { 0, 1, -5, 2, 2, -5, -1, 3, -2, 0, 1, -2, -1, 1, _M, 0, 4, 1, -1, -1, 0, -2, -5, 0, -4, 3},
/* R */  {-2, 0, -4, -1, -1, -4, -3, 2, -2, 0, 3, -3, 0, 0, _M, 0, 1, 6, 0, -1, 0, -2, 2, 0, -4, 0},
30 /* S */  { 1, 0, 0, 0, 0, -3, 1, -1, -1, 0, 0, -3, -2, 1, _M, 1, -1, 0, 2, 1, 0, -1, -2, 0, -3, 0},
/* T */  { 1, 0, -2, 0, 0, -3, 0, -1, 0, 0, 0, -1, -1, 0, _M, 0, -1, -1, 1, 3, 0, 0, -5, 0, -3, 0},
/* U */  { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* V */  { 0, -2, -2, -2, -2, -1, -1, -2, 4, 0, -2, 2, 2, -2, _M, -1, -2, -2, -1, 0, 0, 4, -6, 0, -2, -2},
/* W */  {-6, -5, -8, -7, -7, 0, -7, -3, -5, 0, -3, -2, -4, -4, _M, -6, -5, 2, -2, -5, 0, -6, 17, 0, 0, -6},
35 /* X */  { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* Y */  {-3, -3, 0, -4, -4, 7, -5, 0, -1, 0, -4, -1, -2, -2, _M, -5, -4, -4, -3, -3, 0, -2, 0, 0, 10, -4},
/* Z */  { 0, 1, -5, 2, 3, -5, 0, 2, -2, 0, 0, -2, -1, 1, _M, 0, 3, 0, 0, 0, 0, -2, -6, 0, -4, 4}
};
40

45

50

55

```



**Table 1 (cont')**

```

/*
*/
#include <stdio.h>
#include <ctype.h>

5
#define MAXJMP      16      /* max jumps in a diag */
#define MAXGAP      24      /* don't continue to penalize gaps larger than this */
#define JMPS        1024    /* max jmps in an path */
10
#define MX          4       /* save if there's at least MX-1 bases since last jmp */

#define DMAT        3       /* value of matching bases */
#define DMIS        0       /* penalty for mismatched bases */
#define DINS0       8       /* penalty for a gap */
15
#define DINS1       1       /* penalty per base */
#define PINS0       8       /* penalty for a gap */
#define PINS1       4       /* penalty per residue */

struct jmp {
20
    short            n[MAXJMP]; /* size of jmp (neg for dely) */
    unsigned short   x[MAXJMP]; /* base no. of jmp in seq x */
}; /* limits seq to 2^16 -1 */

struct diag {
25
    int              score;      /* score at last jmp */
    long             offset;     /* offset of prev block */
    short            jmp;        /* current jmp index */
    struct jmp        jp;        /* list of jmps */
};

30
struct path {
    int              spc;         /* number of leading spaces */
    short            n[JMPS]; /* size of jmp (gap) */
    int              x[JMPS]; /* loc of jmp (last elem before gap) */
35
};

char              *ofile;        /* output file name */
char              *namex[2];     /* seq names: getseqs() */
char              *prog;         /* prog name for err msgs */
40
char              *seqx[2];      /* seqs: getseqs() */
int               dmax;          /* best diag: nw() */
int               dmax0;         /* final diag */
int               dna;           /* set if dna: main() */
int               endgaps;       /* set if penalizing end gaps */
45
int               gapx, gapy;     /* total gaps in seqs */
int               len0, len1;    /* seq lens */
int               ngapx, ngapy;  /* total size of gaps */
int               smax;          /* max score: nw() */
int               *xbm;          /* bitmap for matching */
50
long              offset;        /* current offset in jmp file */
struct            diag           /* holds diagonals */
struct            path           /* holds path for seqs */
pp[2];

char              *calloc(), *malloc(), *index(), *strcpy();
55
char              *getseq(), *g_calloc();

```

60

Table 1 (cont')

```

/* Needleman-Wunsch alignment program
*
* usage: progs file1 file2
* where file1 and file2 are two dna or two protein sequences.
5  * The sequences can be in upper- or lower-case and may contain ambiguity
* Any lines beginning with ';', '>' or '<' are ignored
* Max file length is 65535 (limited by unsigned short x in the jmp struct)
* A sequence with 1/3 or more of its elements ACGTU is assumed to be DNA
10 * Output is in the file "align.out"
*
* The program may create a tmp file in /tmp to hold info about traceback.
* Original version developed under BSD 4.3 on a vax 8650
*/
15 #include "nw.h"
#include "day.h"

static _dbval[26] = {
    1,14,2,13,0,0,4,11,0,0,12,0,3,15,0,0,0,5,6,8,8,7,9,0,10,0
20 };

static _pbval[26] = {
    1, 2|(1<<('D'-'A'))|(1<<('N'-'A')), 4, 8, 16, 32, 64,
    128, 256, 0xFFFFFFFF, 1<<10, 1<<11, 1<<12, 1<<13, 1<<14,
25 1<<15, 1<<16, 1<<17, 1<<18, 1<<19, 1<<20, 1<<21, 1<<22,
    1<<23, 1<<24, 1<<25|(1<<('E'-'A'))|(1<<('Q'-'A'))
};

main(ac, av)
30     int      ac;
     char      *av[];
{
    prog = av[0];
    if (ac != 3) {
35         fprintf(stderr, "usage: %s file1 file2\n", prog);
        fprintf(stderr, "where file1 and file2 are two dna or two protein sequences.\n");
        fprintf(stderr, "The sequences can be in upper- or lower-case\n");
        fprintf(stderr, "Any lines beginning with ';' or '<' are ignored\n");
        fprintf(stderr, "Output is in the file \"align.out\"\n");
        exit(1);
40     }
    namex[0] = av[1];
    namex[1] = av[2];
    seqx[0] = getseq(namex[0], &len0);
    seqx[1] = getseq(namex[1], &len1);
45     xbm = (dna)? _dbval : _pbval;

    endgaps = 0; /* 1 to penalize endgaps */
    ofile = "align.out"; /* output file */

50     nw(); /* fill in the matrix, get the possible jumps */
    readjumps(); /* get the actual jumps */
    print(); /* print stats, alignment */

55     cleanup(0); /* unlink any tmp files */
}

```

main

**Table 1 (cont')**

```

/* do the alignment, return best score: main()
* dna: values in Fitch and Smith, PNAS, 80, 1382-1386, 1983
* pro: PAM 250 values
* When scores are equal, we prefer mismatches to any gap, prefer
5  * a new gap to extending an ongoing gap, and prefer a gap in seqx
  * to a gap in seq y.
  */
nw()
{
10      char      *px, *py;      /* seqs and ptrs */
      int      *ndely, *dely;    /* keep track of dely */
      int      ndelx, delx;      /* keep track of delx */
      int      *tmp;            /* for swapping row0, row1 */
      int      mis;             /* score for each type */
15      int      ins0, ins1;      /* insertion penalties */
      register id;              /* diagonal index */
      register ij;              /* jmp index */
      register *col0, *col1;    /* score for curr, last row */
      register xx, yy;          /* index into seqs */
20
      dx = (struct diag *)g_malloc("to get diags", len0+len1+1, sizeof(struct diag));

      ndely = (int *)g_malloc("to get ndely", len1+1, sizeof(int));
      dely = (int *)g_malloc("to get dely", len1+1, sizeof(int));
25      col0 = (int *)g_malloc("to get col0", len1+1, sizeof(int));
      col1 = (int *)g_malloc("to get col1", len1+1, sizeof(int));
      ins0 = (dna)? DINS0 : PINS0;
      ins1 = (dna)? DINS1 : PINS1;

30      smax = -10000;
      if (endgaps) {
          for (col0[0] = dely[0] = -ins0, yy = 1; yy <= len1; yy++) {
              col0[yy] = dely[yy] = col0[yy-1] - ins1;
              ndely[yy] = yy;
35          }
          col0[0] = 0;      /* Waterman Bull Math Biol 84 */
      }
      else
          for (yy = 1; yy <= len1; yy++)
40              dely[yy] = -ins0;

      /* fill in match matrix
      */
45      for (px = seqx[0], xx = 1; xx <= len0; px++, xx++) {
          /* initialize first entry in col
          */
          if (endgaps) {
              if (xx == 1)
                  col1[0] = delx = -(ins0+ins1);
50              else
                  col1[0] = delx = col0[0] - ins1;
              ndelx = xx;
          }
          else {
55              col1[0] = 0;
              delx = -ins0;
              ndelx = 0;
          }
60
      }

```

**Table 1 (cont')**

...nw

```

5      for (py = seqx[1], yy = 1; yy <= len1; py++, yy++) {
        mis = col0[yy-1];
        if (dna)
            mis += (xbm[*px-'A']&xbm[*py-'A'])? DMAT : DMIS;
        else
            mis += _day[*px-'A'][*py-'A'];

10      /* update penalty for del in x seq;
        * favor new del over ongong del
        * ignore MAXGAP if weighting endgaps
        */
        if (endgaps || ndely[yy] < MAXGAP) {
            if (col0[yy] - ins0 >= dely[yy]) {
15                dely[yy] = col0[yy] - (ins0+ins1);
                ndely[yy] = 1;
            } else {
                dely[yy] -= ins1;
                ndely[yy]++;
20            }
        } else {
            if (col0[yy] - (ins0+ins1) >= dely[yy]) {
                dely[yy] = col0[yy] - (ins0+ins1);
                ndely[yy] = 1;
25            } else
                ndely[yy]++;
        }

        /* update penalty for del in y seq;
        * favor new del over ongong del
        */
        if (endgaps || ndelx < MAXGAP) {
            if (col1[yy-1] - ins0 >= delx) {
30                delx = col1[yy-1] - (ins0+ins1);
                ndelx = 1;
            } else {
                delx -= ins1;
                ndelx++;
35            }
        } else {
            if (col1[yy-1] - (ins0+ins1) >= delx) {
                delx = col1[yy-1] - (ins0+ins1);
                ndelx = 1;
40            } else
                ndelx++;
45        }

        /* pick the maximum score; we're favoring
        * mis over any del and delx over dely
        */
50
55
60

```

**Table 1 (cont')**

...nw

```

5      id = xx - yy + len1 - 1;
      if (mis >= delx && mis >= dely[yy])
          coll[yy] = mis;
      else if (delx >= dely[yy]) {
          coll[yy] = delx;
          ij = dx[id].ijmp;
          if (dx[id].jp.n[0] && (!dna || (ndelx >= MAXJMP
10      && xx > dx[id].jp.x[ij]+MX) || mis > dx[id].score+DINS0)) {
              dx[id].ijmp++;
              if (++ij >= MAXJMP) {
                  writejumps(id);
                  ij = dx[id].ijmp = 0;
                  dx[id].offset = offset;
15      offset += sizeof(struct jmp) + sizeof(offset);
              }
          }
          dx[id].jp.n[ij] = ndelx;
          dx[id].jp.x[ij] = xx;
          dx[id].score = delx;
      }
      else {
          coll[yy] = dely[yy];
          ij = dx[id].ijmp;
25      if (dx[id].jp.n[0] && (!dna || (ndely[yy] >= MAXJMP
          && xx > dx[id].jp.x[ij]+MX) || mis > dx[id].score+DINS0)) {
              dx[id].ijmp++;
              if (++ij >= MAXJMP) {
                  writejumps(id);
                  ij = dx[id].ijmp = 0;
                  dx[id].offset = offset;
30      offset += sizeof(struct jmp) + sizeof(offset);
              }
          }
          dx[id].jp.n[ij] = -ndely[yy];
          dx[id].jp.x[ij] = xx;
          dx[id].score = dely[yy];
      }
      if (xx == len0 && yy < len1) {
40      /* last col
         */
         if (endgaps)
             coll[yy] -= ins0+ins1*(len1-yy);
         if (coll[yy] > smax) {
             smax = coll[yy];
             dmax = id;
45      }
     }
 }
 if (endgaps && xx < len0)
     coll[yy-1] -= ins0+ins1*(len0-xx);
 if (coll[yy-1] > smax) {
     smax = coll[yy-1];
     dmax = id;
50 }
 tmp = col0; col0 = coll; coll = tmp;
 }
 (void) free((char *)ndely);
 (void) free((char *)dely);
 (void) free((char *)col0);
60 (void) free((char *)coll);

```

**Table 1 (cont')**

```

/*
 *
 * print() -- only routine visible outside this module
 *
5  * static:
 * getmat() -- trace back best path, count matches: print()
 * pr_align() -- print alignment of described in array p[]: print()
 * dumpblock() -- dump a block of lines with numbers, stars: pr_align()
 * nums() -- put out a number line: dumpblock()
10 * putline() -- put out a line (name, [num], seq, [num]): dumpblock()
 * stars() -- put a line of stars: dumpblock()
 * stripname() -- strip any path and prefix from a seqname
 */

15 #include "nw.h"

#define SPC      3
#define P_LINE  256 /* maximum output line */
#define P_SPC    3 /* space between name or num and seq */

20 extern _day[26][26];
int olen; /* set output line length */
FILE *fx; /* output file */

25 print()
{
    int lx, ly, firstgap, lastgap; /* overlap */

    if ((fx = fopen(ofile, "w")) == 0) {
30         fprintf(stderr, "%s: can't write %s\n", prog, ofile);
        cleanup(1);
    }
    fprintf(fx, "<first sequence: %s (length = %d)\n", namex[0], len0);
    fprintf(fx, "<second sequence: %s (length = %d)\n", namex[1], len1);
35     olen = 60;
    lx = len0;
    ly = len1;
    firstgap = lastgap = 0;
    if (dmax < len1 - 1) { /* leading gap in x */
40         pp[0].spc = firstgap = len1 - dmax - 1;
        ly -= pp[0].spc;
    }
    else if (dmax > len1 - 1) { /* leading gap in y */
45         pp[1].spc = firstgap = dmax - (len1 - 1);
        lx -= pp[1].spc;
    }
    if (dmax0 < len0 - 1) { /* trailing gap in x */
50         lastgap = len0 - dmax0 - 1;
        lx -= lastgap;
    }
    else if (dmax0 > len0 - 1) { /* trailing gap in y */
55         lastgap = dmax0 - (len0 - 1);
        ly -= lastgap;
    }
    getmat(lx, ly, firstgap, lastgap);
    pr_align();
}

60

```

**print**

**Table 1 (cont')**

```

/*
 * trace back the best path, count matches
 */
static
5  getmat(lx, ly, firstgap, lastgap)                                getmat
    int      lx, ly;                                /* "core" (minus endgaps) */
    int      firstgap, lastgap;                      /* leading trailing overlap */
{
    int      nm, i0, i1, siz0, siz1;
10    char    outx[32];
    double   pct;
    register n0, n1;
    register char *p0, *p1;

15    /* get total matches, score
    */
    i0 = i1 = siz0 = siz1 = 0;
    p0 = seqx[0] + pp[1].spc;
    p1 = seqx[1] + pp[0].spc;
20    n0 = pp[1].spc + 1;
    n1 = pp[0].spc + 1;

    nm = 0;
    while ( *p0 && *p1 ) {
25        if (siz0) {
            p1++;
            n1++;
            siz0--;
        }
        else if (siz1) {
30            p0++;
            n0++;
            siz1--;
        }
        else {
35            if (xbm[*p0-'A']&xbm[*p1-'A'])
                nm++;
            if (n0++ == pp[0].x[i0])
                siz0 = pp[0].n[i0++];
40            if (n1++ == pp[1].x[i1])
                siz1 = pp[1].n[i1++];
            p0++;
            p1++;
        }
45    }

    /* pct homology:
    * if penalizing endgaps, base is the shorter seq
    * else, knock off overhangs and take shorter core
    */
50    if (endgaps)
        lx = (len0 < len1)? len0 : len1;
    else
        lx = (lx < ly)? lx : ly;
55    pct = 100.*((double)nm)/((double)lx);
    fprintf(fx, "\n");
    fprintf(fx, "< %d match%s in an overlap of %d: %.2f percent similarity\n",
        nm, (nm == 1)? "" : "es", lx, pct);
60

```

**Table 1 (cont')**

```

fprintf(fx, "<gaps in first sequence: %d", gapx);
if (gapx) {
    (void) sprintf(outx, "(%d %s%s)",
        ngapx, (dna)? "base": "residue", (ngapx == 1)? "": "s");
5      fprintf(fx, "%s", outx);

    fprintf(fx, ", gaps in second sequence: %d", gapy);
    if (gapy) {
        (void) sprintf(outx, "(%d %s%s)",
10        ngapy, (dna)? "base": "residue", (ngapy == 1)? "": "s");
        fprintf(fx, "%s", outx);
    }
    if (dna)
15      fprintf(fx,
        "\n<score: %d (match = %d, mismatch = %d, gap penalty = %d + %d per base)\n",
        smax, DMAT, DMIS, DINS0, DINS1);
    else
        fprintf(fx,
20        "\n<score: %d (Dayhoff PAM 250 matrix, gap penalty = %d + %d per residue)\n",
        smax, PINS0, PINS1);
    if (endgaps)
        fprintf(fx,
25        "<endgaps penalized. left endgap: %d %s%s, right endgap: %d %s%s\n",
        firstgap, (dna)? "base": "residue", (firstgap == 1)? "": "s",
        lastgap, (dna)? "base": "residue", (lastgap == 1)? "": "s");
    else
        fprintf(fx, "<endgaps not penalized\n");
}

30  static      nm;          /* matches in core -- for checking */
    static      lmax;       /* lengths of stripped file names */
    static      ij[2];      /* jmp index for a path */
    static      nc[2];      /* number at start of current line */
    static      ni[2];      /* current elem number -- for gapping */
35  static      siz[2];
    static char  *ps[2];     /* ptr to current element */
    static char  *po[2];     /* ptr to next output char slot */
    static char  out[2][P_LINE]; /* output line */
    static char  star[P_LINE]; /* set by stars() */
40

/*
 * print alignment of described in struct path pp[]
 */
static
45  pr_align()
{
    int          nn;        /* char count */
    int          more;
    register     i;

50    for (i = 0, lmax = 0; i < 2; i++) {
        nn = stripname(nameex[i]);
        if (nn > lmax)
            lmax = nn;

55        nc[i] = 1;
        ni[i] = 1;
        siz[i] = ij[i] = 0;
        ps[i] = seqx[i];
60        po[i] = out[i];
    }

```

...getmat

pr\_align



Table 1 (cont')

```

for (nn = nm = 0, more = 1; more;) {
    for (i = more = 0; i < 2; i++) {
        /*
5         * do we have more of this sequence?
        */
        if (!*ps[i])
            continue;

10        more++;

        if (pp[i].spc) { /* leading space */
            *po[i]++ = ' ';
            pp[i].spc--;
15        }
        else if (siz[i]) { /* in a gap */
            *po[i]++ = '-';
            siz[i]--;
20        }
        else { /* we're putting a seq element
            */
            *po[i] = *ps[i];
            if (islower(*ps[i]))
                *ps[i] = toupper(*ps[i]);
25            po[i]++;
            ps[i]++;

            /*
            * are we at next gap for this seq?
            */
            if (ni[i] == pp[i].x[ij[i]]) {
                /*
                * we need to merge all gaps
                * at this location
                */
                siz[i] = pp[i].n[ij[i] + +];
                while (ni[i] == pp[i].x[ij[i]])
                    siz[i] += pp[i].n[ij[i] + +];
35            }
            ni[i]++;
40        }
    }
    if (++nn == olen || !more && nn) {
        dumpblock();
        for (i = 0; i < 2; i++)
            po[i] = out[i];
        nm = 0;
45    }
}

50 }

/*
 * dump a block of lines, including numbers, stars: pr_align()
 */
55 static
dumpblock()
{
    register i;

60    for (i = 0; i < 2; i++)
        *po[i]-- = '\0';

```

...pr\_align

dumpblock

Table 1 (cont')

...dumpblock

```

5      (void) putc('\n', fx);
      for (i = 0; i < 2; i++) {
10         if (*out[i] && (*out[i] != ' ' || *(po[i]) != ' ')) {
            if (i == 0)
                nums(i);
            if (i == 0 && *out[1])
                stars();
15         putline(i);
            if (i == 0 && *out[1])
                fprintf(fx, star);
            if (i == 1)
                nums(i);
        }
    }

20  /*
    * put out a number line: dumpblock()
    */
    static
    nums(ix)
25  {
        int      ix;      /* index in out[] holding seq line */
        char      nline[P_LINE];
        register  i, j;
        register char *pn, *px, *py;

30      for (pn = nline, i = 0; i < lmax+P_SPC; i++, pn++)
          *pn = ' ';
        for (i = nc[ix], py = out[ix]; *py; py++, pn++) {
            if (*py == ' ' || *py == '-')
                *pn = ' ';
35          else {
                if (i%10 == 0 || (i == 1 && nc[ix] != 1)) {
                    j = (i < 0)? -i : i;
                    for (px = pn; j; j /= 10, px--)
                        *px = j%10 + '0';
40                    if (i < 0)
                        *px = '-';
                }
                else
                    *pn = ' ';
45                i++;
            }
        }
        *pn = '\0';
        nc[ix] = i;
50      for (pn = nline; *pn; pn++)
          (void) putc(*pn, fx);
        (void) putc('\n', fx);
    }

55  /*
    * put out a line (name, [num], seq, [num]): dumpblock()
    */
    static
    putline(ix)
60      int      ix;      {

```

nums

putline

Table 1 (cont')

```

5      int          i;
      register char *px;

      for (px = namex[ix], i = 0; *px && *px != ':'; px++, i++)
          (void) putc(*px, fx);
      for (; i < lmax+P_SPC; i++)
10         (void) putc(' ', fx);

      /* these count from 1:
      * ni[] is current element (from 1)
      * nc[] is number at start of current line
      */
15     for (px = out[ix]; *px; px++)
          (void) putc(*px&0x7F, fx);
      (void) putc('\n', fx);
  }

20  /*
      * put a line of stars (seqs always in out[0], out[1]): dumpblock()
      */
      static
25     stars()
      {
          int          i;
          register char *p0, *p1, cx, *px;

30         if (!*out[0] || (*out[0] == ' ' && *(po[0]) == ' ') ||
            !*out[1] || (*out[1] == ' ' && *(po[1]) == ' '))
            return;
          px = star;
          for (i = lmax+P_SPC; i; i--)
35             *px++ = ' ';

          for (p0 = out[0], p1 = out[1]; *p0 && *p1; p0++, p1++) {
              if (isalpha(*p0) && isalpha(*p1)) {
40                 if (xbm[*p0-'A']&xbm[*p1-'A']) {
                     cx = '*';
                     nm++;
                 }
45                 else if (!dna && _day[*p0-'A'][*p1-'A'] > 0)
                     cx = '.';
                 else
                     cx = ' ';
             }
             else
50                 cx = ' ';
             *px++ = cx;
          }
          *px++ = '\n';
          *px = '\0';
55     }

```

...putline

stars

Table 1 (cont')

```
/*
 * strip path or prefix from pn, return len: pr_align()
 */
static
5 stripname(pn)                                stripname
    char    *pn;    /* file name (may be path) */
{
    register char    *px, *py;
10     py = 0;
    for (px = pn; *px; px++)
        if (*px == '/')
            py = px + 1;
15     if (py)
        (void) strcpy(pn, py);
    return(strlen(pn));
}
20
25
30
35
40
45
50
55
60
```

**Table 1 (cont')**

```

/*
 * cleanup() -- cleanup any tmp file
 * getseq() -- read in seq, set dna, len, maxlen
 * g_alloc() -- calloc() with error checkin
5  * readjumps() -- get the good jumps; from tmp file if necessary
 * writejumps() -- write a filled array of jumps to a tmp file: nw()
 */
#include "nw.h"
#include <sys/file.h>

10 char *jname = "/tmp/homgXXXXXX"; /* tmp file for jumps */
FILE *fj;

int cleanup(); /* cleanup tmp file */
15 long lseek();

/*
 * remove any tmp file if we blow
 */
20 cleanup(i) cleanup
    int i;
{
    if (fj)
        (void) unlink(jname);
25 exit(i);
}

/*
 * read, return ptr to seq, set dna, len, maxlen
 * skip lines starting with ';', '<', or '>'
 * seq in upper or lower case
 */
30 char *
getseq(file, len) getseq
    char *file; /* file name */
    int *len; /* seq len */
{
    char line[1024], *pseq;
    register char *px, *py;
    int natgc, tlen;
    FILE *fp;

    if ((fp = fopen(file, "r")) == 0) {
        fprintf(stderr, "%s: can't read %s\n", prog, file);
        exit(1);
    }
    tlen = natgc = 0;
    while (fgets(line, 1024, fp)) {
        if (*line == ';' || *line == '<' || *line == '>')
            continue;
        for (px = line; *px != '\n'; px++)
            if (isupper(*px) || islower(*px))
                tlen++;
    }
    if ((pseq = malloc((unsigned)(tlen+6))) == 0) {
        fprintf(stderr, "%s: malloc() failed to get %d bytes for %s\n", prog, tlen+6, file);
        exit(1);
    }
    pseq[0] = pseq[1] = pseq[2] = pseq[3] = '\0';
60

```

Table 1 (cont')

...getseq

```

5      py = pseq + 4;
      *len = tlen;
      rewind(fp);

      while (fgets(line, 1024, fp)) {
          if (*line == ';' || *line == '<' || *line == '>')
              continue;
          for (px = line; *px != '\n'; px++) {
10              if (isupper(*px))
                  *py++ = *px;
              else if (islower(*px))
                  *py++ = toupper(*px);
              if (index("ATGCU",*(py-1)))
15                  natgc++;
          }
      }
      *py++ = '\0';
      *py = '\0';
20      (void) fclose(fp);
      dna = natgc > (tlen/3);
      return(pseq+4);
  }

25  char *
  g_alloc(msg, nx, sz)
      char *msg;          /* program, calling routine */
      int nx, sz;         /* number and size of elements */
  {
30      char *px, *calloc();

      if ((px = calloc((unsigned)nx, (unsigned)sz)) == 0) {
          if (*msg) {
35              fprintf(stderr, "%s: g_alloc() failed %s (n=%d, sz=%d)\n", prog, msg, nx, sz);
              exit(1);
          }
      }
      return(px);
  }

40  /*
  * get final jmps from dx[] or tmp file, set pp[], reset dmax: main()
  */
  readjmps()
45  {
      int fd = -1;
      int siz, i0, i1;
      register i, j, xx;

50      if (fj) {
          (void) fclose(fj);
          if ((fd = open(jname, O_RDONLY, 0)) < 0) {
              fprintf(stderr, "%s: can't open() %s\n", prog, jname);
              cleanup(1);
55          }
      }
      for (i = i0 = i1 = 0, dmax0 = dmax, xx = len0; i++) {
          while (1) {
60              for (j = dx[dmax].ijmp; j >= 0 && dx[dmax].jp.x[j] >= xx; j--)

```

g\_alloc

readjmps

**Table 1 (cont')****...readjumps**

```

5         if (j < 0 && dx[dmax].offset && fj) {
            (void) lseek(fd, dx[dmax].offset, 0);
            (void) read(fd, (char *)&dx[dmax].jp, sizeof(struct jmp));
            (void) read(fd, (char *)&dx[dmax].offset, sizeof(dx[dmax].offset));
            dx[dmax].ijmp = MAXJMP-1;
        }
        else
            break;
10    }
    if (i >= JMPS) {
        fprintf(stderr, "%s: too many gaps in alignment\n", prog);
        cleanup(1);
    }
15    if (j >= 0) {
        siz = dx[dmax].jp.n[j];
        xx = dx[dmax].jp.x[j];
        dmax += siz;
        if (siz < 0) { /* gap in second seq */
20            pp[1].n[i1] = -siz;
            xx += siz;
            /* id = xx - yy + len1 - 1
            */
            pp[1].x[i1] = xx - dmax + len1 - 1;
            gapy++;
            ngapy -= siz;
            /* ignore MAXGAP when doing endgaps */
            siz = (-siz < MAXGAP || endgaps)? -siz : MAXGAP;
            i1++;
30        }
        else if (siz > 0) { /* gap in first seq */
            pp[0].n[i0] = siz;
            pp[0].x[i0] = xx;
            gapx++;
            ngapx += siz;
35            /* ignore MAXGAP when doing endgaps */
            siz = (siz < MAXGAP || endgaps)? siz : MAXGAP;
            i0++;
        }
40    }
    else
        break;
}

45    /* reverse the order of jumps
    */
    for (j = 0, i0--; j < i0; j++, i0--) {
        i = pp[0].n[j]; pp[0].n[j] = pp[0].n[i0]; pp[0].n[i0] = i;
        i = pp[0].x[j]; pp[0].x[j] = pp[0].x[i0]; pp[0].x[i0] = i;
50    }
    for (j = 0, i1--; j < i1; j++, i1--) {
        i = pp[1].n[j]; pp[1].n[j] = pp[1].n[i1]; pp[1].n[i1] = i;
        i = pp[1].x[j]; pp[1].x[j] = pp[1].x[i1]; pp[1].x[i1] = i;
55    }
    if (fd >= 0)
        (void) close(fd);
    if (fj) {
        (void) unlink(jname);
        fj = 0;
        offset = 0;
60    }
}

```

Table 1 (cont')

```

/*
 * write a filled jmp struct offset of the prev one (if any): nw()
 */
5  writejumps(ix)                                     writejumps
    int      ix;
    {
        char  *mktemp();
10         if (!fj) {
            if (mktemp(jname) < 0) {
                fprintf(stderr, "%s: can't mktemp() %s\n", prog, jname);
                cleanup(1);
            }
15         if ((fj = fopen(jname, "w")) == 0) {
            fprintf(stderr, "%s: can't write %s\n", prog, jname);
            exit(1);
        }
20         (void) fwrite((char *)&dx[ix].jp, sizeof(struct jmp), 1, fj);
        (void) fwrite((char *)&dx[ix].offset, sizeof(dx[ix].offset), 1, fj);
    }
25
30
35
40
45
50
55
60

```



**Table 2**

PRO	XXXXXXXXXXXXXXXXXX	(Length = 15 amino acids)
Comparison Protein	XXXXXXXXYYYYYY	(Length = 12 amino acids)

5    % amino acid sequence identity =

(the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) =

10    5 divided by 15 = 33.3%

**Table 3**

PRO	XXXXXXXXXX	(Length = 10 amino acids)
15    Comparison Protein	XXXXXXXXYYYYZZYZ	(Length = 15 amino acids)

% amino acid sequence identity =

(the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) =

20    5 divided by 10 = 50%

5 divided by 10 = 50%

**Table 4**

25

PRO-DNA	NNNNNNNNNNNNNN	(Length = 14 nucleotides)
Comparison DNA	NNNNNNLLLLLLLL	(Length = 16 nucleotides)

% nucleic acid sequence identity =

30

(the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the PRO-DNA nucleic acid sequence) =

6 divided by 14 = 42.9%

35

**Table 5**

PRO-DNA	NNNNNNNNNNNN	(Length = 12 nucleotides)
Comparison DNA	NNNNLLLVV	(Length = 9 nucleotides)

5     % nucleic acid sequence identity =

(the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the PRO-DNA nucleic acid sequence) =

10     4 divided by 12 = 33.3%

## II.           Compositions and Methods of the Invention

### A.           Full-Length PRO Polypeptides

15     The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO polypeptides. In particular, cDNAs encoding various PRO polypeptides have been identified and isolated, as disclosed in further detail in the Examples below. It is noted that proteins produced in separate expression rounds may be given different PRO numbers but the UNQ number is unique for any given DNA and the encoded protein, and will not be changed. However, for sake of simplicity, in the present specification the protein encoded by the full length native nucleic acid molecules disclosed herein  
20     as well as all further native homologues and variants included in the foregoing definition of PRO, will be referred to as "PRO/number", regardless of their origin or mode of preparation.

As disclosed in the Examples below, various cDNA clones have been deposited with the ATCC. The actual nucleotide sequences of those clones can readily be determined by the skilled artisan by sequencing of the deposited clone using routine methods in the art. The predicted amino acid sequence can be determined from the  
25     nucleotide sequence using routine skill. For the PRO polypeptides and encoding nucleic acids described herein, Applicants have identified what is believed to be the reading frame best identifiable with the sequence information available at the time.

### B.           PRO Polypeptide Variants

30     In addition to the full-length native sequence PRO polypeptides described herein, it is contemplated that PRO variants can be prepared. PRO variants can be prepared by introducing appropriate nucleotide changes into the PRO DNA, and/or by synthesis of the desired PRO polypeptide. Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of the PRO, such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.

35     Variations in the native full-length sequence PRO or in various domains of the PRO described herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative

mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a substitution, deletion or insertion of one or more codons encoding the PRO that results in a change in the amino acid sequence of the PRO as compared with the native sequence PRO. Optionally the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the PRO. Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may be found by  
5 comparing the sequence of the PRO with that of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, i.e., conservative amino acid replacements. Insertions or deletions may optionally be in the range of about 1 to 5 amino acids. The variation allowed may be determined by  
10 systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.

PRO polypeptide fragments are provided herein. Such fragments may be truncated at the N-terminus or C-terminus, or may lack internal residues, for example, when compared with a full length native protein. Certain fragments lack amino acid residues that are not essential for a desired biological activity of the PRO  
15 polypeptide.

PRO fragments may be prepared by any of a number of conventional techniques. Desired peptide fragments may be chemically synthesized. An alternative approach involves generating PRO fragments by enzymatic digestion, e.g., by treating the protein with an enzyme known to cleave proteins at sites defined by particular amino acid residues, or by digesting the DNA with suitable restriction enzymes and isolating the desired  
20 fragment. Yet another suitable technique involves isolating and amplifying a DNA fragment encoding a desired polypeptide fragment, by polymerase chain reaction (PCR). Oligonucleotides that define the desired termini of the DNA fragment are employed at the 5' and 3' primers in the PCR. Preferably, PRO polypeptide fragments share at least one biological and/or immunological activity with the native PRO polypeptide disclosed herein.

In particular embodiments, conservative substitutions of interest are shown in Table 6 under the heading  
25 of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated exemplary substitutions in Table 6, or as further described below in reference to amino acid classes, are introduced and the products screened.

Table 6

	<u>Original Residue</u>	<u>Exemplary Substitutions</u>	<u>Preferred Substitutions</u>
5	Ala (A)	val; leu; ile	val
	Arg (R)	lys; gln; asn	lys
	Asn (N)	gln; his; lys; arg	gln
	Asp (D)	glu	glu
	Cys (C)	ser	ser
10	Gln (Q)	asn	asn
	Glu (E)	asp	asp
	Gly (G)	pro; ala	ala
	His (H)	asn; gln; lys; arg	arg
	Ile (I)	leu; val; met; ala; phe;	
15		norleucine	leu
	Leu (L)	norleucine; ile; val;	
		met; ala; phe	ile
	Lys (K)	arg; gln; asn	arg
	Met (M)	leu; phe; ile	leu
20	Phe (F)	leu; val; ile; ala; tyr	leu
	Pro (P)	ala	ala
	Ser (S)	thr	thr
	Thr (T)	ser	ser
	Trp (W)	tyr; phe	tyr
25	Tyr (Y)	trp; phe; thr; ser	phe
	Val (V)	ile; leu; met; phe;	
		ala; norleucine	leu

30 Substantial modifications in function or immunological identity of the PRO polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:

- 35 (1) hydrophobic: norleucine, met, ala, val, leu, ile;  
 (2) neutral hydrophilic: cys, ser, thr;  
 (3) acidic: asp, glu;  
 (4) basic: asn, gln, his, lys, arg;  
 (5) residues that influence chain orientation: gly, pro; and  
 40 (6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites.

45 The variations can be made using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis [Carter et al., Nucl. Acids Res., 13:4331 (1986); Zoller et al., Nucl. Acids Res., 10:6487 (1987)], cassette mutagenesis [Wells et al.,

Gene, 34:315 (1985)], restriction selection mutagenesis [Wells et al., Philos. Trans. R. Soc. London SerA, 317:415 (1986)] or other known techniques can be performed on the cloned DNA to produce the PRO variant DNA.

5 Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant [Cunningham and Wells, Science, 244: 1081-1085 (1989)]. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions [Creighton, The Proteins, (W.H. Freeman & Co., N.Y.); Chothia, J. Mol. Biol., 150:1  
10 (1976)]. If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.

### C. Modifications of PRO

Covalent modifications of PRO are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a PRO polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues of the PRO. Derivatization with bifunctional agents is useful, for instance, for crosslinking PRO to a water-insoluble support matrix or surface for use in the method for purifying anti-PRO antibodies, and vice-versa. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimide.

Other modifications include deamidation of glutaminyl and asparaginy residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the  $\alpha$ -amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the PRO polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence PRO (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that are not present in the native sequence PRO. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.

35 Addition of glycosylation sites to the PRO polypeptide may be accomplished by altering the amino acid sequence. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence PRO (for O-linked glycosylation sites). The PRO amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding

the PRO polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

Another means of increasing the number of carbohydrate moieties on the PRO polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the PRO polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of PRO comprises linking the PRO polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

The PRO of the present invention may also be modified in a way to form a chimeric molecule comprising PRO fused to another, heterologous polypeptide or amino acid sequence.

In one embodiment, such a chimeric molecule comprises a fusion of the PRO with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino- or carboxyl- terminus of the PRO. The presence of such epitope-tagged forms of the PRO can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the PRO to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and Cellular Biology, 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp et al., BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)]; an  $\alpha$ -tubulin epitope peptide [Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)].

In an alternative embodiment, the chimeric molecule may comprise a fusion of the PRO with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule (also referred to as an "immunoadhesin"), such a fusion could be to the Fc region of an IgG molecule. The Ig fusions preferably include the substitution of a soluble (transmembrane domain deleted or inactivated) form of a PRO polypeptide in place of at least one variable region within an Ig molecule. In a particularly preferred embodiment, the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CH1, CH2 and CH3 regions of an IgG1 molecule. For the production of immunoglobulin fusions see also US Patent No. 5,428,130 issued June 27,

1995.

#### D. Preparation of PRO

The description below relates primarily to production of PRO by culturing cells transformed or transfected with a vector containing PRO nucleic acid. It is, of course, contemplated that alternative methods, which are well known in the art, may be employed to prepare PRO. For instance, the PRO sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques [see, e.g., Stewart et al., Solid-Phase Peptide Synthesis, W.H. Freeman Co., San Francisco, CA (1969); Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963)]. *In vitro* protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions. Various portions of the PRO may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length PRO.

##### 1. Isolation of DNA Encoding PRO

DNA encoding PRO may be obtained from a cDNA library prepared from tissue believed to possess the PRO mRNA and to express it at a detectable level. Accordingly, human PRO DNA can be conveniently obtained from a cDNA library prepared from human tissue, such as described in the Examples. The PRO-encoding gene may also be obtained from a genomic library or by known synthetic procedures (e.g., automated nucleic acid synthesis).

Libraries can be screened with probes (such as antibodies to the PRO or oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989). An alternative means to isolate the gene encoding PRO is to use PCR methodology [Sambrook et al., supra; Dieffenbach et al., PCR Primer: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1995)].

The Examples below describe techniques for screening a cDNA library. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of labeling are well known in the art, and include the use of radiolabels like <sup>32</sup>P-labeled ATP, biotinylation or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al., supra.

Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined using methods known in the art and as described herein.

Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook et al., supra, to detect precursors and

processing intermediates of mRNA that may not have been reverse-transcribed into cDNA.

## 2. Selection and Transformation of Host Cells

Host cells are transfected or transformed with expression or cloning vectors described herein for PRO production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991) and Sambrook et al., supra.

Methods of eukaryotic cell transfection and prokaryotic cell transformation are known to the ordinarily skilled artisan, for example,  $\text{CaCl}_2$ ,  $\text{CaPO}_4$ , liposome-mediated and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook et al., supra, or electroporation is generally used for prokaryotes. Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw et al., Gene, 23:315 (1983) and WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology, 52:456-457 (1978) can be employed. General aspects of mammalian cell host system transfections have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen et al., J. Bact., 130:946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76:3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g., polybrene, polyornithine, may also be used. For various techniques for transforming mammalian cells, see Keown et al., Methods in Enzymology, 185:527-537 (1990) and Mansour et al., Nature, 336:348-352 (1988).

Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells. Suitable prokaryotes include but are not limited to eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as *E. coli*. Various *E. coli* strains are publicly available, such as *E. coli* K12 strain MM294 (ATCC 31,446); *E. coli* X1776 (ATCC 31,537); *E. coli* strain W3110 (ATCC 27,325) and K5 772 (ATCC 53,635). Other suitable prokaryotic host cells include Enterobacteriaceae such as *Escherichia*, e.g., *E. coli*, *Enterobacter*, *Erwinia*, *Klebsiella*, *Proteus*, *Salmonella*, e.g., *Salmonella typhimurium*, *Serratia*, e.g., *Serratia marcescans*, and *Shigella*, as well as *Bacilli* such as *B. subtilis* and *B. licheniformis* (e.g., *B. licheniformis* 41P disclosed in DD 266,710 published 12 April 1989), *Pseudomonas* such as *P. aeruginosa*, and *Streptomyces*. These examples are illustrative rather than limiting. Strain W3110 is one particularly preferred host or parent host because it is a common host strain for recombinant DNA product fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For example, strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including *E. coli* W3110 strain 1A2, which has the complete genotype *tonA*; *E. coli* W3110 strain 9E4, which has the complete genotype *tonA ptr3*; *E. coli* W3110 strain 27C7 (ATCC



55,244), which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT kan'*; *E. coli* W3110 strain 37D6, which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT rbs7 ilvG kan'*; *E. coli* W3110 strain 40B4, which is strain 37D6 with a non-kanamycin resistant *degP* deletion mutation; and an *E. coli* strain having mutant periplasmic protease disclosed in U.S. Patent No. 4,946,783 issued 7 August 1990. Alternatively, *in vitro* methods of cloning, e.g., PCR or other nucleic acid polymerase reactions, are suitable.

5 In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for PRO-encoding vectors. *Saccharomyces cerevisiae* is a commonly used lower eukaryotic host microorganism. Others include *Schizosaccharomyces pombe* (Beach and Nurse, Nature, 290: 140 [1981]; EP 139,383 published 2 May 1985); *Kluyveromyces* hosts (U.S. Patent No. 4,943,529; Fleer et al., Bio/Technology, 9:968-975 (1991)) such as, e.g., *K. lactis* (MW98-8C, CBS683, CBS4574; Louvencourt et al., J. Bacteriol., 154(2):737-742 [1983]), *K. fragilis* (ATCC 12,424), *K. bulgaricus* (ATCC 16,045), *K. wickerhamii* (ATCC 24,178), *K. waltii* (ATCC 56,500), *K. drosophilum* (ATCC 36,906; Van den Berg et al., Bio/Technology, 8:135 (1990)), *K. thermotolerans*, and *K. marxianus*; *yarrowia* (EP 402,226); *Pichia pastoris* (EP 183,070; Sreekrishna et al., J. Basic Microbiol., 28:265-278 [1988]); *Candida*; *Trichoderma reesia* (EP 244,234); *Neurospora crassa* (Case et al., Proc. Natl. Acad. Sci. USA, 76:5259-5263 [1979]); *Schwanniomyces* such as *Schwanniomyces occidentalis* (EP 394,538 published 31 October 1990); and filamentous fungi such as, e.g., *Neurospora*, *Penicillium*, *Tolypocladium* (WO 91/00357 published 10 January 1991), and *Aspergillus* hosts such as *A. nidulans* (Ballance et al., Biochem. Biophys. Res. Commun., 112:284-289 [1983]; Tilburn et al., Gene, 26:205-221 [1983]; Yelton et al., Proc. Natl. Acad. Sci. USA, 81: 1470-1474 [1984]) and *A. niger* (Kelly and Hynes, EMBO J., 4:475-479 [1985]). Methylophilic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of *Hansenula*, *Candida*, *Kloeckera*, *Pichia*, *Saccharomyces*, *Torulopsis*, and *Rhodotorula*. A list of specific species that are exemplary of this class of yeasts may be found in C. Anthony, The Biochemistry of Methylophilic Yeasts, 269 (1982).

Suitable host cells for the expression of glycosylated PRO are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as *Drosophila* S2 and *Spodoptera* Sf9, as well as plant cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen. Virol., 36:59 (1977)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23:243-251 (1980)); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT 060562, ATCC CCL51). The selection of the appropriate host cell is deemed to be within the skill in the art.

### 3. Selection and Use of a Replicable Vector

The nucleic acid (e.g., cDNA or genomic DNA) encoding PRO may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an

appropriate restriction endonuclease site(s) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.

5       The PRO may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the PRO-encoding DNA that is inserted into the vector. The signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces*  $\alpha$ -factor leaders, the latter described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the *C. albicans* glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990. In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.

15       Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 $\mu$  plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.

20       Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*.

25       An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the PRO-encoding nucleic acid, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA, 77:4216 (1980). A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7 [Stinchcomb et al., Nature, 282:39 (1979); Kingsman et al., Gene, 7:141 (1979); Tschemper et al., Gene, 10:157 (1980)]. The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 [Jones, Genetics, 85:12 (1977)].

30       Expression and cloning vectors usually contain a promoter operably linked to the PRO-encoding nucleic acid sequence to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the  $\beta$ -lactamase and lactose promoter systems [Chang et al., Nature, 275:615 (1978); Goeddel et al., Nature, 281:544 (1979)], alkaline phosphatase, a tryptophan (*trp*) promoter system [Goeddel, Nucleic Acids Res., 8:4057 (1980); EP 36,776], and hybrid

promoters such as the tac promoter [deBoer et al., Proc. Natl. Acad. Sci. USA, 80:21-25 (1983)]. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding PRO.

5 Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman et al., J. Biol. Chem., 255:2073 (1980)] or other glycolytic enzymes [Hess et al., J. Adv. Enzyme Reg., 7:149 (1968); Holland, Biochemistry, 17:4900 (1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

10 Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.

15 PRO transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.

20 Transcription of a DNA encoding the PRO by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin,  $\alpha$ -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-25 270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the PRO coding sequence, but is preferably located at a site 5' from the promoter.

30 Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding PRO.

35 Still other methods, vectors, and host cells suitable for adaptation to the synthesis of PRO in recombinant vertebrate cell culture are described in Gething et al., Nature, 293:620-625 (1981); Mantei et al., Nature, 281:40-46 (1979); EP 117,060; and EP 117,058.

#### 4. Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)], dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence PRO polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to PRO DNA and encoding a specific antibody epitope.

#### 5. Purification of Polypeptide

Forms of PRO may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g. Triton-X 100) or by enzymatic cleavage. Cells employed in expression of PRO can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.

It may be desired to purify PRO from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the PRO. Various methods of protein purification may be employed and such methods are known in the art and described for example in Deutscher, Methods in Enzymology, 182 (1990); Scopes, Protein Purification: Principles and Practice, Springer-Verlag, New York (1982). The purification step(s) selected will depend, for example, on the nature of the production process used and the particular PRO produced.

#### B. Uses for PRO

Nucleotide sequences (or their complement) encoding PRO have various applications in the art of molecular biology, including uses as hybridization probes, in chromosome and gene mapping and in the generation of anti-sense RNA and DNA. PRO nucleic acid will also be useful for the preparation of PRO polypeptides by the recombinant techniques described herein.

The full-length native sequence PRO gene, or portions thereof, may be used as hybridization probes for a cDNA library to isolate the full-length PRO cDNA or to isolate still other cDNAs (for instance, those encoding

naturally-occurring variants of PRO or PRO from other species) which have a desired sequence identity to the native PRO sequence disclosed herein. Optionally, the length of the probes will be about 20 to about 50 bases. The hybridization probes may be derived from at least partially novel regions of the full length native nucleotide sequence wherein those regions may be determined without undue experimentation or from genomic sequences including promoters, enhancer elements and introns of native sequence PRO. By way of example, a screening method will comprise isolating the coding region of the PRO gene using the known DNA sequence to synthesize a selected probe of about 40 bases. Hybridization probes may be labeled by a variety of labels, including radionucleotides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems. Labeled probes having a sequence complementary to that of the PRO gene of the present invention can be used to screen libraries of human cDNA, genomic DNA or mRNA to determine which members of such libraries the probe hybridizes to. Hybridization techniques are described in further detail in the Examples below.

Any EST sequences disclosed in the present application may similarly be employed as probes, using the methods disclosed herein.

Other useful fragments of the PRO nucleic acids include antisense or sense oligonucleotides comprising a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target PRO mRNA (sense) or PRO DNA (antisense) sequences. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment of the coding region of PRO DNA. Such a fragment generally comprises at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, for example, Stein and Cohen (Cancer Res. 48:2659, 1988) and van der Krol et al. (BioTechniques 6:958, 1988).

Binding of antisense or sense oligonucleotides to target nucleic acid sequences results in the formation of duplexes that block transcription or translation of the target sequence by one of several means, including enhanced degradation of the duplexes, premature termination of transcription or translation, or by other means. The antisense oligonucleotides thus may be used to block expression of PRO proteins. Antisense or sense oligonucleotides further comprise oligonucleotides having modified sugar-phosphodiester backbones (or other sugar linkages, such as those described in WO 91/06629) and wherein such sugar linkages are resistant to endogenous nucleases. Such oligonucleotides with resistant sugar linkages are stable *in vivo* (i.e., capable of resisting enzymatic degradation) but retain sequence specificity to be able to bind to target nucleotide sequences.

Other examples of sense or antisense oligonucleotides include those oligonucleotides which are covalently linked to organic moieties, such as those described in WO 90/10048, and other moieties that increases affinity of the oligonucleotide for a target nucleic acid sequence, such as poly-(L-lysine). Further still, intercalating agents, such as ellipticine, and alkylating agents or metal complexes may be attached to sense or antisense oligonucleotides to modify binding specificities of the antisense or sense oligonucleotide for the target nucleotide sequence.

Antisense or sense oligonucleotides may be introduced into a cell containing the target nucleic acid sequence by any gene transfer method, including, for example,  $\text{CaPO}_4$ -mediated DNA transfection, electroporation, or by using gene transfer vectors such as Epstein-Barr virus. In a preferred procedure, an

antisense or sense oligonucleotide is inserted into a suitable retroviral vector. A cell containing the target nucleic acid sequence is contacted with the recombinant retroviral vector, either *in vivo* or *ex vivo*. Suitable retroviral vectors include, but are not limited to, those derived from the murine retrovirus M-MuLV, N2 (a retrovirus derived from M-MuLV), or the double copy vectors designated DCT5A, DCT5B and DCT5C (see WO 90/13641).

5        Sense or antisense oligonucleotides also may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or  
10        receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell.

         Alternatively, a sense or an antisense oligonucleotide may be introduced into a cell containing the target nucleic acid sequence by formation of an oligonucleotide-lipid complex, as described in WO 90/10448. The sense or antisense oligonucleotide-lipid complex is preferably dissociated within the cell by an endogenous lipase.

15        Antisense or sense RNA or DNA molecules are generally at least about 5 bases in length, about 10 bases in length, about 15 bases in length, about 20 bases in length, about 25 bases in length, about 30 bases in length, about 35 bases in length, about 40 bases in length, about 45 bases in length, about 50 bases in length, about 55 bases in length, about 60 bases in length, about 65 bases in length, about 70 bases in length, about 75 bases in length, about 80 bases in length, about 85 bases in length, about 90 bases in length, about 95 bases in length, about 100 bases in length, or more.

20        The probes may also be employed in PCR techniques to generate a pool of sequences for identification of closely related PRO coding sequences.

         Nucleotide sequences encoding a PRO can also be used to construct hybridization probes for mapping the gene which encodes that PRO and for the genetic analysis of individuals with genetic disorders. The nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosome  
25        using known techniques, such as *in situ* hybridization, linkage analysis against known chromosomal markers, and hybridization screening with libraries.

         When the coding sequences for PRO encode a protein which binds to another protein (example, where the PRO is a receptor), the PRO can be used in assays to identify the other proteins or molecules involved in the binding interaction. By such methods, inhibitors of the receptor/ligand binding interaction can be identified.  
30        Proteins involved in such binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction. Also, the receptor PRO can be used to isolate correlative ligand(s). Screening assays can be designed to find lead compounds that mimic the biological activity of a native PRO or a receptor for PRO. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates. Small molecules  
35        contemplated include synthetic organic or inorganic compounds. The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays and cell based assays, which are well characterized in the art.

Nucleic acids which encode PRO or its modified forms can also be used to generate either transgenic animals or "knock out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. A transgenic animal (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A transgene is a DNA which is integrated into the genome of a cell from which a transgenic animal develops. In one embodiment, cDNA encoding PRO can be used to clone genomic DNA encoding PRO in accordance with established techniques and the genomic sequences used to generate transgenic animals that contain cells which express DNA encoding PRO. Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009. Typically, particular cells would be targeted for PRO transgene incorporation with tissue-specific enhancers. Transgenic animals that include a copy of a transgene encoding PRO introduced into the germ line of the animal at an embryonic stage can be used to examine the effect of increased expression of DNA encoding PRO. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this facet of the invention, an animal is treated with the reagent and a reduced incidence of the pathological condition, compared to untreated animals bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition.

Alternatively, non-human homologues of PRO can be used to construct a PRO "knock out" animal which has a defective or altered gene encoding PRO as a result of homologous recombination between the endogenous gene encoding PRO and altered genomic DNA encoding PRO introduced into an embryonic stem cell of the animal. For example, cDNA encoding PRO can be used to clone genomic DNA encoding PRO in accordance with established techniques. A portion of the genomic DNA encoding PRO can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector [see e.g., Thomas and Capecchi, *Cell*, 51:503 (1987) for a description of homologous recombination vectors]. The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected [see e.g., Li et al., *Cell*, 69:915 (1992)]. The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras [see e.g., Bradley, in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152]. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knockout animals can be characterized for instance, for their ability to defend against certain pathological conditions and for their development of pathological conditions due to absence of the PRO polypeptide.

Nucleic acid encoding the PRO polypeptides may also be used in gene therapy. In gene therapy applications, genes are introduced into cells in order to achieve *in vivo* synthesis of a therapeutically effective genetic product, for example for replacement of a defective gene. "Gene therapy" includes both conventional

gene therapy where a lasting effect is achieved by a single treatment, and the administration of gene therapeutic agents, which involves the one time or repeated administration of a therapeutically effective DNA or mRNA. Antisense RNAs and DNAs can be used as therapeutic agents for blocking the expression of certain genes *in vivo*. It has already been shown that short antisense oligonucleotides can be imported into cells where they act as inhibitors, despite their low intracellular concentrations caused by their restricted uptake by the cell membrane.

5 (Zamecnik *et al.*, Proc. Natl. Acad. Sci. USA 83:4143-4146 [1986]). The oligonucleotides can be modified to enhance their uptake, e.g. by substituting their negatively charged phosphodiester groups by uncharged groups.

There are a variety of techniques available for introducing nucleic acids into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells *in vitro*, or *in vivo* in the cells of the intended host. Techniques suitable for the transfer of nucleic acid into mammalian cells *in vitro* include the use of liposomes, electroporation, microinjection, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. The currently preferred *in vivo* gene transfer techniques include transfection with viral (typically retroviral) vectors and viral coat protein-liposome mediated transfection (Dzau *et al.*, Trends in Biotechnology 11, 205-210 [1993]). In some situations it is desirable to provide the nucleic acid source with an agent that targets the target cells, such as an antibody specific for a cell surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc. Where liposomes are employed, proteins which bind to a cell surface membrane protein associated with endocytosis may be used for targeting and/or to facilitate uptake, e.g. capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half-life. The technique of receptor-mediated endocytosis is described, for example, by Wu *et al.*, J. Biol. Chem. 262, 4429-4432 (1987); and Wagner *et al.*, Proc. Natl. Acad. Sci. USA 87, 3410-3414 (1990). For review of gene marking and gene therapy protocols see Anderson *et al.*, Science 256, 808-813 (1992).

10  
15  
20

The PRO polypeptides described herein may also be employed as molecular weight markers for protein electrophoresis purposes and the isolated nucleic acid sequences may be used for recombinantly expressing those markers.

25 The nucleic acid molecules encoding the PRO polypeptides or fragments thereof described herein are useful for chromosome identification. In this regard, there exists an ongoing need to identify new chromosome markers, since relatively few chromosome marking reagents, based upon actual sequence data are presently available. Each PRO nucleic acid molecule of the present invention can be used as a chromosome marker.

The PRO polypeptides and nucleic acid molecules of the present invention may also be used diagnostically for tissue typing, wherein the PRO polypeptides of the present invention may be differentially expressed in one tissue as compared to another, preferably in a diseased tissue as compared to a normal tissue of the same tissue type. PRO nucleic acid molecules will find use for generating probes for PCR, Northern analysis, Southern analysis and Western analysis.

30

The PRO polypeptides described herein may also be employed as therapeutic agents. The PRO polypeptides of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the PRO product hereof is combined in admixture with a pharmaceutically acceptable carrier vehicle. Therapeutic formulations are prepared for storage by mixing the active ingredient

35



having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN<sup>TM</sup>, PLURONICS<sup>TM</sup> or PEG.

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution.

Therapeutic compositions herein generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

The route of administration is in accord with known methods, e.g. injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial or intralesional routes, topical administration, or by sustained release systems.

Dosages and desired drug concentrations of pharmaceutical compositions of the present invention may vary depending on the particular use envisioned. The determination of the appropriate dosage or route of administration is well within the skill of an ordinary physician. Animal experiments provide reliable guidance for the determination of effective doses for human therapy. Interspecies scaling of effective doses can be performed following the principles laid down by Mordenti, J. and Chappell, W. "The use of interspecies scaling in toxicokinetics" In *Toxicokinetics and New Drug Development*, Yacobi et al., Eds., Pergamon Press, New York 1989, pp. 42-96.

When *in vivo* administration of a PRO polypeptide or agonist or antagonist thereof is employed, normal dosage amounts may vary from about 10 ng/kg to up to 100 mg/kg of mammal body weight or more per day, preferably about 1 µg/kg/day to 10 mg/kg/day, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature; see, for example, U.S. Pat. Nos. 4,657,760; 5,206,344; or 5,225,212. It is anticipated that different formulations will be effective for different treatment compounds and different disorders, that administration targeting one organ or tissue, for example, may necessitate delivery in a manner different from that to another organ or tissue.

Where sustained-release administration of a PRO polypeptide is desired in a formulation with release characteristics suitable for the treatment of any disease or disorder requiring administration of the PRO polypeptide, microencapsulation of the PRO polypeptide is contemplated. Microencapsulation of recombinant proteins for sustained release has been successfully performed with human growth hormone (rhGH), interferon- (rhIFN-), interleukin-2, and MN rgp120. Johnson et al., *Nat. Med.*, 2:795-799 (1996); Yasuda, *Biomed. Ther.*, 27:1221-1223 (1993); Hora et al., *Bio/Technology*, 8:755-758 (1990); Cleland, "Design and Production of Single Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems," in *Vaccine Design: The Subunit*

and Adjuvant Approach, Powell and Newman, eds, (Plenum Press: New York, 1995), pp. 439-462; WO 97/03692, WO 96/40072, WO 96/07399; and U.S. Pat. No. 5,654,010.

5 The sustained-release formulations of these proteins were developed using poly-lactic-coglycolic acid (PLGA) polymer due to its biocompatibility and wide range of biodegradable properties. The degradation products of PLGA, lactic and glycolic acids, can be cleared quickly within the human body. Moreover, the degradability of this polymer can be adjusted from months to years depending on its molecular weight and composition. Lewis, "Controlled release of bioactive agents from lactide/glycolide polymer," in: M. Chasin and R. Langer (Eds.), Biodegradable Polymers as Drug Delivery Systems (Marcel Dekker: New York, 1990), pp. 1-41.

10 This invention encompasses methods of screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). Screening assays for antagonist drug candidates are designed to identify compounds that bind or complex with the PRO polypeptides encoded by the genes identified herein, or otherwise interfere with the interaction of the encoded polypeptides with other cellular proteins. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates.

15 The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays, and cell-based assays, which are well characterized in the art.

All assays for antagonists are common in that they call for contacting the drug candidate with a PRO polypeptide encoded by a nucleic acid identified herein under conditions and for a time sufficient to allow these two components to interact.

20 In binding assays, the interaction is binding and the complex formed can be isolated or detected in the reaction mixture. In a particular embodiment, the PRO polypeptide encoded by the gene identified herein or the drug candidate is immobilized on a solid phase, e.g., on a microtiter plate, by covalent or non-covalent attachments. Non-covalent attachment generally is accomplished by coating the solid surface with a solution of the PRO polypeptide and drying. Alternatively, an immobilized antibody, e.g., a monoclonal antibody, specific for the PRO polypeptide to be immobilized can be used to anchor it to a solid surface. The assay is performed by adding the non-immobilized component, which may be labeled by a detectable label, to the immobilized component, e.g., the coated surface containing the anchored component. When the reaction is complete, the non-reacted components are removed, e.g., by washing, and complexes anchored on the solid surface are detected. When the originally non-immobilized component carries a detectable label, the detection of label immobilized on the surface indicates that complexing occurred. Where the originally non-immobilized component does not carry a label, complexing can be detected, for example, by using a labeled antibody specifically binding the immobilized complex.

30 If the candidate compound interacts with but does not bind to a particular PRO polypeptide encoded by a gene identified herein, its interaction with that polypeptide can be assayed by methods well known for detecting protein-protein interactions. Such assays include traditional approaches, such as, e.g., cross-linking, co-immunoprecipitation, and co-purification through gradients or chromatographic columns. In addition, protein-protein interactions can be monitored by using a yeast-based genetic system described by Fields and co-workers (Fields and Song, Nature (London), 340:245-246 (1989); Chien et al., Proc. Natl. Acad. Sci. USA, 88:9578-9582

(1991)) as disclosed by Chevray and Nathans, Proc. Natl. Acad. Sci. USA, 89: 5789-5793 (1991). Many transcriptional activators, such as yeast GAL4, consist of two physically discrete modular domains, one acting as the DNA-binding domain, the other one functioning as the transcription-activation domain. The yeast expression system described in the foregoing publications (generally referred to as the "two-hybrid system") takes advantage of this property, and employs two hybrid proteins, one in which the target protein is fused to the DNA-binding domain of GAL4, and another, in which candidate activating proteins are fused to the activation domain. The expression of a GAL1-*lacZ* reporter gene under control of a GAL4-activated promoter depends on reconstitution of GAL4 activity via protein-protein interaction. Colonies containing interacting polypeptides are detected with a chromogenic substrate for  $\beta$ -galactosidase. A complete kit (MATCHMAKER™) for identifying protein-protein interactions between two specific proteins using the two-hybrid technique is commercially available from Clontech. This system can also be extended to map protein domains involved in specific protein interactions as well as to pinpoint amino acid residues that are crucial for these interactions.

Compounds that interfere with the interaction of a gene encoding a PRO polypeptide identified herein and other intra- or extracellular components can be tested as follows: usually a reaction mixture is prepared containing the product of the gene and the intra- or extracellular component under conditions and for a time allowing for the interaction and binding of the two products. To test the ability of a candidate compound to inhibit binding, the reaction is run in the absence and in the presence of the test compound. In addition, a placebo may be added to a third reaction mixture, to serve as positive control. The binding (complex formation) between the test compound and the intra- or extracellular component present in the mixture is monitored as described hereinabove. The formation of a complex in the control reaction(s) but not in the reaction mixture containing the test compound indicates that the test compound interferes with the interaction of the test compound and its reaction partner.

To assay for antagonists, the PRO polypeptide may be added to a cell along with the compound to be screened for a particular activity and the ability of the compound to inhibit the activity of interest in the presence of the PRO polypeptide indicates that the compound is an antagonist to the PRO polypeptide. Alternatively, antagonists may be detected by combining the PRO polypeptide and a potential antagonist with membrane-bound PRO polypeptide receptors or recombinant receptors under appropriate conditions for a competitive inhibition assay. The PRO polypeptide can be labeled, such as by radioactivity, such that the number of PRO polypeptide molecules bound to the receptor can be used to determine the effectiveness of the potential antagonist. The gene encoding the receptor can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting. Coligan et al., Current Protocols in Immun., 1(2): Chapter 5 (1991). Preferably, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the PRO polypeptide and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the PRO polypeptide. Transfected cells that are grown on glass slides are exposed to labeled PRO polypeptide. The PRO polypeptide can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase. Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an interactive sub-pooling and re-screening process, eventually yielding a single,

clone that encodes the putative receptor.

As an alternative approach for receptor identification, labeled PRO polypeptide can be photoaffinity-linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE and exposed to X-ray film. The labeled complex containing the receptor can be excised, resolved into peptide fragments, and subjected to protein micro-sequencing. The amino acid sequence obtained from micro-sequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the gene encoding the putative receptor.

In another assay for antagonists, mammalian cells or a membrane preparation expressing the receptor would be incubated with labeled PRO polypeptide in the presence of the candidate compound. The ability of the compound to enhance or block this interaction could then be measured.

More specific examples of potential antagonists include an oligonucleotide that binds to the fusions of immunoglobulin with PRO polypeptide, and, in particular, antibodies including, without limitation, poly- and monoclonal antibodies and antibody fragments, single-chain antibodies, anti-idiotypic antibodies, and chimeric or humanized versions of such antibodies or fragments, as well as human antibodies and antibody fragments. Alternatively, a potential antagonist may be a closely related protein, for example, a mutated form of the PRO polypeptide that recognizes the receptor but imparts no effect, thereby competitively inhibiting the action of the PRO polypeptide.

Another potential PRO polypeptide antagonist is an antisense RNA or DNA construct prepared using antisense technology, where, e.g., an antisense RNA or DNA molecule acts to block directly the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes the mature PRO polypeptides herein, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res., 6:3073 (1979); Cooney et al., Science, 241: 456 (1988); Dervan et al., Science, 251:1360 (1991)), thereby preventing transcription and the production of the PRO polypeptide. The antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into the PRO polypeptide (antisense - Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression (CRC Press: Boca Raton, FL, 1988). The oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed *in vivo* to inhibit production of the PRO polypeptide. When antisense DNA is used, oligodeoxyribonucleotides derived from the translation-initiation site, e.g., between about -10 and +10 positions of the target gene nucleotide sequence, are preferred.

Potential antagonists include small molecules that bind to the active site, the receptor binding site, or growth factor or other relevant binding site of the PRO polypeptide, thereby blocking the normal biological activity of the PRO polypeptide. Examples of small molecules include, but are not limited to, small peptides or peptide-like molecules, preferably soluble peptides, and synthetic non-peptidyl organic or inorganic compounds.

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA.

Ribozymes act by sequence-specific hybridization to the complementary target RNA, followed by endonucleolytic cleavage. Specific ribozyme cleavage sites within a potential RNA target can be identified by known techniques. For further details see, e.g., Rossi, Current Biology, 4:469-471 (1994), and PCT publication No. WO 97/33551 (published September 18, 1997).

5 Nucleic acid molecules in triple-helix formation used to inhibit transcription should be single-stranded and composed of deoxynucleotides. The base composition of these oligonucleotides is designed such that it promotes triple-helix formation via Hoogsteen base-pairing rules, which generally require sizeable stretches of purines or pyrimidines on one strand of a duplex. For further details see, e.g., PCT publication No. WO 97/33551, *supra*.

10 These small molecules can be identified by any one or more of the screening assays discussed hereinabove and/or by any other screening techniques well known for those skilled in the art.

Diagnostic and therapeutic uses of the herein disclosed molecules may also be based upon the positive functional assay hits disclosed and described below.

#### F. Anti-PRO Antibodies

15 The present invention further provides anti-PRO antibodies. Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies.

##### 1. Polyclonal Antibodies

20 The anti-PRO antibodies may comprise polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include the PRO polypeptide or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).  
25 The immunization protocol may be selected by one skilled in the art without undue experimentation.

##### 30 2. Monoclonal Antibodies

The anti-PRO antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically  
35 bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*.

The immunizing agent will typically include the PRO polypeptide or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or

lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63].

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against PRO. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980).

After the desired hybridoma cells are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods [Goding, *supra*]. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown *in vivo* as ascites in a mammal.

The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding

sequence for human heavy and light chain constant domains in place of the homologous murine sequences [U.S. Patent No. 4,816,567; Morrison et al., *supra*] or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

5       The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.

10       *In vitro* methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art.

### 3.       Human and Humanized Antibodies

15       The anti-PRO antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a  
20       complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially  
25       all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-329 (1988); and Presta, *Curr. Op. Struct. Biol.*,  
30       2:593-596 (1992)].

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers  
35       [Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeyen et al., *Science*, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No.

4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, *J. Mol. Biol.*, 227:381 (1991); Marks et al., *J. Mol. Biol.*, 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, p. 77 (1985) and Boerner et al., *J. Immunol.*, 147(1):86-95 (1991)]. Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks *et al.*, *Bio/Technology* 10, 779-783 (1992); Lonberg *et al.*, *Nature* 368 856-859 (1994); Morrison, *Nature* 368, 812-13 (1994); Fishwild *et al.*, *Nature Biotechnology* 14, 845-51 (1996); Neuberger, *Nature Biotechnology* 14, 826 (1996); Lonberg and Huszar, *Intern. Rev. Immunol.* 13 65-93 (1995).

The antibodies may also be affinity matured using known selection and/or mutagenesis methods as described above. Preferred affinity matured antibodies have an affinity which is five times, more preferably 10 times, even more preferably 20 or 30 times greater than the starting antibody (generally murine, humanized or human) from which the matured antibody is prepared.

#### 4. Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for the PRO, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities [Milstein and Cuello, *Nature*, 305:537-539 (1983)]. Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., *EMBO J.*, 10:3655-3659 (1991).

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least



one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986).

5 According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

10 Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab')<sub>2</sub> bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')<sub>2</sub> fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

20 Fab' fragments may be directly recovered from *E. coli* and chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab')<sub>2</sub> molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected to directed chemical coupling *in vitro* to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

25 Various technique for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V<sub>H</sub>) connected to a light-chain variable domain (V<sub>L</sub>) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V<sub>H</sub> and V<sub>L</sub> domains of one fragment are forced to pair with the complementary

$V_L$  and  $V_H$  domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber *et al.*, J. Immunol., 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt *et al.*, J. Immunol., 147:60 (1991).

5 Exemplary bispecific antibodies may bind to two different epitopes on a given PRO polypeptide herein. Alternatively, an anti-PRO polypeptide arm may be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (Fc $\gamma$ R), such as Fc $\gamma$ RI (CD64), Fc $\gamma$ RII (CD32) and Fc $\gamma$ RIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular PRO polypeptide. Bispecific antibodies may also be used to localize cytotoxic  
10 agents to cells which express a particular PRO polypeptide. These antibodies possess a PRO-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the PRO polypeptide and further binds tissue factor (TF).

#### 5. Heteroconjugate Antibodies

15 Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells [U.S. Patent No. 4,676,980], and for treatment of HIV infection [WO 91/00360; WO 92/200373; EP 03089]. It is contemplated that the antibodies may be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example,  
20 immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

#### 6. Effector Function Engineering

25 It may be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, *e.g.*, the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) may be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron *et al.*, J. Exp Med., 176:  
30 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff *et al.* Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson *et al.*, Anti-Cancer Drug Design, 3: 219-230 (1989).

35

#### 7. Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent

such as a chemotherapeutic agent, toxin (*e.g.*, an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (*i.e.*, a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, *Aleurites fordii* proteins, dianthin proteins, *Phytolaca americana* proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include  $^{212}\text{Bi}$ ,  $^{131}\text{I}$ ,  $^{131}\text{In}$ ,  $^{90}\text{Y}$ , and  $^{186}\text{Re}$ .

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta *et al.*, Science, **238**: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

In another embodiment, the antibody may be conjugated to a "receptor" (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (*e.g.*, avidin) that is conjugated to a cytotoxic agent (*e.g.*, a radionucleotide).

#### 8. Immunoliposomes

The antibodies disclosed herein may also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein *et al.*, Proc. Natl. Acad. Sci. USA, **82**: 3688 (1985); Hwang *et al.*, Proc. Natl. Acad. Sci. USA, **77**: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin *et al.*, J. Biol. Chem., **257**: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon *et al.*, J. National Cancer Inst., **81**(19): 1484 (1989).

#### 9. Pharmaceutical Compositions of Antibodies

Antibodies specifically binding a PRO polypeptide identified herein, as well as other molecules identified

by the screening assays disclosed hereinbefore, can be administered for the treatment of various disorders in the form of pharmaceutical compositions.

If the PRO polypeptide is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, lipofections or liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., Marasco *et al.*, Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition may comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, *supra*.

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and  $\gamma$  ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT<sup>TM</sup> (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

### G. Uses for anti-PRO Antibodies

The anti-PRO antibodies of the invention have various utilities. For example, anti-PRO antibodies may be used in diagnostic assays for PRO, *e.g.*, detecting its expression (and in some cases, differential expression) in specific cells, tissues, or serum. Various diagnostic assay techniques known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either heterogeneous or homogeneous phases [Zola, Monoclonal Antibodies: A Manual of Techniques, CRC Press, Inc. (1987) pp. 147-158]. The antibodies used in the diagnostic assays can be labeled with a detectable moiety. The detectable moiety should be capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , or  $^{125}\text{I}$ , a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase. Any method known in the art for conjugating the antibody to the detectable moiety may be employed, including those methods described by Hunter et al., Nature, 144:945 (1962); David et al., Biochemistry, 13:1014 (1974); Pain et al., J. Immunol. Meth., 40:219 (1981); and Nygren, J. Histochem. and Cytochem., 30:407 (1982).

Anti-PRO antibodies also are useful for the affinity purification of PRO from recombinant cell culture or natural sources. In this process, the antibodies against PRO are immobilized on a suitable support, such as Sephadex resin or filter paper, using methods well known in the art. The immobilized antibody then is contacted with a sample containing the PRO to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the PRO, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent that will release the PRO from the antibody.

The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.

### EXAMPLES

Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Manassas, VA.

#### EXAMPLE 1: Extracellular Domain Homology Screening to Identify Novel Polypeptides and cDNA Encoding Therefor

The extracellular domain (ECD) sequences (including the secretion signal sequence, if any) from about 950 known secreted proteins from the Swiss-Prot public database were used to search EST databases. The EST databases included public databases (*e.g.*, Dayhoff, GenBank), and proprietary databases (*e.g.* LIFESEQ<sup>TM</sup>, Incyte Pharmaceuticals, Palo Alto, CA). The search was performed using the computer program BLAST or

BLAST-2 (Altschul *et al.*, Methods in Enzymology, 266:460-480 (1996)) as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequences. Those comparisons with a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into consensus DNA sequences with the program "phrap" (Phil Green, University of Washington, Seattle, WA).

5 Using this extracellular domain homology screen, consensus DNA sequences were assembled relative to the other identified EST sequences using phrap. In addition, the consensus DNA sequences obtained were often (but not always) extended using repeated cycles of BLAST or BLAST-2 and phrap to extend the consensus sequence as far as possible using the sources of EST sequences discussed above.

10 Based upon the consensus sequences obtained as described above, oligonucleotides were then synthesized and used to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for a PRO polypeptide. Forward and reverse PCR primers generally range from 20 to 30 nucleotides and are often designed to give a PCR product of about 100-1000 bp in length. The probe sequences are typically 40-55 bp in length. In some cases, additional oligonucleotides are synthesized when the consensus sequence is greater than about 1-1.5kbp. In order to screen several libraries for a full-length clone, DNA from the libraries was screened by PCR amplification, as per Ausubel *et al.*, Current  
15 Protocols in Molecular Biology, with the PCR primer pair. A positive library was then used to isolate clones encoding the gene of interest using the probe oligonucleotide and one of the primer pairs.

The cDNA libraries used to isolate the cDNA clones were constructed by standard methods using commercially available reagents such as those from Invitrogen, San Diego, CA. The cDNA was primed with oligo dT containing a NotI site, linked with blunt to SalI hemikinased adaptors, cleaved with NotI, sized  
20 appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as pRKB or pRKD; pRK5B is a precursor of pRK5D that does not contain the SfiI site; *see*, Holmes *et al.*, Science, 253:1278-1280 (1991)) in the unique XhoI and NotI sites.

#### EXAMPLE 2: Isolation of cDNA clones by Amylase Screening

##### 25 1. Preparation of oligo dT primed cDNA library

mRNA was isolated from a human tissue of interest using reagents and protocols from Invitrogen, San Diego, CA (Fast Track 2). This RNA was used to generate an oligo dT primed cDNA library in the vector pRK5D using reagents and protocols from Life Technologies, Gaithersburg, MD (Super Script Plasmid System). In this procedure, the double stranded cDNA was sized to greater than 1000 bp and the SalI/NotI linked cDNA  
30 was cloned into XhoI/NotI cleaved vector. pRK5D is a cloning vector that has an sp6 transcription initiation site followed by an SfiI restriction enzyme site preceding the XhoI/NotI cDNA cloning sites.

##### 2. Preparation of random primed cDNA library

35 A secondary cDNA library was generated in order to preferentially represent the 5' ends of the primary cDNA clones. Sp6 RNA was generated from the primary library (described above), and this RNA was used to generate a random primed cDNA library in the vector pSST-AMY.0 using reagents and protocols from Life Technologies (Super Script Plasmid System, referenced above). In this procedure the double stranded cDNA was

sized to 500-1000 bp, linker with blunt to NotI adaptors, cleaved with SfiI, and cloned into SfiI/NotI cleaved vector. pSST-AMY.0 is a cloning vector that has a yeast alcohol dehydrogenase promoter preceding the cDNA cloning sites and the mouse amylase sequence (the mature sequence without the secretion signal) followed by the yeast alcohol dehydrogenase terminator, after the cloning sites. Thus, cDNAs cloned into this vector that are fused in frame with amylase sequence will lead to the secretion of amylase from appropriately transfected yeast colonies.

### 3. Transformation and Detection

DNA from the library described in paragraph 2 above was chilled on ice to which was added electrocompetent DH10B bacteria (Life Technologies, 20 ml). The bacteria and vector mixture was then electroporated as recommended by the manufacturer. Subsequently, SOC media (Life Technologies, 1 ml) was added and the mixture was incubated at 37°C for 30 minutes. The transformants were then plated onto 20 standard 150 mm LB plates containing ampicillin and incubated for 16 hours (37°C). Positive colonies were scraped off the plates and the DNA was isolated from the bacterial pellet using standard protocols, *e.g.* CsCl-gradient. The purified DNA was then carried on to the yeast protocols below.

The yeast methods were divided into three categories: (1) Transformation of yeast with the plasmid/cDNA combined vector; (2) Detection and isolation of yeast clones secreting amylase; and (3) PCR amplification of the insert directly from the yeast colony and purification of the DNA for sequencing and further analysis.

The yeast strain used was HD56-5A (ATCC-90785). This strain has the following genotype: MAT alpha, ura3-52, leu2-3, leu2-112, his3-11, his3-15, MAL<sup>+</sup>, SUC<sup>+</sup>, GAL<sup>+</sup>. Preferably, yeast mutants can be employed that have deficient post-translational pathways. Such mutants may have translocation deficient alleles in *sec71*, *sec72*, *sec62*, with truncated *sec71* being most preferred. Alternatively, antagonists (including antisense nucleotides and/or ligands) which interfere with the normal operation of these genes, other proteins implicated in this post translation pathway (*e.g.*, SEC61p, SEC72p, SEC62p, SEC63p, TDJ1p or SSA1p-4p) or the complex formation of these proteins may also be preferably employed in combination with the amylase-expressing yeast.

Transformation was performed based on the protocol outlined by Gietz *et al.*, Nucl. Acid. Res., 20:1425 (1992). Transformed cells were then inoculated from agar into YEPD complex media broth (100 ml) and grown overnight at 30°C. The YEPD broth was prepared as described in Kaiser *et al.*, Methods in Yeast Genetics, Cold Spring Harbor Press, Cold Spring Harbor, NY, p. 207 (1994). The overnight culture was then diluted to about 2 x 10<sup>6</sup> cells/ml (approx. OD<sub>600</sub>=0.1) into fresh YEPD broth (500 ml) and regrown to 1 x 10<sup>7</sup> cells/ml (approx. OD<sub>600</sub>=0.4-0.5).

The cells were then harvested and prepared for transformation by transfer into GS3 rotor bottles in a Sorval GS3 rotor at 5,000 rpm for 5 minutes, the supernatant discarded, and then resuspended into sterile water, and centrifuged again in 50 ml falcon tubes at 3,500 rpm in a Beckman GS-6KR centrifuge. The supernatant was discarded and the cells were subsequently washed with LiAc/TE (10 ml, 10 mM Tris-HCl, 1 mM EDTA pH 7.5, 100 mM Li<sub>2</sub>OOCCH<sub>3</sub>), and resuspended into LiAc/TE (2.5 ml).

Transformation took place by mixing the prepared cells (100 µl) with freshly denatured single stranded

salmon testes DNA (Lofstrand Labs, Gaithersburg, MD) and transforming DNA (1  $\mu$ g, vol. < 10  $\mu$ l) in microfuge tubes. The mixture was mixed briefly by vortexing, then 40% PEG/TE (600  $\mu$ l, 40% polyethylene glycol-4000, 10 mM Tris-HCl, 1 mM EDTA, 100 mM Li<sub>2</sub>OOCCH<sub>3</sub>, pH 7.5) was added. This mixture was gently mixed and incubated at 30°C while agitating for 30 minutes. The cells were then heat shocked at 42°C for 15 minutes, and the reaction vessel centrifuged in a microfuge at 12,000 rpm for 5-10 seconds, decanted and resuspended into TE (500  $\mu$ l, 10 mM Tris-HCl, 1 mM EDTA pH 7.5) followed by recentrifugation. The cells were then diluted into TE (1 ml) and aliquots (200  $\mu$ l) were spread onto the selective media previously prepared in 150 mm growth plates (VWR).

Alternatively, instead of multiple small reactions, the transformation was performed using a single, large scale reaction, wherein reagent amounts were scaled up accordingly.

The selective media used was a synthetic complete dextrose agar lacking uracil (SCD-Ura) prepared as described in Kaiser *et al.*, Methods in Yeast Genetics, Cold Spring Harbor Press, Cold Spring Harbor, NY, p. 208-210 (1994). Transformants were grown at 30°C for 2-3 days.

The detection of colonies secreting amylase was performed by including red starch in the selective growth media. Starch was coupled to the red dye (Reactive Red-120, Sigma) as per the procedure described by Biely *et al.*, Anal. Biochem., 172:176-179 (1988). The coupled starch was incorporated into the SCD-Ura agar plates at a final concentration of 0.15% (w/v), and was buffered with potassium phosphate to a pH of 7.0 (50-100 mM final concentration).

The positive colonies were picked and streaked across fresh selective media (onto 150 mm plates) in order to obtain well isolated and identifiable single colonies. Well isolated single colonies positive for amylase secretion were detected by direct incorporation of red starch into buffered SCD-Ura agar. Positive colonies were determined by their ability to break down starch resulting in a clear halo around the positive colony visualized directly.

#### 4. Isolation of DNA by PCR Amplification

When a positive colony was isolated, a portion of it was picked by a toothpick and diluted into sterile water (30  $\mu$ l) in a 96 well plate. At this time, the positive colonies were either frozen and stored for subsequent analysis or immediately amplified. An aliquot of cells (5  $\mu$ l) was used as a template for the PCR reaction in a 25  $\mu$ l volume containing: 0.5  $\mu$ l KlenTaq (Clontech, Palo Alto, CA); 4.0  $\mu$ l 10 mM dNTP's (Perkin Elmer-Cetus); 2.5  $\mu$ l Kentaq buffer (Clontech); 0.25  $\mu$ l forward oligo 1; 0.25  $\mu$ l reverse oligo 2; 12.5  $\mu$ l distilled water. The sequence of the forward oligonucleotide 1 was:

5'-TGTAACGACGCGCCAGTTAAATAGACCTGCAATTATTAATCT-3' (SEQ ID NO:611)

The sequence of reverse oligonucleotide 2 was:

5'-CAGGAAACAGCTATGACCACCTGCACACCTGCAAATCCATT-3' (SEQ ID NO:612)

PCR was then performed as follows:

- |    |              |                  |
|----|--------------|------------------|
| a. | Denature     | 92°C, 5 minutes  |
| b. | 3 cycles of: |                  |
|    | Denature     | 92°C, 30 seconds |
|    | Anneal       | 59°C, 30 seconds |



		Extend	72°C, 60 seconds
5	c.	3 cycles of:	
		Denature	92°C, 30 seconds
		Anneal	57°C, 30 seconds
		Extend	72°C, 60 seconds
	d.	25 cycles of:	
		Denature	92°C, 30 seconds
		Anneal	55°C, 30 seconds
		Extend	72°C, 60 seconds
10	e.	Hold	4°C

The underlined regions of the oligonucleotides annealed to the ADH promoter region and the amylase region, respectively, and amplified a 307 bp region from vector pSST-AMY.0 when no insert was present. Typically, the first 18 nucleotides of the 5' end of these oligonucleotides contained annealing sites for the sequencing primers. Thus, the total product of the PCR reaction from an empty vector was 343 bp. However, signal sequence-fused cDNA resulted in considerably longer nucleotide sequences.

Following the PCR, an aliquot of the reaction (5 µl) was examined by agarose gel electrophoresis in a 1% agarose gel using a Tris-Borate-EDTA (TBE) buffering system as described by Sambrook *et al.*, *supra*. Clones resulting in a single strong PCR product larger than 400 bp were further analyzed by DNA sequencing after purification with a 96 Qiaquick PCR clean-up column (Qiagen Inc., Chatsworth, CA).

#### EXAMPLE 3: Isolation of cDNA Clones Using Signal Algorithm Analysis

Various polypeptide-encoding nucleic acid sequences were identified by applying a proprietary signal sequence finding algorithm developed by Genentech, Inc. (South San Francisco, CA) upon ESTs as well as clustered and assembled EST fragments from public (*e.g.*, GenBank) and/or private (LIFESEQ®, Incyte Pharmaceuticals, Inc., Palo Alto, CA) databases. The signal sequence algorithm computes a secretion signal score based on the character of the DNA nucleotides surrounding the first and optionally the second methionine codon(s) (ATG) at the 5'-end of the sequence or sequence fragment under consideration. The nucleotides following the first ATG must code for at least 35 unambiguous amino acids without any stop codons. If the first ATG has the required amino acids, the second is not examined. If neither meets the requirement, the candidate sequence is not scored. In order to determine whether the EST sequence contains an authentic signal sequence, the DNA and corresponding amino acid sequences surrounding the ATG codon are scored using a set of seven sensors (evaluation parameters) known to be associated with secretion signals. Use of this algorithm resulted in the identification of numerous polypeptide-encoding nucleic acid sequences.

#### EXAMPLE 4: Isolation of cDNA clones Encoding Human PRO Polypeptides

Using the techniques described in Examples 1 to 3 above, numerous full-length cDNA clones were identified as encoding PRO polypeptides as disclosed herein. These cDNAs were then deposited under the terms of the Budapest Treaty with the American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209, USA (ATCC) as shown in Table 7 below.

Table 7

	<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
	DNA16435-1208	209930	June 2, 1998
	DNA23318-1211	209787	April 21, 1998
	DNA23322-1393	203400	October 27, 1998
5	DNA23334-1392	209918	June 2, 1998
	DNA26843-1389	203099	August 4, 1998
	DNA 26844-1394	209926	June 2, 1998
	DNA30867-1335	209807	April 28, 1998
	DNA33470-1175	209398	October 17, 1997
10	DNA34436-1238	209523	December 10, 1997
	DNA35557-1137	209255	September 16, 1997
	DNA35599-1168	209373	October 16, 1997
	DNA35668-1171	209371	October 16, 1997
	DNA36992-1168	209382	October 16, 1997
15	DNA39423-1182	209387	October 17, 1997
	DNA39427-1179	209395	October 17, 1997
	DNA39510-1181	209392	October 17, 1997
	DNA39518-1247	209529	December 10, 1997
	DNA39975-1210	209783	April 21, 1998
20	DNA39976-1215	209524	December 10, 1997
	DNA39979-1213	209789	April 21, 1998
	DNA40594-1233	209617	February 5, 1998
	DNA40603-1232	209486	November 21, 1997
	DNA40604-1187	209394	October 17, 1997
25	DNA40625-1189	209788	April 21, 1998
	DNA41225-1217	209491	November 21, 1997
	DNA41379-1236	209488	November 21, 1997
	DNA41386-1316	209703	March 26, 1998
	DNA44161-1434	209907	May 27, 1998
30	DNA44179-1362	209851	May 6, 1998
	DNA44192-1246	209531	December 10, 1997
	DNA44694-1500	203114	August 11, 1998
	DNA45234-1277	209654	March 5, 1998
	DNA45409-2511	203579	January 12, 1999
35	DNA45415-1318	209810	April 28, 1998
	DNA45417-1432	209910	May 27, 1998
	DNA45493-1349	209805	April 28, 1998

Table 7 (cont')

	<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
	DNA46776-1284	209721	March 31, 1998
	DNA48296-1292	209668	March 11, 1998
	DNA48306-1291	209911	May 27, 1998
5	DNA48328-1355	209843	May 6, 1998
	DNA48329-1290	209785	April 21, 1998
	DNA48334-1435	209924	June 2, 1998
	DNA49141-1431	203003	June 23, 1998
	DNA49624-1279	209655	March 5, 1998
10	DNA49647-1398	209919	June 2, 1998
	DNA49819-1439	209931	June 2, 1998
	DNA50911-1288	209714	March 31, 1998
	DNA50914-1289	209722	March 31, 1998
	DNA50919-1361	209848	May 6, 1998
15	DNA50980-1286	209717	March 31, 1998
	DNA52185-1370	209861	May 14, 1998
	DNA53906-1368	209747	April 7, 1998
	DNA53912-1457	209870	May 14, 1998
	DNA53913-1490	203162	August 25, 1998
20	DNA53977-1371	209862	May 14, 1998
	DNA53978-1443	209983	June 16, 1998
	DNA53996-1442	209921	June 2, 1998
	DNA54002-1367	209754	April 7, 1998
	DNA55737-1345	209753	April 7, 1998
25	DNA56050-1455	203011	June 23, 1998
	DNA56052-1454	203026	June 23, 1998
	DNA56107-1415	203405	October 27, 1998
	DNA56110-1437	203113	August 11, 1998
	DNA56406-1704	203478	November 17, 1998
30	DNA56409-1377	209882	May 20, 1998
	DNA56410-1414	209923	June 2, 1998
	DNA56436-1448	209902	May 27, 1998
	DNA56529-1647	203293	September 29, 1998
	DNA56855-1447	203004	June 23, 1998
35	DNA56859-1445	203019	June 23, 1998
	DNA56860-1510	209952	June 9, 1998
	DNA56865-1491	203022	June 23, 1998

Table 7 (cont')

	<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
	DNA56868-1478	203024	June 23, 1998
	DNA56869-1545	203161	August 25, 1998
	DNA56870-1492	209925	June 2, 1998
5	DNA57039-1402	209777	April 14, 1998
	DNA57253-1382	209867	May 14, 1998
	DNA57254-1477	203289	September 29, 1998
	DNA57699-1412	203020	June 23, 1998
	DNA57704-1452	209953	June 9, 1998
10	DNA57710-1451	203048	July 1, 1998
	DNA57827-1493	203045	July 1, 1998
	DNA57844-1410	203010	June 23, 1998
	DNA58723-1588	203133	August 18, 1998
	DNA58727-1474	203171	September 1, 1998
15	DNA58730-1607	203221	September 15, 1998
	DNA58732-1650	203290	September 29, 1998
	DNA58737-1473	203136	August 18, 1998
	DNA58743-1609	203154	August 25, 1998
	DNA58747-1384	209868	May 14, 1998
20	DNA58828-1519	203172	September 1, 1998
	DNA58846-1409	209957	June 9, 1998
	DNA58848-1472	209955	June 9, 1998
	DNA58849-1494	209958	June 9, 1998
	DNA58850-1495	209956	June 9, 1998
25	DNA58852-1637	203271	September 22, 1998
	DNA58853-1423	203016	June 23, 1998
	DNA58855-1422	203018	June 23, 1998
	DNA59211-1450	209960	June 9, 1998
	DNA59212-1627	203245	September 9, 1998
30	DNA59213-1487	209959	June 9, 1998
	DNA59219-1613	203220	September 15, 1998
	DNA59497-1496	209941	June 4, 1998
	DNA59602-1436	203051	July 1, 1998
	DNA59603-1419	209944	June 9, 1998
35	DNA59605-1418	203005	June 23, 1998
	DNA59607-1497	209946	June 9, 1998
	DNA59610-1556	209990	June 16, 1998

Table 7 (cont')

	<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
	DNA59612-1466	209947	June 9, 1998
	DNA59613-1417	203007	June 23, 1998
	DNA59616-1465	209991	June 16, 1998
5	DNA59619-1464	203041	July 1, 1998
	DNA59625-1498	209992	June 16, 1998
	DNA59817-1703	203470	November 17, 1998
	DNA59827-1426	203089	August 4, 1998
	DNA59828-1608	203158	August 25, 1998
10	DNA59837-2545	203658	February 9, 1999
	DNA59844-2542	203650	February 9, 1999
	DNA59853-1505	209985	June 16, 1998
	DNA59854-1459	209974	June 16, 1998
	DNA59855-1485	209987	June 16, 1998
15	DNA60278-1530	203170	September 1, 1998
	DNA60283-1484	203043	July 1, 1998
	DNA60608-1577	203126	August 18, 1998
	DNA60611-1524	203175	September 1, 1998
	DNA60619-1482	209993	June 16, 1998
20	DNA60625-1507	209975	June 16, 1998
	DNA60629-1481	209979	June 16, 1998
	DNA60740-1615	203456	November 3, 1998
	DNA61608-1606	203239	September 9, 1998
	DNA61755-1554	203112	August 11, 1998
25	DNA62809-1531	203237	September 9, 1998
	DNA62812-1594	203248	September 9, 1998
	DNA62813-2544	203655	February 9, 1999
	DNA62845-1684	203361	October 20, 1998
	DNA64849-1604	203468	November 17, 1998
30	DNA64852-1589	203127	August 18, 1998
	DNA64863-1573	203251	September 9, 1998
	DNA64881-1602	203240	September 9, 1998
	DNA64902-1667	203317	October 6, 1998
	DNA64952-1568	203222	September 15, 1998
35	DNA65403-1565	203230	September 15, 1998
	DNA65413-1534	203234	September 15, 1998
	DNA65423-1595	203227	September 15, 1998

Table 7 (cont')

	<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
	DNA66304-1546	203321	October 6, 1998
	DNA66308-1537	203159	August 25, 1998
	DNA66511-1563	203228	September 15, 1998
5	DNA66512-1564	203218	September 15, 1998
	DNA66519-1535	203236	September 15, 1998
	DNA66521-1583	203225	September 15, 1998
	DNA66658-1584	203229	September 15, 1998
	DNA66660-1585	203279	September 22, 1998
10	DNA66669-1597	203272	September 22, 1998
	DNA66674-1599	203281	September 22, 1998
	DNA68836-1656	203455	November 3, 1998
	DNA68862-2546	203652	February 9, 1999
	DNA68866-1644	203283	September 22, 1998
15	DNA68869-1610	203164	August 25, 1998
	DNA68871-1638	203280	September 22, 1998
	DNA68879-1631	203274	September 22, 1998
	DNA68880-1676	203319	October 6, 1998
	DNA68882-1677	203318	October 6, 1998
20	DNA68883-1691	203535	December 15, 1998
	DNA68885-1678	203311	October 6, 1998
	DNA71180-1655	203403	October 27, 1998
	DNA71184-1634	203266	September 22, 1998
	DNA71213-1659	203401	October 27, 1998
25	DNA71234-1651	203402	October 27, 1998
	DNA71269-1621	203284	September 22, 1998
	DNA71277-1636	203285	September 22, 1998
	DNA71286-1687	203357	October 20, 1998
	DNA71883-1660	203475	November 17, 1998
30	DNA73401-1633	203273	September 22, 1998
	DNA73492-1671	203324	October 6, 1998
	DNA73730-1679	203320	October 6, 1998
	DNA73734-1680	203363	October 20, 1998
	DNA73735-1681	203356	October 20, 1998
35	DNA73742-1662	203316	October 6, 1998
	DNA73746-1654	203411	October 27, 1998
	DNA73760-1672	203314	October 6, 1998

Table 7 (cont')

	<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
	DNA76393-1664	203323	October 6, 1998
	DNA76398-1699	203474	November 17, 1998
	DNA76399-1700	203472	November 17, 1998
5	DNA76522-2500	203469	November 17, 1998
	DNA76533-1689	203410	October 27, 1998
	DNA77303-2502	203479	November 17, 1998
	DNA77626-1705	203536	December 15, 1998
	DNA77648-1688	203408	October 27, 1998
10	DNA81754-2532	203542	December 15, 1998
	DNA81757-2512	203543	December 15, 1998
	DNA82302-2529	203534	December 15, 1998
	DNA82340-2530	203547	December 22, 1998
	DNA87991-2540	203656	February 9, 1999
15	DNA92238-2539	203602	January 20, 1999
	DNA115291-2681	PTA-202	June 8, 1999
	DNA23336-2861	PTA-1673	April 11, 2000
	DNA30862-1396	209920	June 2, 1998
	DNA30871-1157	209380	October 16, 1997
20	DNA32279-1131	209259	September 16, 1997
	DNA33206-1165	209372	October 16, 1997
	DNA35673-1201	209418	October 28, 1997
	DNA47361-1154-2	209431	November 7, 1997
	DNA49631-1328	209806	April 28, 1998
25	DNA52594-1270	209679	March 17, 1998
	DNA55800-1263	209680	March 17, 1998
	DNA56531-1648	203286	September 29, 1998
	DNA56965-1356	209842	May 6, 1998
	DNA57037-1444	209903	May 27, 1998
30	DNA57695-1340	203006	June 23, 1998
	DNA57834-1339	209954	June 9, 1998
	DNA57841-1522	203458	November 3, 1998
	DNA58847-1383	209879	May 20, 1998
	DNA59493-1420	203050	July 1, 1998
35	DNA59586-1520	203288	September 29, 1998
	DNA59608-2577	203870	March 23, 1999
	DNA59849-1504	209986	June 16, 1998

Table 7 (cont')

	<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
	DNA60292-1506	203540	December 15, 1998
	DNA62377-1381-1	203552	December 22, 1998
	DNA62880-1513	203097	August 4, 1998
5	DNA66672-1586	203265	September 22, 1998
	DNA67962-1649	203291	September 29, 1998
	DNA69555-2867	PTA-1632	April 4, 2000
	DNA71162-2764	PTA-860	October 19, 1999
	DNA71290-1630	203275	September 22, 1998
10	DNA76401-1683	203360	October 20, 1998
	DNA76541-1675	203409	October 27, 1998
	DNA76788-2526	203551	December 22, 1998
	DNA77623-2524	203546	December 22, 1998
	DNA80136-2503	203541	December 15, 1998
15	DNA83568-2692	PTA-386	July 20, 1999
	DNA84210-2576	203818	March 2, 1999
	DNA86576-2595	203868	March 23, 1999
	DNA87976-2593	203888	March 30, 1999
	DNA92256-2596	203891	March 30, 1999
20	DNA92289-2598	PTA-131	May 25, 1999
	DNA96850-2705	PTA-479	August 3, 1999
	DNA96855-2629	PTA-18	May 4, 1999
	DNA96857-2636	PTA-17	May 4, 1999
	DNA96860-2700	PTA-478	August 3, 1999
25	DNA96861-2844	PTA-1436	March 2, 2000
	DNA96866-2698	PTA-491	August 3, 1999
	DNA96870-2676	PTA-254	June 22, 1999
	DNA96872-2674	PTA-550	August 17, 1999
	DNA96878-2626	PTA-23	May 4, 1999
30	DNA96879-2619	203967	April 27, 1999
	DNA96889-2641	PTA-119	May 25, 1999
	DNA96893-2621	PTA-12	May 4, 1999
	DNA96897-2688	PTA-379	July 20, 1999
	DNA98564-2643	PTA-125	May 25, 1999
35	DNA107443-2718	PTA-490	August 3, 1999
	DNA107786-2723	PTA-474	August 3, 1999
	DNA108682-2712	PTA-486	August 3, 1999



Table 7 (cont')

	<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
	DNA108684-2761	PTA-653	September 14, 1999
	DNA108701-2749	PTA-554	August 17, 1999
	DNA108720-2717	PTA-511	August 10, 1999
5	DNA108726-2729	PTA-514	August 10, 1999
	DNA108728-2760	PTA-654	September 14, 1999
	DNA108738-2767	PTA-862	October 19, 1999
	DNA108743-2722	PTA-508	August 10, 1999
	DNA108758-2759	PTA-655	September 14, 1999
10	DNA108765-2758	PTA-657	September 14, 1999
	DNA108783-2747	PTA-616	August 31, 1999
	DNA108789-2748	PTA-547	August 17, 1999
	DNA108806-2724	PTA-610	August 31, 1999
	DNA108936-2719	PTA-519	August 10, 1999
15	DNA119510-2771	PTA-947	November 9, 1999
	DNA119517-2778	PTA-951	November 16, 1999
	DNA119535-2756	PTA-613	August 31, 1999
	DNA119537-2777	PTA-956	November 16, 1999
	DNA119714-2851	PTA-1537	March 21, 2000
20	DNA125170-2780	PTA-953	November 16, 1999
	DNA129594-2841	PTA-1481	March 14, 2000
	DNA129793-2857	PTA-1733	April 18, 2000
	DNA130809-2769	PTA-949	November 9, 1999
	DNA131639-2874	PTA-1784	April 25, 2000
25	DNA131649-2855	PTA-1482	March 14, 2000
	DNA131652-2876	PTA-1628	April 4, 2000
	DNA131658-2875	PTA-1671	April 11, 2000
	DNA132162-2770	PTA-950	November 9, 1999
	DNA136110-2763	PTA-652	September 14, 1999
30	DNA139592-2866	PTA-1587	March 28, 2000
	DNA139608-2856	PTA-1581	March 28, 2000
	DNA143292-2848	PTA-1778	April 25, 2000
	DNA144844-2843	PTA-1536	March 21, 2000
	DNA144857-2845	PTA-1589	March 28, 2000
35	DNA145841-2868	PTA-1678	April 11, 2000
	DNA148004-2882	PTA-1779	April 25, 2000
	DNA149893-2873	PTA-1672	April 11, 2000

Table 7 (cont')

	<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
	DNA149930-2884	PTA-1668	April 11, 2000
	DNA150157-2898	PTA-1777	April 25, 2000
	DNA150163-2842	PTA-1533	March 21, 2000
5	DNA153579-2894	PTA-1729	April 18, 2000
	DNA164625-2890	PTA-1535	March 21, 2000
	DNA57838-1337	203014	June 23, 1998
	DNA59777-1480	203111	August 11, 1998
	DNA66675-1587	203282	September 22, 1998
10	DNA76532-1702	203473	November 17, 1998
	DNA105849-2704	PTA-473	August 3, 1999
	DNA83500-2506	203391	October 29, 1998

15 These deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture of the deposit for 30 years from the date of deposit. The deposits will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the culture of the deposit to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one 20 determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC § 122 and the Commissioner's rules pursuant thereto (including 37 CFR § 1.14 with particular reference to 886 OG 638).

25 The assignee of the present application has agreed that if a culture of the materials on deposit should die or be lost or destroyed when cultivated under suitable conditions, the materials will be promptly replaced on notification with another of the same. Availability of the deposited material is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

### 30 EXAMPLE 5: Use of PRO as a hybridization probe

The following method describes use of a nucleotide sequence encoding PRO as a hybridization probe.

DNA comprising the coding sequence of full-length or mature PRO as disclosed herein is employed as a probe to screen for homologous DNAs (such as those encoding naturally-occurring variants of PRO) in human tissue cDNA libraries or human tissue genomic libraries.

35 Hybridization and washing of filters containing either library DNAs is performed under the following high stringency conditions. Hybridization of radiolabeled PRO-derived probe to the filters is performed in a solution of 50% formamide, 5x SSC, 0.1% SDS, 0.1% sodium pyrophosphate, 50 mM sodium phosphate, pH

6.8, 2x Denhardt's solution, and 10% dextran sulfate at 42°C for 20 hours. Washing of the filters is performed in an aqueous solution of 0.1x SSC and 0.1% SDS at 42°C.

DNAs having a desired sequence identity with the DNA encoding full-length native sequence PRO can then be identified using standard techniques known in the art.

5 **EXAMPLE 6: Expression of PRO in *E. coli***

This example illustrates preparation of an unglycosylated form of PRO by recombinant expression in *E. coli*.

The DNA sequence encoding PRO is initially amplified using selected PCR primers. The primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector. A variety of expression vectors may be employed. An example of a suitable vector is pBR322 (derived from *E. coli*; see Bolivar et al., Gene, 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance. The vector is digested with restriction enzyme and dephosphorylated. The PCR amplified sequences are then ligated into the vector. The vector will preferably include sequences which encode for an antibiotic resistance gene, a trp promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage site), the PRO coding region, lambda transcriptional terminator, and an argU gene.

The ligation mixture is then used to transform a selected *E. coli* strain using the methods described in Sambrook et al., supra. Transformants are identified by their ability to grow on LB plates and antibiotic resistant colonies are then selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing.

Selected clones can be grown overnight in liquid culture medium such as LB broth supplemented with antibiotics. The overnight culture may subsequently be used to inoculate a larger scale culture. The cells are then grown to a desired optical density, during which the expression promoter is turned on.

After culturing the cells for several more hours, the cells can be harvested by centrifugation. The cell pellet obtained by the centrifugation can be solubilized using various agents known in the art, and the solubilized PRO protein can then be purified using a metal chelating column under conditions that allow tight binding of the protein.

PRO may be expressed in *E. coli* in a poly-His tagged form, using the following procedure. The DNA encoding PRO is initially amplified using selected PCR primers. The primers will contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector, and other useful sequences providing for efficient and reliable translation initiation, rapid purification on a metal chelation column, and proteolytic removal with enterokinase. The PCR-amplified, poly-His tagged sequences are then ligated into an expression vector, which is used to transform an *E. coli* host based on strain 52 (W3110 fuhA(tonA) lon galE rpoHts(htpRts) clpP(lacIq)). Transformants are first grown in LB containing 50 mg/ml carbenicillin at 30°C with shaking until an O.D.600 of 3-5 is reached. Cultures are then diluted 50-100 fold into CRAP media (prepared by mixing 3.57 g (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.71 g sodium citrate•2H<sub>2</sub>O, 1.07 g KCl, 5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 mL water, as well as 110 mM MPOS, pH 7.3, 0.55% (w/v) glucose and 7 mM MgSO<sub>4</sub>) and grown for approximately 20-30 hours at 30°C with shaking. Samples are removed to verify

expression by SDS-PAGE analysis, and the bulk culture is centrifuged to pellet the cells. Cell pellets are frozen until purification and refolding.

*E. coli* paste from 0.5 to 1 L fermentations (6-10 g pellets) is resuspended in 10 volumes (w/v) in 7 M guanidine, 20 mM Tris, pH 8 buffer. Solid sodium sulfite and sodium tetrathionate is added to make final concentrations of 0.1M and 0.02 M, respectively, and the solution is stirred overnight at 4°C. This step results in a denatured protein with all cysteine residues blocked by sulfitolization. The solution is centrifuged at 40,000 rpm in a Beckman Ultracentrifuge for 30 min. The supernatant is diluted with 3-5 volumes of metal chelate column buffer (6 M guanidine, 20 mM Tris, pH 7.4) and filtered through 0.22 micron filters to clarify. The clarified extract is loaded onto a 5 ml Qiagen Ni-NTA metal chelate column equilibrated in the metal chelate column buffer. The column is washed with additional buffer containing 50 mM imidazole (Calbiochem, Utrol grade), pH 7.4. The protein is eluted with buffer containing 250 mM imidazole. Fractions containing the desired protein are pooled and stored at 4°C. Protein concentration is estimated by its absorbance at 280 nm using the calculated extinction coefficient based on its amino acid sequence.

The proteins are refolded by diluting the sample slowly into freshly prepared refolding buffer consisting of: 20 mM Tris, pH 8.6, 0.3 M NaCl, 2.5 M urea, 5 mM cysteine, 20 mM glycine and 1 mM EDTA. Refolding volumes are chosen so that the final protein concentration is between 50 to 100 micrograms/ml. The refolding solution is stirred gently at 4°C for 12-36 hours. The refolding reaction is quenched by the addition of TFA to a final concentration of 0.4% (pH of approximately 3). Before further purification of the protein, the solution is filtered through a 0.22 micron filter and acetonitrile is added to 2-10% final concentration. The refolded protein is chromatographed on a Poros R1/H reversed phase column using a mobile buffer of 0.1% TFA with elution with a gradient of acetonitrile from 10 to 80%. Aliquots of fractions with A280 absorbance are analyzed on SDS polyacrylamide gels and fractions containing homogeneous refolded protein are pooled. Generally, the properly refolded species of most proteins are eluted at the lowest concentrations of acetonitrile since those species are the most compact with their hydrophobic interiors shielded from interaction with the reversed phase resin. Aggregated species are usually eluted at higher acetonitrile concentrations. In addition to resolving misfolded forms of proteins from the desired form, the reversed phase step also removes endotoxin from the samples.

Fractions containing the desired folded PRO polypeptide are pooled and the acetonitrile removed using a gentle stream of nitrogen directed at the solution. Proteins are formulated into 20 mM Hepes, pH 6.8 with 0.14 M sodium chloride and 4% mannitol by dialysis or by gel filtration using G25 Superfine (Pharmacia) resins equilibrated in the formulation buffer and sterile filtered.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

#### EXAMPLE 7: Expression of PRO in mammalian cells

This example illustrates preparation of a potentially glycosylated form of PRO by recombinant expression in mammalian cells.

The vector, pRK5 (see EP 307,247, published March 15, 1989), is employed as the expression vector. Optionally, the PRO DNA is ligated into pRK5 with selected restriction enzymes to allow insertion of the PRO DNA using ligation methods such as described in Sambrook et al., *supra*. The resulting vector is called pRK5-

PRO.

In one embodiment, the selected host cells may be 293 cells. Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components and/or antibiotics. About 10  $\mu$ g pRK5-PRO DNA is mixed with about 1  $\mu$ g DNA encoding the VA RNA gene [Thimmappaya et al., *Cell*, 31:543 (1982)] and dissolved in 500  $\mu$ l of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M  $\text{CaCl}_2$ . To this mixture is added, dropwise, 500  $\mu$ l of 50 mM HEPES (pH 7.35), 280 mM NaCl, 1.5 mM  $\text{NaPO}_4$ , and a precipitate is allowed to form for 10 minutes at 25°C. The precipitate is suspended and added to the 293 cells and allowed to settle for about four hours at 37°C. The culture medium is aspirated off and 2 ml of 20% glycerol in PBS is added for 30 seconds. The 293 cells are then washed with serum free medium, fresh medium is added and the cells are incubated for about 5 days.

Approximately 24 hours after the transfections, the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200  $\mu$ Ci/ml  $^{35}\text{S}$ -cysteine and 200  $\mu$ Ci/ml  $^{35}\text{S}$ -methionine. After a 12 hour incubation, the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 15% SDS gel. The processed gel may be dried and exposed to film for a selected period of time to reveal the presence of PRO polypeptide. The cultures containing transfected cells may undergo further incubation (in serum free medium) and the medium is tested in selected bioassays.

In an alternative technique, PRO may be introduced into 293 cells transiently using the dextran sulfate method described by Somparyrac et al., *Proc. Natl. Acad. Sci.*, 12:7575 (1981). 293 cells are grown to maximal density in a spinner flask and 700  $\mu$ g pRK5-PRO DNA is added. The cells are first concentrated from the spinner flask by centrifugation and washed with PBS. The DNA-dextran precipitate is incubated on the cell pellet for four hours. The cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5  $\mu$ g/ml bovine insulin and 0.1  $\mu$ g/ml bovine transferrin. After about four days, the conditioned media is centrifuged and filtered to remove cells and debris. The sample containing expressed PRO can then be concentrated and purified by any selected method, such as dialysis and/or column chromatography.

In another embodiment, PRO can be expressed in CHO cells. The pRK5-PRO can be transfected into CHO cells using known reagents such as  $\text{CaPO}_4$  or DEAE-dextran. As described above, the cell cultures can be incubated, and the medium replaced with culture medium (alone) or medium containing a radiolabel such as  $^{35}\text{S}$ -methionine. After determining the presence of PRO polypeptide, the culture medium may be replaced with serum free medium. Preferably, the cultures are incubated for about 6 days, and then the conditioned medium is harvested. The medium containing the expressed PRO can then be concentrated and purified by any selected method.

Epitope-tagged PRO may also be expressed in host CHO cells. The PRO may be subcloned out of the pRK5 vector. The subclone insert can undergo PCR to fuse in frame with a selected epitope tag such as a poly-his tag into a Baculovirus expression vector. The poly-his tagged PRO insert can then be subcloned into a SV40 driven vector containing a selection marker such as DHFR for selection of stable clones. Finally, the CHO cells can be transfected (as described above) with the SV40 driven vector. Labeling may be performed, as described above, to verify expression. The culture medium containing the expressed poly-His tagged PRO can then be

concentrated and purified by any selected method, such as by  $\text{Ni}^{2+}$ -chelate affinity chromatography.

PRO may also be expressed in CHO and/or COS cells by a transient expression procedure or in CHO cells by another stable expression procedure.

Stable expression in CHO cells is performed using the following procedure. The proteins are expressed as an IgG construct (immunoadhesin), in which the coding sequences for the soluble forms (e.g. extracellular domains) of the respective proteins are fused to an IgG1 constant region sequence containing the hinge, CH2 and CH2 domains and/or is a poly-His tagged form.

Following PCR amplification, the respective DNAs are subcloned in a CHO expression vector using standard techniques as described in Ausubel et al., Current Protocols of Molecular Biology, Unit 3.16, John Wiley and Sons (1997). CHO expression vectors are constructed to have compatible restriction sites 5' and 3' of the DNA of interest to allow the convenient shuttling of cDNA's. The vector used expression in CHO cells is as described in Lucas et al., Nucl. Acids Res. 24:9 (1774-1779 (1996), and uses the SV40 early promoter/enhancer to drive expression of the cDNA of interest and dihydrofolate reductase (DHFR). DHFR expression permits selection for stable maintenance of the plasmid following transfection.

Twelve micrograms of the desired plasmid DNA is introduced into approximately 10 million CHO cells using commercially available transfection reagents Superfect<sup>®</sup> (Qiagen), Dosper<sup>®</sup> or Fugene<sup>®</sup> (Boehringer Mannheim). The cells are grown as described in Lucas et al., supra. Approximately  $3 \times 10^7$  cells are frozen in an ampule for further growth and production as described below.

The ampules containing the plasmid DNA are thawed by placement into water bath and mixed by vortexing. The contents are pipetted into a centrifuge tube containing 10 mLs of media and centrifuged at 1000 rpm for 5 minutes. The supernatant is aspirated and the cells are resuspended in 10 mL of selective media (0.2  $\mu\text{m}$  filtered PS20 with 5% 0.2  $\mu\text{m}$  diafiltered fetal bovine serum). The cells are then aliquoted into a 100 mL spinner containing 90 mL of selective media. After 1-2 days, the cells are transferred into a 250 mL spinner filled with 150 mL selective growth medium and incubated at 37°C. After another 2-3 days, 250 mL, 500 mL and 2000 mL spinners are seeded with  $3 \times 10^5$  cells/mL. The cell media is exchanged with fresh media by centrifugation and resuspension in production medium. Although any suitable CHO media may be employed, a production medium described in U.S. Patent No. 5,122,469, issued June 16, 1992 may actually be used. A 3L production spinner is seeded at  $1.2 \times 10^6$  cells/mL. On day 0, the cell number pH is determined. On day 1, the spinner is sampled and sparging with filtered air is commenced. On day 2, the spinner is sampled, the temperature shifted to 33°C, and 30 mL of 500 g/L glucose and 0.6 mL of 10% antifoam (e.g., 35% polydimethylsiloxane emulsion, Dow Corning 365 Medical Grade Emulsion) taken. Throughout the production, the pH is adjusted as necessary to keep it at around 7.2. After 10 days, or until the viability dropped below 70%, the cell culture is harvested by centrifugation and filtering through a 0.22  $\mu\text{m}$  filter. The filtrate was either stored at 4°C or immediately loaded onto columns for purification.

For the poly-His tagged constructs, the proteins are purified using a Ni-NTA column (Qiagen). Before purification, imidazole is added to the conditioned media to a concentration of 5 mM. The conditioned media is pumped onto a 6 ml Ni-NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml/min. at 4°C. After loading, the column is washed with additional

equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein is subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.

Immunoadhesin (Fc-containing) constructs are purified from the conditioned media as follows. The conditioned medium is pumped onto a 5 ml Protein A column (Pharmacia) which had been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column is washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5. The eluted protein is immediately neutralized by collecting 1 ml fractions into tubes containing 275  $\mu$ L of 1 M Tris buffer, pH 9. The highly purified protein is subsequently desalted into storage buffer as described above for the poly-His tagged proteins. The homogeneity is assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

#### EXAMPLE 8: Expression of PRO in Yeast

The following method describes recombinant expression of PRO in yeast.

First, yeast expression vectors are constructed for intracellular production or secretion of PRO from the ADH2/GAPDH promoter. DNA encoding PRO and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression of PRO. For secretion, DNA encoding PRO can be cloned into the selected plasmid, together with DNA encoding the ADH2/GAPDH promoter, a native PRO signal peptide or other mammalian signal peptide, or, for example, a yeast alpha-factor or invertase secretory signal/leader sequence, and linker sequences (if needed) for expression of PRO.

Yeast cells, such as yeast strain AB110, can then be transformed with the expression plasmids described above and cultured in selected fermentation media. The transformed yeast supernatants can be analyzed by precipitation with 10% trichloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.

Recombinant PRO can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters. The concentrate containing PRO may further be purified using selected column chromatography resins.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

#### EXAMPLE 9: Expression of PRO in Baculovirus-Infected Insect Cells

The following method describes recombinant expression of PRO in Baculovirus-infected insect cells.

The sequence coding for PRO is fused upstream of an epitope tag contained within a baculovirus expression vector. Such epitope tags include poly-his tags and immunoglobulin tags (like Fc regions of IgG). A variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pVL1393 (Novagen). Briefly, the sequence encoding PRO or the desired portion of the coding sequence of PRO such as the sequence encoding the extracellular domain of a transmembrane protein or the sequence encoding the mature protein if the protein is extracellular is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then

digested with those selected restriction enzymes and subcloned into the expression vector.

Recombinant baculovirus is generated by co-transfecting the above plasmid and BaculoGold™ virus DNA (Pharmingen) into *Spodoptera frugiperda* ("Sf9") cells (ATCC CRL 1711) using lipofectin (commercially available from GIBCO-BRL). After 4 - 5 days of incubation at 28°C, the released viruses are harvested and used for further amplifications. Viral infection and protein expression are performed as described by O'Reilley et al.,

5 Baculovirus expression vectors: A Laboratory Manual, Oxford: Oxford University Press (1994).

Expressed poly-his tagged PRO can then be purified, for example, by Ni<sup>2+</sup>-chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert et al., Nature, 362:175-179 (1993). Briefly, Sf9 cells are washed, resuspended in sonication buffer (25 mL Hepes, pH 7.9; 12.5 mM MgCl<sub>2</sub>; 0.1 mM EDTA; 10% glycerol; 0.1% NP-40; 0.4 M KCl), and sonicated  
10 twice for 20 seconds on ice. The sonicates are cleared by centrifugation, and the supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 300 mM NaCl, 10% glycerol, pH 7.8) and filtered through a 0.45 µm filter. A Ni<sup>2+</sup>-NTA agarose column (commercially available from Qiagen) is prepared with a bed volume of 5 mL, washed with 25 mL of water and equilibrated with 25 mL of loading buffer. The filtered cell extract is loaded  
15 onto the column at 0.5 mL per minute. The column is washed to baseline A<sub>280</sub> with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer (50 mM phosphate; 300 mM NaCl, 10% glycerol, pH 6.0), which elutes nonspecifically bound protein. After reaching A<sub>280</sub> baseline again, the column is developed with a 0 to 500 mM Imidazole gradient in the secondary wash buffer. One mL fractions are collected and analyzed by SDS-PAGE and silver staining or Western blot with Ni<sup>2+</sup>-NTA-conjugated to alkaline phosphatase (Qiagen). Fractions containing the eluted His<sub>10</sub>-tagged PRO are pooled and dialyzed  
20 against loading buffer.

Alternatively, purification of the IgG tagged (or Fc tagged) PRO can be performed using known chromatography techniques, including for instance, Protein A or protein G column chromatography.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

## 25 EXAMPLE 10: Preparation of Antibodies that Bind PRO

This example illustrates preparation of monoclonal antibodies which can specifically bind PRO.

Techniques for producing the monoclonal antibodies are known in the art and are described, for instance, in Goding, supra. Immunogens that may be employed include purified PRO, fusion proteins containing PRO, and cells expressing recombinant PRO on the cell surface. Selection of the immunogen can be made by the skilled  
30 artisan without undue experimentation.

Mice, such as Balb/c, are immunized with the PRO immunogen emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1-100 micrograms. Alternatively, the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected  
into the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional  
35 immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections. Serum samples may be periodically obtained from the mice by retro-orbital bleeding for testing in ELISA assays to detect anti-PRO antibodies.



After a suitable antibody titer has been detected, the animals "positive" for antibodies can be injected with a final intravenous injection of PRO. Three to four days later, the mice are sacrificed and the spleen cells are harvested. The spleen cells are then fused (using 35% polyethylene glycol) to a selected murine myeloma cell line such as P3X63AgU.1, available from ATCC, No. CRL 1597. The fusions generate hybridoma cells which can then be plated in 96 well tissue culture plates containing HAT (hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.

The hybridoma cells will be screened in an ELISA for reactivity against PRO. Determination of "positive" hybridoma cells secreting the desired monoclonal antibodies against PRO is within the skill in the art.

The positive hybridoma cells can be injected intraperitoneally into syngeneic Balb/c mice to produce ascites containing the anti-PRO monoclonal antibodies. Alternatively, the hybridoma cells can be grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished using ammonium sulfate precipitation, followed by gel exclusion chromatography. Alternatively, affinity chromatography based upon binding of antibody to protein A or protein G can be employed.

#### EXAMPLE 11: Purification of PRO Polypeptides Using Specific Antibodies

Native or recombinant PRO polypeptides may be purified by a variety of standard techniques in the art of protein purification. For example, pro-PRO polypeptide, mature PRO polypeptide, or pre-PRO polypeptide is purified by immunoaffinity chromatography using antibodies specific for the PRO polypeptide of interest. In general, an immunoaffinity column is constructed by covalently coupling the anti-PRO polypeptide antibody to an activated chromatographic resin.

Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway, N.J.). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated SEPHAROSE™ (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.

Such an immunoaffinity column is utilized in the purification of PRO polypeptide by preparing a fraction from cells containing PRO polypeptide in a soluble form. This preparation is derived by solubilization of the whole cell or of a subcellular fraction obtained via differential centrifugation by the addition of detergent or by other methods well known in the art. Alternatively, soluble PRO polypeptide containing a signal sequence may be secreted in useful quantity into the medium in which the cells are grown.

A soluble PRO polypeptide-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of PRO polypeptide (*e.g.*, high ionic strength buffers in the presence of detergent). Then, the column is eluted under conditions that disrupt antibody/PRO polypeptide binding (*e.g.*, a low pH buffer such as approximately pH 2-3, or a high concentration of a chaotrope such as urea or thiocyanate ion), and PRO polypeptide is collected.

**EXAMPLE 12: Drug Screening**

This invention is particularly useful for screening compounds by using PRO polypeptides or binding fragment thereof in any of a variety of drug screening techniques. The PRO polypeptide or fragment employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the PRO polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between PRO polypeptide or a fragment and the agent being tested. Alternatively, one can examine the diminution in complex formation between the PRO polypeptide and its target cell or target receptors caused by the agent being tested.

Thus, the present invention provides methods of screening for drugs or any other agents which can affect a PRO polypeptide-associated disease or disorder. These methods comprise contacting such an agent with an PRO polypeptide or fragment thereof and assaying (i) for the presence of a complex between the agent and the PRO polypeptide or fragment, or (ii) for the presence of a complex between the PRO polypeptide or fragment and the cell, by methods well known in the art. In such competitive binding assays, the PRO polypeptide or fragment is typically labeled. After suitable incubation, free PRO polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to PRO polypeptide or to interfere with the PRO polypeptide/cell complex.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to a polypeptide and is described in detail in WO 84/03564, published on September 13, 1984. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. As applied to a PRO polypeptide, the peptide test compounds are reacted with PRO polypeptide and washed. Bound PRO polypeptide is detected by methods well known in the art. Purified PRO polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies can be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding PRO polypeptide specifically compete with a test compound for binding to PRO polypeptide or fragments thereof. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PRO polypeptide.

**EXAMPLE 13: Rational Drug Design**

The goal of rational drug design is to produce structural analogs of biologically active polypeptide of interest (*i.e.*, a PRO polypeptide) or of small molecules with which they interact, *e.g.*, agonists, antagonists, or inhibitors. Any of these examples can be used to fashion drugs which are more active or stable forms of the PRO polypeptide or which enhance or interfere with the function of the PRO polypeptide *in vivo* (*c.f.*, Hodgson, Bio/Technology, 9: 19-21 (1991)).

In one approach, the three-dimensional structure of the PRO polypeptide, or of an PRO

polypeptide-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the PRO polypeptide must be ascertained to elucidate the structure and to determine active site(s) of the molecule. Less often, useful information regarding the structure of the PRO polypeptide may be gained by modeling based on the structure of homologous proteins. In both cases, relevant structural information is used to design analogous PRO polypeptide-like molecules or to identify efficient inhibitors. Useful examples of rational drug design may include molecules which have improved activity or stability as shown by Braxton and Wells, Biochemistry, 31:7796-7801 (1992) or which act as inhibitors, agonists, or antagonists of native peptides as shown by Athauda *et al.*, J. Biochem., 113:742-746 (1993).

It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and then to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids would be expected to be an analog of the original receptor. The anti-id could then be used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides would then act as the pharmacore.

By virtue of the present invention, sufficient amounts of the PRO polypeptide may be made available to perform such analytical studies as X-ray crystallography. In addition, knowledge of the PRO polypeptide amino acid sequence provided herein will provide guidance to those employing computer modeling techniques in place of or in addition to x-ray crystallography.

#### 20 EXAMPLE 14: Identification of PRO Polypeptides That Stimulate TNF- $\alpha$ Release In Human Blood (Assay 128)

This assay shows that certain PRO polypeptides of the present invention act to stimulate the release of TNF- $\alpha$  in human blood. PRO polypeptides testing positive in this assay are useful for, among other things, research purposes where stimulation of the release of TNF- $\alpha$  would be desired and for the therapeutic treatment of conditions wherein enhanced TNF- $\alpha$  release would be beneficial. Specifically, 200  $\mu$ l of human blood supplemented with 50mM Hepes buffer (pH 7.2) is aliquoted per well in a 96 well test plate. To each well is then added 300 $\mu$ l of either the test PRO polypeptide in 50 mM Hepes buffer (at various concentrations) or 50 mM Hepes buffer alone (negative control) and the plates are incubated at 37°C for 6 hours. The samples are then centrifuged and 50 $\mu$ l of plasma is collected from each well and tested for the presence of TNF- $\alpha$  by ELISA assay. A positive in the assay is a higher amount of TNF- $\alpha$  in the PRO polypeptide treated samples as compared to the negative control samples.

The following PRO polypeptides tested positive in this assay:

PRO1079, PRO827, PRO791, PRO1131, PRO1316, PRO1183, PRO1343, PRO1760, PRO1567, and PRO4333.

#### 35 EXAMPLE 15: Promotion of Chondrocyte Redifferentiation (Assay 129)

This assay is designed to determine whether PRO polypeptides of the present invention show the ability to induce the proliferation and/or redifferentiation of chondrocytes in culture. PRO polypeptides testing positive in this assay would be expected to be useful for the therapeutic treatment of various bone and/or cartilage

disorders such as, for example, sports injuries and arthritis.

Porcine chondrocytes are isolated by overnight collagenase digestion of articular cartilage of the metacarpophalangeal joint of 4-6 month old female pigs. The isolated cells are then seeded at 25,000 cells/cm<sup>2</sup> in Ham F-12 containing 10% FBS and 4 µg/ml gentamycin. The culture media is changed every third day. On day 12, the cells are seeded in 96 well plates at 5,000 cells/well in 100 µl of the same media without serum and 100 µl of either serum-free medium (negative control), staurosporin (final concentration of 5 nM; positive control) or the test PRO polypeptide are added to give a final volume of 200 µl/well. After 5 days at 37°C, 22 µl of media containing 100 µg/ml Hoechst 33342 and 50 µg/ml 5-CFDA is added to each well and incubated for an additional 10 minutes at 37°C. A picture of the green fluorescence is taken for each well and the differentiation state of the chondrocytes is calculated by morphometric analysis. A positive result in the assay is obtained when the >50% of the PRO polypeptide treated cells are differentiated (compared to the background obtained by the negative control).

PRO6029 polypeptide tested positive in this assay.

EXAMPLE 16: Microarray Analysis to Detect Overexpression of PRO Polypeptides in Cancerous Tumors

Nucleic acid microarrays, often containing thousands of gene sequences, are useful for identifying differentially expressed genes in diseased tissues as compared to their normal counterparts. Using nucleic acid microarrays, test and control mRNA samples from test and control tissue samples are reverse transcribed and labeled to generate cDNA probes. The cDNA probes are then hybridized to an array of nucleic acids immobilized on a solid support. The array is configured such that the sequence and position of each member of the array is known. For example, a selection of genes known to be expressed in certain disease states may be arrayed on a solid support. Hybridization of a labeled probe with a particular array member indicates that the sample from which the probe was derived expresses that gene. If the hybridization signal of a probe from a test (disease tissue) sample is greater than hybridization signal of a probe from a control (normal tissue) sample, the gene or genes overexpressed in the disease tissue are identified. The implication of this result is that an overexpressed protein in a diseased tissue is useful not only as a diagnostic marker for the presence of the disease condition, but also as a therapeutic target for treatment of the disease condition.

The methodology of hybridization of nucleic acids and microarray technology is well known in the art. In the present example, the specific preparation of nucleic acids for hybridization and probes, slides, and hybridization conditions are all detailed in U.S. Provisional Patent Application Serial No. 60/193,767, filed on March 31, 2000 and which is herein incorporated by reference.

In the present example, cancerous tumors derived from various human tissues were studied for PRO polypeptide-encoding gene expression relative to non-cancerous human tissue in an attempt to identify those PRO polypeptides which are overexpressed in cancerous tumors. Two sets of experimental data were generated. In one set, cancerous human colon tumor tissue and matched non-cancerous human colon tumor tissue from the same patient ("matched colon control") were obtained and analyzed for PRO polypeptide expression using the above described microarray technology. In the second set of data, cancerous human tumor tissue from any of a variety of different human tumors was obtained and compared to a "universal" epithelial control sample which was

prepared by pooling non-cancerous human tissues of epithelial origin, including liver, kidney, and lung. mRNA isolated from the pooled tissues represents a mixture of expressed gene products from these different tissues. Microarray hybridization experiments using the pooled control samples generated a linear plot in a 2-color analysis. The slope of the line generated in a 2-color analysis was then used to normalize the ratios of (test:control detection) within each experiment. The normalized ratios from various experiments were then compared and used to identify clustering of gene expression. Thus, the pooled "universal control" sample not only allowed effective relative gene expression determinations in a simple 2-sample comparison, it also allowed multi-sample comparisons across several experiments.

In the present experiments, nucleic acid probes derived from the herein described PRO polypeptide-encoding nucleic acid sequences were used in the creation of the microarray and RNA from the tumor tissues listed above were used for the hybridization thereto. A value based upon the normalized ratio:experimental ratio was designated as a "cutoff ratio". Only values that were above this cutoff ratio were determined to be significant. Table 8 below shows the results of these experiments, demonstrating that various PRO polypeptides of the present invention are significantly overexpressed in various human tumor tissues as compared to a non-cancerous human tissue control. As described above, these data demonstrate that the PRO polypeptides of the present invention are useful not only as diagnostic markers for the presence of one or more cancerous tumors, but also serve as therapeutic targets for the treatment of those tumors.

Table 8

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
20	PRO276	lung tumor	universal normal control
	PRO284	colon tumor	universal normal control
	PRO284	lung tumor	universal normal control
	PRO284	breast tumor	universal normal control
	PRO193	colon tumor	universal normal control
	PRO193	lung tumor	universal normal control
25	PRO193	breast tumor	universal normal control
	PRO193	prostate tumor	universal normal control
	PRO190	colon tumor	universal normal control
	PRO190	lung tumor	universal normal control
	PRO190	breast tumor	universal normal control
30	PRO180	colon tumor	universal normal control
	PRO180	lung tumor	universal normal control
	PRO180	breast tumor	universal normal control
	PRO194	colon tumor	universal normal control
	PRO194	lung tumor	universal normal control
35	PRO194	breast tumor	universal normal control
	PRO194	cervical tumor	universal normal control
	PRO218	colon tumor	universal normal control
	PRO218	lung tumor	universal normal control
40	PRO260	colon tumor	universal normal control
	PRO260	lung tumor	universal normal control
	PRO260	breast tumor	universal normal control
	PRO260	rectal tumor	universal normal control
	PRO233	colon tumor	universal normal control
	PRO233	lung tumor	universal normal control
45	PRO233	breast tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO234	colon tumor	universal normal control
	PRO234	lung tumor	universal normal control
	PRO234	breast tumor	universal normal control
5	PRO234	liver tumor	universal normal control
	PRO236	colon tumor	universal normal control
	PRO236	lung tumor	universal normal control
	PRO236	breast tumor	universal normal control
	PRO244	colon tumor	universal normal control
10	PRO244	lung tumor	universal normal control
	PRO262	colon tumor	universal normal control
	PRO262	lung tumor	universal normal control
	PRO262	breast tumor	universal normal control
	PRO271	colon tumor	universal normal control
15	PRO271	lung tumor	universal normal control
	PRO268	colon tumor	universal normal control
	PRO268	lung tumor	universal normal control
	PRO268	breast tumor	universal normal control
	PRO270	colon tumor	universal normal control
20	PRO270	lung tumor	universal normal control
	PRO270	breast tumor	universal normal control
	PRO270	liver tumor	universal normal control
	PRO355	lung tumor	universal normal control
	PRO355	breast tumor	universal normal control
25	PRO355	prostate tumor	universal normal control
	PRO298	colon tumor	universal normal control
	PRO298	lung tumor	universal normal control
	PRO298	breast tumor	universal normal control
	PRO299	colon tumor	universal normal control
30	PRO299	lung tumor	universal normal control
	PRO299	breast tumor	universal normal control
	PRO296	colon tumor	universal normal control
	PRO296	breast tumor	universal normal control
35	PRO329	colon tumor	universal normal control
	PRO329	lung tumor	universal normal control
	PRO329	breast tumor	universal normal control
	PRO330	colon tumor	universal normal control
	PRO330	lung tumor	universal normal control
	PRO294	lung tumor	universal normal control
40	PRO294	breast tumor	universal normal control
	PRO300	colon tumor	universal normal control
	PRO300	lung tumor	universal normal control
	PRO300	breast tumor	universal normal control
	PRO307	lung tumor	universal normal control
45	PRO334	colon tumor	universal normal control
	PRO334	lung tumor	universal normal control
	PRO334	breast tumor	universal normal control
	PRO334	prostate tumor	universal normal control
	PRO352	colon tumor	universal normal control
50	PRO352	lung tumor	universal normal control
	PRO352	breast tumor	universal normal control
	PRO352	liver tumor	universal normal control
	PRO710	breast tumor	universal normal control
	PRO873	colon tumor	universal normal control
55	PRO873	lung tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO873	breast tumor	universal normal control
	PRO873	prostate tumor	universal normal control
	PRO354	colon tumor	universal normal control
5	PRO354	lung tumor	universal normal control
	PRO354	breast tumor	universal normal control
	PRO1151	lung tumor	universal normal control
	PRO1151	breast tumor	universal normal control
	PRO382	colon tumor	universal normal control
10	PRO382	lung tumor	universal normal control
	PRO382	breast tumor	universal normal control
	PRO1864	lung tumor	universal normal control
	PRO1864	breast tumor	universal normal control
	PRO1864	liver tumor	universal normal control
15	PRO386	colon tumor	universal normal control
	PRO386	lung tumor	universal normal control
	PRO386	prostate tumor	universal normal control
	PRO541	colon tumor	universal normal control
	PRO541	lung tumor	universal normal control
20	PRO541	breast tumor	universal normal control
	PRO852	breast tumor	universal normal control
	PRO700	colon tumor	universal normal control
	PRO700	lung tumor	universal normal control
	PRO700	breast tumor	universal normal control
25	PRO700	rectal tumor	universal normal control
	PRO708	colon tumor	universal normal control
	PRO708	lung tumor	universal normal control
	PRO708	breast tumor	universal normal control
	PRO707	colon tumor	universal normal control
30	PRO707	lung tumor	universal normal control
	PRO864	colon tumor	universal normal control
	PRO864	lung tumor	universal normal control
	PRO864	breast tumor	universal normal control
	PRO706	colon tumor	universal normal control
35	PRO706	lung tumor	universal normal control
	PRO706	breast tumor	universal normal control
	PRO706	liver tumor	universal normal control
	PRO732	lung tumor	universal normal control
	PRO732	breast tumor	universal normal control
40	PRO732	cervical tumor	universal normal control
	PRO537	colon tumor	universal normal control
	PRO537	lung tumor	universal normal control
	PRO537	breast tumor	universal normal control
	PRO545	lung tumor	universal normal control
45	PRO545	breast tumor	universal normal control
	PRO718	lung tumor	universal normal control
	PRO718	breast tumor	universal normal control
	PRO872	lung tumor	universal normal control
	PRO872	breast tumor	universal normal control
50	PRO872	liver tumor	universal normal control
	PRO704	colon tumor	universal normal control
	PRO704	lung tumor	universal normal control
	PRO704	breast tumor	universal normal control
	PRO705	lung tumor	universal normal control
55	PRO705	breast tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO871	lung tumor	universal normal control
	PRO871	breast tumor	universal normal control
5	PRO871	liver tumor	universal normal control
	PRO702	lung tumor	universal normal control
	PRO944	colon tumor	universal normal control
	PRO944	lung tumor	universal normal control
	PRO944	rectal tumor	universal normal control
	PRO739	lung tumor	universal normal control
10	PRO739	breast tumor	universal normal control
	PRO739	prostate tumor	universal normal control
	PRO941	colon tumor	universal normal control
	PRO941	lung tumor	universal normal control
	PRO941	breast tumor	universal normal control
15	PRO941	rectal tumor	universal normal control
	PRO1082	lung tumor	universal normal control
	PRO1082	breast tumor	universal normal control
	PRO1133	colon tumor	universal normal control
	PRO1133	lung tumor	universal normal control
20	PRO983	colon tumor	universal normal control
	PRO983	lung tumor	universal normal control
	PRO983	breast tumor	universal normal control
	PRO784	colon tumor	universal normal control
	PRO784	lung tumor	universal normal control
25	PRO784	breast tumor	universal normal control
	PRO784	prostate tumor	universal normal control
	PRO783	colon tumor	universal normal control
	PRO783	lung tumor	universal normal control
	PRO783	breast tumor	universal normal control
30	PRO783	liver tumor	universal normal control
	PRO940	colon tumor	universal normal control
	PRO940	lung tumor	universal normal control
	PRO940	breast tumor	universal normal control
	PRO768	colon tumor	universal normal control
35	PRO768	lung tumor	universal normal control
	PRO768	breast tumor	universal normal control
	PRO1079	colon tumor	universal normal control
	PRO1079	lung tumor	universal normal control
	PRO1079	breast tumor	universal normal control
40	PRO1079	rectal tumor	universal normal control
	PRO1078	colon tumor	universal normal control
	PRO1078	lung tumor	universal normal control
	PRO1018	colon tumor	universal normal control
	PRO1018	lung tumor	universal normal control
45	PRO1018	breast tumor	universal normal control
	PRO793	colon tumor	universal normal control
	PRO793	lung tumor	universal normal control
	PRO793	breast tumor	universal normal control
	PRO793	rectal tumor	universal normal control
50	PRO1773	colon tumor	universal normal control
	PRO1773	lung tumor	universal normal control
	PRO1773	prostate tumor	universal normal control
	PRO1014	lung tumor	universal normal control
	PRO1014	breast tumor	universal normal control
55	PRO1013	colon tumor	universal normal control



Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO1013	lung tumor	universal normal control
	PRO1013	breast tumor	universal normal control
	PRO1013	liver tumor	universal normal control
5	PRO937	colon tumor	universal normal control
	PRO937	lung tumor	universal normal control
	PRO937	breast tumor	universal normal control
	PRO937	cervical tumor	universal normal control
	PRO937	rectal tumor	universal normal control
10	PRO1477	lung tumor	universal normal control
	PRO1477	breast tumor	universal normal control
	PRO1477	rectal tumor	universal normal control
	PRO842	colon tumor	universal normal control
	PRO842	lung tumor	universal normal control
15	PRO842	breast tumor	universal normal control
	PRO839	colon tumor	universal normal control
	PRO1180	colon tumor	universal normal control
	PRO1180	lung tumor	universal normal control
	PRO1180	liver tumor	universal normal control
20	PRO1134	lung tumor	universal normal control
	PRO1134	breast tumor	universal normal control
	PRO1134	prostate tumor	universal normal control
	PRO1115	colon tumor	universal normal control
	PRO1115	lung tumor	universal normal control
25	PRO1115	breast tumor	universal normal control
	PRO1277	colon tumor	universal normal control
	PRO1277	lung tumor	universal normal control
	PRO1135	lung tumor	universal normal control
	PRO1135	breast tumor	universal normal control
30	PRO1135	cervical tumor	universal normal control
	PRO827	colon tumor	universal normal control
	PRO827	lung tumor	universal normal control
	PRO827	prostate tumor	universal normal control
	PRO827	cervical tumor	universal normal control
35	PRO1057	lung tumor	universal normal control
	PRO1057	breast tumor	universal normal control
	PRO1113	colon tumor	universal normal control
	PRO1113	lung tumor	universal normal control
40	PRO1006	colon tumor	universal normal control
	PRO1006	lung tumor	universal normal control
	PRO1006	breast tumor	universal normal control
	PRO1006	rectal tumor	universal normal control
	PRO1074	lung tumor	universal normal control
	PRO1074	rectal tumor	universal normal control
45	PRO1073	lung tumor	universal normal control
	PRO1073	breast tumor	universal normal control
	PRO1136	colon tumor	universal normal control
	PRO1136	lung tumor	universal normal control
	PRO1136	breast tumor	universal normal control
50	PRO1004	lung tumor	universal normal control
	PRO1344	colon tumor	universal normal control
	PRO1344	lung tumor	universal normal control
	PRO1344	breast tumor	universal normal control
	PRO1344	rectal tumor	universal normal control
55	PRO1110	colon tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO1110	lung tumor	universal normal control
	PRO1110	breast tumor	universal normal control
5	PRO1378	colon tumor	universal normal control
	PRO1378	lung tumor	universal normal control
	PRO1378	prostate tumor	universal normal control
	PRO1378	cervical tumor	universal normal control
	PRO1481	colon tumor	universal normal control
	PRO1481	lung tumor	universal normal control
10	PRO1109	lung tumor	universal normal control
	PRO1109	breast tumor	universal normal control
	PRO1383	colon tumor	universal normal control
	PRO1383	lung tumor	universal normal control
	PRO1383	breast tumor	universal normal control
15	PRO1072	lung tumor	universal normal control
	PRO1189	colon tumor	universal normal control
	PRO1189	lung tumor	universal normal control
	PRO1189	breast tumor	universal normal control
	PRO1189	prostate tumor	universal normal control
20	PRO1003	colon tumor	universal normal control
	PRO1003	lung tumor	universal normal control
	PRO1003	breast tumor	universal normal control
	PRO1003	liver tumor	universal normal control
	PRO1003	rectal tumor	universal normal control
25	PRO1108	colon tumor	universal normal control
	PRO1108	lung tumor	universal normal control
	PRO1108	breast tumor	universal normal control
	PRO1137	colon tumor	universal normal control
	PRO1137	lung tumor	universal normal control
30	PRO1137	breast tumor	universal normal control
	PRO1138	colon tumor	universal normal control
	PRO1138	lung tumor	universal normal control
	PRO1138	breast tumor	universal normal control
	PRO1415	colon tumor	universal normal control
35	PRO1415	lung tumor	universal normal control
	PRO1415	prostate tumor	universal normal control
	PRO1054	lung tumor	universal normal control
	PRO1054	breast tumor	universal normal control
	PRO994	colon tumor	universal normal control
40	PRO994	lung tumor	universal normal control
	PRO994	rectal tumor	universal normal control
	PRO1069	lung tumor	universal normal control
	PRO1069	breast tumor	universal normal control
	PRO1411	colon tumor	universal normal control
45	PRO1411	lung tumor	universal normal control
	PRO1129	lung tumor	universal normal control
	PRO1129	rectal tumor	universal normal control
	PRO1359	colon tumor	universal normal control
	PRO1359	lung tumor	universal normal control
50	PRO1359	breast tumor	universal normal control
	PRO1359	prostate tumor	universal normal control
	PRO1139	lung tumor	universal normal control
	PRO1065	lung tumor	universal normal control
	PRO1028	colon tumor	universal normal control
55	PRO1028	lung tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO1028	breast tumor	universal normal control
	PRO1028	cervical tumor	universal normal control
	PRO1027	colon tumor	universal normal control
5	PRO1027	lung tumor	universal normal control
	PRO1027	breast tumor	universal normal control
	PRO1140	colon tumor	universal normal control
	PRO1140	breast tumor	universal normal control
	PRO1291	colon tumor	universal normal control
10	PRO1291	breast tumor	universal normal control
	PRO1105	colon tumor	universal normal control
	PRO1105	lung tumor	universal normal control
	PRO1026	lung tumor	universal normal control
	PRO1026	prostate tumor	universal normal control
15	PRO1104	colon tumor	universal normal control
	PRO1104	lung tumor	universal normal control
	PRO1104	breast tumor	universal normal control
	PRO1100	colon tumor	universal normal control
	PRO1100	lung tumor	universal normal control
20	PRO1100	breast tumor	universal normal control
	PRO1100	rectal tumor	universal normal control
	PRO1141	lung tumor	universal normal control
	PRO1772	colon tumor	universal normal control
	PRO1772	lung tumor	universal normal control
25	PRO1772	breast tumor	universal normal control
	PRO1772	cervical tumor	universal normal control
	PRO1064	colon tumor	universal normal control
	PRO1064	lung tumor	universal normal control
	PRO1379	colon tumor	universal normal control
30	PRO1379	lung tumor	universal normal control
	PRO1379	cervical tumor	universal normal control
	PRO3573	lung tumor	universal normal control
	PRO3573	breast tumor	universal normal control
	PRO3566	colon tumor	universal normal control
35	PRO3566	lung tumor	universal normal control
	PRO1156	lung tumor	universal normal control
	PRO1156	breast tumor	universal normal control
	PRO1156	prostate tumor	universal normal control
	PRO1098	colon tumor	universal normal control
40	PRO1098	lung tumor	universal normal control
	PRO1098	rectal tumor	universal normal control
	PRO1128	colon tumor	universal normal control
	PRO1128	lung tumor	universal normal control
	PRO1128	breast tumor	universal normal control
45	PRO1248	lung tumor	universal normal control
	PRO1248	breast tumor	universal normal control
	PRO1127	colon tumor	universal normal control
	PRO1127	lung tumor	universal normal control
	PRO1127	breast tumor	universal normal control
50	PRO1316	colon tumor	universal normal control
	PRO1316	lung tumor	universal normal control
	PRO1316	breast tumor	universal normal control
	PRO1197	colon tumor	universal normal control
55	PRO1197	lung tumor	universal normal control
	PRO1197	breast tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO1125	lung tumor	universal normal control
	PRO1158	breast tumor	universal normal control
	PRO1124	colon tumor	universal normal control
5	PRO1124	lung tumor	universal normal control
	PRO1380	colon tumor	universal normal control
	PRO1380	lung tumor	universal normal control
	PRO1380	breast tumor	universal normal control
	PRO1380	liver tumor	universal normal control
10	PRO1377	colon tumor	universal normal control
	PRO1377	lung tumor	universal normal control
	PRO1287	lung tumor	universal normal control
	PRO1287	breast tumor	universal normal control
	PRO1249	lung tumor	universal normal control
15	PRO1249	breast tumor	universal normal control
	PRO1335	colon tumor	universal normal control
	PRO1335	lung tumor	universal normal control
	PRO1335	breast tumor	universal normal control
	PRO3572	lung tumor	universal normal control
20	PRO1599	colon tumor	universal normal control
	PRO1599	lung tumor	universal normal control
	PRO1599	breast tumor	universal normal control
	PRO1374	lung tumor	universal normal control
	PRO1374	breast tumor	universal normal control
25	PRO1345	lung tumor	universal normal control
	PRO1345	breast tumor	universal normal control
	PRO1311	lung tumor	universal normal control
	PRO1311	breast tumor	universal normal control
	PRO1357	colon tumor	universal normal control
30	PRO1357	lung tumor	universal normal control
	PRO1557	colon tumor	universal normal control
	PRO1557	lung tumor	universal normal control
	PRO1557	breast tumor	universal normal control
	PRO1305	colon tumor	universal normal control
35	PRO1305	lung tumor	universal normal control
	PRO1305	breast tumor	universal normal control
	PRO1302	colon tumor	universal normal control
	PRO1302	lung tumor	universal normal control
	PRO1302	breast tumor	universal normal control
40	PRO1302	rectal tumor	universal normal control
	PRO1266	colon tumor	universal normal control
	PRO1336	colon tumor	universal normal control
	PRO1336	lung tumor	universal normal control
	PRO1336	breast tumor	universal normal control
45	PRO1278	colon tumor	universal normal control
	PRO1278	lung tumor	universal normal control
	PRO1270	breast tumor	universal normal control
	PRO1298	colon tumor	universal normal control
	PRO1298	lung tumor	universal normal control
50	PRO1301	lung tumor	universal normal control
	PRO1301	breast tumor	universal normal control
	PRO1268	colon tumor	universal normal control
	PRO1268	breast tumor	universal normal control
	PRO1327	lung tumor	universal normal control
55	PRO1327	breast tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO1328	colon tumor	universal normal control
	PRO1328	lung tumor	universal normal control
5	PRO1328	breast tumor	universal normal control
	PRO1329	colon tumor	universal normal control
	PRO1329	lung tumor	universal normal control
	PRO1329	breast tumor	universal normal control
	PRO1339	colon tumor	universal normal control
	PRO1339	lung tumor	universal normal control
10	PRO1342	colon tumor	universal normal control
	PRO1342	lung tumor	universal normal control
	PRO1342	breast tumor	universal normal control
	PRO1342	rectal tumor	universal normal control
15	PRO1487	colon tumor	universal normal control
	PRO1487	breast tumor	universal normal control
	PRO3579	lung tumor	universal normal control
	PRO3579	breast tumor	universal normal control
	PRO1472	colon tumor	universal normal control
20	PRO1472	lung tumor	universal normal control
	PRO1385	lung tumor	universal normal control
	PRO1385	breast tumor	universal normal control
	PRO1461	colon tumor	universal normal control
	PRO1461	lung tumor	universal normal control
	PRO1461	breast tumor	universal normal control
25	PRO1429	colon tumor	universal normal control
	PRO1429	lung tumor	universal normal control
	PRO1429	breast tumor	universal normal control
	PRO1568	lung tumor	universal normal control
	PRO1568	breast tumor	universal normal control
30	PRO1569	colon tumor	universal normal control
	PRO1569	lung tumor	universal normal control
	PRO1569	breast tumor	universal normal control
	PRO1753	colon tumor	universal normal control
	PRO1753	lung tumor	universal normal control
35	PRO1570	colon tumor	universal normal control
	PRO1570	lung tumor	universal normal control
	PRO1570	breast tumor	universal normal control
	PRO1570	prostate tumor	universal normal control
	PRO1570	rectal tumor	universal normal control
40	PRO1559	colon tumor	universal normal control
	PRO1559	lung tumor	universal normal control
	PRO1559	breast tumor	universal normal control
	PRO1486	lung tumor	universal normal control
	PRO1486	breast tumor	universal normal control
45	PRO1433	colon tumor	universal normal control
	PRO1433	lung tumor	universal normal control
	PRO1433	breast tumor	universal normal control
	PRO1433	rectal tumor	universal normal control
	PRO1490	lung tumor	universal normal control
50	PRO1490	breast tumor	universal normal control
	PRO1482	lung tumor	universal normal control
	PRO1482	breast tumor	universal normal control
	PRO1409	colon tumor	universal normal control
	PRO1409	lung tumor	universal normal control
55	PRO1409	breast tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO1446	colon tumor	universal normal control
	PRO1446	lung tumor	universal normal control
	PRO1446	breast tumor	universal normal control
5	PRO1446	prostate tumor	universal normal control
	PRO1604	colon tumor	universal normal control
	PRO1604	lung tumor	universal normal control
	PRO1604	breast tumor	universal normal control
	PRO1491	colon tumor	universal normal control
10	PRO1491	lung tumor	universal normal control
	PRO1491	breast tumor	universal normal control
	PRO1431	colon tumor	universal normal control
	PRO1431	lung tumor	universal normal control
	PRO1563	colon tumor	universal normal control
15	PRO1563	lung tumor	universal normal control
	PRO1563	breast tumor	universal normal control
	PRO1571	colon tumor	universal normal control
	PRO1571	lung tumor	universal normal control
	PRO1571	breast tumor	universal normal control
20	PRO1572	lung tumor	universal normal control
	PRO1572	prostate tumor	universal normal control
	PRO1573	lung tumor	universal normal control
	PRO1573	breast tumor	universal normal control
	PRO1508	lung tumor	universal normal control
25	PRO1508	breast tumor	universal normal control
	PRO1485	colon tumor	universal normal control
	PRO1485	lung tumor	universal normal control
	PRO1564	colon tumor	universal normal control
	PRO1564	lung tumor	universal normal control
30	PRO1564	breast tumor	universal normal control
	PRO1550	colon tumor	universal normal control
	PRO1550	lung tumor	universal normal control
	PRO1550	breast tumor	universal normal control
	PRO1757	lung tumor	universal normal control
35	PRO1757	breast tumor	universal normal control
	PRO1757	prostate tumor	universal normal control
	PRO1758	lung tumor	universal normal control
	PRO1781	colon tumor	universal normal control
	PRO1781	lung tumor	universal normal control
40	PRO1781	breast tumor	universal normal control
	PRO1606	lung tumor	universal normal control
	PRO1606	breast tumor	universal normal control
	PRO1784	colon tumor	universal normal control
	PRO1784	lung tumor	universal normal control
45	PRO1784	breast tumor	universal normal control
	PRO1774	colon tumor	universal normal control
	PRO1774	lung tumor	universal normal control
	PRO1774	breast tumor	universal normal control
	PRO1605	colon tumor	universal normal control
50	PRO1605	lung tumor	universal normal control
	PRO1605	prostate tumor	universal normal control
	PRO1928	colon tumor	universal normal control
	PRO1928	lung tumor	universal normal control
	PRO1928	cervical tumor	universal normal control
55	PRO1865	lung tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO1865	liver tumor	universal normal control
	PRO1925	lung tumor	universal normal control
	PRO1926	liver tumor	universal normal control
5	PRO2630	colon tumor	universal normal control
	PRO2630	lung tumor	universal normal control
	PRO2630	breast tumor	universal normal control
	PRO2630	liver tumor	universal normal control
	PRO3443	colon tumor	universal normal control
10	PRO3443	lung tumor	universal normal control
	PRO3443	breast tumor	universal normal control
	PRO3301	colon tumor	universal normal control
	PRO3301	lung tumor	universal normal control
	PRO3301	breast tumor	universal normal control
15	PRO3301	rectal tumor	universal normal control
	PRO3442	colon tumor	universal normal control
	PRO3442	lung tumor	universal normal control
	PRO3442	rectal tumor	universal normal control
	PRO4978	colon tumor	universal normal control
20	PRO4978	lung tumor	universal normal control
	PRO4978	breast tumor	universal normal control
	PRO4978	rectal tumor	universal normal control
	PRO5801	colon tumor	universal normal control
	PRO5801	breast tumor	universal normal control
25	PRO19630	colon tumor	universal normal control
	PRO203	colon tumor	universal normal control
	PRO204	colon tumor	universal normal control
	PRO204	lung tumor	universal normal control
	PRO204	breast tumor	universal normal control
30	PRO204	prostate tumor	universal normal control
	PRO210	colon tumor	universal normal control
	PRO210	lung tumor	universal normal control
	PRO223	lung tumor	universal normal control
	PRO223	breast tumor	universal normal control
35	PRO247	colon tumor	universal normal control
	PRO247	lung tumor	universal normal control
	PRO247	breast	universal normal control
	PRO358	lung tumor	universal normal control
	PRO358	breast tumor	universal normal control
40	PRO358	prostate tumor	universal normal control
	PRO724	lung tumor	universal normal control
	PRO868	colon tumor	universal normal control
	PRO868	lung tumor	universal normal control
	PRO868	prostate tumor	universal normal control
45	PRO868	rectal tumor	universal normal control
	PRO740	colon tumor	universal normal control
	PRO1478	colon tumor	universal normal control
	PRO1478	lung tumor	universal normal control
	PRO162	colon tumor	universal normal control
50	PRO162	lung tumor	universal normal control
	PRO162	breast tumor	universal normal control
	PRO828	colon tumor	universal normal control
	PRO828	lung tumor	universal normal control
	PRO828	breast tumor	universal normal control
55	PRO828	cervical tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO828	liver tumor	universal normal control
	PRO819	lung tumor	universal normal control
	PRO819	breast tumor	universal normal control
5	PRO819	rectal tumor	universal normal control
	PRO813	colon tumor	universal normal control
	PRO813	lung tumor	universal normal control
	PRO813	breast tumor	universal normal control
	PRO813	prostate tumor	universal normal control
10	PRO1194	colon tumor	universal normal control
	PRO1194	lung tumor	universal normal control
	PRO1194	breast tumor	universal normal control
	PRO887	colon tumor	universal normal control
	PRO887	lung tumor	universal normal control
15	PRO887	rectal tumor	universal normal control
	PRO1071	colon tumor	universal normal control
	PRO1071	lung tumor	universal normal control
	PRO1071	breast tumor	universal normal control
	PRO1029	colon tumor	universal normal control
20	PRO1029	lung tumor	universal normal control
	PRO1029	breast tumor	universal normal control
	PRO1190	lung tumor	universal normal control
	PRO1190	breast tumor	universal normal control
	PRO4334	lung tumor	universal normal control
25	PRO1155	colon tumor	universal normal control
	PRO1155	lung tumor	universal normal control
	PRO1157	breast tumor	universal normal control
	PRO1157	cervical tumor	universal normal control
	PRO1122	lung tumor	universal normal control
30	PRO1122	breast tumor	universal normal control
	PRO1183	colon tumor	universal normal control
	PRO1183	lung tumor	universal normal control
	PRO1183	breast tumor	universal normal control
	PRO1337	colon tumor	universal normal control
35	PRO1337	lung tumor	universal normal control
	PRO1337	breast tumor	universal normal control
	PRO1480	colon tumor	universal normal control
	PRO1480	lung tumor	universal normal control
	PRO1480	breast tumor	universal normal control
40	PRO19645	colon tumor	universal normal control
	PRO9782	colon tumor	universal normal control
	PRO1419	colon tumor	universal normal control
	PRO1575	colon tumor	universal normal control
	PRO1575	lung tumor	universal normal control
45	PRO1567	colon tumor	universal normal control
	PRO1567	lung tumor	universal normal control
	PRO1567	breast tumor	universal normal control
	PRO1891	colon tumor	universal normal control
	PRO1889	colon tumor	universal normal control
50	PRO1889	lung tumor	universal normal control
	PRO1785	lung tumor	universal normal control
	PRO1785	prostate tumor	universal normal control
	PRO6003	colon tumor	universal normal control
	PRO4333	colon tumor	universal normal control
55	PRO4356	colon tumor	universal normal control



Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO4352	colon tumor	universal normal control
	PRO4354	colon tumor	universal normal control
	PRO4354	lung tumor	universal normal control
5	PRO4354	prostate tumor	universal normal control
	PRO4369	colon tumor	universal normal control
	PRO6030	colon tumor	universal normal control
	PRO4433	colon tumor	universal normal control
	PRO4424	colon tumor	universal normal control
10	PRO4424	breast tumor	universal normal control
	PRO6017	colon tumor	universal normal control
	PRO19563	colon tumor	universal normal control
	PRO6015	colon tumor	universal normal control
	PRO5779	colon tumor	universal normal control
15	PRO5776	colon tumor	universal normal control
	PRO4430	lung tumor	universal normal control
	PRO4421	colon tumor	universal normal control
	PRO4499	colon tumor	universal normal control
	PRO4423	colon tumor	universal normal control
20	PRO5998	colon tumor	universal normal control
	PRO5998	lung tumor	universal normal control
	PRO4501	colon tumor	universal normal control
	PRO6240	colon tumor	universal normal control
	PRO6245	colon tumor	universal normal control
25	PRO6175	colon tumor	universal normal control
	PRO9742	colon tumor	universal normal control
	PRO7179	colon tumor	universal normal control
	PRO6239	colon tumor	universal normal control
	PRO6493	colon tumor	universal normal control
30	PRO9741	colon tumor	universal normal control
	PRO9822	colon tumor	universal normal control
	PRO6244	colon tumor	universal normal control
	PRO9740	colon tumor	universal normal control
	PRO9739	colon tumor	universal normal control
35	PRO7177	colon tumor	universal normal control
	PRO7178	colon tumor	universal normal control
	PRO6246	colon tumor	universal normal control
	PRO6241	colon tumor	universal normal control
	PRO9835	colon tumor	universal normal control
40	PRO9857	colon tumor	universal normal control
	PRO7436	colon tumor	universal normal control
	PRO9856	colon tumor	universal normal control
	PRO19605	colon tumor	universal normal control
	PRO9859	colon tumor	universal normal control
45	PRO12970	colon tumor	universal normal control
	PRO19626	colon tumor	universal normal control
	PRO9883	colon tumor	universal normal control
	PRO19670	colon tumor	universal normal control
	PRO19624	colon tumor	universal normal control
50	PRO19680	colon tumor	universal normal control
	PRO19675	colon tumor	universal normal control
	PRO9834	colon tumor	universal normal control
	PRO9744	colon tumor	universal normal control
	PRO19644	colon tumor	universal normal control
55	PRO19625	colon tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO19597	colon tumor	universal normal control
	PRO16090	colon tumor	universal normal control
	PRO19576	colon tumor	universal normal control
5	PRO19646	colon tumor	universal normal control
	PRO19814	colon tumor	universal normal control
	PRO19669	colon tumor	universal normal control
	PRO19818	colon tumor	universal normal control
	PRO20088	colon tumor	universal normal control
10	PRO16089	colon tumor	universal normal control
	PRO20025	colon tumor	universal normal control
	PRO20040	colon tumor	universal normal control
	PRO1760	adrenal tumor	universal normal control
	PRO1760	breast tumor	universal normal control
15	PRO1760	cervical tumor	universal normal control
	PRO1760	colon tumor	universal normal control
	PRO1760	liver tumor	universal normal control
	PRO1760	lung tumor	universal normal control
	PRO1760	prostate tumor	universal normal control
20	PRO1760	rectal tumor	universal normal control
	PRO6029	adrenal tumor	universal normal control
	PRO6029	colon tumor	universal normal control
	PRO6029	prostate tumor	universal normal control
	PRO1801	colon tumor	universal normal control
25	PRO1801	lung tumor	universal normal control

WHAT IS CLAIMED IS:

1. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16),  
5 Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54),  
10 Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92),  
15 Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID

NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure  
262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID  
NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure  
276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID  
NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure  
5 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID  
NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure  
304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID  
NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure  
318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID  
10 NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure  
332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID  
NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure  
346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID  
NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure  
15 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID  
NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372), Figure  
374 (SEQ ID NO:374), Figure 376 (SEQ ID NO:376), Figure 378 (SEQ ID NO:378), Figure 380 (SEQ ID  
NO:380), Figure 382 (SEQ ID NO:382), Figure 384 (SEQ ID NO:384), Figure 386 (SEQ ID NO:386), Figure  
388 (SEQ ID NO:388), Figure 390 (SEQ ID NO:390), Figure 392 (SEQ ID NO:392), Figure 394 (SEQ ID  
20 NO:394), Figure 396 (SEQ ID NO:396), Figure 398 (SEQ ID NO:398), Figure 400 (SEQ ID NO:400), Figure  
402 (SEQ ID NO:402), Figure 404 (SEQ ID NO:404), Figure 406 (SEQ ID NO:406), Figure 408 (SEQ ID  
NO:408), Figure 410 (SEQ ID NO:410), Figure 412 (SEQ ID NO:412), Figure 414 (SEQ ID NO:414), Figure  
416 (SEQ ID NO:416), Figure 418 (SEQ ID NO:418), Figure 420 (SEQ ID NO:420), Figure 422 (SEQ ID  
NO:422), Figure 424 (SEQ ID NO:424), Figure 426 (SEQ ID NO:426), Figure 428 (SEQ ID NO:428), Figure  
25 430 (SEQ ID NO:430), Figure 432 (SEQ ID NO:432), Figure 434 (SEQ ID NO:434), Figure 436 (SEQ ID  
NO:436), Figure 438 (SEQ ID NO:438), Figure 440 (SEQ ID NO:440), Figure 442 (SEQ ID NO:442), Figure  
444 (SEQ ID NO:444), Figure 446 (SEQ ID NO:446), Figure 448 (SEQ ID NO:448), Figure 450 (SEQ ID  
NO:450), Figure 452 (SEQ ID NO:452), Figure 454 (SEQ ID NO:454), Figure 456 (SEQ ID NO:456), Figure  
458 (SEQ ID NO:458), Figure 460 (SEQ ID NO:460), Figure 462 (SEQ ID NO:462), Figure 464 (SEQ ID  
30 NO:464), Figure 466 (SEQ ID NO:466), Figure 468 (SEQ ID NO:468), Figure 470 (SEQ ID NO:470), Figure  
472 (SEQ ID NO:472), Figure 474 (SEQ ID NO:474), Figure 476 (SEQ ID NO:476), Figure 478 (SEQ ID  
NO:478), Figure 480 (SEQ ID NO:480), Figure 482 (SEQ ID NO:482), Figure 484 (SEQ ID NO:484), Figure  
486 (SEQ ID NO:486), Figure 488 (SEQ ID NO:488), Figure 490 (SEQ ID NO:490), Figure 492 (SEQ ID  
NO:492), Figure 494 (SEQ ID NO:494), Figure 496 (SEQ ID NO:496), Figure 498 (SEQ ID NO:498), Figure  
35 500 (SEQ ID NO:500), Figure 502 (SEQ ID NO:502), Figure 504 (SEQ ID NO:504), Figure 506 (SEQ ID  
NO:506), Figure 508 (SEQ ID NO:508), Figure 510 (SEQ ID NO:510), Figure 512 (SEQ ID NO:512), Figure  
514 (SEQ ID NO:514), Figure 516 (SEQ ID NO:516), Figure 518 (SEQ ID NO:518), Figure 520 (SEQ ID

NO:520), Figure 522 (SEQ ID NO:522), Figure 524 (SEQ ID NO:524), Figure 526 (SEQ ID NO:526), Figure 528 (SEQ ID NO:528), Figure 530 (SEQ ID NO:530), Figure 532 (SEQ ID NO:532), Figure 534 (SEQ ID NO:534), Figure 536 (SEQ ID NO:536), Figure 538 (SEQ ID NO:538), Figure 540 (SEQ ID NO:540), Figure 542 (SEQ ID NO:542), Figure 544 (SEQ ID NO:544), Figure 546 (SEQ ID NO:546), Figure 548 (SEQ ID NO:548), Figure 550 (SEQ ID NO:550), Figure 552 (SEQ ID NO:552), Figure 554 (SEQ ID NO:554), Figure 556 (SEQ ID NO:556), Figure 558 (SEQ ID NO:558), Figure 560 (SEQ ID NO:560), Figure 562 (SEQ ID NO:562), Figure 564 (SEQ ID NO:564), Figure 566 (SEQ ID NO:566), Figure 568 (SEQ ID NO:568), Figure 570 (SEQ ID NO:570), Figure 572 (SEQ ID NO:572), Figure 574 (SEQ ID NO:574), Figure 576 (SEQ ID NO:576), Figure 578 (SEQ ID NO:578), Figure 580 (SEQ ID NO:580), Figure 582 (SEQ ID NO:582), Figure 584 (SEQ ID NO:584), Figure 586 (SEQ ID NO:586), Figure 588 (SEQ ID NO:588), Figure 590 (SEQ ID NO:590), Figure 592 (SEQ ID NO:592), Figure 594 (SEQ ID NO:594), Figure 596 (SEQ ID NO:596), Figure 598 (SEQ ID NO:598), Figure 600 (SEQ ID NO:600), Figure 602 (SEQ ID NO:602), Figure 604 (SEQ ID NO:604), Figure 606 (SEQ ID NO:606), Figure 608 (SEQ ID NO:608), and Figure 610 (SEQ ID NO:610).

2. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39), Figure 41 (SEQ ID NO:41), Figure 43 (SEQ ID NO:43), Figure 45 (SEQ ID NO:45), Figure 47 (SEQ ID NO:47), Figure 49 (SEQ ID NO:49), Figure 51 (SEQ ID NO:51), Figure 53 (SEQ ID NO:53), Figure 55 (SEQ ID NO:55), Figure 57 (SEQ ID NO:57), Figure 59 (SEQ ID NO:59), Figure 61 (SEQ ID NO:61), Figure 63 (SEQ ID NO:63), Figure 65 (SEQ ID NO:65), Figure 67 (SEQ ID NO:67), Figure 69 (SEQ ID NO:69), Figure 71 (SEQ ID NO:71), Figure 73 (SEQ ID NO:73), Figures 75A-75B (SEQ ID NO:75), Figure 77 (SEQ ID NO:77), Figure 79 (SEQ ID NO:79), Figure 81 (SEQ ID NO:81), Figure 83 (SEQ ID NO:83), Figure 85 (SEQ ID NO:85), Figure 87 (SEQ ID NO:87), Figure 89 (SEQ ID NO:89), Figure 91 (SEQ ID NO:91), Figure 93 (SEQ ID NO:93), Figure 95 (SEQ ID NO:95), Figure 97 (SEQ ID NO:97), Figure 99 (SEQ ID NO:99), Figure 101 (SEQ ID NO:101), Figure 103 (SEQ ID NO:103), Figure 105 (SEQ ID NO:105), Figure 107 (SEQ ID NO:107), Figure 109 (SEQ ID NO:109), Figure 111 (SEQ ID NO:111), Figure 113 (SEQ ID NO:113), Figure 115 (SEQ ID NO:115), Figure 117 (SEQ ID NO:117), Figure 119 (SEQ ID NO:119), Figure 121 (SEQ ID NO:121), Figure 123 (SEQ ID NO:123), Figure 125 (SEQ ID NO:125), Figure 127 (SEQ ID NO:127), Figure 129 (SEQ ID NO:129), Figure 131 (SEQ ID NO:131), Figure 133 (SEQ ID NO:133), Figure 135 (SEQ ID NO:135), Figure 137 (SEQ ID NO:137), Figure 139 (SEQ ID NO:139), Figure 141 (SEQ ID NO:141), Figure 143 (SEQ ID NO:143), Figure 145 (SEQ ID NO:145), Figure 147 (SEQ ID NO:147), Figure 149 (SEQ ID NO:149), Figure 151 (SEQ ID NO:151), Figure 153 (SEQ ID NO:153), Figure 155 (SEQ ID NO:155), Figure 157 (SEQ ID NO:157), Figure 159 (SEQ ID NO:159), Figure 161 (SEQ ID NO:161), Figure 163 (SEQ ID NO:163), Figure 165 (SEQ ID

NO:165), Figure 167 (SEQ ID NO:167), Figure 169 (SEQ ID NO:169), Figure 171 (SEQ ID NO:171), Figure 173 (SEQ ID NO:173), Figure 175 (SEQ ID NO:175), Figure 177 (SEQ ID NO:177), Figure 179 (SEQ ID NO:179), Figure 181 (SEQ ID NO:181), Figure 183 (SEQ ID NO:183), Figure 185 (SEQ ID NO:185), Figure 187 (SEQ ID NO:187), Figure 189 (SEQ ID NO:189), Figure 191 (SEQ ID NO:191), Figure 193 (SEQ ID NO:193), Figure 195 (SEQ ID NO:195), Figure 197 (SEQ ID NO:197), Figure 199 (SEQ ID NO:199), Figure 201 (SEQ ID NO:201), Figure 203 (SEQ ID NO:203), Figure 205 (SEQ ID NO:205), Figure 207 (SEQ ID NO:207), Figure 209 (SEQ ID NO:209), Figure 211 (SEQ ID NO:211), Figure 213 (SEQ ID NO:213), Figure 215 (SEQ ID NO:215), Figure 217 (SEQ ID NO:217), Figure 219 (SEQ ID NO:219), Figure 221 (SEQ ID NO:221), Figure 223 (SEQ ID NO:223), Figure 225 (SEQ ID NO:225), Figure 227 (SEQ ID NO:227), Figure 229 (SEQ ID NO:229), Figure 231 (SEQ ID NO:231), Figure 233 (SEQ ID NO:233), Figure 235 (SEQ ID NO:235), Figure 237 (SEQ ID NO:237), Figure 239 (SEQ ID NO:239), Figure 241 (SEQ ID NO:241), Figure 243 (SEQ ID NO:243), Figure 245 (SEQ ID NO:245), Figure 247 (SEQ ID NO:247), Figure 249 (SEQ ID NO:249), Figure 251 (SEQ ID NO:251), Figure 253 (SEQ ID NO:253), Figure 255 (SEQ ID NO:255), Figure 257 (SEQ ID NO:257), Figure 259 (SEQ ID NO:259), Figure 261 (SEQ ID NO:261), Figure 263 (SEQ ID NO:263), Figure 265 (SEQ ID NO:265), Figure 267 (SEQ ID NO:267), Figure 269 (SEQ ID NO:269), Figure 271 (SEQ ID NO:271), Figure 273 (SEQ ID NO:273), Figure 275 (SEQ ID NO:275), Figure 277 (SEQ ID NO:277), Figure 279 (SEQ ID NO:279), Figure 281 (SEQ ID NO:281), Figure 283 (SEQ ID NO:283), Figure 285 (SEQ ID NO:285), Figure 287 (SEQ ID NO:287), Figures 289A-289B (SEQ ID NO:289), Figure 291 (SEQ ID NO:291), Figure 293 (SEQ ID NO:293), Figure 295 (SEQ ID NO:295), Figure 297 (SEQ ID NO:297), Figure 299 (SEQ ID NO:299), Figure 301 (SEQ ID NO:301), Figure 303 (SEQ ID NO:303), Figure 305 (SEQ ID NO:305), Figure 307 (SEQ ID NO:307), Figure 309 (SEQ ID NO:309), Figures 311A-311B (SEQ ID NO:311), Figure 313 (SEQ ID NO:313), Figure 315 (SEQ ID NO:315), Figure 317 (SEQ ID NO:317), Figure 319 (SEQ ID NO:319), Figure 321 (SEQ ID NO:321), Figure 323 (SEQ ID NO:323), Figure 325 (SEQ ID NO:325), Figure 327 (SEQ ID NO:327), Figure 329 (SEQ ID NO:329), Figure 331 (SEQ ID NO:331), Figure 333 (SEQ ID NO:333), Figure 335 (SEQ ID NO:335), Figure 337 (SEQ ID NO:337), Figure 339 (SEQ ID NO:339), Figure 341 (SEQ ID NO:341), Figure 343 (SEQ ID NO:343), Figure 345 (SEQ ID NO:345), Figure 347 (SEQ ID NO:347), Figure 349 (SEQ ID NO:349), Figures 351A-351B (SEQ ID NO:351), Figure 353 (SEQ ID NO:353), Figure 355 (SEQ ID NO:355), Figure 357 (SEQ ID NO:357), Figure 359 (SEQ ID NO:359), Figure 361 (SEQ ID NO:361), Figure 363 (SEQ ID NO:363), Figure 365 (SEQ ID NO:365), Figure 367 (SEQ ID NO:367), Figure 369 (SEQ ID NO:369), Figure 371 (SEQ ID NO:371), Figure 373 (SEQ ID NO:373), Figure 375 (SEQ ID NO:375), Figure 377 (SEQ ID NO:377), Figure 379 (SEQ ID NO:379), Figure 381 (SEQ ID NO:381), Figure 383 (SEQ ID NO:383), Figure 385 (SEQ ID NO:385), Figure 387 (SEQ ID NO:387), Figure 389 (SEQ ID NO:389), Figure 391 (SEQ ID NO:391), Figure 393 (SEQ ID NO:393), Figure 395 (SEQ ID NO:395), Figure 397 (SEQ ID NO:397), Figure 399 (SEQ ID NO:399), Figure 401 (SEQ ID NO:401), Figure 403 (SEQ ID NO:403), Figure 405 (SEQ ID NO:405), Figure 407 (SEQ ID NO:407), Figure 409 (SEQ ID NO:409), Figure 411 (SEQ ID NO:411), Figure 413 (SEQ ID NO:413), Figure 415 (SEQ ID NO:415), Figure 417 (SEQ ID NO:417), Figure 419 (SEQ ID NO:419), Figure 421 (SEQ ID NO:421), Figure 423 (SEQ ID NO:423), Figure 425 (SEQ ID NO:425), Figure 427 (SEQ ID NO:427), Figure 429 (SEQ ID NO:429), Figure 431 (SEQ ID

NO:431), Figure 433 (SEQ ID NO:433), Figure 435 (SEQ ID NO:435), Figure 437 (SEQ ID NO:437), Figure 439 (SEQ ID NO:439), Figure 441 (SEQ ID NO:441), Figure 443 (SEQ ID NO:443), Figure 445 (SEQ ID NO:445), Figure 447 (SEQ ID NO:447), Figure 449 (SEQ ID NO:449), Figure 451 (SEQ ID NO:451), Figure 453 (SEQ ID NO:453), Figure 455 (SEQ ID NO:455), Figure 457 (SEQ ID NO:457), Figure 459 (SEQ ID NO:459), Figure 461 (SEQ ID NO:461), Figure 463 (SEQ ID NO:463), Figure 465 (SEQ ID NO:465), Figure 467 (SEQ ID NO:467), Figure 469 (SEQ ID NO:469), Figure 471 (SEQ ID NO:471), Figure 473 (SEQ ID NO:473), Figure 475 (SEQ ID NO:475), Figure 477 (SEQ ID NO:477), Figure 479 (SEQ ID NO:479), Figure 481 (SEQ ID NO:481), Figure 483 (SEQ ID NO:483), Figure 485 (SEQ ID NO:485), Figure 487 (SEQ ID NO:487), Figure 489 (SEQ ID NO:489), Figure 491 (SEQ ID NO:491), Figure 493 (SEQ ID NO:493), Figure 495 (SEQ ID NO:495), Figure 497 (SEQ ID NO:497), Figure 499 (SEQ ID NO:499), Figure 501 (SEQ ID NO:501), Figure 503 (SEQ ID NO:503), Figure 505 (SEQ ID NO:505), Figure 507 (SEQ ID NO:507), Figure 509 (SEQ ID NO:509), Figure 511 (SEQ ID NO:511), Figure 513 (SEQ ID NO:513), Figure 515 (SEQ ID NO:515), Figure 517 (SEQ ID NO:517), Figure 519 (SEQ ID NO:519), Figure 521 (SEQ ID NO:521), Figure 523 (SEQ ID NO:523), Figures 525A-525B (SEQ ID NO:525), Figure 527 (SEQ ID NO:527), Figure 529 (SEQ ID NO:529), Figure 531 (SEQ ID NO:531), Figure 533 (SEQ ID NO:533), Figure 535 (SEQ ID NO:535), Figure 537 (SEQ ID NO:537), Figure 539 (SEQ ID NO:539), Figure 541 (SEQ ID NO:541), Figure 543 (SEQ ID NO:543), Figure 545 (SEQ ID NO:545), Figure 547 (SEQ ID NO:547), Figure 549 (SEQ ID NO:549), Figure 551 (SEQ ID NO:551), Figure 553 (SEQ ID NO:553), Figure 555 (SEQ ID NO:555), Figure 557 (SEQ ID NO:557), Figure 559 (SEQ ID NO:559), Figure 561 (SEQ ID NO:561), Figure 563 (SEQ ID NO:563), Figure 565 (SEQ ID NO:565), Figure 567 (SEQ ID NO:567), Figure 569 (SEQ ID NO:569), Figure 571 (SEQ ID NO:571), Figure 573 (SEQ ID NO:573), Figure 575 (SEQ ID NO:575), Figure 577 (SEQ ID NO:577), Figure 579 (SEQ ID NO:579), Figure 581 (SEQ ID NO:581), Figure 583 (SEQ ID NO:583), Figure 585 (SEQ ID NO:585), Figure 587 (SEQ ID NO:587), Figure 589 (SEQ ID NO:589), Figure 591 (SEQ ID NO:591), Figure 593 (SEQ ID NO:593), Figure 595 (SEQ ID NO:595), Figure 597 (SEQ ID NO:597), Figure 599 (SEQ ID NO:599), Figure 601 (SEQ ID NO:601), Figure 603 (SEQ ID NO:603), Figure 605 (SEQ ID NO:605), Figure 607 (SEQ ID NO:607), and Figure 609 (SEQ ID NO:609).

3. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the full-length coding sequence of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39), Figure 41 (SEQ ID NO:41), Figure 43 (SEQ ID NO:43), Figure 45 (SEQ ID NO:45), Figure 47 (SEQ ID NO:47), Figure 49 (SEQ ID NO:49), Figure 51 (SEQ ID NO:51), Figure 53 (SEQ ID NO:53), Figure 55 (SEQ ID NO:55), Figure 57 (SEQ ID NO:57), Figure 59 (SEQ ID NO:59), Figure 61 (SEQ ID NO:61), Figure 63 (SEQ ID NO:63), Figure 65 (SEQ ID NO:65), Figure 67 (SEQ ID NO:67), Figure 69 (SEQ ID NO:69), Figure

71 (SEQ ID NO:71), Figure 73 (SEQ ID NO:73), Figures 75A-75B (SEQ ID NO:75), Figure 77 (SEQ ID NO:77), Figure 79 (SEQ ID NO:79), Figure 81 (SEQ ID NO:81), Figure 83 (SEQ ID NO:83), Figure 85 (SEQ ID NO:85), Figure 87 (SEQ ID NO:87), Figure 89 (SEQ ID NO:89), Figure 91 (SEQ ID NO:91), Figure 93 (SEQ ID NO:93), Figure 95 (SEQ ID NO:95), Figure 97 (SEQ ID NO:97), Figure 99 (SEQ ID NO:99), Figure 101 (SEQ ID NO:101), Figure 103 (SEQ ID NO:103), Figure 105 (SEQ ID NO:105), Figure 107 (SEQ ID NO:107), Figure 109 (SEQ ID NO:109), Figure 111 (SEQ ID NO:111), Figure 113 (SEQ ID NO:113), Figure 115 (SEQ ID NO:115), Figure 117 (SEQ ID NO:117), Figure 119 (SEQ ID NO:119), Figure 121 (SEQ ID NO:121), Figure 123 (SEQ ID NO:123), Figure 125 (SEQ ID NO:125), Figure 127 (SEQ ID NO:127), Figure 129 (SEQ ID NO:129), Figure 131 (SEQ ID NO:131), Figure 133 (SEQ ID NO:133), Figure 135 (SEQ ID NO:135), Figure 137 (SEQ ID NO:137), Figure 139 (SEQ ID NO:139), Figure 141 (SEQ ID NO:141), Figure 143 (SEQ ID NO:143), Figure 145 (SEQ ID NO:145), Figure 147 (SEQ ID NO:147), Figure 149 (SEQ ID NO:149), Figure 151 (SEQ ID NO:151), Figure 153 (SEQ ID NO:153), Figure 155 (SEQ ID NO:155), Figure 157 (SEQ ID NO:157), Figure 159 (SEQ ID NO:159), Figure 161 (SEQ ID NO:161), Figure 163 (SEQ ID NO:163), Figure 165 (SEQ ID NO:165), Figure 167 (SEQ ID NO:167), Figure 169 (SEQ ID NO:169), Figure 171 (SEQ ID NO:171), Figure 173 (SEQ ID NO:173), Figure 175 (SEQ ID NO:175), Figure 177 (SEQ ID NO:177), Figure 179 (SEQ ID NO:179), Figure 181 (SEQ ID NO:181), Figure 183 (SEQ ID NO:183), Figure 185 (SEQ ID NO:185), Figure 187 (SEQ ID NO:187), Figure 189 (SEQ ID NO:189), Figure 191 (SEQ ID NO:191), Figure 193 (SEQ ID NO:193), Figure 195 (SEQ ID NO:195), Figure 197 (SEQ ID NO:197), Figure 199 (SEQ ID NO:199), Figure 201 (SEQ ID NO:201), Figure 203 (SEQ ID NO:203), Figure 205 (SEQ ID NO:205), Figure 207 (SEQ ID NO:207), Figure 209 (SEQ ID NO:209), Figure 211 (SEQ ID NO:211), Figure 213 (SEQ ID NO:213), Figure 215 (SEQ ID NO:215), Figure 217 (SEQ ID NO:217), Figure 219 (SEQ ID NO:219), Figure 221 (SEQ ID NO:221), Figure 223 (SEQ ID NO:223), Figure 225 (SEQ ID NO:225), Figure 227 (SEQ ID NO:227), Figure 229 (SEQ ID NO:229), Figure 231 (SEQ ID NO:231), Figure 233 (SEQ ID NO:233), Figure 235 (SEQ ID NO:235), Figure 237 (SEQ ID NO:237), Figure 239 (SEQ ID NO:239), Figure 241 (SEQ ID NO:241), Figure 243 (SEQ ID NO:243), Figure 245 (SEQ ID NO:245), Figure 247 (SEQ ID NO:247), Figure 249 (SEQ ID NO:249), Figure 251 (SEQ ID NO:251), Figure 253 (SEQ ID NO:253), Figure 255 (SEQ ID NO:255), Figure 257 (SEQ ID NO:257), Figure 259 (SEQ ID NO:259), Figure 261 (SEQ ID NO:261), Figure 263 (SEQ ID NO:263), Figure 265 (SEQ ID NO:265), Figure 267 (SEQ ID NO:267), Figure 269 (SEQ ID NO:269), Figure 271 (SEQ ID NO:271), Figure 273 (SEQ ID NO:273), Figure 275 (SEQ ID NO:275), Figure 277 (SEQ ID NO:277), Figure 279 (SEQ ID NO:279), Figure 281 (SEQ ID NO:281), Figure 283 (SEQ ID NO:283), Figure 285 (SEQ ID NO:285), Figure 287 (SEQ ID NO:287), Figures 289A-289B (SEQ ID NO:289), Figure 291 (SEQ ID NO:291), Figure 293 (SEQ ID NO:293), Figure 295 (SEQ ID NO:295), Figure 297 (SEQ ID NO:297), Figure 299 (SEQ ID NO:299), Figure 301 (SEQ ID NO:301), Figure 303 (SEQ ID NO:303), Figure 305 (SEQ ID NO:305), Figure 307 (SEQ ID NO:307), Figure 309 (SEQ ID NO:309), Figures 311A-311B (SEQ ID NO:311), Figure 313 (SEQ ID NO:313), Figure 315 (SEQ ID NO:315), Figure 317 (SEQ ID NO:317), Figure 319 (SEQ ID NO:319), Figure 321 (SEQ ID NO:321), Figure 323 (SEQ ID NO:323), Figure 325 (SEQ ID NO:325), Figure 327 (SEQ ID NO:327), Figure 329 (SEQ ID NO:329), Figure 331 (SEQ ID NO:331), Figure 333 (SEQ ID NO:333), Figure 335 (SEQ ID NO:335), Figure 337 (SEQ ID NO:337), Figure



339 (SEQ ID NO:339), Figure 341 (SEQ ID NO:341), Figure 343 (SEQ ID NO:343), Figure 345 (SEQ ID NO:345), Figure 347 (SEQ ID NO:347), Figure 349 (SEQ ID NO:349), Figures 351A-351B (SEQ ID NO:351), Figure 353 (SEQ ID NO:353), Figure 355 (SEQ ID NO:355), Figure 357 (SEQ ID NO:357), Figure 359 (SEQ ID NO:359), Figure 361 (SEQ ID NO:361), Figure 363 (SEQ ID NO:363), Figure 365 (SEQ ID NO:365), Figure 367 (SEQ ID NO:367), Figure 369 (SEQ ID NO:369), Figure 371 (SEQ ID NO:371), Figure 373 (SEQ ID NO:373), Figure 375 (SEQ ID NO:375), Figure 377 (SEQ ID NO:377), Figure 379 (SEQ ID NO:379), Figure 381 (SEQ ID NO:381), Figure 383 (SEQ ID NO:383), Figure 385 (SEQ ID NO:385), Figure 387 (SEQ ID NO:387), Figure 389 (SEQ ID NO:389), Figure 391 (SEQ ID NO:391), Figure 393 (SEQ ID NO:393), Figure 395 (SEQ ID NO:395), Figure 397 (SEQ ID NO:397), Figure 399 (SEQ ID NO:399), Figure 401 (SEQ ID NO:401), Figure 403 (SEQ ID NO:403), Figure 405 (SEQ ID NO:405), Figure 407 (SEQ ID NO:407), Figure 409 (SEQ ID NO:409), Figure 411 (SEQ ID NO:411), Figure 413 (SEQ ID NO:413), Figure 415 (SEQ ID NO:415), Figure 417 (SEQ ID NO:417), Figure 419 (SEQ ID NO:419), Figure 421 (SEQ ID NO:421), Figure 423 (SEQ ID NO:423), Figure 425 (SEQ ID NO:425), Figure 427 (SEQ ID NO:427), Figure 429 (SEQ ID NO:429), Figure 431 (SEQ ID NO:431), Figure 433 (SEQ ID NO:433), Figure 435 (SEQ ID NO:435), Figure 437 (SEQ ID NO:437), Figure 439 (SEQ ID NO:439), Figure 441 (SEQ ID NO:441), Figure 443 (SEQ ID NO:443), Figure 445 (SEQ ID NO:445), Figure 447 (SEQ ID NO:447), Figure 449 (SEQ ID NO:449), Figure 451 (SEQ ID NO:451), Figure 453 (SEQ ID NO:453), Figure 455 (SEQ ID NO:455), Figure 457 (SEQ ID NO:457), Figure 459 (SEQ ID NO:459), Figure 461 (SEQ ID NO:461), Figure 463 (SEQ ID NO:463), Figure 465 (SEQ ID NO:465), Figure 467 (SEQ ID NO:467), Figure 469 (SEQ ID NO:469), Figure 471 (SEQ ID NO:471), Figure 473 (SEQ ID NO:473), Figure 475 (SEQ ID NO:475), Figure 477 (SEQ ID NO:477), Figure 479 (SEQ ID NO:479), Figure 481 (SEQ ID NO:481), Figure 483 (SEQ ID NO:483), Figure 485 (SEQ ID NO:485), Figure 487 (SEQ ID NO:487), Figure 489 (SEQ ID NO:489), Figure 491 (SEQ ID NO:491), Figure 493 (SEQ ID NO:493), Figure 495 (SEQ ID NO:495), Figure 497 (SEQ ID NO:497), Figure 499 (SEQ ID NO:499), Figure 501 (SEQ ID NO:501), Figure 503 (SEQ ID NO:503), Figure 505 (SEQ ID NO:505), Figure 507 (SEQ ID NO:507), Figure 509 (SEQ ID NO:509), Figure 511 (SEQ ID NO:511), Figure 513 (SEQ ID NO:513), Figure 515 (SEQ ID NO:515), Figure 517 (SEQ ID NO:517), Figure 519 (SEQ ID NO:519), Figure 521 (SEQ ID NO:521), Figure 523 (SEQ ID NO:523), Figures 525A-525B (SEQ ID NO:525), Figure 527 (SEQ ID NO:527), Figure 529 (SEQ ID NO:529), Figure 531 (SEQ ID NO:531), Figure 533 (SEQ ID NO:533), Figure 535 (SEQ ID NO:535), Figure 537 (SEQ ID NO:537), Figure 539 (SEQ ID NO:539), Figure 541 (SEQ ID NO:541), Figure 543 (SEQ ID NO:543), Figure 545 (SEQ ID NO:545), Figure 547 (SEQ ID NO:547), Figure 549 (SEQ ID NO:549), Figure 551 (SEQ ID NO:551), Figure 553 (SEQ ID NO:553), Figure 555 (SEQ ID NO:555), Figure 557 (SEQ ID NO:557), Figure 559 (SEQ ID NO:559), Figure 561 (SEQ ID NO:561), Figure 563 (SEQ ID NO:563), Figure 565 (SEQ ID NO:565), Figure 567 (SEQ ID NO:567), Figure 569 (SEQ ID NO:569), Figure 571 (SEQ ID NO:571), Figure 573 (SEQ ID NO:573), Figure 575 (SEQ ID NO:575), Figure 577 (SEQ ID NO:577), Figure 579 (SEQ ID NO:579), Figure 581 (SEQ ID NO:581), Figure 583 (SEQ ID NO:583), Figure 585 (SEQ ID NO:585), Figure 587 (SEQ ID NO:587), Figure 589 (SEQ ID NO:589), Figure 591 (SEQ ID NO:591), Figure 593 (SEQ ID NO:593), Figure 595 (SEQ ID NO:595), Figure 597 (SEQ ID NO:597), Figure 599 (SEQ ID NO:599), Figure 601 (SEQ ID NO:601), Figure 603 (SEQ ID NO:603), Figure

605 (SEQ ID NO:605), Figure 607 (SEQ ID NO:607), and Figure 609 (SEQ ID NO:609).

4. Isolated nucleic acid having at least 80% nucleic acid sequence identity to the full-length coding sequence of the DNA deposited under any ATCC accession number shown in Table 7.

5. A vector comprising the nucleic acid of Claim 1.

6. A host cell comprising the vector of Claim 5.

7. The host cell of Claim 6, wherein said cell is a CHO cell.

10

8. The host cell of Claim 6, wherein said cell is an *E. coli*.

9. The host cell of Claim 6, wherein said cell is a yeast cell.

15

10. A process for producing a PRO polypeptide comprising culturing the host cell of Claim 6 under conditions suitable for expression of said PRO polypeptide and recovering said PRO polypeptide from the cell culture.

11. An isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID

NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure  
138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID  
NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure  
152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID  
NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure  
5 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID  
NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure  
180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID  
NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure  
10 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID  
NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure  
208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID  
NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure  
222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID  
NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure  
15 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID  
NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure  
250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID  
NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure  
264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID  
20 NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure  
278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID  
NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure  
292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID  
NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure  
25 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID  
NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure  
320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID  
NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure  
334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID  
30 NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure  
348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID  
NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure  
362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID  
NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372), Figure 374 (SEQ ID NO:374), Figure  
35 376 (SEQ ID NO:376), Figure 378 (SEQ ID NO:378), Figure 380 (SEQ ID NO:380), Figure 382 (SEQ ID  
NO:382), Figure 384 (SEQ ID NO:384), Figure 386 (SEQ ID NO:386), Figure 388 (SEQ ID NO:388), Figure  
390 (SEQ ID NO:390), Figure 392 (SEQ ID NO:392), Figure 394 (SEQ ID NO:394), Figure 396 (SEQ ID

NO:396), Figure 398 (SEQ ID NO:398), Figure 400 (SEQ ID NO:400), Figure 402 (SEQ ID NO:402), Figure 404 (SEQ ID NO:404), Figure 406 (SEQ ID NO:406), Figure 408 (SEQ ID NO:408), Figure 410 (SEQ ID NO:410), Figure 412 (SEQ ID NO:412), Figure 414 (SEQ ID NO:414), Figure 416 (SEQ ID NO:416), Figure 418 (SEQ ID NO:418), Figure 420 (SEQ ID NO:420), Figure 422 (SEQ ID NO:422), Figure 424 (SEQ ID NO:424), Figure 426 (SEQ ID NO:426), Figure 428 (SEQ ID NO:428), Figure 430 (SEQ ID NO:430), Figure 432 (SEQ ID NO:432), Figure 434 (SEQ ID NO:434), Figure 436 (SEQ ID NO:436), Figure 438 (SEQ ID NO:438), Figure 440 (SEQ ID NO:440), Figure 442 (SEQ ID NO:442), Figure 444 (SEQ ID NO:444), Figure 446 (SEQ ID NO:446), Figure 448 (SEQ ID NO:448), Figure 450 (SEQ ID NO:450), Figure 452 (SEQ ID NO:452), Figure 454 (SEQ ID NO:454), Figure 456 (SEQ ID NO:456), Figure 458 (SEQ ID NO:458), Figure 460 (SEQ ID NO:460), Figure 462 (SEQ ID NO:462), Figure 464 (SEQ ID NO:464), Figure 466 (SEQ ID NO:466), Figure 468 (SEQ ID NO:468), Figure 470 (SEQ ID NO:470), Figure 472 (SEQ ID NO:472), Figure 474 (SEQ ID NO:474), Figure 476 (SEQ ID NO:476), Figure 478 (SEQ ID NO:478), Figure 480 (SEQ ID NO:480), Figure 482 (SEQ ID NO:482), Figure 484 (SEQ ID NO:484), Figure 486 (SEQ ID NO:486), Figure 488 (SEQ ID NO:488), Figure 490 (SEQ ID NO:490), Figure 492 (SEQ ID NO:492), Figure 494 (SEQ ID NO:494), Figure 496 (SEQ ID NO:496), Figure 498 (SEQ ID NO:498), Figure 500 (SEQ ID NO:500), Figure 502 (SEQ ID NO:502), Figure 504 (SEQ ID NO:504), Figure 506 (SEQ ID NO:506), Figure 508 (SEQ ID NO:508), Figure 510 (SEQ ID NO:510), Figure 512 (SEQ ID NO:512), Figure 514 (SEQ ID NO:514), Figure 516 (SEQ ID NO:516), Figure 518 (SEQ ID NO:518), Figure 520 (SEQ ID NO:520), Figure 522 (SEQ ID NO:522), Figure 524 (SEQ ID NO:524), Figure 526 (SEQ ID NO:526), Figure 528 (SEQ ID NO:528), Figure 530 (SEQ ID NO:530), Figure 532 (SEQ ID NO:532), Figure 534 (SEQ ID NO:534), Figure 536 (SEQ ID NO:536), Figure 538 (SEQ ID NO:538), Figure 540 (SEQ ID NO:540), Figure 542 (SEQ ID NO:542), Figure 544 (SEQ ID NO:544), Figure 546 (SEQ ID NO:546), Figure 548 (SEQ ID NO:548), Figure 550 (SEQ ID NO:550), Figure 552 (SEQ ID NO:552), Figure 554 (SEQ ID NO:554), Figure 556 (SEQ ID NO:556), Figure 558 (SEQ ID NO:558), Figure 560 (SEQ ID NO:560), Figure 562 (SEQ ID NO:562), Figure 564 (SEQ ID NO:564), Figure 566 (SEQ ID NO:566), Figure 568 (SEQ ID NO:568), Figure 570 (SEQ ID NO:570), Figure 572 (SEQ ID NO:572), Figure 574 (SEQ ID NO:574), Figure 576 (SEQ ID NO:576), Figure 578 (SEQ ID NO:578), Figure 580 (SEQ ID NO:580), Figure 582 (SEQ ID NO:582), Figure 584 (SEQ ID NO:584), Figure 586 (SEQ ID NO:586), Figure 588 (SEQ ID NO:588), Figure 590 (SEQ ID NO:590), Figure 592 (SEQ ID NO:592), Figure 594 (SEQ ID NO:594), Figure 596 (SEQ ID NO:596), Figure 598 (SEQ ID NO:598), Figure 600 (SEQ ID NO:600), Figure 602 (SEQ ID NO:602), Figure 604 (SEQ ID NO:604), Figure 606 (SEQ ID NO:606), Figure 608 (SEQ ID NO:608), and Figure 610 (SEQ ID NO:610).

12. An isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence encoded by the full-length coding sequence of the DNA deposited under any ATCC accession number shown in Table 7.

13. A chimeric molecule comprising a polypeptide according to Claim 11 fused to a heterologous amino acid sequence.

14. The chimeric molecule of Claim 13, wherein said heterologous amino acid sequence is an epitope tag sequence.

15. The chimeric molecule of Claim 13, wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.

5

16. An antibody which specifically binds to a polypeptide according to Claim 11.

17. The antibody of Claim 16, wherein said antibody is a monoclonal antibody, a humanized antibody or a single-chain antibody.

10

18. Isolated nucleic acid having at least 80% nucleic acid sequence identity to:

(a) a nucleotide sequence encoding the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure

35

188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372), Figure 374 (SEQ ID NO:374), Figure 376 (SEQ ID NO:376), Figure 378 (SEQ ID NO:378), Figure 380 (SEQ ID NO:380), Figure 382 (SEQ ID NO:382), Figure 384 (SEQ ID NO:384), Figure 386 (SEQ ID NO:386), Figure 388 (SEQ ID NO:388), Figure 390 (SEQ ID NO:390), Figure 392 (SEQ ID NO:392), Figure 394 (SEQ ID NO:394), Figure 396 (SEQ ID NO:396), Figure 398 (SEQ ID NO:398), Figure 400 (SEQ ID NO:400), Figure 402 (SEQ ID NO:402), Figure 404 (SEQ ID NO:404), Figure 406 (SEQ ID NO:406), Figure 408 (SEQ ID NO:408), Figure 410 (SEQ ID NO:410), Figure 412 (SEQ ID NO:412), Figure 414 (SEQ ID NO:414), Figure 416 (SEQ ID NO:416), Figure 418 (SEQ ID NO:418), Figure 420 (SEQ ID NO:420), Figure 422 (SEQ ID NO:422), Figure 424 (SEQ ID NO:424), Figure 426 (SEQ ID NO:426), Figure 428 (SEQ ID NO:428), Figure 430 (SEQ ID NO:430), Figure 432 (SEQ ID NO:432), Figure 434 (SEQ ID NO:434), Figure 436 (SEQ ID NO:436), Figure 438 (SEQ ID NO:438), Figure 440 (SEQ ID NO:440), Figure 442 (SEQ ID NO:442), Figure 444 (SEQ ID NO:444), Figure 446 (SEQ ID NO:446), Figure 448 (SEQ ID NO:448), Figure 450 (SEQ ID NO:450), Figure 452 (SEQ ID NO:452), Figure

454 (SEQ ID NO:454), Figure 456 (SEQ ID NO:456), Figure 458 (SEQ ID NO:458), Figure 460 (SEQ ID NO:460), Figure 462 (SEQ ID NO:462), Figure 464 (SEQ ID NO:464), Figure 466 (SEQ ID NO:466), Figure 468 (SEQ ID NO:468), Figure 470 (SEQ ID NO:470), Figure 472 (SEQ ID NO:472), Figure 474 (SEQ ID NO:474), Figure 476 (SEQ ID NO:476), Figure 478 (SEQ ID NO:478), Figure 480 (SEQ ID NO:480), Figure 482 (SEQ ID NO:482), Figure 484 (SEQ ID NO:484), Figure 486 (SEQ ID NO:486), Figure 488 (SEQ ID NO:488), Figure 490 (SEQ ID NO:490), Figure 492 (SEQ ID NO:492), Figure 494 (SEQ ID NO:494), Figure 496 (SEQ ID NO:496), Figure 498 (SEQ ID NO:498), Figure 500 (SEQ ID NO:500), Figure 502 (SEQ ID NO:502), Figure 504 (SEQ ID NO:504), Figure 506 (SEQ ID NO:506), Figure 508 (SEQ ID NO:508), Figure 510 (SEQ ID NO:510), Figure 512 (SEQ ID NO:512), Figure 514 (SEQ ID NO:514), Figure 516 (SEQ ID NO:516), Figure 518 (SEQ ID NO:518), Figure 520 (SEQ ID NO:520), Figure 522 (SEQ ID NO:522), Figure 524 (SEQ ID NO:524), Figure 526 (SEQ ID NO:526), Figure 528 (SEQ ID NO:528), Figure 530 (SEQ ID NO:530), Figure 532 (SEQ ID NO:532), Figure 534 (SEQ ID NO:534), Figure 536 (SEQ ID NO:536), Figure 538 (SEQ ID NO:538), Figure 540 (SEQ ID NO:540), Figure 542 (SEQ ID NO:542), Figure 544 (SEQ ID NO:544), Figure 546 (SEQ ID NO:546), Figure 548 (SEQ ID NO:548), Figure 550 (SEQ ID NO:550), Figure 552 (SEQ ID NO:552), Figure 554 (SEQ ID NO:554), Figure 556 (SEQ ID NO:556), Figure 558 (SEQ ID NO:558), Figure 560 (SEQ ID NO:560), Figure 562 (SEQ ID NO:562), Figure 564 (SEQ ID NO:564), Figure 566 (SEQ ID NO:566), Figure 568 (SEQ ID NO:568), Figure 570 (SEQ ID NO:570), Figure 572 (SEQ ID NO:572), Figure 574 (SEQ ID NO:574), Figure 576 (SEQ ID NO:576), Figure 578 (SEQ ID NO:578), Figure 580 (SEQ ID NO:580), Figure 582 (SEQ ID NO:582), Figure 584 (SEQ ID NO:584), Figure 586 (SEQ ID NO:586), Figure 588 (SEQ ID NO:588), Figure 590 (SEQ ID NO:590), Figure 592 (SEQ ID NO:592), Figure 594 (SEQ ID NO:594), Figure 596 (SEQ ID NO:596), Figure 598 (SEQ ID NO:598), Figure 600 (SEQ ID NO:600), Figure 602 (SEQ ID NO:602), Figure 604 (SEQ ID NO:604), Figure 606 (SEQ ID NO:606), Figure 608 (SEQ ID NO:608), or Figure 610 (SEQ ID NO:610), lacking its associated signal peptide;

(b) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ

ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure  
116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID  
NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure  
130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID  
NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure  
5 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID  
NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure  
158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID  
NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure  
10 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID  
NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure  
186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID  
NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure  
200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID  
NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure  
15 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID  
NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure  
228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID  
NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure  
20 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID  
NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure  
256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID  
NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure  
270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID  
NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure  
25 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID  
NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure  
298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID  
NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure  
312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID  
30 NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure  
326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID  
NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure  
340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID  
NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure  
35 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID  
NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure  
368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372), Figure 374 (SEQ ID



NO:374), Figure 376 (SEQ ID NO:376), Figure 378 (SEQ ID NO:378), Figure 380 (SEQ ID NO:380), Figure 382 (SEQ ID NO:382), Figure 384 (SEQ ID NO:384), Figure 386 (SEQ ID NO:386), Figure 388 (SEQ ID NO:388), Figure 390 (SEQ ID NO:390), Figure 392 (SEQ ID NO:392), Figure 394 (SEQ ID NO:394), Figure 396 (SEQ ID NO:396), Figure 398 (SEQ ID NO:398), Figure 400 (SEQ ID NO:400), Figure 402 (SEQ ID NO:402), Figure 404 (SEQ ID NO:404), Figure 406 (SEQ ID NO:406), Figure 408 (SEQ ID NO:408), Figure 410 (SEQ ID NO:410), Figure 412 (SEQ ID NO:412), Figure 414 (SEQ ID NO:414), Figure 416 (SEQ ID NO:416), Figure 418 (SEQ ID NO:418), Figure 420 (SEQ ID NO:420), Figure 422 (SEQ ID NO:422), Figure 424 (SEQ ID NO:424), Figure 426 (SEQ ID NO:426), Figure 428 (SEQ ID NO:428), Figure 430 (SEQ ID NO:430), Figure 432 (SEQ ID NO:432), Figure 434 (SEQ ID NO:434), Figure 436 (SEQ ID NO:436), Figure 438 (SEQ ID NO:438), Figure 440 (SEQ ID NO:440), Figure 442 (SEQ ID NO:442), Figure 444 (SEQ ID NO:444), Figure 446 (SEQ ID NO:446), Figure 448 (SEQ ID NO:448), Figure 450 (SEQ ID NO:450), Figure 452 (SEQ ID NO:452), Figure 454 (SEQ ID NO:454), Figure 456 (SEQ ID NO:456), Figure 458 (SEQ ID NO:458), Figure 460 (SEQ ID NO:460), Figure 462 (SEQ ID NO:462), Figure 464 (SEQ ID NO:464), Figure 466 (SEQ ID NO:466), Figure 468 (SEQ ID NO:468), Figure 470 (SEQ ID NO:470), Figure 472 (SEQ ID NO:472), Figure 474 (SEQ ID NO:474), Figure 476 (SEQ ID NO:476), Figure 478 (SEQ ID NO:478), Figure 480 (SEQ ID NO:480), Figure 482 (SEQ ID NO:482), Figure 484 (SEQ ID NO:484), Figure 486 (SEQ ID NO:486), Figure 488 (SEQ ID NO:488), Figure 490 (SEQ ID NO:490), Figure 492 (SEQ ID NO:492), Figure 494 (SEQ ID NO:494), Figure 496 (SEQ ID NO:496), Figure 498 (SEQ ID NO:498), Figure 500 (SEQ ID NO:500), Figure 502 (SEQ ID NO:502), Figure 504 (SEQ ID NO:504), Figure 506 (SEQ ID NO:506), Figure 508 (SEQ ID NO:508), Figure 510 (SEQ ID NO:510), Figure 512 (SEQ ID NO:512), Figure 514 (SEQ ID NO:514), Figure 516 (SEQ ID NO:516), Figure 518 (SEQ ID NO:518), Figure 520 (SEQ ID NO:520), Figure 522 (SEQ ID NO:522), Figure 524 (SEQ ID NO:524), Figure 526 (SEQ ID NO:526), Figure 528 (SEQ ID NO:528), Figure 530 (SEQ ID NO:530), Figure 532 (SEQ ID NO:532), Figure 534 (SEQ ID NO:534), Figure 536 (SEQ ID NO:536), Figure 538 (SEQ ID NO:538), Figure 540 (SEQ ID NO:540), Figure 542 (SEQ ID NO:542), Figure 544 (SEQ ID NO:544), Figure 546 (SEQ ID NO:546), Figure 548 (SEQ ID NO:548), Figure 550 (SEQ ID NO:550), Figure 552 (SEQ ID NO:552), Figure 554 (SEQ ID NO:554), Figure 556 (SEQ ID NO:556), Figure 558 (SEQ ID NO:558), Figure 560 (SEQ ID NO:560), Figure 562 (SEQ ID NO:562), Figure 564 (SEQ ID NO:564), Figure 566 (SEQ ID NO:566), Figure 568 (SEQ ID NO:568), Figure 570 (SEQ ID NO:570), Figure 572 (SEQ ID NO:572), Figure 574 (SEQ ID NO:574), Figure 576 (SEQ ID NO:576), Figure 578 (SEQ ID NO:578), Figure 580 (SEQ ID NO:580), Figure 582 (SEQ ID NO:582), Figure 584 (SEQ ID NO:584), Figure 586 (SEQ ID NO:586), Figure 588 (SEQ ID NO:588), Figure 590 (SEQ ID NO:590), Figure 592 (SEQ ID NO:592), Figure 594 (SEQ ID NO:594), Figure 596 (SEQ ID NO:596), Figure 598 (SEQ ID NO:598), Figure 600 (SEQ ID NO:600), Figure 602 (SEQ ID NO:602), Figure 604 (SEQ ID NO:604), Figure 606 (SEQ ID NO:606), Figure 608 (SEQ ID NO:608), or Figure 610 (SEQ ID NO:610), with its associated signal peptide; or

(c) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18

(SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID

NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372), Figure 374 (SEQ ID NO:374), Figure 376 (SEQ ID NO:376), Figure 378 (SEQ ID NO:378), Figure 380 (SEQ ID NO:380), Figure 382 (SEQ ID NO:382), Figure 384 (SEQ ID NO:384), Figure 386 (SEQ ID NO:386), Figure 388 (SEQ ID NO:388), Figure 390 (SEQ ID NO:390), Figure 392 (SEQ ID NO:392), Figure 394 (SEQ ID NO:394), Figure 396 (SEQ ID NO:396), Figure 398 (SEQ ID NO:398), Figure 400 (SEQ ID NO:400), Figure 402 (SEQ ID NO:402), Figure 404 (SEQ ID NO:404), Figure 406 (SEQ ID NO:406), Figure 408 (SEQ ID NO:408), Figure 410 (SEQ ID NO:410), Figure 412 (SEQ ID NO:412), Figure 414 (SEQ ID NO:414), Figure 416 (SEQ ID NO:416), Figure 418 (SEQ ID NO:418), Figure 420 (SEQ ID NO:420), Figure 422 (SEQ ID NO:422), Figure 424 (SEQ ID NO:424), Figure 426 (SEQ ID NO:426), Figure 428 (SEQ ID NO:428), Figure 430 (SEQ ID NO:430), Figure 432 (SEQ ID NO:432), Figure 434 (SEQ ID NO:434), Figure 436 (SEQ ID NO:436), Figure 438 (SEQ ID NO:438), Figure 440 (SEQ ID NO:440), Figure 442 (SEQ ID NO:442), Figure 444 (SEQ ID NO:444), Figure 446 (SEQ ID NO:446), Figure 448 (SEQ ID NO:448), Figure 450 (SEQ ID NO:450), Figure 452 (SEQ ID NO:452), Figure 454 (SEQ ID NO:454), Figure 456 (SEQ ID NO:456), Figure 458 (SEQ ID NO:458), Figure 460 (SEQ ID NO:460), Figure 462 (SEQ ID NO:462), Figure 464 (SEQ ID NO:464), Figure 466 (SEQ ID NO:466), Figure 468 (SEQ ID NO:468), Figure 470 (SEQ ID NO:470), Figure 472 (SEQ ID NO:472), Figure 474 (SEQ ID NO:474), Figure 476 (SEQ ID NO:476), Figure 478 (SEQ ID NO:478), Figure 480 (SEQ ID NO:480), Figure 482 (SEQ ID NO:482), Figure 484 (SEQ ID NO:484), Figure 486 (SEQ ID NO:486), Figure 488 (SEQ ID NO:488), Figure 490 (SEQ ID NO:490), Figure 492 (SEQ ID NO:492), Figure 494 (SEQ ID NO:494), Figure 496 (SEQ ID NO:496), Figure 498 (SEQ ID NO:498), Figure 500 (SEQ ID NO:500), Figure 502 (SEQ ID NO:502), Figure 504 (SEQ ID NO:504), Figure 506 (SEQ ID NO:506), Figure 508 (SEQ ID NO:508), Figure 510 (SEQ ID NO:510), Figure 512 (SEQ ID NO:512), Figure 514 (SEQ ID NO:514), Figure 516 (SEQ ID NO:516), Figure 518 (SEQ ID NO:518), Figure 520 (SEQ ID NO:520), Figure 522 (SEQ ID NO:522), Figure 524 (SEQ ID NO:524), Figure 526 (SEQ ID NO:526), Figure 528 (SEQ ID NO:528), Figure 530 (SEQ ID NO:530), Figure 532 (SEQ ID NO:532), Figure 534 (SEQ ID NO:534), Figure 536 (SEQ ID NO:536), Figure 538 (SEQ ID NO:538), Figure 540 (SEQ ID NO:540), Figure 542 (SEQ ID NO:542), Figure 544 (SEQ ID NO:544), Figure 546 (SEQ ID NO:546), Figure 548 (SEQ ID NO:548), Figure 550 (SEQ ID NO:550), Figure 552 (SEQ ID NO:552), Figure 554 (SEQ ID NO:554), Figure 556 (SEQ ID

NO:556), Figure 558 (SEQ ID NO:558), Figure 560 (SEQ ID NO:560), Figure 562 (SEQ ID NO:562), Figure 564 (SEQ ID NO:564), Figure 566 (SEQ ID NO:566), Figure 568 (SEQ ID NO:568), Figure 570 (SEQ ID NO:570), Figure 572 (SEQ ID NO:572), Figure 574 (SEQ ID NO:574), Figure 576 (SEQ ID NO:576), Figure 578 (SEQ ID NO:578), Figure 580 (SEQ ID NO:580), Figure 582 (SEQ ID NO:582), Figure 584 (SEQ ID NO:584), Figure 586 (SEQ ID NO:586), Figure 588 (SEQ ID NO:588), Figure 590 (SEQ ID NO:590), Figure 592 (SEQ ID NO:592), Figure 594 (SEQ ID NO:594), Figure 596 (SEQ ID NO:596), Figure 598 (SEQ ID NO:598), Figure 600 (SEQ ID NO:600), Figure 602 (SEQ ID NO:602), Figure 604 (SEQ ID NO:604), Figure 606 (SEQ ID NO:606), Figure 608 (SEQ ID NO:608), or Figure 610 (SEQ ID NO:610), lacking its associated signal peptide.

10           19.       An isolated polypeptide having at least 80% amino acid sequence identity to:

(a)       an amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ  
ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID  
NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ  
ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28  
15 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure  
36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42),  
Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID  
NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ  
ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66  
20 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure  
74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80),  
Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID  
NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ  
ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure  
25 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID  
NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure  
118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID  
NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure  
132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID  
NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure  
30 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID  
NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure  
160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID  
NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure  
35 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID  
NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure  
188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID

NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372), Figure 374 (SEQ ID NO:374), Figure 376 (SEQ ID NO:376), Figure 378 (SEQ ID NO:378), Figure 380 (SEQ ID NO:380), Figure 382 (SEQ ID NO:382), Figure 384 (SEQ ID NO:384), Figure 386 (SEQ ID NO:386), Figure 388 (SEQ ID NO:388), Figure 390 (SEQ ID NO:390), Figure 392 (SEQ ID NO:392), Figure 394 (SEQ ID NO:394), Figure 396 (SEQ ID NO:396), Figure 398 (SEQ ID NO:398), Figure 400 (SEQ ID NO:400), Figure 402 (SEQ ID NO:402), Figure 404 (SEQ ID NO:404), Figure 406 (SEQ ID NO:406), Figure 408 (SEQ ID NO:408), Figure 410 (SEQ ID NO:410), Figure 412 (SEQ ID NO:412), Figure 414 (SEQ ID NO:414), Figure 416 (SEQ ID NO:416), Figure 418 (SEQ ID NO:418), Figure 420 (SEQ ID NO:420), Figure 422 (SEQ ID NO:422), Figure 424 (SEQ ID NO:424), Figure 426 (SEQ ID NO:426), Figure 428 (SEQ ID NO:428), Figure 430 (SEQ ID NO:430), Figure 432 (SEQ ID NO:432), Figure 434 (SEQ ID NO:434), Figure 436 (SEQ ID NO:436), Figure 438 (SEQ ID NO:438), Figure 440 (SEQ ID NO:440), Figure 442 (SEQ ID NO:442), Figure 444 (SEQ ID NO:444), Figure 446 (SEQ ID NO:446), Figure 448 (SEQ ID NO:448), Figure 450 (SEQ ID NO:450), Figure 452 (SEQ ID NO:452), Figure 454 (SEQ ID NO:454), Figure 456 (SEQ ID NO:456), Figure 458 (SEQ ID NO:458), Figure 460 (SEQ ID

NO:460), Figure 462 (SEQ ID NO:462), Figure 464 (SEQ ID NO:464), Figure 466 (SEQ ID NO:466), Figure 468 (SEQ ID NO:468), Figure 470 (SEQ ID NO:470), Figure 472 (SEQ ID NO:472), Figure 474 (SEQ ID NO:474), Figure 476 (SEQ ID NO:476), Figure 478 (SEQ ID NO:478), Figure 480 (SEQ ID NO:480), Figure 482 (SEQ ID NO:482), Figure 484 (SEQ ID NO:484), Figure 486 (SEQ ID NO:486), Figure 488 (SEQ ID NO:488), Figure 490 (SEQ ID NO:490), Figure 492 (SEQ ID NO:492), Figure 494 (SEQ ID NO:494), Figure 496 (SEQ ID NO:496), Figure 498 (SEQ ID NO:498), Figure 500 (SEQ ID NO:500), Figure 502 (SEQ ID NO:502), Figure 504 (SEQ ID NO:504), Figure 506 (SEQ ID NO:506), Figure 508 (SEQ ID NO:508), Figure 510 (SEQ ID NO:510), Figure 512 (SEQ ID NO:512), Figure 514 (SEQ ID NO:514), Figure 516 (SEQ ID NO:516), Figure 518 (SEQ ID NO:518), Figure 520 (SEQ ID NO:520), Figure 522 (SEQ ID NO:522), Figure 524 (SEQ ID NO:524), Figure 526 (SEQ ID NO:526), Figure 528 (SEQ ID NO:528), Figure 530 (SEQ ID NO:530), Figure 532 (SEQ ID NO:532), Figure 534 (SEQ ID NO:534), Figure 536 (SEQ ID NO:536), Figure 538 (SEQ ID NO:538), Figure 540 (SEQ ID NO:540), Figure 542 (SEQ ID NO:542), Figure 544 (SEQ ID NO:544), Figure 546 (SEQ ID NO:546), Figure 548 (SEQ ID NO:548), Figure 550 (SEQ ID NO:550), Figure 552 (SEQ ID NO:552), Figure 554 (SEQ ID NO:554), Figure 556 (SEQ ID NO:556), Figure 558 (SEQ ID NO:558), Figure 560 (SEQ ID NO:560), Figure 562 (SEQ ID NO:562), Figure 564 (SEQ ID NO:564), Figure 566 (SEQ ID NO:566), Figure 568 (SEQ ID NO:568), Figure 570 (SEQ ID NO:570), Figure 572 (SEQ ID NO:572), Figure 574 (SEQ ID NO:574), Figure 576 (SEQ ID NO:576), Figure 578 (SEQ ID NO:578), Figure 580 (SEQ ID NO:580), Figure 582 (SEQ ID NO:582), Figure 584 (SEQ ID NO:584), Figure 586 (SEQ ID NO:586), Figure 588 (SEQ ID NO:588), Figure 590 (SEQ ID NO:590), Figure 592 (SEQ ID NO:592), Figure 594 (SEQ ID NO:594), Figure 596 (SEQ ID NO:596), Figure 598 (SEQ ID NO:598), Figure 600 (SEQ ID NO:600), Figure 602 (SEQ ID NO:602), Figure 604 (SEQ ID NO:604), Figure 606 (SEQ ID NO:606), Figure 608 (SEQ ID NO:608), or Figure 610 (SEQ ID NO:610), lacking its associated signal peptide;

(b) an amino acid sequence of an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ

ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure  
124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID  
NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure  
138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID  
NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure  
5 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID  
NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure  
166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID  
NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure  
10 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID  
NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure  
194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID  
NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure  
208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID  
NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure  
15 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID  
NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure  
236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID  
NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure  
250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID  
20 NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure  
264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID  
NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure  
278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID  
NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure  
25 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID  
NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure  
306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID  
NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure  
320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID  
30 NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure  
334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID  
NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure  
348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID  
NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure  
35 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID  
NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372), Figure 374 (SEQ ID NO:374), Figure  
376 (SEQ ID NO:376), Figure 378 (SEQ ID NO:378), Figure 380 (SEQ ID NO:380), Figure 382 (SEQ ID

NO:382), Figure 384 (SEQ ID NO:384), Figure 386 (SEQ ID NO:386), Figure 388 (SEQ ID NO:388), Figure 390 (SEQ ID NO:390), Figure 392 (SEQ ID NO:392), Figure 394 (SEQ ID NO:394), Figure 396 (SEQ ID NO:396), Figure 398 (SEQ ID NO:398), Figure 400 (SEQ ID NO:400), Figure 402 (SEQ ID NO:402), Figure 404 (SEQ ID NO:404), Figure 406 (SEQ ID NO:406), Figure 408 (SEQ ID NO:408), Figure 410 (SEQ ID NO:410), Figure 412 (SEQ ID NO:412), Figure 414 (SEQ ID NO:414), Figure 416 (SEQ ID NO:416), Figure 418 (SEQ ID NO:418), Figure 420 (SEQ ID NO:420), Figure 422 (SEQ ID NO:422), Figure 424 (SEQ ID NO:424), Figure 426 (SEQ ID NO:426), Figure 428 (SEQ ID NO:428), Figure 430 (SEQ ID NO:430), Figure 432 (SEQ ID NO:432), Figure 434 (SEQ ID NO:434), Figure 436 (SEQ ID NO:436), Figure 438 (SEQ ID NO:438), Figure 440 (SEQ ID NO:440), Figure 442 (SEQ ID NO:442), Figure 444 (SEQ ID NO:444), Figure 446 (SEQ ID NO:446), Figure 448 (SEQ ID NO:448), Figure 450 (SEQ ID NO:450), Figure 452 (SEQ ID NO:452), Figure 454 (SEQ ID NO:454), Figure 456 (SEQ ID NO:456), Figure 458 (SEQ ID NO:458), Figure 460 (SEQ ID NO:460), Figure 462 (SEQ ID NO:462), Figure 464 (SEQ ID NO:464), Figure 466 (SEQ ID NO:466), Figure 468 (SEQ ID NO:468), Figure 470 (SEQ ID NO:470), Figure 472 (SEQ ID NO:472), Figure 474 (SEQ ID NO:474), Figure 476 (SEQ ID NO:476), Figure 478 (SEQ ID NO:478), Figure 480 (SEQ ID NO:480), Figure 482 (SEQ ID NO:482), Figure 484 (SEQ ID NO:484), Figure 486 (SEQ ID NO:486), Figure 488 (SEQ ID NO:488), Figure 490 (SEQ ID NO:490), Figure 492 (SEQ ID NO:492), Figure 494 (SEQ ID NO:494), Figure 496 (SEQ ID NO:496), Figure 498 (SEQ ID NO:498), Figure 500 (SEQ ID NO:500), Figure 502 (SEQ ID NO:502), Figure 504 (SEQ ID NO:504), Figure 506 (SEQ ID NO:506), Figure 508 (SEQ ID NO:508), Figure 510 (SEQ ID NO:510), Figure 512 (SEQ ID NO:512), Figure 514 (SEQ ID NO:514), Figure 516 (SEQ ID NO:516), Figure 518 (SEQ ID NO:518), Figure 520 (SEQ ID NO:520), Figure 522 (SEQ ID NO:522), Figure 524 (SEQ ID NO:524), Figure 526 (SEQ ID NO:526), Figure 528 (SEQ ID NO:528), Figure 530 (SEQ ID NO:530), Figure 532 (SEQ ID NO:532), Figure 534 (SEQ ID NO:534), Figure 536 (SEQ ID NO:536), Figure 538 (SEQ ID NO:538), Figure 540 (SEQ ID NO:540), Figure 542 (SEQ ID NO:542), Figure 544 (SEQ ID NO:544), Figure 546 (SEQ ID NO:546), Figure 548 (SEQ ID NO:548), Figure 550 (SEQ ID NO:550), Figure 552 (SEQ ID NO:552), Figure 554 (SEQ ID NO:554), Figure 556 (SEQ ID NO:556), Figure 558 (SEQ ID NO:558), Figure 560 (SEQ ID NO:560), Figure 562 (SEQ ID NO:562), Figure 564 (SEQ ID NO:564), Figure 566 (SEQ ID NO:566), Figure 568 (SEQ ID NO:568), Figure 570 (SEQ ID NO:570), Figure 572 (SEQ ID NO:572), Figure 574 (SEQ ID NO:574), Figure 576 (SEQ ID NO:576), Figure 578 (SEQ ID NO:578), Figure 580 (SEQ ID NO:580), Figure 582 (SEQ ID NO:582), Figure 584 (SEQ ID NO:584), Figure 586 (SEQ ID NO:586), Figure 588 (SEQ ID NO:588), Figure 590 (SEQ ID NO:590), Figure 592 (SEQ ID NO:592), Figure 594 (SEQ ID NO:594), Figure 596 (SEQ ID NO:596), Figure 598 (SEQ ID NO:598), Figure 600 (SEQ ID NO:600), Figure 602 (SEQ ID NO:602), Figure 604 (SEQ ID NO:604), Figure 606 (SEQ ID NO:606), Figure 608 (SEQ ID NO:608), or Figure 610 (SEQ ID NO:610), with its associated signal peptide; or

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure



34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40),  
Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID  
NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ  
ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64  
(SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure  
5 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78),  
Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID  
NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ  
ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102  
(SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108),  
10 Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ  
ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure  
124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID  
NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure  
138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID  
15 NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure  
152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID  
NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure  
166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID  
NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure  
20 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID  
NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure  
194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID  
NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure  
208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID  
25 NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure  
222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID  
NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure  
236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID  
NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure  
30 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID  
NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure  
264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID  
NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure  
278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID  
35 NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure  
292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID  
NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure

[illegible]

572 (SEQ ID NO:572), Figure 574 (SEQ ID NO:574), Figure 576 (SEQ ID NO:576), Figure 578 (SEQ ID NO:578), Figure 580 (SEQ ID NO:580), Figure 582 (SEQ ID NO:582), Figure 584 (SEQ ID NO:584), Figure 586 (SEQ ID NO:586), Figure 588 (SEQ ID NO:588), Figure 590 (SEQ ID NO:590), Figure 592 (SEQ ID NO:592), Figure 594 (SEQ ID NO:594), Figure 596 (SEQ ID NO:596), Figure 598 (SEQ ID NO:598), Figure 600 (SEQ ID NO:600), Figure 602 (SEQ ID NO:602), Figure 604 (SEQ ID NO:604), Figure 606 (SEQ ID NO:606), Figure 608 (SEQ ID NO:608), or Figure 610 (SEQ ID NO:610), lacking its associated signal peptide.

20. A method for stimulating the release of TNF- $\alpha$  from human blood, said method comprising contacting said blood with a PRO1079, PRO827, PRO791, PRO1131, PRO1316, PRO1183, PRO1343, PRO1760, PRO1567 or PRO4333 polypeptide, wherein the release of TNF- $\alpha$  from said blood is stimulated.

10

21. A method for stimulating the proliferation or differentiation of chondrocyte cells, said method comprising contacting said cells with a PRO6029 polypeptide, wherein the proliferation or differentiation of said cells is stimulated.

15

22. A method for detecting the presence of tumor in a mammal, said method comprising comparing the level of expression of any PRO polypeptide shown in Table 8 in (a) a test sample of cells taken from said mammal and (b) a control sample of normal cells of the same cell type, wherein a higher level of expression of said PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of tumor in said mammal.

20

23. The method of Claim 22, wherein said tumor is adrenal tumor, lung tumor, colon tumor, breast tumor, prostate tumor, rectal tumor, cervical tumor or liver tumor.

24. An oligonucleotide probe derived from any of the nucleotide sequences shown in the accompanying figures.

25

1/615

**FIGURE 1**

GAAGGCTGCCTCGCTGGTCCGAATTCGGTGGCGCCACGTCCGCCCGCTCCGCCTTCTGCATCGCGGGCTTCGGCG  
GCTTCCACCTAGACACCTAACAGTCGCGGAGCCGGCCGCGCTCGTGAGGGGGTGGGCACGGGGAGTCGGGCGGTCT  
TGTGCATCTTGGCTACCTGTGGGTCTGAAGATGTCGGACATCGGAGACTGGTTTACGGAGCATCCCGGCGATCACGC  
GCTATTGGTTTCGCCGCCACCGTCGCCGTGCCCTTGGTCGGCAAACTCGGCCTCATCAGCCCGGCTACCTCTTCC  
TCTGGCCCGAAGCCTTCCTTTATCGCTTTCAGATTGGAGGCCAATCACTGCCACCTTTTATTTCCCTGTGGGT  
CAGGAACGGATTTCCTTTATTTGGTCAATTTATATTTCTTATATCAGTATTCTACGCGACTTGAACAGGAGCTT  
TTGATGGGAGGCCAGACACTATTTATTCATGCTCCTCTTTAACTGGATTGTCATCGTGATTACTGGCTTAGCAA  
TGGATATGCAGTTGCTGATGATTCTCTGATCATGTCAGTACTTTATGTCTGGGCCAGCTGAACAGAGACATGA  
TTGTATCATTTTGGTTTGGAAACACGATTTAAGGCCTGCTATTTACCCTGGGTATCCTTGGATTCAACTATATCA  
TCGGAGGCTCGGTAATCAATGAGCTTATTGGAAATCTGGTTGGACATCTTTATTTTTCTAATGTTTCAGATACC  
CAATGGACTTGGGAGGAAGAAATTTCTATCCACACCTCAGTTTTTGTACCGCTGGCTGCCAGTAGGAGAGGAG  
GAGTATCAGGATTTGGTGTGCCCCCTGCTAGCATGAGGCGAGCTGCTGATCAGAATGGCGGAGGCGGGAGACACA  
ACTGGGGCCAGGCTTTCGACTTGGAGACCAGTGAAGGGGCGGCTCGGGCAGCCGCTCCTCTCAAGCCACATTT  
CCTCCAGTGTGGTGCCTTAACAACCTGCGTTCTGGCTAACACTGTTGGACCTGACCCACACTGAATGTAGTC  
TTTCAGTACGAGACAAAGTTTCTTAAATCCCGAAGAAAAATATAAGTGTTCCACAAGTTTACGATTCTCATTCA  
AGTCTTACTGCTGTGAAGAACAATAACCACTGTGCAATTGCAAACTGACTACATTTTTTGGTGTCTTCTCT  
TCTCCCTTTCCGCTCTGAATAATGGGTTTTAGCGGGTCTTAATCTGCTGGCATTGAGCTGGGCTGGGTACCAA  
ACCCTTCCCAAAAGGACCTTATCTCTTCTTGCACACATGCCTCTCTCCACTTTTCCCAACCCACATTTGCA  
ACTAGAAAAAGTTGCCATAAAATGCTCTGCCCTTGACAGGTTCTGTTATTTATTGACTTTTGCAAGGCTGGT  
CACAACAATCATATTCACGTTATTTTCCCTTTTGGTGGCAGAACTGTTACCAATAGGGGGAGAAGACAGCCACG  
GATGAAGCGTTTCTCAGCTTTTGGAAATGCTTCGACTGACATCCGTTGTTAACCCTTTGCCACTCTTCAGATATT  
TTTTATAAAAAAAGTACCACTGAGTTTCATGAGGGCCACAGATTGGTTATTAATGAGATACGAGGGTTGGTGCTGG  
GTGTTTGTCTCTGAGCTAAGTGATCAAGACTGTAGTGGAGTTGCAGCTAACATGGGTAGGTTTAAACCATGGG  
GGATGCACCCCTTTGCGTTTTCATATGTAGCCCTACTGGCTTTGTGTAGCTGGAGTAGTTGGGTTGCTTTGTGTTA  
GGAGGATCCAGATCATGTTGGCTACAGGGAGATGCTCTCTTTGAGAGGTCTTGGGCATTGATTCCCATTTCAATC  
TCATTTCTGGATATGTGTTTATTGAGTAAAGGAGGAGAGACCCTCATACGCTATTTAAATGTCACTTTTTTGCCTA  
TCCCCCGTTTTTTGGTTCATGTTTCAATTAATTGTGAGGAAGGCGCAGCTCCTCTCTGCACGTAGATCATTTTTTA  
AAGCTAATGTAAGCACATCTAAGGGAATAACATGATTTAAGGTTGAAATGGCTTTAGAATCATTTGGGTTTGAGG  
GTGTGTTATTTTGTGATCATGAATGTACAAGCTCTGTGAATCAGACCAGCTTAAATACCCACACCTTTTTTTCGTA  
GGTGGGCTTTTCTATCAGAGCTTGGCTCATAACCAAAATAAAGTTTTTTGAAGGCCATGGCTTTTCACACAGTTA  
TTTTATTTTATGACGTTATCTGAAAGCAGACTGTTAGGAGCAGTATTGAGTGGCTGTACACTTTGAGGCAACTA  
AAAAGGCTTCAAACGTTTTTGATCAGTTTCTTTTCAGGAAACATTGTGCTCTAACAGTATGACTATTTTCCCCC  
ACTCTTAAACAGTGTGATGTGTGTTATCCTAGGAAATGAGAGTTGGCAAACAACCTCTCATTTTGAATAGAGTTT  
GTGTGTAATCTCCATATTTAATTTATATGATAAAATAGGTGGGGAGAGTCTGAACCTTAACGTGATGTTTTGT  
TGTTTCATCTGTGGCCACAATAAAGTTTACTTGTAAAATTTTAGAGGCCATTACTCCAATTATGTTGCACGTACAC  
TCATTTGTACAGGCGTGGAGACTCATTGTATGTATAAGAATATTTCTGACAGTGAGTGACCCGGAGTCTCTGGTGT  
ACCCTCTTACCAGTCAGCTGCCTGCGAGCAGTCATTTTTTCTAAAGGTTTACAAGTATTTAGAAGTTTTCAGTT  
CAGGGCAAAATGTTTCATGAAGTTATTTCTCTTAAACATGGTTAGGAAGCTGATGACGTTATTTGATTTTGTCTGGA  
TTATGTTTCTGGAATAATTTTACCAAAACAAGCTATTTGAGTTTTGACTTGACAAGGCAAAACATGACAGTGGAT  
TCTCTTTACAAATGGAAAAAAAATCCTTATTTTGATAAAGGACTTCCCTTTTTTGTAAACTAATCCTTTTTTAT  
TGGTAAAAATGTAAATTAATGTGCAACTTG

2/615

**FIGURE 2**

MSDIGDWFRSIPAITRYWFAATVAVPLVGKLGGLISPAYLFLWPEAFLYRFQIWRPITATFYFPVGPGTGFLYLVN  
LYFLYQYSTRLETGAFDGRPADYLFMLLFNWICIVITGLAMDMQLLMIPLIMSVLYVWAQLNRDMIVSFWFGTRF  
KACYLPWVILGFNYIIIGGSVINELIGNLVGHLYFFLMFRYPMDLGGRNFLSTPQFLYRWLPSTRRGVSGFGVPPA  
SMRRAADQNGGGGRHNWQGFR LGDQ

**Transmembrane domain:**

amino acids 98-116, 152-172

**N-myristoylation site.**

amino acids 89-95, 168-174, 176-182, 215-221, 221-227, 237-243

**Glycosaminoglycan attachment site.**

amino acids 218-222

3/615

**FIGURE 3**

GAGCGAGGCCGGGGACTGAAGGTGTGGGTGTGCGAGCCCTCTGGCAGAGGGTTAACCTGGGTCAAATGCACGGATT  
CTCACCTCGTACAGTTACGCTCTCCCGGGCACGTCCGCGAGGACTTGAAGTCCTGAGCGCTCAAGTTTGTCCGT  
AGGTGCGAGAGAAGGCCATGGAGGTGCCGCCACCGGCACCGCGAGCTTTCTCTGTAGAGCATTGTGCCTATTTCC  
CCGAGTCTTTGCTGCCGAAGCTGTGACTGCCGATTCGGAAGTCCTTGAGGAGCGTCAGAAGCGGCTTCCCTACGT  
CCCAGAGCCCTATTACCCGGAATCTGGATGGGACCGCCTCCGGGAGCTGTTTGGCAAAGATGAACAGCAGAGAAT  
TTCAAAGGACCTTGCTAATATCTGTAAGACGGCAGCTACAGCAGGCATCATTGGCTGGGTGTATGGGGGAATACC  
AGCTTTTATTTCATGCTAAACAACAATACATTGAGCAGAGCCAGGCAGAAATTTATCATAACCGGTTTGATGCTGT  
GCAATCTGCACATCGTGCTGCCACACGAGGCTTCATTTCGTTATGGCTGGCGCTGGGGTTGGAGAACTGCAGTGTT  
TGTGACTATATTCAACACAGTGAACACTAGTCTGAATGTATACCGAAATAAAGATGCCTTAAGCCATTTTGTAAAT  
TGCAGGAGCTGTACGGGAAGTCTTTTTAGGATAAACGTAGGCCTGCGTGGCCTGGTGGCTGGTGGCATAATTGG  
AGCCTTGCTGGGCACTCCTGTAGGAGGCCTGCTGATGGCATTTCAGAAGTACGCTGGTGAGACTGTTCAAGGAAAG  
AAAACAGAAGGATCGAAAGGCACTCCATGAGCTAAACTGGAAGAGTGGAAGGCAGACTACAAGTTACTGAGCA  
CCTCCCTGAGAAAATTGAAAGTAGTTTACGGGAAGATGAACCTGAGAATGATGCTAAGAAAATTGAAGCACTGCT  
AAACCTTCCTAGAAACCCTTCAGTAATAGATAAACAAGACAAGGACTGAAAGTGCTCTGAACCTGAAACTCACTG  
GAGAGCTGAAGGGAGCTGCCATGTCCGATGAATGCCAACAGACAGGCCACTCTTTGGTCAGCCTGCTGACAAATT  
TAAGTGCTGGTACCTGTGGTGGCAGTGGCTTGCTCTTGTCTTTTCTTTTCTTTTAACTAAGAATGGGGCTGTT  
GTACTCTCACTTTACTTATCCTTAAATTTAAATACATACTTATGTTTGTTATTAATCTATCAATATATGCATACAT  
GGATATATCCACCCACCTAGATTTTAAGCAGTAAATAAAACATTTTCGCAAAAGATTAAAGTTGAATTTTACAGTTT

4/615

**FIGURE 4**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA23318
><subunit 1 of 1, 285 aa, 1 stop
><MW: 32190, pI: 9.03, NX(S/T): 2
MEVPPPAPRSFLCRALCLFPRVFAAEAVTADSEVLEERQKRLPYVPEPYYPESGWDRLRELFQKDEQQRISKDLA
NICKTAATAGIIGWVYGGIPAFIHAKQQYIEQSQAIEYHNRFDAVQSAHRAATRGFIRYGWRWGWRTAVFVTIFN
TVNTSLNVYRNKDALSDFVIAGAVTGSLFRINVGLRGLVAGGIIGALLGTPVGGLLMAFQKYAGETVQERKQKDR
KALHELKLEEWKGRLQVTEHLPEKIESSLREDEPENDAKKIEALLNLPRNPSVIDKQDKD
```

**Important Features:****Signal Peptide:**

amino acids 1-24

**Transmembrane domains:**

amino acids 76-96 and 171-195

**N-glycosylation site:**

amino acids 153-156

5/615

**FIGURE 5**

CGGACGCGTGGGCGCGGGACGCCGGCAGGGTTGTGGCGCAGCAGTCTCCTTCCTGCGCGCGCGCCTGAAGTCGGC  
GTGGGCGTTTTGAGGAAGCTGGGATACAGCATTTAATGAAAAATTTATGCTTAAGAAGTAAAAATGGCAGGCTTCC  
TAGATAATTTTCGTTGGCCAGAATGTGAATGTATTGACTGGAGTGAGAGAAGAAATGCTGTGGCATCTGTTGTCTG  
CAGGTATATTGTTTTTACAGGCTGGTGGATAATGATTGATGCAGCTGTGGTGTATCCTAAGCCAGAACAGTTGA  
ACCATGCCTTTCACACATGTGGTGTATTTTCCACATTGGCTTCTTCATGATAAATGCTGTATCCAATGCTCAGG  
TGAGAGGTGATAGCTATGAAAGCGGCTGTTTAGGAAGAACAGGTGCTCGAGTTTGGCTTTTCATTGGTTTCATGT  
TGATGTTTGGGTCACTTATTGCTTCCATGTGGATTCTTTTGGTGCATATGTTACCCAAAATACTGATGTTTATC  
CGGGACTAGCTGTGTTTTTCAAATGCACTTATATTTTGTAGCACTCTGATCTACAAATTTGGAAGAACCGAAG  
AGCTATGGACCTGAGATCACTTCTTAAGTCACATTTTCCTTTTGTATATTCTGTTTGTAGATAGGTTTTTATC  
TCTCAGTACACATTGCCAAATGGAGTAGATTGTACATTAAATGTTTTGTTTCTTTACATTTTATGTTCTGAGTT  
TTGAAATAGTTTTATGAAATTTCTTTATTTTTCATTGCATAGACTGTTAATATGTATATAATACAAGACTATATG  
AATTGGATAATGAGTATCAGTTTTTTATTCCTGAGATTTAGAACTTGATCTACTCCCTGAGCCAGGGTTACATCA  
TCTTGTCATTTTAGAAAGTAACCACTCTTGTCTCTCTGGCTGGGCACGGTGGCTCATGCCCTGTAATCCCAGCACTT  
TGGGAGGCCGAGGCGGGCCGATTGCTTGAGGTCAAGTGTGTTGAGACCAGCCTGGCCAACATGGCGAAACCCCATC  
TACTAAAAATACAAAAATTAGCCAGGCATGGTGGTGGGTGCCGTGTAATCCCAGCTACCTGGGAGGCTGAGGCAGG  
AGAATCGCTTGAACCCGGGGGGCAGAGGTTGCAGTGAGCTGAGTTTGCGCCACTGCACTCTAGCCTGGGGGAGAA  
AGTGAAACTCCCTCTCAAAAAAAGACCACTCTCAGTATCTCTGATTTCTGAAGATGTACAAAAAATATAGCTT  
CATATATCTGGAATGAGCACTGAGCCATAAAAGGTTTTCAGCAAGTTGTAACCTATTTTGGCCTAAAAATGAGGT  
TTTTTTGGTAAAGAAAAAATATTTGTTCTTATGTATTGAAGAAGTGTACTTTTATATAATGATTTTTTAAATGCC  
CAAAGGACTAGTTTGAAAGCTTCTTTTAAAAAGAAATTCCTCTAATATGACTTTATGTGAGAA



6/615

## **FIGURE 6**

MAGFLDNFRWPECECIDWSERRNAVASVVAGILFFTGWIMIDAADVYPKPEQLNHAFHTCGVFSTLAFFMINAV  
SNAQVRGDSYESGCLGRTGARVWLFIFGMLMFGSLIASMWILFGAYVTQNTDVYPGLAVFFQNALIFFSTLIYKF  
GRTEELWT

**Important features:**

**Signal peptide:**

amino acids 1-44

**Transmembrane domains:**

amino acids 23-42 (type II), 60-80, 97-117, 128-148

7/615

**FIGURE 7**

GCCTGGTTTTTGTCTGCAATAGGCGGCTTAGAGGGAGGGGCTTTTTCGCCTATACCTACTGTAGCTTCTCCACG  
TATGGACCCTAAAGGCTACTGCTGCTACTACGGGGCTAGACAGTTACTGTCTCAGCTCTAGGATGTGCGTTCTTC  
CACTAGAAGCTCTTCTGAGGGAGGTAATTAACAAACAGTGGAAATGGAAAAACAGTGCTGTAGTCATCCTGTAATA  
TGCTCCTTGTCAACAATGTATACATTCTCTGCTAGGTGCCATATTCATTGCTTTAAGCTCAAGTCGCATCTTACTA  
GTGAAGTATTCTGCCAATGAAGAAAAACAAGTATGATTATCTTCCAACACTGTGAATGTGTGCTCAGAACTGGTG  
AAGCTAGTTTTCTGTGTGCTTGTGTCAATTCTGTGTTATAAAGAAAGATCATCAAAGTAGAAATTTGAAATATGCT  
TCCTGGAAGGAATCTCTGATTTTCATGAAGTGGTCCATTCTGCCTTTCTTTATTTCTGGATAACTTGATTGTC  
TTCTATGTCCTGTCTTATCTTCAACCAGCCATGGCTGTTATCTTCTCAAATTTTAGCATTATAACAACAGCTCTT  
CTATTCAAGATAGTGCTGAAGAGGCGCTAAACTGGATCCAGTGGGCTTCCCTCCTGACTTTATTTTTGTCTATT  
GTGGCCTTGACTGCCGGGACTAAAACCTTACAGCACAACTTGGCAGGACGTGGATTTCATCACGATGCCCTTTTTCT  
AGCCCTTCCAATTCTGCCTTCTTTTTCAGAAAGTGAGTGTCCTCAGAAAAGACAATTGTACAGCAAAGGAATGGACT  
TTTTCTGAAGCTAAATGGAACACCACAGCCAGAGTTTTTCAGTCACATCCGTCTTGGCATGGGCCATGTTCTTATT  
ATAGTCCAGTGTTTTATTTCTTCAATGGCTAATATCTATAATGAAAAGATACTGAAGGAGGGGAACCAGCTCACT  
GAAAGCATCTTCATACAGAACAGCAAACTCTATTTCTTTGGCATTCTGTTTAATGGGCTGACTCTGGGCCCTTCAG  
AGGAGTAACCGTGATCAGATTAAGAACTGTGGATTTTTTATGGCCACAGTGCATTTTCAGTAGCCCTTATTTTT  
GTAACATGCATTTCCAGGGCCTTTTCAGTGGCTTTTCATTCTGAAGTTCTGATAAACATGTTCCATGTCTTGATGGCC  
CAGGTTACCACTGTCTATTATCACAACAGTGTCTGTCTGGTCTTTGACTTCAGGCCCTCCCTGGAATTTTTCTTG  
GAAGCCCCATCAGTCTTCTCTCTATATTTATTTATAATGCCAGCAAGCCTCAAGTTCGGGAATACGCACCTAGG  
CAAGAAAGGATCCGAGATCTAAGTGGCAATCTTTGGGAGCGTTCCAGTGGGGATGGAGAAGAACTAGAAAGACTT  
ACCAAACCCAAGAGTGATGAGTCAGATGAAGATACTTTCTAACTGGTACCCACATAGTTTGCAGCTCTCTTGAAC  
CTTATTTTTCACATTTTCAGTGTGTTGTAATATTTATCTTTTCACTTTGATAAACAGAAATGTTTCTAAATCCTAA  
TATTTCTTTGCATATATCTAGCTACTCCCTAAATGGTTCCATCCAAGGCTTAGAGTACCCAAAGGCTAAGAAATTC  
TAAAGAACTGATACAGGAGTAACAATATGAAGAATTCATTAATATCTCAGTACTTGATAAATCAGAAAAGTTATAT  
GTGCAGATTATTTTCTTGGCCTTCAAGCTTCCAAAAAAGTTGTAATAATCATGTTAGCTATAGCTTGTATATAC  
ACATAGAGATCAATTTGCCAAATATTCACAATCATGTAGTTCTAGTTTACATGCCAAAGTCTTCCCTTTTAAACA  
TTATAAAAGCTAGGTTGTCTCTTGAATTTTGAGGCCCTAGAGATAGTCATTTTGCAAGTAAAGAGCAACGGGACC  
CTTTCTAAAAACGTTGGTTGAAGGACCTAAATACCTGGCCATACCATAGATTTGGGATGATGTAGTCTGTGCTAA  
ATATTTTGTGAAGAAGCAGTTTCTCAGACACAACATCTCAGAATTTTAATTTTGTAGAAATTCATGGGAAATTTGG  
ATTTTTGTAAATAATCTTTTGATGTTTTTAAACATTGGTTCCCTAGTCACCATAGTTACCACCTGTATTTTAAAGTCA  
TTTAAACAAGCCACGGTGGGGCTTTTTCTCCTCAGTTTGAGGAGAAAAATCTTGATGTCTTACTCTCTGAATTA  
TTACATTTTGGAGAATAAGAGGGCATTTTATTTTATTAGTTACTAATTCAGCTGTGACTATTGTATATCTTTCC  
AAGAGTTGAAATGCTGGCTTCAGAATCATACCAGATTGTCAAGTGAAGCTGATGCCTAGGAACTTTAAAGGGATC  
CTTTCAAAGGATCACTTAGCAAACACATGTTGACTTTTAACTGATGTATGAATATTAATACTCTAAAAATAGAA  
AGACCAGTAATATATAAGTCACTTTACAGTGCTACTTCACACTTAAAGTGCATGGTATTTTTCATGGTATTTTG  
CATGCAGCCAGTTAACTCTCGTAGATAGAGAAGTCAGGTGATAGATGATATTAATAATAGCAAACAAAAGTGAC  
TTGCTCAGGGTCATGCAGCTGGGTGATGATAGAAGAGTGGGCTTAACTGGCAGGCCGTGATGTTTACAGACTAC  
CATACTGTAAATATGAGCTTTATGGGTGTCATTCTCAGAACTTATACATTTCTGCTCTCCTTTCTCCTAAGTTTC  
ATGCAGATGAATATAAGGTAATATACTATTATATAATTCATTTGTGATATCCACAATAATATGACTGGCAAGAAAT  
TGGTGGAAATTTGTAATTAATAATATTATTAACCT

8/615

**FIGURE 8**

MEKQCCSHPVICSLSTMYTFLLGAIFIALSSSRILLVKYSANEENKYDYLPTTVNVCSELVKLVFCVLVSFCVIK  
KDHQSRNLKYASWKEFSDFMKWSIPAFLYFLDNLIVFYVLSYLPAMAVIFS NFSIITTALLFRIVLKRRLNWIQ  
WASLLTLFLSIVALTAGTKTLQHNLAGRGFHHDAFFSPSNSCLLFRSECPRKDNC TAKEWTFPEAKWNTTARVFS  
HIRLGMGHVLIIVQCFISSMANIYNEKILKEGNQLTESIFIQNSKLYFFGILFNGLTLGLQRSNRDQIKNCGFFY  
GHSAFSVALIFVTAFQGLSVAFILKFLDNMFHVLMAQVTTVIITTVSVLVFDFRPSLEFFLEAPSVLLSIFIYNA  
SKPQVPEYAPRQERIRDLSGNLWERSSSGDGEELERLTKPKSDEDEDTF

**Transmembrane domains:**

amino acids 16-36 (type II), 50-74, 147-168, 229-250, 271-293, 298-318,  
328-368

**N-glycosylation sites.**

amino acids 128-132, 204-208, 218-222, 374-378

**Glycosaminoglycan attachment site.**

amino acids 402-406

**N-myristoylation sites.**

amino acids 257-263, 275-281, 280-286, 284-290, 317-323

9/615

**FIGURE 9**

GGGGCTTCGGCGCCAGCGGCCAGCGCTAGTCGGTCTGGTAAGGATTTACAAAAGGTGCAGGTATGAGCAGGTCTG  
AAGACTAACATTTTGTGAAGTTGTAAAACAGAAAACCTGTTAGAAATGTTGGTGGTTTCAGCAAGGCCTCAGTTTC  
CTTCCTTCAGCCCTTGTAATTTGGACATCTGCTGCTTCATATTTTCATACATTACTGCAGTAACACTCCACCAT  
ATAGACCCGGCTTTACCTTATATCAGTGACACTGGTACAGTAGCTCCAGAAAAATGCTTATTTGGGGCAATGCTA  
AATATTGCGGCAGTTTTATGCATTGCTACCATTATGTTTCGTTATAAGCAAGTTCATGCTCTGAGTCCTGAAGAG  
AACGTTATCATCAAATTAACAAGGCTGGCCTTGTAAGTACTGAGTTGTTTAGGACTTTCTATTGTGGCA  
AACTTCCAGAAAACAACCCTTTTTGCTGCACATGTAAGTGGAGCTGTGCTTACCTTTGGTATGGGCTCATTATAT  
ATGTTTGTTTTCAGACCATCCTTTCTACCAAATGCAGCCCAAAATCCATGGCAAACAAGTCTTCTGGATCAGACTG  
TTGTTGGTTATCTGGTGTGGAGTAAGTGCACCTAGCATGCTGACTTGCTCATCAGTTTTGCACAGTGGCAATTTT  
GGGACTGATTTAGAACAGAACTCCATTGGAACCCCGAGGACAAAGGTTATGTGCTTCACATGATCACTACTGCA  
GCAGAAATGGTCTATGTCATTTTCTTCTTTGGTTTTTCTGACTTACATTCGTGATTTTCAGAAAATTTCTTTA  
CGGGTGGAAGCCAATTTACATGGATTAACCTCTATGACACTGCACCTTGCCCTATTAACAATGAACGAACACGG  
CTACTTTCAGAGATATTTTGATGAAAGGATAAAATATTTCTGTAATGATTATGATTCTCAGGGATTGGGGAAAGG  
TTCACAGAAGTIGCTTATTCTTCTCTGAAATTTTCAACCACTTAATCAAGGCTGACAGTAACACTGATGAATGCT  
GATAATCAGGAAACATGAAAGAAGCCATTTGATAGATTATTCTAAAGGATATCATCAAGAAGACTATTAAAAACA  
CCTATGCCTATACTTTTTTATCTCAGAAAATAAAGTCAAAGACTATG

10/615

**FIGURE 10**

MWWFQQGLSFLPSALVIWTSAAFI FSYITAVTLHHIDPALPYISDTGTVAPEKCLFGAMLNIAAVLCIATYVRY  
KQVHALSPEENVIIKLNKAGLVLGILSCLGLSIVANFQKTTLFAAHVSGAVLTFGMGSLYMFVQTILSYQMOPKI  
HGKQVFWIRLLLVIWCGVSALSMLTCSSVLHSGNFGTDLEQKLHWNPEDKGYVLHMITTAAEWSMSFSFFGFFLT  
YIRDFQKISLRVEANLHGLTLYDTAPCPINNERTRLLSRDI

11/615

**FIGURE 11**

CCCACGCGTCCGCCCCGCGTGCCTCCCGAGTGCAAGTGAGCTTCTCGGCTGCCCCGCGGGCCGGGGTGCGGAG  
CCGACATGCGCCCCGCTTCTCGGCCTCCTTCTGGTCTTCGCCGGCTGCACCTTCGCCTTGTACTTGTGTGACGC  
GACTGCCCCGCGGGCGGAGACTGGGCTCCACCGAGGAGGCTGGAGGCAGGTCGCTGTGGTTCCTCCGACCTGG  
CAGAGCTGCGGGAGCTCTCTGAGGTCTTCGAGAGTACCGGAAGGAGCACAGGCCTACGTGTTCTGTCTTCT  
GCGGCGCCTACCTCTACAAACAGGGCTTTGCCATCCCCGGCTCCAGCTTCCTGAATGTTTTAGCTGGTGCCTTGT  
TTGGGCCATGGCTGGGGCTTCTGCTGTGCTGTGTGTTGACCTCGGTGGGTGCCACATGCTGCTACCTGCTCTCCA  
GTATTTTTGGCAAACAGTTGGTGGTGTCTACTTTCTGATAAAGTGGCCCTGCTGCAGAGAAAGGTGGAGGAGA  
ACAGAAACAGCTTGTTTTTTTTCTTATTGTTTTGAGACTTTTCCCCTATGACACCAAACCTGGTTCCTGAACCTCT  
CGGCCCCAATTCTGAACATTCCTCATCGTGCAGTTCCTTCTCTCAGTTCCTTATCGGTTTGATCCCATATAATTTCA  
TCTGTGTGCAGACAGGGTCCATCCTGTCAACCCTAACCTCTCTGGATGCTCTTTTCTCCTGGGACACTGTCTTTA  
AGCTGTTGGCCATTGCCATGGTGGCATTAAATTCCTGGAACCTCATTAAAAAATTTAGTCAGAAACATCTGCAAT  
TGAATGAAACAAGTACTGCTAATCATATACACAGTAGAAAAGACACATGATCTGGATTTTCTGTTTGCCACATCC  
CTGGACTCAGTTGCTTATTTGTGTAATGGATGTGGTCTCTAAAGCCCCTCATTGTTTTTGATTGCCTTCTATAG  
GTGATGTGGACACTGTGCATCAATGTGCAGTGTCTTTTCAGAAAGGACACTCTGCTCTTGAGGTGTATTACATC  
AGGTTTTCAAACCAGCCCTGGTGTAGCAGACACTGCAACAGATGCCTCCTAGAAAATGCTGTTTGTGGCCGGGCG  
CGGTGGCTCACGCCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCCGGTGATTACAAGGTCAGGAGTTCAAGACC  
AGCCTGGCCAAGATGGTGAAATCCTGTCTCTAATAAAAAATACAAAAATTAGCCAGGCGTGGTGGCAGGCACCTGT  
AATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATTGCTTGAACCAAGGTGGCAGAGGTTGCAGTAAGCCAAGAT  
CACACCACTGCACTCCAGCCTGGGTGATAGAGTGAGACACTGTCTTGAC

12/615

**FIGURE 12**

MRPLLGLLLVFAGCTFALYLLSTRLPGRRLGSTEAGGRSLWFPSDLAELRELSEVLREYRKEHQAYVFLFCG  
AYLYKQGFAIPGSSFLNVLGALFGPWLGLLLCCVLTSGATCCYLLSSIFGKQLVVSYPDKVALLQRKVEENR  
NSLFFFLFLRLFPMTPNWFLNLSAPILNIPVQFFSVLIGLIPYNFICVQTGSILSTLTSLDALFSWDTVFKL  
LAIAMVALIPGTLIKKFSQKHLQLNETSTANHIHSRKDT

**Important features:****Signal peptide:**

amino acids 1-17

**Transmembrane domains:**

amino acids 101-123, 189-211

**N-glycosylation sites.**

amino acids 172-176, 250-254

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 240-244, 261-265

**N-myristoylation site.**

amino acids 13-19, 104-110, 115-121, 204-210

**Amidation site.**

amino acids 27-31

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 4-15

**Protein splicing proteins.**

amino acids 25-31

**Sugar transport proteins.**

amino acids 162-172

13/615

**FIGURE 13**

CGGACGCGTGGGCGGACGCGTGGGGGAGAGCCGAGTCCCGGCTGCAGCACCTGGGAGAAGGCAGACCGTGTGAG  
GGGGCCTGTGGCCCCAGCGTGCTGTGGCCTCGGGGAGTGGGAAGTGGAGGCAGGAGCCTTCCTTACACTTCGCCA  
**TG**AGTTTTCTCATCGACTCCAGCATCATGATTACCTCCCAGATACTATTTTTTGGATTTGGGTGGCTTTTCTTCA  
TGCGCCAATTGTTTAAAGACTATGAGATACGTAGTATGTTGTACAGGTGATCTTCTCCGTGACGTTTGCATTTT  
CTTGACCATGTTTGAGCTCATCATCTTTGAAATCTTAGGAGTATTGAATAGCAGCTCCCGTTATTTTCACTGGA  
AAATGAACCTGTGTGTAATTCTGCTGATCCTGGTTTTTCATGGTGCCTTTTACATTGGCTATTTTATGTGAGCA  
ATATCCGACTACTGCATAAACAACGACTGCTTTTTTCTGTCTCTTATGGCTGACCTTTATGTATTTCTTCTGGA  
AACTAGGAGATCCCTTTCCCATTTCTCAGCCCAAACATGGGATCTTATCCATAGAACAGCTCATCAGCCGGGTTG  
GTGTGATTGGAGTGACTCTCATGGCTCTTCTTTCTGGATTTGGTGTCTCAACTGCCCATACACTTACATGTCTT  
ACTTCCTCAGGAATGTGACTGACACGGATATTCTAGCCCTGGAACGGCGACTGCTGCAAACCATGGATATGATCA  
TAAGCAAAAAGAAAAGGATGGCAATGGCACGGAGAACAATGTTCCAGAAGGGGGAAGTGCATAACAACCATCAG  
GTTTCTGGGGAATGATAAAAAGTGTTACCACTTCAGCATCAGGAAGTGAAAATCTTACTCTTATTCAACAGGAAG  
TGGATGCTTTGGAAGAATTAAGCAGGCAGCTTTTTCTGGAAACAGCTGATCTATATGCTACCAAGGAGAGAATAG  
AATACTCCAAAACCTTCAAGGGGAAATATTTTAATTTTCTGGTTACTTTTTCTCTATTTACTGTGTTTGGAAAA  
TTTTCATGGCTACCATCAATATTGTTTTTGATCGAGTTGGGAAAACGGATCCTGTCCAAAGAGGCATTGAGATCA  
CTGTGAATTATCTGGGAATCCAATTTGATGTGAAGTTTTGGTCCCAACACATTTCTTTCATTCTTGTGGAATAA  
TCATCGTCACATCCATCAGAGGATTGCTGATCACTCTTACCAAGTTCTTTTATGCCATCTCTAGCAGTAAGTCCT  
CCAATGTCTATTGCTCTATTAGCACAGATAATGGGCATGTACTTTGTCTCCTCTGTGCTGCTGATCCGAATGA  
GTATGCCPTTTAGAATACCGCACCATAATCACTGAAGTCCTTGGAGAAGTGCAGTTCAACTTCTATCACCCTTGGT  
TTGATGTGATCTTCTGGTCTCAGCGCTCTCTCTAGCATACTCTTCTCTATTTGGCTCACAAACAGGCACCAGAGA  
AGCAAATGGCACCT**TGA**ACTTAAGCCTACTACAGACTGTTAGAGGCCAGTGGTTTCAAATTTAGATATAAGAGG  
GGGGAAAAATGGAACAGGGCCTGACATTTTATAAACAAACAAAATGCTATGGTAGCATTTTTCACCTTCATAGC  
ATACTCCTTCCCCGTGAGGTGATACTATGACCATGAGTAGCATCAGCCAGAACATGAGAGGGAGAACTAACTCAA  
GACAATACTCAGCAGAGAGCATCCCGTGTGGATATGAGGCTGGTGTAGAGGCGGAGAGGAGCCAAGAACTAAAG  
GTGAAAAATACACTGGAACCTCTGGGGCAAGACATGTCTATGGTAGCTGAGCCAAACACGTAGGATTTCCGTTTTA  
AGGTTACATGGAAGGTTATAGCTTTGCCTTGAGATTGACTCATTAAATCAGAGACTGTAACAAAAA  
AAAAAAGGGCGCGGCGACTCTAGAGTCGACCTGCAGAAGCTTGGCCGCCATGGCCCACTTGTTTATTG  
CAGCTTATAATG



14/615

**FIGURE 14**

MSFLIDSSIMITSQILFFGFGWLFFMRQLFKDYEIRQYVVQVIFSVTFAFSCTMFELIIFEILGVLNSSSRYPFW  
KMNLGVILLILVFMVPFYIGYFIVSNIRLLHKQRLLFSCLLWLTFMYFFWKLGDPPILSPKHGILSIEQLISRV  
GVIGVTLMALLSGFGAVNCPYTYMSYFLRNVTDTDILALERLLQTMDMIISKKKRMAMARRTMFQKGEVHNKPS  
GFWGMIKSVTTSASGSENLTLLIQQEVDLEELSRQLFLETADLYATKERIEYSKTFKGKYFNFLGYFFSIYCVWK  
IFMATINIVFDRVGKTDVPVTRGIEITVNYLGIQFDVKFWSQHISFILVGIIIVTSIRGLLITLTKFFYAISSSKS  
SNVIVLLLAQIMGMFYVSSVLLIRMSMPLEYRTIITEVLGELQFNFYHRWFDVIFLVSAISSILFLYLAHKQAPE  
KQMAP

**Important features:****Signal peptide:**

amino acids 1-23

**Potential transmembrane domains:**

amino acids 37-55, 81-102, 150-168, 288-311, 338-356, 375-398, 425-444

**N-glycosylation sites.**

amino acids 67-70, 180-183 and 243-246

**Eukaryotic cobalamin-binding proteins**

amino acids 151-160

15/615

**FIGURE 15**

GACGGAAGAACAGCGCTCCCGAGGCCGCGGGAGCCTGCAGAGAGGACAGCCGGCCTGCGCCGGGACATGCGGCCC  
CAGGAGCTCCCCAGGCTCGCGTTCCCGTTGCTGCTGTTGCTGTTGCTGCTGCTGCCGCCGCCGCGTGCCCTGCC  
CACAGCGCCACGCGCTTCGACCCACCTGGGAGTCCCTGGACGCCGCCAGCTGCCCGCGTGGTTTGACCAAGGCC  
AAGTTCGGCATCTTCATCCACTGGGGAGTGTTCCTGCGCCAGCTTCGGTAGCGAGTGGTCTGGTGGTATTGG  
CAAAAGGAAAAGATACCGAAGTATGTGGAATTTATGAAAGATAATTACCCTCCTAGTTTCAAATATGAAGATTTT  
GGACCACTATTTACAGCAAAATTTTTTAATGCCAACCACTGGGCAGATATTTTTCAGGCCTCTGGTGCCAAATAC  
ATTGCTCTTAACCTCCAAACATCATGAAGGCTTTACCTTGTGGGGGTCAGAATATTCGTGGAACCTGGAATGCCATA  
GATGAGGGGGCCCAAGAGGGACATTGTCAAGGAACCTTGAGGTAGCCATTAGGAACAGAACTGACCTGCGTTTTGGA  
CTGTACTATTCCCTTTTTGAATGGTTTCATCCGCTCTTCCTTGAGGATGAATCCAGTTCATTCCATAAGCGGCAA  
TTTCCAGTTTCTAAGACATTGCCAGAGCTCTATGAGTTAGTGAACAACCTATCAGCCTGAGGTTCTGTGGTCGGAT  
GGTGACGGAGGAGCACCGGATCAATACTGGAACAGCACAGGCTTCTTGGCCTGGTTATATAATGAAAGCCAGTT  
CGGGGCACAGTAGTCACCAATGATCGTTGGGGAGCTGGTAGCATCTGTAAGCATGGTGGCTTCTATACCTGCAGT  
GATCGTTATAACCCAGGACATCTTTTGCCACATAAATGGGAAAACCTGCATGACAATAGACAACTGTCTGGGGC  
TATAGGAGGGAAGCTGGAATCTCTGACTATCTTACAATTGAAGAATTTGGTGAAGCAACTGTAGAGACAGTTTCA  
TGTGGAGGAAATCTTTTGATGAATATTGGGCCACACTAGATGGCACCATTCTGTAGTTTTTGAGGAGCGACTG  
AGGCAAGTGGGGTCTGGCTAAAAGTCAATGGAGAAGCTATTTATGAAACCTATACCTGGCGATCCCAGAATGAC  
ACTGTCACCCAGATGTGTGGTACACATCCAAGCCTAAAGAAAAATTAGTCTATGCCATTTTTCTTAAATGGCCC  
ACATCAGGACAGCTGTTCCCTTGGCCATCCCAAAGCTATTCTGGGGGCAACAGAGGTGAACTACTGGGCCATGGA  
CAGCCACTTAACTGGATTTCTTTGGAGCAAAATGGCATTATGGTAGAACTGCCACAGCTAACCATTCATCAGATG  
CCGTGTAAATGGGGCTGGGCTCTAGCCCTAACTAATGTGATCTAAAGTGCAGCAGAGTGGCTGATGCTGCAAGTT  
ATGTCTAAGGCTAGGAACCTATCAGGTGTCTATAATTGTAGCACATGGAGAAAGCAATGTAACTGGATAAGAAAA  
TTATTTGGCAGTTTCCGCTTTTCCCTTTTTCCCACTAAATTTTTCTTAAATTACCCATGTAACCATTTTAACTCT  
CCAGTGCATTTGCCATTAAAGTCTCTTACATTGATTTGTTTCCATGTGTGACTCAGAGGTGAGAATTTTTTCA  
CATTATAGTAGCAAGGAATTGGTGGTATTATGGACCGAACTGAAAATTTTATGTTGAAGCCATATCCCCCATGAT  
TATATAGTTATGCATCACTTAATATGGGGATATTTTCTGGGAAATGCATTGCTAGTCAATTTTTTTTGTGCCAA  
CATCATAGAGTGTATTTACAAAATCCTAGATGGCATAGCCTACTACACACCTAATGTGTATGGTATAGACTGTTG  
CTCCTAGGCTACAGACATATACAGCATGTTACTGAATACTGTAGGCAATAGTAACAGTGGTATTTGTATATCGAA  
ACATATGGAAACATAGAGAAGGTACAGTAAAAATACTGTAAATAAATGGTGCACCTGTATAGGGCACTTACCAC  
GAATGGAGCTTACAGGACTGGAAGTTGCTCTGGGTGAGTCAGTGAGTGAATGTGAAGGCCCTAGGACATTATTGAA  
CACTGCCAGACGTTATAAATACTGTATGCTTAGGCTACACTACATTTATAAAAAAAGTTTTCTTCTTCAATT  
ATAAATTAACATAAGTGTACTGTAACCTTACAAACGTTTAAATTTTTAAACCTTTTTGGCTCTTTGTAAATAAC  
ACTTAGCTTAAACATAAACTCATTGTGCAATGTAA

16/615

**FIGURE 16**

MRPQELPRLAFPLLLLLLLLLLPPPPCPAHSATRFDPWTWESLDARQLPAWFDQAKFGIFIHGVSFVPSFGSEWFW  
WYWQKEKIPKYVEFMKDNYPSPFKYEDFGPLFTAKFFNANQWADIFQASGAKYIVLTSKHHEGFTLWGSEYSWNW  
NAIDEGPKRDIVKELEVAIRNRTDLRFGLYYSLEFWFHPLFLEDESSSFHKRQFPVSKTLPELYELVNNYQPEVL  
WSDGDGGAPDQYWNSTGFLAWLYNESPVRGTVVTNDRWGAGSICKHGGFYTCSDRYNPGHLLPHKWENCMTIDKL  
SWGYYRREAGISDYLTIEELVKQLVETVSCGGNLLMNIGPTLDGTISVVFEERLRQVGSWLKVNGEAIYETYTWRS  
QNDTVTPDVWYTSKPKEKLVIYAIFLKWPTSGQLFLGHPKAILGATEVKLLGHCQPLNWISEQNGIMVELPQLTI  
HQMPCCKWGVALALTNI

**Signal sequence:**

amino acids 1-28

**N-glycosylation site.**

amino acids 171-175, 239-243, 377-381

**Casein kinase II phosphorylation site.**

amino acids 32-36, 182-186, 209-213, 227-231, 276-280, 315-319, 375-375

**Tyrosine kinase phosphorylation site.**

amino acids 361-369, 389-397

**N-myristoylation site.**

amino acids 143-149, 178-184, 255-261, 272-278, 428-434

**Leucine zipper pattern.**

amino acids 410-432

**Alpha-L-fucosidase putative active site.**

amino acids 283-295

**FIGURE 17**

[illegible]

18/615

**FIGURE 18**

MKFLLDILLLLPLLIIVCSLESFVKLFIPKRRKSVTGEIVLITGAGHGIGRLTAYEFAKLKSKL  
VLWDINKHGLEETAACKCKGLGAKVHTFVVDCSNREDIYSSAKKVKAIEIGDVSILVNNAGVVYT  
SDLFATQDPQIEKTFEVNVLAHFWTTKAFLPAMTKNNHGHIVTVASAAGHVSVPELLAYCSSK  
FAAVGFHKTLTDELAALQITGVKTTCLCPNFVNTGFIKNPSTSLGPTLEPEEVNRLMHGILT  
EQKMIFIPSSIAFLTTLERILPERFLAVLKRRKISVKFDAVIGYKMQ

**Signal sequence:**

amino acids 1-19

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 30-34, 283-287

**Casein kinase II phosphorylation site.**

amino acids 52-56, 95-99, 198-202, 267-271

**N-myristoylation site.**

amino acids 43-49, 72-78, 122-128, 210-216

19/615

**FIGURE 19**

CCCACGCGTCCGCTCCGCGCCCTCCCCCGCCTCCCGTGCGGTCCGTCGGTGGCCTAGAGAT  
GCTGCTGCCGCGGTTGCAGTTGTCGCGCACGCCTCTGCCCGCCAGCCCGCTCCACCGCCGTAG  
CGCCCGAGTGTCGGGGGGCGCACCCGAGTCGGGGCCATGAGGCCGGGAACCGCGCTACAGGCCG  
TGCTGCTGGCCGTGCTGCTGGTGGGGCTGCGGGCCGCGACGGGTGCGCTGCTGAGTGCCTCGG  
ATTTGGACCTCAGAGGAGGGCAGCCAGTCTGCCGGGGAGGGACACAGAGGCCCTTGTTATAAAG  
TCATTTACTTCCATGATACTTCTCGAAGACTGAACTTTGAGGAAGCCAAAGAAGCCTGCAGGA  
GGGATGGAGGCCAGCTAGTCAGCATCGAGTCTGAAGATGAACAGAACTGATAGAAAAGTTCA  
TTGAAAACCTCTTGCCATCTGATGGTGAATTTCTGGATTGGGCTCAGGAGGCGTGAGGAGAAAC  
AAAGCAATAGCACAGCCTGCCAGGACCTTTATGCTTGGACTGATGGCAGCATATCACAAATTTA  
GGAAC TGGTATGTGGATGAGCCGTCTTGGCGCAGCGAGGTCTGCGTGGTCACTGTACCATCAGC  
CATCGGCACCCGCTGGCATCGGAGGCCCTACATGTTCCAGTGGAAATGATGACCGGTGCAACA  
TGAAGAACAATTTCAATTTGCAAATATTCTGATGAGAAACCAGCAGTTCCTTCTAGAGAAGCTG  
AAGGTGAGGAAACAGAGCTGACAACACCTGTACTTCCAGAAGAAACACAGGAAGAAGATGCCA  
AAAAAACATTTAAAGAAAGTAGAGAAGCTGCCTTGAATCTGGCCTACATCCTAATCCCCAGCA  
TTCCCCTTCTCCTCCTCCTTGTGGTCACCCACAGTTGTATGTTGGGTTTGGATCTGTAGAAAAA  
GAAAACGGGAGCAGCCAGACCCTAGCACAAAGAAGCAACACACCATCTGGCCCTCTCCTCACC  
AGGGAAACAGCCCGGACCTAGAGGTCTACAATGTCATAAGAAAACAAAGCGAAGCTGACTTAG  
CTGAGACCCGGCCAGACCTGAAGAATATTTCAATTCGAGTGTGTTCCGGGAGAAGCCACTCCCG  
ATGACATGTCTTGTGACTATGACAACATGGCTGTGAACCCATCAGAAAGTGGGTTTGTGACTC  
TGGTGAGCGTGGAGAGTGGATTTGTGACCAATGACATTTATGAGTTCTCCCCAGACCAAATGG  
GGAGGAGTAAGGAGTCTGGATGGGTGGAAAATGAAATATATGGTTATTAGGACATATAAAAAA  
CTGAAACTGACAACAATGGAAAAGAAATGATAAGCAAAATCCTCTTATTTTCTATAAGGAAAA  
TACACAGAAGGTCTATGAACAAGCTTAGATCAGGTCCTGTGGATGAGCATGTGGTCCCCACGA  
CCTCCTGTTGGACCCCCACGTTTTTGGCTGTATCCTTTATCCCAGCCAGTCATCCAGCTCGACC  
TTATGAGAAGGTACCTTGCCAGGTCTGGCACATAGTAGAGTCTCAATAAATGTCACTTGGTT  
GGTTGTATCTAACTTTTAAGGGACAGAGCTTTACCTGGCAGTGATAAAGATGGGCTGTGGAGC  
TTGGAAAACCACTCTGTTTTCTTGTCTATACAGCAGCACATATTATCATAACAGACAGAAA  
ATCCAGAATCTTTTCAAAGCCCACATATGGTAGCACAGGTTGGCCTGTGCATCGGCAATTCTC  
ATATCTGTTTTTTTTCAAAGAATAAAATCAAATAAAGAGCAGGAAAAAAAAA

20/615

**FIGURE 20**

MRPGTALQAVLLAVLLVGLRAATGRLLSASDLDLRGGQPVCRRGGTQRPCYKVIYFHDTSRRLN  
FEEAKEACRRDGGQLVSI ESEDEQKLIKFIENLLPSDGDGFWIGLRRREEKQSNSTACQDLYA  
WTDGSISQFRNWYVDEPSCGSEVCVVMYHQPSAPAGIGGPYMFQWNDDRCNMKNNFICKYSDE  
KPAVPSREAEGEETELTPVLPEETQEEDAKKTFKESREAALNLAYILIPSIPLLLLLLVVTTV  
VCWVWICRKRKREQPD PSTKKQHTIWPSPHQGN SPDLEVYNVIRKQSEADLAETRPDLKNISF  
RVCSGEATPDDMSCDYDNMAVNPSESGFVTLSVESGFVTNDIYEFSPDQMGRSKESGWVENE  
IYGY

**Signal sequence:**

amino acids 1-21

**Transmembrane domain:**

amino acids 235-254

**N-glycosylation site.**

amino acids 117-121, 312-316

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 296-300

**Casein kinase II phosphorylation site.**amino acids 28-32, 30-34, 83-87, 100-104, 214-218, 222-226,  
299-303, 306-310, 323-327**N-myristoylation site.**

amino acids 18-24, 37-43, 76-82, 146-152

21/615

**FIGURE 21**

AGGCTCCCGCGCGCGGCTGAGTGCGGACTGGAGTGGGAACCCGGGTCCCGCGCTTAGAGAACACGCGATGACCA  
CGTGGAGCCTCCGCGGAGGCGCGGCCGACGCTGGGACTCCTGCTGCTGGTCTGCTTGGGCTTCTGGTGCTCC  
GCAGGCTGGACTGGAGCACCTTGGTCCCTCTGCGGCTCCGCCATCGACAGCTGGGGCTGCAGGCCAAGGGCTGGA  
ACTTCATGCTGGAGGATTCCACCTTCTGGATCTTCGGGGGCTCCATCCACTATTTCCGTGTGCCAGGGAGTACT  
GGAGGGACCGCTGCTGAAGATGAAGGCCTGTGGCTTGAACACCTCACCACCTATGTTCCGTGGAACCTGCATG  
AGCCAGAAAGAGGCAAATTTGACTTCTCTGGGAACCTGGACCTGGAGGCCTTCGTCTGATGGCCGCGAGAGATCG  
GGCTGTGGGTGATTCTGCGTCCAGGCCCTACATCTGCAGTGAGATGGACCTCGGGGGCTTGCCAGCTGGCTAC  
TCCAAGACCTGGCATGAGGCTGAGGACAATTACAAGGGCTTACCGAAGCAGTGGACCTTTATTTTGAACCACC  
TGATGTCCAGGGTGGTGCCACTCCAGTACAAGCGTGGGGGACCTATCATTGCCGTGCAGGTGGAGAATGAATATG  
GTTCTTATAATAAAGACCCCGCATACATGCCCTACGTCAAGAAGGCACTGGAGGACCGTGGCATTTGTGGAACCTGC  
TCCTGACTTCAGACAACAAGGATGGGCTGAGCAAGGGGATTGTCCAGGGAGTCTTGGCCACCATCAACTTGCAGT  
CAACACACGAGCTGCAGCTACTGACCACCTTTCTCTTCAACGTCCAGGGGACTCAGCCCAAGATGGTGATGGAGT  
ACTGGACGGGGTGGTTTGTGCTGGGGAGGCCCTCACAATATCTTGGATTCTTCTGAGGTTTTGAAAACCGTGT  
CTGCCATTGTGGACGCCGGCTCCTCCATCAACCTCTACATGTTCCACGGAGGCACCAACTTTGGCTTCATGAATG  
GAGCCATGCACTTCCATGACTACAAGTCAGATGTACCAGCTATGACTATGATGCTGTGCTGACAGAAGCCGGCG  
ATTACACGGCCAAGTACATGAAGCTTCGAGACTTCTTCGGCTCCATCTCAGGCATCCCTCTCCCTCCCCACCTG  
ACCTTCTTCCCAAGATGCCGTATGAGCCCTTAACGCCAGTCTTGTACCTGTCTCTGTGGGACGCCCTCAAGTACC  
TGGGGGAGCCAATCAAGTCTGAAAAGCCCATCAACATGGAGAACCTGCCAGTCAATGGGGGAAATGGACAGTCCCT  
TCGGGTACATTCTCTATGAGACCAGCATCACCTCGTCTGGCATCCTCAGTGGCCACGTGCATGATCGGGGGCAGG  
TGTTTTGTGAACACAGTATCCATAGGATTCTTGGACTACAAGACAACGAAGATTGCTGTCCCCCTGATCCAGGGTT  
ACACCGTGCTGAGGATCTTGGTGGAGAATCGTGGGCGAGTCAACTATGGGGAGAATATTGATGACCAGCGCAAAG  
GCTTAATTGGAAATCTCTATCTGAATGATTCAACCCCTGAAAAAATTGAGAATCTATAGCCTGGATATGAAGAAGA  
GCTTCTTTTCAAGAGTTTGGCCTGGACAAATGNGTTCCCTCCCAGAAACACCCACATTACCTGCTTTCTTCTTGG  
GTAGCTTGTCCATCAGCTCCAGCCTTGTGACACCTTTCTGAAGCTGGAGGGCTGGGAGAAGGGGGTTGTATTCA  
TCAATGGCCAGAACCTTGGACGTTACTGGAACATTGGACCCCAAGACGCTTTACCTCCCAGGTCCCTGGTTGA  
GCAGCGGAATCAACCAGGTCTCGTTTTTTGAGGAGACGATGGCGGGCCCTGCATTACAGTTACGGAAACCCCC  
ACCTGGGCAGGAACCACTACATTAAGTGAAGCGTGGCACCCCTCCTGCTGGTGCCAGTGGGAGACTGCCGCCCTC  
CTCTTGACCTGAAGCCTGGTGGCTGCTGCCCCACCCCTCACTGCAAAAGCATCTCCTTAAGTAGCAACCTCAGGG  
ACTGGGGGCTACAGTCTGCCCTGTCTCAGCTCAAACCTTAAGCCTGCAGGGAAAGGTGGGATGGCTCTGGGCC  
TGGCTTTGTTGATGATGGCTTTCTACAGCCCTGCTCTTGTGCCGAGGCTGTGGGGCTGTCTTAGGGTGGGAGC  
AGCTAATCAGATCGCCAGCCTTTGGCCCTCAGAAAAAGTGCTGAAACGTGCCCTTGACCCGACGTACAGCCC  
TGCGAGCATCTGCTGGACTCAGGCGTGCTCTTTGCTGGTTCTGGGAGGCTTGGCCACATCCCTCATGGCCCCAT  
TTTATCCCCGAAATCCTGGGTGTGTACACAGTGTAGAGGGTGGGGAAGGGGTGTCTCACCTGAGCTGACTTTGTT  
CTTCTTTCACAACTTCTGAGCCTTCTTTGGGATTCTGGAAGGAACCTCGGCGTGAGAAACATGTGACTTCCCTT  
TCCCTTCCACTCGCTGCTTCCACAGGGTGACAGGCTGGGCTGGAGAAACAGAAATCTCACCCTGCGTCTTCC  
CAAGTTAGCAGGTGTCTCTGGTGTTCAGTGAGGAGGACATGTGAGTCTTGGCAGAAGCCATGGCCCATGTCTGCA  
CATCCAGGGAGGAGGACAGAAGGCCAGCTCACATGTGAGTCTTGGCAGAAGCCATGGCCCATGTCTGCACATCC  
AGGGAGGAGGACAGAAGGCCAGCTCACATGTGAGTCTTGGCAGAAGCCATGGCCCATGTCTGCACATCCAGGGA  
GGAGGACAGAAGGCCAGCTCACATGTGAGTCTTGGCAGAAGCCATGGCCCATGTCTGCACATCCAGGGAGGAGG  
ACAGAAGGCCAGCTCAGTGGCCCCGCTCCCCACCCCCACGCCCCGAACAGCAGGGGCAGAGCAGCCCTCCTTC  
GAAGTGTGTCCAAGTCCGCATTTGAGCCTTGTCTGGGGCCAGCCCAACACCTGGCTTGGGCTCACTGTCTGTA  
GTTGCAGTAAAGCTATAACCTTGAATCACAA



22/615

**FIGURE 22**

MTTWSLRRRPPARTLGLLLLVVLGFLVLRRLDWSTLVPLRLRHRQLGLQAKGWNFMLEDSTFWI  
FGGSIHYFRVPREYWRDRLLKMKACGLNTLTITYVPWNLHEPERGKFDFSGNLDLEAFVLMMAE  
IGLWVILRPGPYICSEMDLGGLPSWLLQDPGMRLRTTYKGFTEAVDLYFDHLSRVVPLQYKR  
GGPIIAVQVENEGSYNKDPAYMPYVKKALEDRGIVELLLTSDNKDGLSKGIVQGVLATINLQ  
STHELQLLTTFLFNVQGTQPKVMMEYWTGWFDSWGPHNILDSSEVLKTVSAIVDAGSSINLY  
MFHGGTNFGFMNGAMHFHDYKSDVTSYDYDAVLTEAGDYTAKYMKLRDFFGSISGIPLPPPPD  
LLPKMPYEPLTPVLYLSLWDALKYLGEPIKSEKPINMENLPVNGGNGQSFGYILYETSITSSG  
ILSGHVHDRGQVFVNTVVSIGFLDYKTTKIAVPLIQGYTVLRILVENRGRVNYGENIDDQRKGL  
IGNLYLNDSPKKNFRIYSLDMKKSFFQRFGLDKWXSLETPPTLPAFFLGSLSSISSTPCDTFLK  
LEGWEKGVVFINGQNLGRYWNIGPQKTLYLPGPWLSSGINQVIVFEETMAGPALQFTETPHLG  
RNQYIK

**Signal sequence:**

amino acids 1-27

**Casein kinase II phosphorylation site.**

amino acids 141-118, 253-257, 340-344, 395-399, 540-544, 560-564

**N-myristoylation site.**amino acids 146-152, 236-242, 240-246, 244-250, 287-293, 309-315,  
320-326, 366-372, 423-429, 425-431, 441-447, 503-509, 580-586

23 / 615

## FIGURE 23

[illegible]

24/615

**FIGURE 24**

MNSSKSSETQCTERGCFSSQMFLWTVAGIPILFLSACFITRCVVTFRI FQTCDEKKFQLPENF  
TELSYNYGSGSVKNCCPLNWEYFQSSCYFFSTDTISWALSLKNCSAMGAHLVVINSQEEQEF  
LSYKKPKMREFFIGLSDQVVEGQWQWVDGTPLTKSLSFWDVGEPNNIATLED CATMRDSSNPR  
QNWNDVTCFLNYFRICEMVGINPLNKGKSL

**Signal sequence:**

amino acids 1-42

**N-glycosylation site.**

amino acids 2-6, 62-66, 107-111

**Casein kinase II phosphorylation site.**

amino acids 51-55, 120-124, 163-167, 175-179, 181-185

**N-myristoylation site.**

amino acids 15-21, 74-80, 155-161

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 27-38

25/615

**FIGURE 25**

GGGGACGCGGAGCTGAGAGGCTCCGGGCTAGCTAGGTGTAGGGGTGGACGGGTCCCAGGACCC  
TGGTGAGGGTTCTCTACTTGGCCTTCGGTGGGGGTCAAGACGCAGGCACCTACGCCAAAGGGG  
AGCAAAGCCGGGCTCGGCCCCGAGGCCCCCAGGACCTCCATCTCCCAATGTTGGAGGAATCCGA  
CACGTGACGGTCTGTCCGCCGTCTCAGACTAGAGGAGCGCTGTAAACGCC**ATG**GGCTCCCAAGA  
AGCTGTCCTGCCTTCGTTCCCTGCTGCTGCCGCTCAGCCTGACGCTACTGCTGCCCCAGGCAG  
ACACTCGGTTCGTTTCGTAGTGGATAGGGGTCATGACCGGTTTCTCCTAGACGGGGCCCCGTTCC  
GCTATGTGTCTGGCAGCCTGCACTACTTTCGGGTACCGCGGGTGCTTTGGGCCGACCGGCTTT  
TGAAGATGCGATGGAGCGGCCTCAACGCCATACAGTTTTATGTGCCCTGGAACCTACCACGAGC  
CACAGCCTGGGGTCTATACTTTAATGGCAGCCGGGACCTCATTGCCTTTCTGAATGAGGCAG  
CTCTAGCGAACCTGTTGGTCATACTGAGACCAGGACCTTACATCTGTGCAGAGTGGGAGATGG  
GGGGTCTCCCATCCTGGTTGCTTCGAAAACCTGAAATTCATCTAAGAACCTCAGATCCAGACT  
TCCTTGCCGCAGTGGACTCCTGGTTCAAGGTCTTGCTGCCCAAGATATATCCATGGCTTTATC  
ACAATGGGGGCAACATCATTAGCATTTCAGGTGGAGAATGAATATGGTAGCTACAGAGCCTGTG  
ACTTCAGCTACATGAGGCACCTTGGCTGGGCTCTTCCGTGCACTGCTAGGAGAAAAGATCTTGC  
TCTTCACCACAGATGGGCCTGAAGGACTCAAGTGTGGCTCCCTCCGGGGACTCTATACCACTG  
TAGATTTTGGCCAGCTGACAACATGACCAAAATCTTTACCCTGCTTCGGAAGTATGAACCCC  
ATGGGCCATTGGTAAACTCTGAGTACTACACAGGCTGGCTGGATTACTGGGGCCAGAATCACT  
CCACACGGTCTGTGTGCTGTAACCAAAGGACTAGAGAACATGCTCAAGTTGGGAGCCAGTG  
TGAACATGTACATGTTCCATGGAGGTACCAACTTTGGATATTGGAATGGTGCCGATAAGAAGG  
GACGCTTCCTTCGATTACTACCAGCTATGACTATGATGCACCTATATCTGAAGCAGGGGACC  
CCACACCTAAGCTTTTTTGCTCTTCGAGATGTCATCAGCAAGTTCAGGAAGTTCCTTTGGGAC  
CTTTACCTCCCCGAGCCCCAAGATGATGCTTGGACCTGTGACTCTGCACCTGGTTGGGCATT  
TACTGGCTTTCTAGACTTGCTTTGCCCCCGTGGGCCCATTCAATCAATCTTGCCAATGACCT  
TTGAGGCTGTCAAGCAGGACCATGGCTTCATGTTGTACCGAACCTATATGACCCATACCATTT  
TTGAGCCAACACCATTCTGGGTGCCAAATAATGGAGTCCATGACCGTGCCCTATGTGATGGTGG  
ATGGGGTGTTCCAGGGTGTTGTGGAGCGAAATATGAGAGACAAACTATTTTGGACGGGGAAAC  
TGGGGTCCAAACTGGATATCTTGGTGGAGAACATGGGGAGGCTCAGCTTTGGGTCTAACAGCA  
GTGACTTCAAGGGCCTGTTGAAGCCACCAATTCTGGGGCAAACAATCCTTACCCAGTGGATGA  
TGTTCCCTCTGAAAATTGATAACCTTGTGAAGTGGTGGTTTCCCTCCAGTTGCCAAAATGGC  
CATATCCTCAAGCTCCTTCTGGCCCCACATTCTACTCCAAAACATTTCCAATTTTAGGCTCAG  
TTGGGGACACATTTCTATATCTACCTGGATGGACCAAGGGCCAAGTCTGGATCAATGGGTTTA  
ACTTGGGCCGGTACTGGACAAAGCAGGGGCCACAACAGACCCTCTACGTGCCAAGATTCCTGC  
TGTTTCCTAGGGGAGCCCTCAACAAAATTACATTGCTGGAAGTAGAAGATGTACCTCTCCAGC  
CCCAAGTCCAATTTTTGGATAAGCCTATCCTCAATAGCACTAGTACTTTGCACAGGACACATA  
TCAATTCCTTTTTCAGCTGATACACTGAGTGCCTCTGAACCAATGGAGTTAAGTGGGCAC**TCAA**  
AGGTAGGCCGGGCATGGTGGCTCATGCCTGTAATCCAGCACTTTGGGAGGCTGAGACGGGTG  
GATTACCTGAGGTCAGGACTTCAAGACCAGCCTGGCCAACATGGTGAACCCCGTCTCCACTA  
AAAATACAAAAATTAGCCGGGCGTGATGGTGGGCACCTCTAATCCAGCTACTTGGGAGGCTG  
AGGGCAGGAGAATTGCTTGAATCCAGGAGGCAGAGGTTGCAGTGAGTGGAGGTTGTACCACTG  
CACTCCAGCCTGGCTGACAGTGAGACACTCCATCTCAAAAAAAAAAAAA

26/615

**FIGURE 26**

MAPKKLSCLRSLLLPLSLTLLLPQADTRSFVVDGRGHRFLLDGAPFRYVSGSLHYFRVPRVLW  
ADRLKMRWSGLNAIQFYVPWNYHEPQPGVYNFNGSRDLIAFLNEAALANLLVILRPGPYICA  
EWEMGGGLPSWLLRKPEIHLRTSDPDLAAVDSWFKVLLPKIYPWLYHNGGNIISIQVENEYGS  
YRACDFSVMRHLAGLFRALLGEKILLFTTDGPEGLKCGSLRGLYTTVDGFPADNMTKIFTLLR  
KYEPHGPIVNSEYYTGWLDYWGQNHSTRSVSAVTKGLENMLKLGASVNMVMFHGGTNFGYWNG  
ADKKGRFLPITTSYDYDAPISEAGDPTPKLFALRDVISKFQEVPLGPLPPPSPKMMLGPVTLH  
LVGHLLAFLDLLCPRGPIHSILPMTFEAVKQDHGFMLYRTYMTHTIFEPTPFWVPNNGVHRA  
YVMVDGVFQGVVERNMRDKLFLTGKLGSKLDILVENMGRLSFGSNSSDFKGLLKPPILGQTIL  
TQWMMFPLKIDNLVKWWFPLQLPKWPYPQAPSGPTFYSKTFPILGSVGDFFLYLPGWTKGQVW  
INGFNLGRYWKQGPQQTLYVPRFLLFPRGALNKITLLELEDVPLQPQVQFLDKPILNSTSTL  
HRTHINSLSADTLSASEPMELSGH

**Signal sequence:**

amino acids 1-27

**N-glycosylation site.**

amino acids 97-101, 243-247, 276-280, 486-490, 625-629

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 4-8

**Casein kinase II phosphorylation site.**amino acids 148-152, 234-238, 327-331, 423-427, 469-473, 550-554,  
603-607, 644-648**Tyrosine kinase phosphorylation site.**

amino acids 191-198

**N-myristoylation site.**amino acids 131-137, 176-182, 188-194, 203-209, 223-229, 227-233,  
231-237, 274-280, 296-300, 307-313, 447-453, 484-490

FIGURE 27

[illegible]

28/615

**FIGURE 28**

MGLLLLVLPLLLLPGSYGLPFYNGFYYSNSANDQNLGNHGHGKDLLNGVKLVVETPEETLFTYQG  
ASVILPCRYRYEPALVSPRRVRVKWWKLSNGAPEKDVLVAIGLRHRSFGDYQGRVHLRQDKE  
HDVSLEIQDLRLLEDYGRYRCEVIDGLEDESGLVELELRGVVFPYQSPNGRYQFNFHEGQQVCA  
EQAAVVASFEQLFRAWEEGLDWCNAGWLQDATVQYPIMLPRQPCGGPGLAPGVRSYGPRHRL  
HRYDVFCFATALKGRVYYLEHPEKLTLTTEAREACQEDDATIAKVGQLFAAWKFHGLDRCDAGW  
LADGSVRYPVVHPHPNCGPPEPGVRSFGFPDPQSRLYGVYCYRQH

**Signal sequence:**

amino acids 1-17

**Casein kinase II phosphorylation site.**

amino acids 29-33, 53-57, 111-115, 278-282

**Tyrosine kinase phosphorylation site.**

amino acids 137-145

**N-myristoylation site.**amino acids 36-42, 184-190, 208-214, 237-243, 297-303,  
307-313

29/615

**FIGURE 29**

GCAAGCGGCGAAATGGCGCCCTCCGGGAGTCTTGCAAGTTCCTGGCAGTCTGGTGCTGTTG  
CTTTGGGGTGCTCCCTGGACGCACGGGCGGCGGAGCAACGTTGCGGTCATCACGGACGAGAAC  
TGGAGAGAACTGCTGGAAGGAGACTGGATGATAGAATTTTATGCCCCGTGGTGCCCTGCTTGT  
CAAAATCTTCAACCGGAATGGGAAAGTTTTGCTGAATGGGGAAGATCTTGAGGTTAATATT  
GCGAAAGTAGATGTACAGAGCAGCCAGGACTGAGTGGACGGTTTATCATAACTGCTCTTCCT  
ACTATTTTATCATTGTAAAGATGGTGAATTTAGGCGCTATCAGGGTCCAAGGACTAAGAAGGAC  
TTCATAAACTTTATAAGTGATAAAGAGTGGAAGAGTATTGAGCCCGTTTCATCATGGTTTGGT  
CCAGGTTCTGTTCTGATGAGTAGTATGTCAGCACTCTTTCAGCTATCTATGTGGATCAGGACG  
TGCCATAACTACTTTATTGAAGACCTTGGATTGCCAGTGTGGGGATCATATACTGTTTTGCT  
TTAGCAACTCTGTTTTCCGGACTGTTATTAGGACTCTGTATGATATTTGTGGCAGATTGCCTT  
TGTCCTTCAAAAAGGCGCAGACCACAGCCATACCCATACCCTTCAAAAAAATTATTATCAGAA  
TCTGCACAACCTTTGAAAAAAGTGGAGGAGGAACAAGAGGCGGATGAAGAAGATGTTTCAGAA  
GAAGAAGCTGAAAGTAAAGAAGGAACAAACAAGACTTTCACAGAATGCCATAAGACAACGC  
TCTCTGGGTCCATCATTGGCCACAGATAAATCCTAGTTAAATTTTATAGTTATCTTAATATTA  
TGATTTTGATAAAACAGAAGATTGATCATTGTTTGGTTTGAAGTGAAGTGTGACTTTTTTT  
GAATATTGCAGGGTTCAGTCTAGATTGTCATTAAATTGAAGAGTCTACATTCAGAACATAAAA  
GCACTAGGTATACAAGTTTGAAATATGATTTAAGCACAGTATGATGGTTTAAATAGTTCTCTA  
ATTTTTGAAAAATCGTGCCAAGCAATAAGATTTATGTATATTTGTTTAAATAAATACCTATTTT  
AAGTCTGAGTTTTGAAAATTTACATTTCCCAAGTATTGCATTATTGAGGTATTTAAGAAGATT  
ATTTTAGAGAAAAATATTTCTCATTTGATATAATTTTCTCTGTTTCACTGTGTGAAAAAAG  
AAGATATTTCCCATAAATGGGAAGTTTGCCCATTTGTCTCAAGAAATGTGTATTTCAAGTACAA  
TTTCGTGGTCTTTTTTAGAGGTATATTTCCAAAATTTCTTGTATTTTAGGTTATGCAACTAAT  
AAAACTACCTTACATTAATTAATTACAGTTTTCTACACATGGTAATACAGGATATGCTACTG  
ATTTAGGAAGTTTTTAAGTTCATGGTATTCTCTTGATTCCAACAAAGTTTGATTTTCTCTTGT  
ATTTTCTTACTTACTATGGGTTACATTTTTTATTTTTCAAATTGGATGATAATTTCTTGGA  
ACATTTTTTATGTTTTAGTAAACAGTATTTTTTGTGTTTCAAAGTTTACTGAGAGA  
TCCATCAAATGAACAATCTGTTGTAATTTAAATTTTGGCCACTTTTTTCAGATTTTACATC  
ATTCTTGCTGAAGTTCAAGTTGAAATGTTTTTTTTTTTTCTTTTGGATGTGAAGGTGAACATT  
CCTGATTTTTGTCTGATGTGAAAAAGCCTTGGTATTTTACATTTTGAAGTTCAAAGAAGCTT  
AATATAAAGTTTGCATTCTACTCAGGAAAAAGCATCTTCTGTATATGTCTTAAATGTATTT  
TTGTCCTCATATACAGAAAGTTCTTAATTGATTTTACAGTCTGTAATGCTTGATGTTTTAAAA  
TAATAACATTTTTATATTTTTTAAAGACAACTTCATATTATCCTGTGTTCTTTCTGACTG  
GTAATATTGTGTGGGATTTACAGGTAAAAGTCAAGTGGATGGAACATTTTAGTGTATTTTA  
CTCCTTAAAGAGCTAGAATACATAGTTTTTACCTTAAAGAGGGGGGAAATCATAAATACAA  
TGAATCAACTGACCATTACGTAGTAGACAATTTCTGTAATGTCCCTTCTTTCTAGGCTCTGT  
TGCTGTGTGAATCCATTAGATTTACAGTATCGTAATATACAAGTTTTCTTTAAAGCCCTCTCC  
TTTAGAATTTAAATATTTGTACCATTAAAGAGTTTGGATGTGTAAGTGTGATGCCTTAGAAA  
AATATCCTAAGCACAAAATAAACCTTTCTAACCACTTCATTAAAGCTGAAAAAAAAAAAAAA  
AAA



30/615

**FIGURE 30**

MAPSGSLAVPLAVLVLLLWGAPWTHGRRSNVRVITDENWRELLEGDWMIEFYAPWCPACQNLQ  
PEWESFAEWGEDLEVNIKVDVTEQPGLSGRFIITALPTIYHCKDGEFRRYQGPRTKKDFINF  
ISDKEWKSI EPVSSWFGPGSVLMSSMSALFQLSMWIRTCHNYFIEDLGLPVWGSYTVFALATL  
FSGLLLGLCMIFVADCLCPSKRRRPQYPYPSPSKLLSESAQPLKKVEEEQEAEDEEDVSEEEAE  
SKEGTNKFDPQNAIRQRS LGPSLATDKS

**Signal sequence:**

amino acids 1-26

**Transmembrane domain:**

amino acids 182-201

**Casein kinase II phosphorylation site.**

amino acids 68-72, 119-123, 128-132, 247-251, 257-261

**Tyrosine kinase phosphorylation site.**

amino acids 107-115

**N-myristoylation site.**

amino acids 20-26, 192-198

**Amidation site.**

amino acids 25-29

31/615

**FIGURE 31**

AGATGGCGGTCTTGGCACCTCTAATTGCTCTCGTGTATTCGGTGCCGCGACTTTCACGATGGC  
TCGCCCCAACCTTACTACCTTCTGTGCGGCCCTGCTCTCTGCTGCCTTCCTACTCGTGAGGAAAC  
TGCCGCGGCTCTGCCACGGTCTGCCCACCCAACGCGAAGACGGTAACCCGTGTGACTTTGACT  
GGAGAGAAGTGGAGATCCTGATGTTTCTCAGTGCCATTGTGATGATGAAGAACCGCAGATCCA  
TCACTGTGGAGCAACATATAGGCAACATTTTCATGTTTAGTAAAGTGGCCAACACAATTCTTT  
TCTTCCGCTTGGATATTGCGCATGGGCCCTACTTTACATCACACTCTGCATAGTGTTCTTGATGA  
CGTGCAAACCCCCCTATATATGGGCCCTGAGTATATCAAGTACTTCAATGATAAAACCATTG  
ATGAGGAACTAGAACGGGACAAGAGGGTCACTTGGATTGTGGAGTTCTTTGCCAATTGGTCTA  
ATGACTGCCAATCATTTGCCCCCTATCTATGCTGACCTCTCCCTTAAATACAACCTGTACAGGGC  
TAAATTTTGGGAAGGTGGATGTTGGACGCTATACTGATGTTAGTACGCGGTACAAAGTGAGCA  
CATCACCCCTCACCAAGCAACTCCCTACCCTGATCCTGTTCCAAGGTGGCAAGGAGGCAATGC  
GGCGGCCACAGATTGACAAGAAAGGACGGGCTGTCTCATGGACCTTCTCTGAGGAGAATGTGA  
TCCGAGAATTTAACTTAAATGAGCTATACCAGCGGGCCAAGAACTATCAAAGGCTGGAGACA  
ATATCCCTGAGGAGCAGCCTGTGGCTTCAACCCCCACCACAGTGTGAGATGGGGAAAACAAGA  
AGGATAAAATAAGATCCTCACTTTGGCAGTGCTTCCTCTCCTGTCAATTCAGGCTCTTTCCAT  
AACCACAAGCCTGAGGCTGCAGCCTTTNATTNATGTTTTCCCTTTGGCTGNGACTGGNTGGGG  
CAGCATGCAGCTTCTGATTTTAAAGAGGCATCTAGGGAATTGTCAGGCACCCTACAGGAAGGC  
CTGCCATGCTGTGGCCAACCTGTTTCACTGGAGCAAGAAAGAGATCTCATAGGACGGAGGGGGA  
AATGGTTTTCCCTCCAAGCTTGGGTCAGTGTGTTAACTGCTTATCAGCTATTGAGACATCTCCA  
TGGTTTCTCCATGAAACTCTGTGGTTTCATCATTCCTTCTTAGTTGACCTGCACAGCTTGGTT  
AGACCTAGATTTAACCCTAAGGTAAGATGCTGGGGTATAGAACGCTAAGAATTTTCCCCCAAG  
GACTCTTGCTTCCTTAAGCCCTTCTGGCTTCGTTTATGGTCTTCATTAAAAGTATAAGCCTAA  
CTTTGTGCTAGTCCTAAGGAGAAACCTTTAACCACAAAGTTTTTATCATTGAAGACAATATT  
GAACAACCCCTATTTTGTGGGGATTGAGAAGGGGTGAATAGAGGCTTGAGACTTTCCTTTGT  
GTGGTAGGACTTGGAGGAGAAATCCCCTGGACTTTCACCTAACCTCTGACATACTCCCCACAC  
CCAGTTGATGGCTTTCGGTAATAAAAAGATTGGGATTTCTTTTG

32/615

**FIGURE 32**

MAVLAPLIALVYSVPRLSRWLAQPYLLSALLSAAFLVRKLPPLCHGLPTQREDGNPCDFDW  
REVEILMFLSAIVMMKNRRSITVEQHIGNIFMFSKVANTILFFRLDIRMGLLYITLCIVFLMT  
CKPPLYMGPEYIKYFNDKTIDEELERDKRVTWIVEFFANWSNDCQSFAPIYADLSLKYNCTGL  
NFGKVDVGRYTDVSTRYKVSTSPLTKQLPTLILFQGGKEAMRRPQIDKKGRAVSWTFSEENV  
REFNLNELYQRAKKLSKAGDNIPEEQPVASTPTTVSDGENKKDK

**Signal sequence:**

amino acids 1-48

**Transmembrane domain:**

amino acids 111-125

**N-glycosylation site.**

amino acids 165-169, 185-189

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 154-158, 265-269

**Casein kinase II phosphorylation site.**

amino acids 51-55, 145-149, 245-249, 286-290, 288-292

**N-myristoylation site.**

amino acids 188-194, 225-231

**Myb DNA-binding domain repeat signature 1.**

amino acids 244-253

33/615

**FIGURE 33**

CGGACGCGTGGGGTGCCCGAC**ATG**GCGAGTGTAGTGCTGCCGAGCGGATCCCAGTGTGCGGCG  
GCAGCGGCGGGCGGCGCCTCCCGGGCTCCGGCTTCTGCTGTTGCTCTTCTCCGCCGCGGCA  
CTGATCCCCACAGGTGATGGGCAGAATCTGTTTACGAAAGACGTGACAGTGATCGAGGGAGAG  
GTTGCGACCATCAGTTGCCAAGTCAATAAGAGTGACGACTCTGTGATTGAGTACTGAATCCC  
AACAGGCAGACCATTATTTTCAGGGACTTCAGGCCTTTGAAGGACAGCAGGTTTCAGTTGCTG  
AATTTTTCTAGCAGTGAACCTCAAAGTATCATTGACAAACGTCTCAATTTCTGATGAAGGAAGA  
TACTTTTGCCAGCTCTATAACCGATCCCCCACAGGAAAGTTACACCACCATCACAGTCCTGGTC  
CCACCACGTAATCTGATGATCGATATCCAGAAAGACACTGCGGTGGAAGGTGAGGAGATTGAA  
GTCAACTGCACTGCTATGGCCAGCAAGCCAGCCACGACTATCAGGTGGTTCAAAGGGAACACA  
GAGCTAAAAGGCAAATCGGAGGTGGAAGAGTGGTCAGACATGTACACTGTGACCAGTCAGCTG  
ATGCTGAAGGTGCACAAGGAGGACGATGGGGTCCCAGTGATCTGCCAGGTGGAGCACCCCTGCG  
GTCAGTGGAAACCTGCAGACCCAGCGGTATCTAGAAGTACAGTATAAGCCTCAAGTGCACATT  
CAGATGACTTATCCTCTACAAGGCTTAACCCGGGAAGGGGACGCGCTTGAGTTAACATGTGAA  
GCCATCGGGAAGCCCCAGCCTGTGATGGTAACTTGGGTGAGAGTCGATGATGAAATGCCTCAA  
CACGCCGTACTGTCTGGGCCCCAACCTGTTTCATCAATAACCTAAACAAAACAGATAATGGTACA  
TACCGCTGTGAAGCTTCAAACATAGTGGGGAAAGCTCACTCGGATTATATGCTGTATGTATAC  
GATCCCCCCCACAACCTATCCCTCCTCCCACAACAACCACCACCACCACCACCACCACCACC  
ACCATCCTTACCATCATCACAGATTCCTGAGCAGGTGAAGAAGGCTCGATCAGGGCAGTGGAT  
CATGCCGTGATCGGTGGCGTCGTGGCGGTGGTGGTGTTCGCCATGCTGTGCTTGCTCATCATT  
CTGGGGCGCTATTTTGCCAGACATAAAGGTACATACTTCACTCATGAAGCCAAAGGAGCCGAT  
GACGCAGCAGACGCAGACACAGCTATAATCAATGCAGAAGGAGGACAGAACAACCTCCGAAGAA  
AAGAAAGAGTACTTCATC**TAG**ATCAGCCTTTTTGTTTCAATGAGGTGTCCAACCTGGCCCTATT  
TAGATGATAAAGAGACAGTGATATTGG

34/615

**FIGURE 34**

</usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA39518  
<subunit 1 of 1, 440 aa, 1 stop  
<MW: 48240, pI: 4.93, NX(S/T): 7  
MASVVLPSGSQCAAAAAAAPPGLRLLLLLFSAAALIPTGDGQNLFTKDVTVIEGEVATISCQ  
VNKSDDSVIQLLNPNRQTIYFRDFRPLKDSRFQLLNFSSELKVSLTNVSIISDEGRYFCQLYT  
DPPQESYTTITVLVPPRNLMDIQKDTAVEGEEIEVNCTAMASKPATTIRWFKGNTTELKGKSE  
VEEWSDMYTVTSQMLMLKVHKEDDGVPVICQVEHPAVTGNLQTQRYLEVQYKQVHIQMTYPLQ  
GLTREGDALELTCEAIGKPQPVMTWVRVDDEMPQHAVLSGPNLFINNLNKTDNGTYRCEASN  
IVGKAHSDYMLYVYDPPTTIPPTTTTTTTTTTTTTTILTIITDSRAGEEGSIRAVDHAIVGGV  
VAVVVFAMLCLLIILGRYFARHKGTYFTHEAKGADDAADADTAIINAEGGQNNSEEKKEYFI

**Signal sequence.**

amino acids 1-36

**Transmembrane domain.**

amino acids 372-393

**N-glycosylation sites.**amino acids 65-69, 99-103, 111-115, 163-167, 302-306, 306-310,  
430-434**Tyrosine kinase phosphorylation sites.**

amino acids 233-240, 319-328

**N-myristoylation sites.**amino acids 9-15, 227-233, 307-313, 365-371, 376-382, 402-408,  
411-417, 427-433, 428-432

35/615

**FIGURE 35**

GGTTGCCACAGCTGGTTTTAGGGCCCCGACCACTGGGGCCCCCTTGTCTAGGAGGAGACAGCCTCCCGGCCCGGGGAG  
GACAAGTCGCTGCCACCTTTGGCTGCCGACGTGATTCCCTGGGACGGTCCGTTTCCTGCCGTGAGCTGCCGGCCG  
AGTTGGGTCTCCGTGTTTCAGGCCGGCTCCCCCTTCTGGTCTCCCTTCTCCCGCTGGGCCGGTTTATCGGGAGG  
AGATTGCTTCCAGGGCTAGCAATTGGACTTTTGATGATGTTTGACCCAGCGGCAGGAATAGCAGGCAACGTGAT  
TTCAAAGCTGGGCTCAGCCTCTGTTTCTTCTCTCGTGTAATCGCAAAACCCATTTTGGAGCAGGAATCCAATCA  
TGTCTGTGATGGTGGTGAGAAAGAAGGTGACACGGAAATGGGAGAACTCCCAGGCAGGAACACCTTTTGCTGTG  
ATGGCCCGCTCATGATGGCCCGGCAAAAGGGCATTTTCTACCTGACCCTTTTCTCATCTGGGGACATGTACAC  
TCTTCTTCGCCCTTTGAGTGCCGCTACCTGGCTGTTTACGTGTCTCCTGCCATCCCTGTATTGCTGCCATGCTCT  
TCCTTTTCTCCATGGCTACACTGTTGAGGACCAGCTTCAGTGACCCTGGAGTGATTCTCGGGCGCTACCAGATG  
AAGCAGCTTTTCATAGAAATGGAGATAGAAGCTACCAATGGTGCGGTGCCCCAGGGCCAGCGACCACCGCCTCGTA  
TCAAGAATTTCCAGATAAACAACCAGATTGTGAAACTGAAATACTGTTACACATGCAAGATCTTCCGGCCTCCCC  
GGCCCTCCCATTTGCAGCATCTGTGACAACTGTGTGGAGCGCTTCGACCATCACTGCCCTGGGTGGGGAATTGTG  
TTGGAAAGAGGAACTACCGCTACTTCTACCTCTTCATCCTTTCTCTCTCCCTCCTCACAATCTATGTCTTCGCCCT  
TCAACATCGTCTATGTGGCCCTCAAATCTTTGAAAATTGGCTTCTTGGAGACATTGAAAGAACTCCTGGAAGTGG  
TTCTAGAAGTCCTCATTTTGCTTCTTTACACTCTGGTCCGTCGTGGGACTGACTGGATTTTCATACTTTCTCGTGG  
CTCTCAACCAGACAACCAATGAAGACATCAAAGGATCATGGACAGGGAAGAATCGCGTCCAGAATCCCTACAGCC  
ATGGCAATATTGTGAAGAACTGCTGTGAAGTGCTGTGTGGCCCTTGCCCCCAGTGTGCTGGATCGAAGGGGTA  
TTTTGCCACTGGAGGAAAGTGGAAGTCGACCTCCCACTCAAGAGACCAGTAGCAGCCTCTTGCCACAGAGCC  
CAGCCCCACAGAACACCTGAACTCAAATGAGATGCCGGAGGACAGCAGCACTCCCGAAGAGATGCCACCTCCAG  
AGCCCCCAGAGCCACCACAGGAGGCAGCTGAAGCTGAGAAGTAGCCTATCTATGGAAGAGACTTTTGTGTTGTGTT  
TAATTAGGGCTATGAGAGATTTAGGTGAGAAGTTAAACCTGAGACAGAGAGCAAGTAAGCTGTCCCTTTTAACT  
GTTTTTCTTTGGTCTTTAGTCACCCAGTTGCACACTGGCATTCTTCTTGCTGCAAGCTTTTAAATTTCTGAACT  
CAAGGCAGTGGCAGAAGATGTCAGTCACCTCTGATAACTGGAATAATGGGTCTCTTGGGCCCTGGCACTGGTTCT  
CCATGGCCTCAGCCACAGGGTCCCCTTGACCCCCCTCTCTCCCTCCAGATCCCAAGCTGCTGCACGTGCTGAGTCCAGA  
TGGTCTCATTTCTGGGGCTAAAAGTTTTTGAGACTGGCTCAAATCCTCCCAAGCTGCTGCACGTGCTGAGTCCAGA  
GGCAGTCACAGAGACCTCTGGCCAGGGGATCCTAACTGGGTCTTGGGGTCTTCAGGACTGAAGAGGAGGGAGAG  
TGGGGTCAGAAGATTCTCCTGGCCACCAAGTGCCAGCATTGCCCAAAATCCTTTTAGGAATGGGACAGGTACCT  
TCCACTTGTGTANNNNNNNNNNNNNNNNNNNNNNNNNNNNTTGTTTTTCTTTGACTCCTGCTCCCATTAGGAG  
CAGGAATGGCAGTAATAAAAGTCTGCACTTTGGTCATTTCTTTTCTCAGAGGAAGCCCAGTGCTCACTTAAAC  
ACTATCCCCCTCAGACTCCCTGTGTGAGGCCTGCAGAGGCCCTGAATGCACAAATGGGAAACCAAGGCACAGAGAG  
GCTCTCCTCTCCTCTCCTCTCCCCGATGTACCTCAAAAAAAAAAAAAATGCTAACCAGTTCTTCCATTAGCCT  
CGGCTGAGTGAGGGAAAGCCAGCACTGCTGCCCTCTCGGGTAACCTACCCTAAGGCCTCGGCCACCTCTGGCT  
ATGGTAACCACTGGGGGCTTCTCCAAGCCCCGCTCTTCCAGCACTTCCACCGGCAGAGTCCAGAGCCACTT  
CACCCTGGGGTGGGCTGTGGCCCCCAGTCAGCTCTGCTCAGGACCTGCTCTATTTAGGGAAGAAGATTTATGT  
ATTATATGTGGCTATATTTCTAGAGCACCTGTGTTTCTCTTCTAAGCCAGGGTCTGTCTGGATGACTTAT  
GCGGTGGGGGAGTGTAACCGGAACTTTCATCTATTTGAAGGCGATTAACTGTGTCTAATGCA

36/615

**FIGURE 36**

MSVMVVRKKVTRKWEKLPGRNTFCCDGRVMMARQKGI FYLTLFLILGTCTLFFAFECRYLAVQ  
LSPAIPVFAAMLFLFSMATLLRTSFSDPGVIPRALPDEAAFIEMEIEATNGAVPQGQRPPPRI  
KNFQINNQIVKLKYCYTCKIFRPPRASHCSICDNCVERFDHHC PWVGNCVGNRYRYFYLFIL  
SLSLLTIYVFAFNIVYVALKSLKIGFLETLKETPGTVLEVLI CFFTLWSVVGLTGFHTFLVAL  
NQT TNEDIKGSWTGKNRVQNPYSHGNIVKNCCEVLCGPLPPSVLDRRGILPLEESGSRPPSTQ  
ETSSSLLPQSPAPTEHLNSNEMPEDSSTPEEMPPEPPEPPQEAAEAEK

**Putative transmembrane domains:**

amino acids 36-55 (type II TM), 65-84, 188-208, 229-245

37/615

**FIGURE 37**

GGCGGAGCAGCCCTAGCCGCCACCGTCTGCTCTCGCAGCTCTCGTCGCCACTGCCACCGCCGCCGCCGCTCACTGCG  
TCCTGGCTCCCGCTCCCGCGCCCTCCCGGCCGCCATGAGCCCGCCGCCCGCCAGGCGCCCGGTGCGCAGCTGCG  
TGCCCGCGCTGGCCCTGCTGCTGCTGCTGCTCGGAGCGGGGCCCGAGGCAGCTCCCTGGCCAAACCCGGTGCCCG  
CCGCGCCCTTGTCTGCGCCCGGGCCGTGCGCCGCGCAGCCCTGCCGGAATGGGGGTGTGTGCACCTCGCGCCCTG  
AGCCGGACCCGACGACCCCGGCCCGCCCGGCGAGCCTGGCTACAGCTGCACCTGCCCGCCCGGGATCTCCGGCG  
CCAACTGCCAGCTTGTGTCAGATCCTTGTGCCAGCAACCCCTGTACCATGGCAACTGCAGCAGCAGCAGCAGCA  
GCAGCAGCGATGGCTACCTCTGCATTTGCAATGAAGGCTATGAAGGTCCCAACTGTGAACAGGCACTTCCAGTC  
TCCCAGCCACTGGCTGGACCGAATCCATGGCACCCGACAGCTTCAGCCTGTTCTGCTACTCAGGAGCCTGACA  
AAATCCTGCCTGCTCTCAGGCAACGGTGACACTGCCTACCTGGCAGCCGAAAACAGGGCAGAAAGTTGTAGAAA  
TGAAATGGGATCAAGTGGAGGTGATCCAGATATTGCCCTGTGGGAATGCCAGTTCTAACAGCTCTGCGGGTGGCC  
GCCTGGTATCCTTTGAAGTGCCACAGAACACCTCAGTCAAGATTGGCAAGATGCCACTGCCTCACTGATTTTGC  
TCTGGAAGGTCACGGCCACAGGATTCCAACAGTGCTCCCTCATAGATGGACGAAGTGTGACCCCCCTTCAGGCTT  
CAGGGGGACTGGTCTCTGGAGGAGATGCTCGCCTTGGGGAATAATCACTTTATTGGTTTTGTGAATGATTCTG  
TGACTAAGTCTATTGTGGCTTTGCGCTTAACCTCTGGTGGTGAAGGTCAGCACCTGTGTGCCGGGGGAGAGTCACG  
CAAATGACTTGGAGTGTTCAGGAAAAGGAAAATGCACCACGAAGCCGTGAGAGGCAACTTTTTCTGTACCTGTG  
AGGAGCAGTACGTGGGTACTTTCTGTGAAGAATACGATGCTTGCCAGAGGAAACCTTGCCAAAACAACGCGAGCT  
GTATTGATGCAAAATGAAAAGCAAGATGGGAGCAATTTACCTGTGTTTGCCTTCTGGTTATACTGGAGAGCTTT  
GCCAGTCCAAGATTGATTACTGCATCCTAGACCCATGCAGAAATGGAGCAACATGCATTTCCAGTCTCAGTGGAT  
TCACCTGCCAGTGTCCAGAAGGATACTTCGGATCTGCTTGTGAAGAAAAGGTGGACCCCTGCGCCTCGTCTCCGT  
GCCAGAACAACGGCACCTGCTATGTGGACGGGGTACACTTTACCTGCAACTGCAGCCCGGGCTTCACAGGGCCGA  
CCTGTGCCAGCTTATTGACTTCTGTGCCCTCAGCCCTGTGCTCATGGCACGTGCCGCAGCGTGGGCACCACT  
ACAAATGCCTCTGTGATCCAGGTTACCATGGCCTCTACTGTGAGGAGGAATATAATGAGTGCCTCTCCGCTCCAT  
GCCATGAATGCGCCACCTGCAGGGACCTCGTTAATGGCTATGAGTGTGTGTGCCCTGGCAGAATACAAAGGAACAC  
ACTGTGAATTGTACAAGGATCCCTGCGCTAACGTCAGCTGTCTGAACGGAGCCACCTGTGACAGCGACGGCCTGA  
ATGGCACGTGCATCTGTGCACCCGGGTTTACAGGTGAAGAGTGGCAGATTGACATAAATGAATGTGACAGTAACC  
CCTGCCACCATGGTGGGAGCTGCCTGGACCAGCCCAATGGTTATAACTGCCACTGCCGCATGGTTGGGTGGGAG  
CAAATGTGAGATCCACCTCCAATGGAAGTCCGGGCACATGGCGGAGAGCCTCACCACATGCCACGGCACTCCC  
TCTACATCATCATTGGAGCCCTCTGCGTGGCCTTCATCCTTATGCTGATCATCCTGATCGTGGGGATTTGCCGCA  
TCAGCCGCATTGAATACCAGGGTTCTTCAGGGCAGCCTATGAGGAGTTCTACAACCTGCCGCAGCATCGACAGCG  
AGTTCAGCAATGCCATTGCATCCATCCGGCATGCCAGGTTTGGAAAGAAATCCCGGCCCTGCAATGTATGATGTGA  
GCCCCATCGCCTATGAAGATTACAGTCCTGATGACAAACCCCTGGTCACTGATTAAAACTAAAGATTTGTAAT  
CTTTTTTTGGATTATTTTTCAAAAAGATGAGATACTACACTCATTTAAATATTTTTTAAGAAAATAAAAAGCTTAA  
GAAATTTAAATGCTAGCTGCTCAAGAGTTTTCAGTAGAATATTTAAGAATAATTTTCTGCAGCTTTTAGTTTG  
GAAAAATATTTTAAAAACAAAATTTGTGAACCTATAGACGATGTTTTAATGTACCTTCAGCTCTCTAAACTGT  
GTGCTTCTACTAGTGTGTGCTCTTTTCACTGTAGACACTATCACGAGACCCAGATTAAATTTCTGTGGTTGTTACA  
GAATAAGTCTAATCAAGGAGAAGTTTCTGTTTGACGTTTGAAGTGGCGGCTTTCTGAGTAGAGTTAGGAAAACCAC  
GTAACGTAGCATATGATGTATAATAGAGTATACCCGTTACTTAAAAAGAAGTCTGAAATGTTGCTTTTGTGGAAA  
AGAACTAGTTAAATTTACTATTCTTAACCCGAATGAAATTAGCCTTTGCCTTATTCTGTGCATGGGTAAGTAAC  
TTATTTCTGCACGTGTTTTGTTGAACCTTTGTGGAACATTCTTTGAGTTTGTTTTTGTCAATTTTCGTAACAGTCG  
TCGAACTAGGCCTCAAAAACATACGTAACGAAAAGGCCTAGCGAGGCAATTTCTGATTGATTTGAATCTATATTT  
TTCTTTTAAAGTCAAGGGTTCTATATTGTGAGTAAATTAATTTACATTTGAGTTGTTTGTGCTAAGAGGTAG  
TAAATGTAAGAGAGTACTGGTTCCTTCAGTAGTGAGTATTTCTCATAGTGCAGCTTTATTTATCTCCAGGATGTT  
TTTGTGGCTGATTTGATTGATATGTGCTTCTCTGATTCTTGCTAATTTCCAACCATATTGAATAAATGTGATC  
AAGTCA



38/615

**FIGURE 38**

><subunit 1 of 1, 737 aa, 1 stop  
><MW: 78475, pI: 5.09, NX(S/T): 11  
MQPRRAQAPGAQQLPALALLLLLLGAGPRGSSLANPVPAAPLSAPGPCAAQPCRNNGGVCTSRP  
EPDPQHPAPAGEPGYSCTCPAGISGANCQLVADPCASNPCHHGNCSSSSSSSDGYLCICNEG  
YEGPNCEQALPSLPATGWTESMAPRQLQPVPAEQEPDKILPRSQATVTLPTWQPKTGQKVEM  
KWDQVEVIPDIACGNASSNSAGGRLVSFEVPQNTSVKIRQDATASLILLWKVTATGFGQCSL  
IDGRSVTPLQASGGLVLLLEMLALGNNHFIGFVNDSVTKSIVALRLTLVVKVSTCVPGESHAN  
DLECSGKKGKCTTKPSEATFSCTEEQYVGTFCEEYDACQRKPCQNNASCIDANEKQDGSNFTC  
VCLPGYTGELCQSKIDYCILDPNRGATCISSLSGFTCQCPEGYFGSACEEKVDPCASSPCQN  
NGTCYVDGVBHFTCNCSPGFTGPTCAQLIDFCALSPCAHGTCRSVGTSYKCLCDPGYHGLYCEE  
EYNECLSAPCLNAATCRDLVNGYECVCLAEYKGTHCELYKDPCANVSCLNGATCDSGLNGTC  
ICAPGFTGEECDIDINECDSNPCHHGGSCLDQPNGYNCHCPHGWVGANCEIHLQWKS GHMAES  
LTNMPRHSLYIIIGALCVAFILMLIILIVGICRISRIEYQGSSRPAYEEFYNCRSIDSEFSNA  
IASIRHARFGKKS RPAMYDVSP IAYEDYSPDDKPLVTLIKTKDL

**Signal sequence.**

amino acids 1-28

**Transmembrane domain.**

amino acids 641-660

**N-glycosylation sites.**amino acids 107-111, 204-208, 208-212, 223-227, 286-290, 361-365,  
375-379, 442-446, 549-553, 564-568**Glycosaminoglycan attachment site.**

amino acids 320-324

**Tyrosine kinase phosphorylation sites.**

amino acids 490-498, 674-682

**N-myristoylation sites.**amino acids 30-36, 56-62, 57-63, 85-91, 106-112, 203-209,  
373-379, 449-455, 480-486, 562-568, 565-571**Amidation site.**

amino acids 702-706

**Aspartic acid and asparagine hydroxylation site.**

amino acids 520-532, 596-608

**EGF-like domain cysteine pattern signatures.**amino acids 80-92, 121-133, 336-348, 378-390, 416-428, 454-466,  
491-503, 529-541, 567-579, 605-617

39/615

**FIGURE 39**

GAGCCGCCGCCGCGCGCGCGCGCGCGCACTGCAGCCCCAGGCCCGGCCCGCCCCACCCACGTCTG  
CGTTGCTGCCCCGCCTGGGCCAGGCCCCAAAGGCAAGGACAAAGCAGCTGTCAGGGAACCTCC  
GCCGGAGTCGAATTTACGTGCAGCTGCCGGCAACCACAGGTTCCAAGATGCTTTGCGGGGGCT  
TCGCGTGTTCCAAGAACTGCCTGTGCGCCCTCAACCTGCTTTACACCTTGGTTAGTCTGCTGC  
TAATTGGAATTGCTGCGTGGGGCATTTGGCTTCGGGCTGATTTCCAGTCTCCGAGTGGTCGGCG  
TGGTCATTGCAGTGGGCATCTTCTTGTTCCTGATTGCTTTAGTGGGTCTGATTGGAGCTGTAA  
AACATCATCAGGTGTTGCTATTTTTTTATATGATTATTCTGTTACTTGTATTTATTGTTTCAGT  
TTTCTGTATCTTGCCTTGTTTAGCCCTGAACCAGGAGCAACAGGGTCAGCTTCTGGAGGTTG  
GTTGGAACAATACGGCAAGTGCTCGAAATGACATCCAGAGAAATCTAAACTGCTGTGGGTTCC  
GAAGTGTTAACCCAAATGACACCTGTCTGGCTAGCTGTGTTAAAAGTGACCACTCGTGCTCGC  
CATGTGCTCCAATCATAGGAGAATATGCTGGAGAGGTTTTGAGATTTGTTGGTGGCATTGGCC  
TGTTCTTCAGTTTTACAGAGATCCTGGGTGTTTGGCTGACCTACAGATACAGGAACCAGAAAG  
ACCCCGCGCGCAATCCTAGTGCAATTCCTTTGATGAGAAAACAAGGAAGATTTCTTTTCGTATT  
ATGATCTTGTTCACTTTCTGTAATTTTCTGTTAAGCTCCATTTGCCAGTTTAAGGAAGGAAAC  
ACTATCTGAAAAGTACCTTATTGATAGTGGAATTATATATTTTTTACTCTATGTTTCTCTACA  
TGTTTTTTTTCTTTCCGTTGCTGAAAAATATTTGAAACTTGTGGTCTCTGAAGCTCGGTGGCAC  
CTGGAATTTACTGTATTCATTGTCGGGCACTGTCCACTGTGGCCTTTCTTAGCATTTTTTACCT  
GCAGAAAAACTTTGTATGGTACCACTGTGTTGGTTATATGGTGAATCTGAACGTACATCTCAC  
TGGTATAATTATATGTAGCACTGTGCTGTGTAGATAGTTCCTACTGGAAAAAGAGTGGAATT  
TATTAAATCAGAAAGTATGAGATCCTGTTATGTTAAGGGAAATCCAAATCCCAATTTTTTT  
TGGTCTTTTTTAGGAAAGATTGTTGTGGTAAAAAGTGTTAGTATAAAAATGATAATTTACTTGT  
AGTCTTTTTATGATTACACCAATGTATTCTAGAAATAGTTATGTCTTAGGAAATTGTGGTTTAA  
TTTTTGACTTTTACAGGTAAGTGCAAAGGAGAAGTGGTTTCATGAAATGTTCTAATGTATAAT  
AACATTTACCTTCAGCCTCCATCAGAATGGAACGAGTTTTGAGTAATCAGGAAGTATATCTAT  
ATGATCTTGATATTGTTTTATAATAATTTGAAGTCTAAAAGACTGCATTTTTTAAACAAGTTAG  
TATTAATGCGTTGGCCACGTAGCAAAAAGATATTTGATTATCTTAAAAATTGTTAAATACCG  
TTTTCATGAAATTTCTCAGTATTGTAACAGCAACTTGTCAAACCTAAGCATATTTGAATATGA  
TCTCCATAATTTGAAATTGAAATCGTATTGTGTGGCTCTGTATATTCTGTTAAAAAATTAAA  
GGACAGAAACCTTTCTTTGTGTATGCATGTTTGAATTAAGAAAGTAATGGAAG

40/615

**FIGURE 40**

&gt;&lt;/usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA39979

&gt;&lt;subunit 1 of 1, 204 aa, 1 stop

&gt;&lt;MW: 22147, pI: 8.37, NX(S/T): 3

MVCGGFACSKNCLCALNLLYTLVSLLLIGIAAWGIGFGLISSLRVVGVVIAVGIFLFLIALVG  
LIGAVKHHQVLLFFYMIILLLVFIVQFSVSCACLAALNQEQQGQLLEVGVNNTASARNDIQRL  
NCCGFRSVNPNDTCLASCVKSDHSCSPCAPIIGEYAGEVLRFRVGGIGLFFSFTEILGVWLTYS  
YRNQKDPRANPSAFL

**Signal Peptide:**

amino acids 1-34

**Transmembrane domains:**

amino acids 47-63, 72-95 and 162-182

41/615

**FIGURE 41**

CAGTCACCAATGAAGCTGGGCTGTGTCCTCATGGCCTGGGCCCTCTACCTTTCCCTTGGTGTGC  
TCTGGGTGGCCAGATGCTACTGGCTGCCAGTTTTGAGACGCTGCAGTGTGAGGGACCTGTCT  
GCACTGAGGAGAGCAGCTGCCACACGGAGGATGACTTGACTGATGCAAGGGAAGCTGGCTTCC  
AGGTCAAGGCCTACACTTTCAGTGAACCTTCCACCTGATTGTGTCTATGACTGGCTGATCC  
TCCAAGGTCCAGCCAAGCCAGTTTTTGAAGGGGACCTGCTGGTTCTGCGCTGCCAGGCCTGGC  
AAGACTGGCCACTGACTCAGGTGACCTTCTACCGAGATGGCTCAGCTCTGGGTCCCCCGGGC  
CTAACAGGGAATTCTCCATCACCGTGGTACAAAAGGCAGACAGCGGGCACTACCACTGCAGTG  
GCATCTTCCAGAGCCCTGGTCCTGGGATCCCAGAAACAGCATCTGTTGTGGCTATCACAGTCC  
AAGAACTGTTTCCAGCGCCAATTCTCAGAGCTGTACCTCAGCTGAACCCCAAGCAGGAAGCC  
CCATGACCCTGAGTTGTCAGACAAAGTTGCCCTGCAGAGGTCAGCTGCCCGCCTCCTCTTCT  
CCTTCTACAAGGATGGAAGGATAGTGCAAAGCAGGGGGCTCTCCTCAGAATTCCAGATCCCCA  
CAGCTTCAGAAGATCACTCCGGGTCACTACTGGTGTGAGGCAGCCACTGAGGACAACCAAGTTT  
GGAAACAGAGCCCCCAGCTAGAGATCAGAGTGCAGGGTGCTTCCAGCTCTGCTGCACCTCCCA  
CATTGAATCCAGCTCCTCAGAAATCAGCTGCTCCAGGAACGCTCCTGAGGAGGCCCTGGGC  
CTCTGCCTCCGCCGCCAACCCCATCTTCTGAGGATCCAGGCTTTTCTTCTCCTCTGGGGATGC  
CAGATCCTCATCTGTATCACCAGATGGGCCTTCTTCTCAAACACATGCAGGATGTGAGAGTCC  
TCCTCGGTCACTGCTCATGGAGTTGAGGGAATTATCTGGCCACCAGAAGCCTGGGACCACAA  
AGGCTACTGCTGAATTAGAAGTAAACAGTTCATCCATGATCTCACTTAACCACCCCAATAAATC  
TGATTCTTTATTTTCTCTCCTGTCTGCACATATGCATAAGTACTTTTACAAGTTGTCCCAG  
TGTTTTGTTAGAATAATGTAGTTAGGTGAGTGTAATAAATTTATATAAAGTGAGAATTAGAG  
TTTAGCTATAATTGTGTATTCTCTCTTAACACAACAGAATTCTGCTGTCTAGATCAGGAATTT  
CTATCTGTTATATCGACCAGAATGTTGTGATTTAAAGAGAACTAATGGAAGTGGATTGAATAC  
AGCAGTCTCAACTGGGGGCAATTTTGCCCCCAGAGGACATTGGGCAATGTTTGGAGACATTT  
TGGTCATTATACTTGGGGGGTGGGGGATGGTGGGATGTGTGTCTACTGGCATCCAGTAAATA  
GAAGCCAGGGGTGCCGCTAAACATCCTATAATGCACAGGGCAGTACCCCAACGAAAAATAA  
TCTGGCCCAAAATGTCAAGTTGTACTGAGTTTGAGAAACCCAGCCTAATGAAACCCTAGGTGT  
TGGGCTCTGGAATGGGACTTTGTCCCTTCTAATTATTATCTCTTTCCAGCCTCATTCACTAT  
TCTTACTGACATACCAGTCTTTAGCTGGTGCTATGGTCTGTTCTTTAGTTCTAGTTTGTATCC  
CCTCAAAGCCATTATGTTGAAATCCTAATCCCCAAGGTGATGGCATTAAAGAAGTGGGCCTTT  
GGGAAGTGATTAGATCAGGAGTGCAGAGCCCTCATGATTAGGATTAGTGCCCTTATTTAAAAA  
GGCCCCAGAGAGCTAACTCACCTTCCACCATATGAGGACGTGGCAAGAAGATGACATGTATG  
AGAACCAAAAACAGCTGTCGCCAAACACCGACTCTGTCGTTGCCTTGATCTTGAACCTCCAG  
CCTCCAGAACTATGAGAAATAAAATCTGGTTGTTGTAGCCTAA

42/615

**FIGURE 42**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA40594
><subunit 1 of 1, 359.aa, 1 stop
><MW: 38899, pI: 5.21, NX(S/T): 0
MKLGCVLMAWALYLSLGLWVAQMLLAASFETLQCEGPVCTEESCHTEDDLTDAREAGFQVK
AYTFSEPFHLIVSYDWLILQGPAKPVFEGDLLVLRQAWQDWPLTQVTFYRDGSALGPPGPNR
EFSITVVQKADSGHYHCSGIFQSPGPGIPETASVVAITVQELFPAPILRAVPSAEPQAGSPMT
LSCQTKLPLQRSAARLLFSFYKDGRIVQSRGLSSEFQIPTASEDHSGSYWCEAATEDNQVWKQ
SPQLEIRVQGASSSAAPPTLNPAAPQKSAAPGTAPEEAPGPLPPPPPTPSSSEDPGFSSPLGMPDP
HLYHQMGLLLKHMQDVRVLLGHLLELRELSGHQKPGTTKATAE
```

**Signal sequence:**  
amino acids 1-17

**Leucine zipper pattern sequence:**  
amino acids 12-33

**Protein kinase C phosphorylation site:**  
amino acids 353-355

43/615

**FIGURE 43**

GCGAGTGTCCAGCTGCGGAGACCCGTGATAATTTCGTTAACTAATTCAACAAACGGGACCCCTTC  
TGTGTGCCAGAAACCGCAAGCAGTTGCTAACCCAGTGGGACAGGCGGATTGGAAGAGCGGGAA  
GGTCCTGGCCCAGAGCAGTGTGACACTTCCCTCTGTGACCATGAAACTCTGGGTGTCTGCATT  
GCTGATGGCCTGGTTTGGTGTCTGAGCTGTGTGCAGGCCGAATTCTTCACCTCTATTGGGCA  
CATGACTGACCTGATTTATGCAGAGAAAGAGCTGGTGCAGTCTCTGAAAGAGTACATCCTTGT  
GGAGGAAGCCAAGCTTTCCAAGATTAAGAGCTGGGCCAACAAAATGGAAGCCTTGACTAGCAA  
GTCAGCTGCTGATGCTGAGGGCTACCTGGCTCACCTGTGAATGCCTACAACTGGTGAAGCG  
GCTAAACACAGACTGGCCTGCGCTGGAGGACCTTGTCTGCAGGACTCAGCTGCAGGTTTTAT  
CGCCAACCTCTCTGTGCAGCGGCAGTTCTTCCCCACTGATGAGGACGAGATAGGAGCTGCCAA  
AGCCCTGATGAGACTTCAGGACACATACAGGCTGGACCCAGGCACAATTTCCAGAGGGGAACT  
TCCAGGAACCAAGTACCAGGCAATGCTGAGTGTGGATGACTGCTTTGGGATGGGCCGCTCGGC  
CTACAATGAAGGGGACTATTATCATACGGTGTTGTGGATGGAGCAGGTGCTAAAGCAGCTTGA  
TGCCGGGGAGGAGGCCACCACAACCAAGTCACAGGTGCTGGACTACCTCAGCTATGCTGTCTT  
CCAGTTGGGTGATCTGCACCGTGCCCTGGAGCTACCCGCCGCCTGCTCTCCCTTGACCCAAG  
CCACGAACGAGCTGGAGGGAATCTGCGGTACTTTGAGCAGTTATTGGAGGAAGAGAGAGAAAA  
AACGTTAACAAATCAGACAGAAGCTGAGCTAGCAACCCAGAAGGCATCTATGAGAGGCCTGT  
GGACTACCTGCCTGAGAGGGATGTTTACGAGAGCCTCTGTCTGTGGGAGGGTGTCAAACCTGAC  
ACCCCGTAGACAGAAGAGGCTTTTCTGTAGGTACCACCATGGCAACAGGGCCCCACAGCTGCT  
CATTGCCCCCTTCAAAGAGGAGGACGAGTGGGACAGCCCGCACATCGTCAGGTACTACGATGT  
CATGTCTGATGAGGAAATCGAGAGGATCAAGGAGATCGCAAAACCTAAACTTGCACGAGCCAC  
CGTTTCGTGATCCCAAGACAGGAGTCCTCACTGTGCGCAGCTACCGGGTTTTCCAAAAGCTCCTG  
GCTAGAGGAAGATGATGACCCTGTTGTGGCCCGAGTAAATCGTCGGATGCAGCATATCACAGG  
GTTAACAGTAAAGACTGCAGAATTGTTACAGGTTGCAAATTATGGAGTGGGAGGACAGTATGA  
ACCGCACTTCGACTTCTCTAGGCGACCTTTTGACAGCGGCCTCAAAACAGAGGGGAATAGGTT  
AGCGACGTTTCTTAACTACATGAGTGATGTAGAAGCTGGTGGTGCCACCGTCTTCCCTGATCT  
GGGGGCTGCAATTTGGCCTAAGAAGGGTACAGCTGTGTTCTGGTACAACCTCTTGCGGAGCGG  
GGAAGGTGACTACCGAACAAAGACATGCTGCCTGCCCTGTGCTTGTGGGCTGCAAGTGGGTCTC  
CAATAAGTGGTTCCATGAACGAGGACAGGAGTTCTTGAGACCTTGTGGATCAACAGAAGTTGA  
CTGACATCCTTTTCTGTCTTCCCCTTCCCTGGTCCCTCAGCCCATGTCAACGTGACAGACACC  
TTTGTATGTTCTTTGTATGTTCTATCAGGCTGATTTTGGAGAAATGAATGTTTGTCTGGA  
GCAGAGGGAGACCATACTAGGGCGACTCCTGTGTGACTGAAGTCCAGCCCTTCCATTACGCC  
TGTGCCATCCCTGGCCCCAAGGCTAGGATCAAAGTGGCTGCAGCAGAGTTAGCTGTCTAGCC  
CTAGCAAGGTGCCTTTGTACCTCAGGTGTTTTAGGTGTGAGATGTTTCAGTGAACCAAAGTTC  
TGATACCTTGTTTACATGTTTTGTTTTATGGCATTCTATCTATTGTGGCTTTACCAAAAAAT  
AAAATGTCCCTACCAGAAAAA

44/615

**FIGURE 44**

MKLWVSALLMAWFGVLSCVQAEFFTSIGHMTDLIYAEKELVQSLKEYILVEEAKLSKIKSWAN  
KMEALTSKSAADAEGYLAHPVNAYKLVKRLNTDWPALDVLQDSAAGFIANLSVQRQFFPTD  
EDEIGAALKMRLQDQTYRLDPGTISRGEPLGTYQAMLSVDDCFGMGRSAYNEGDDYYHTVLWM  
EQVLKQLDAGEEATTTKSQVLDYLSYAVFQLGDLHRALELTRRLSLDPSHERAGGNLRYFEQ  
LLEEREKTLTNQTEAELATPEGIYERPVLDYLPEDVYESLCRGEGVKLTTPRQKRLFCRYHH  
GNRAPQLLIAPFKEEDEWDSPIVRYDDVMSDEEIERIKEIAKPKLARATVRDPKTGVLTVAS  
YRVSKSSWLEEDDDPVVARVNRMQHITGLTVKTAELLQVANYGVGGQYEPHDFSRPFDSG  
LKTEGNRLATFLNYMSDVEAGGATVFPDLGAAIWPKKGTAVFWYNLLRSGECDYRTRHAACP  
LVGCKWVSNNKWFHERGQEFRLRPGSTEVD

**Signal sequence:**

amino acids 1-17

**N-glycosylation site.**

amino acids 115-119, 264-268

**Glycosaminoglycan attachment site.**

amino acids 490-494

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 477-481

**Casein kinase II phosphorylation site.**amino acids 43-47, 72-76, 125-129, 151-155, 165-169, 266-270,  
346-350, 365-369, 385-389, 457-461, 530-534**Tyrosine kinase phosphorylation site.**

amino acids 71-80, 489-496

**N-myristoylation site.**

amino acids 14-20, 131-137, 171-177, 446-452

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 8-19

**Leucine zipper pattern.**

amino acids 213-235

45/615

**FIGURE 45**

GGGGCCTTGCCTTCCGCACTCGGGCGCAGCCGGGTGGATCTCGAGCAGGTGCGGAGCCCCGGG  
CGGCGGGCGCGGGTGCGAGGGATCCCTGACGCCTCTGTCCCTGTTTCTTTGTGCTCCAGCC  
TGTCTGTGTCGTGTTTTGGCGCCCCCGCCTCCCCGCGGTGCGGGGTTGCACACCGATCCTGGGC  
TTCGCTCGATTTGCCGCGAGGCGCCTCCCAGACCTAGAGGGGCGCTGGCCTGGAGCAGCGGG  
TCGTCTGTGTCCTCTCTCCTCTGCGCCGCGCCCGGGGATCCGAAGGGTGCGGGGCTCTGAGGA  
GGTGACGCGCGGGGCTCCCGCACCTGGCCTTGCCCGCATTCTCCCTCTCTCCCAGGTGTGA  
GCAGCCTATCAGTCACC**ATG**TCCGCAGCCTGGATCCCGGCTCTCGGCCTCGGTGTGTGTCTGC  
TGCTGCTGCCGGGGCCCCGCGGGCAGCGAGGGAGCCGCTCCCATTGCTATCACATGTTTTACCA  
GAGGCTTGACATCAGGAAAGAGAAAGCAGATGTCTCTGCCAGGGGGCTGCCCTCTTGAGG  
AATTCTCTGTGTATGGGAACATAGTATATGCTTCTGTATCGAGCATATGTGGGGCTGCTGTCC  
ACAGGGGAGTAATCAGCAACTCAGGGGGACCTGTACGAGTCTATAGCCTACCTGGTCGAGAAA  
ACTATTCTCAGTAGATGCCAATGGCATCCAGTCTCAAATGCTTTCTAGATGGTCTGCTTCTT  
TCACAGTAACTAAAGGCAAAAGTAGTACACAGGAGGCCACAGGACAAGCAGTGTCCACAGCAC  
ATCCACCAACAGGTAAACGACTAAAGAAAACACCCGAGAAGAAAACCTGGCAATAAAGATTGTA  
AAGCAGACATTGCATTTCTGATTGATGGAAGCTTTAATATTGGGCAGCGCCGATTTAATTTAC  
AGAAGAATTTTGTGGAAAAGTGGCTCTAATGTTGGGAATTGGAACAGAAGGACCACATGTGG  
GCCTTGTTCAAGCCAGTGAACATCCCAAATAGAATTTTACTTGAAAACTTTACATCAGCCA  
AAGATGTTTTGTTTGCCATAAAGGAAGTAGGTTTCAGAGGGGGTAATTCCAATACAGGAAAAG  
CCTTGAAGCATACTGCTCAGAAATTCCTCACGGTAGATGCTGGAGTAAGAAAAGGGATCCCCA  
AAGTGGTGGTGGTATTTATTGATGGTTGGCCTTCTGATGACATCGAGGAAGCAGGCATTGTGG  
CCAGAGAGTTTGGTGTCAATGTATTTATAGTTTCTGTGGCCAAGCCTATCCCTGAAGAACTGG  
GGATGGTTCAGGATGTCACATTTGTTGACAAGGCTGTCTGTGCGGAATAATGGCTTCTTCTCTT  
ACCACATGCCCAACTGGTTTGGCACCACAAAATACGTAAAGCCTCTGGTACAGAAGCTGTGCA  
CTCATGAACAAATGATGTGCAGCAAGACCTGTTATAACTCAGTGAACATTGCCTTTCTAATTG  
ATGGCTCCAGCAGTGTGGAGATAGCAATTTCCGCCTCATGCTTGAATTTGTTTCCAACATAG  
CCAAGACTTTTGAAATCTCGGACATTGGTGCCAAGATAGCTGCTGTACAGTTTACTTATGATC  
AGCGCACGGAGTTCAGTTTCACTGACTATAGCACCAAAGAGAATGTCCTAGCTGTCATCAGAA  
ACATCCGCTATATGAGTGGTGGAACAGCTACTGGTGATGCCATTTCCCTTCACTGTTAGAAATG  
TGTTTGGCCCTATAAAGGAGAGCCCCAACAAGAACTTCCTAGTAATTGTCACAGATGGGCAGT  
CCTATGATGATGTCCAAGGCCCTGCAGCTGCTGCACATGATGCAGGAATCACTATCTTCTCTG  
TTGGTGTGGCTTGGGCACCTCTGGATGACCTGAAAGATATGGCTTCTAAACCGAAGGAGTCTC  
ACGCTTTCTTCACAAGAGAGTTTACAGGATTAGAACCAATTGTTTCTGATGTCATCAGAGGCA  
TTTGTAGAGATTTCTTAGAATCCCAGCAAT**TAA**TGGTAACATTTTGACAACCTGAAAGAAAAAGT  
ACAAGGGGATCCAGTGTGTAAATTGTATTCTCATAATACTGAAATGCTTTAGCATACTAGAAT  
CAGATACAAAACCTATTAAGTATGTCAACAGCCATTTAGGCAAATAAGCACTCCTTTAAAGCCG  
CTGCCCTTCTGGTTACAATTTACAGTGTACTTTGTTAAAAACACTGCTGAGGCTTCATAATCAT  
GGCTCTTAGAACTCAGGAAAGAGGAGATAATGTGGATTAAACCTTAAGAGTTCTAACCATG  
CCTACTAAATGTACAGATATGCAAATTCATAGCTCAATAAAAGAATCTGATACTTAGACCAA  
AAAAAAA



46/615

**FIGURE 46**

MSAAWI PALGLGVCLLLLPGPAGSEGAAPIAITCFTRGLDIRKEKADVLC PGGCPLEEF SVYG  
NIVYASVSSICGA AVHRGVISNSGGPVRVYSLPGRENYSSVDANGIQS QMLSRWSASF TVTKG  
KSSTQEATGQAVSTAHPPTGKRLKKTPEKKTGNKDCKADIAFLIDGSFNIGQRREN LQKNFVG  
KVALMLGIGTEGPHVGLVQASEHPKIEFYLNFTSAKDVLFAIKEVGFRGGNSNTGKALKHTA  
QKFFTVDAGVRKGIPKVVVVFIDGWPSDDIEEAGIVAREFGVNVFIVSVAKPIPEELGMVQDV  
TFVDKAVCRNNGFFSYHMPNWF GTTKYVKPLVQKLCTHEQMMCSKTCYNSVNIAFLIDGSSSV  
GDSNFRMLLEFVS NIAKTFEISDIGAKIAAVQFTYDQRTFESFTDYSTKENVLAVIRNIRYMS  
GGTATGDAISFTVRNVFGPIRES PNKNFLVIVTDGQSYDDVQGPAAAHDAGITIFSVGVAWA  
PLDDLKDMASKPKESHAF FTREFTGLEPIVSDVIRGICRDFLESQQ

**Signal sequence:**

amino acids 1-24

**N-glycosylation site.**

amino acids 100-104, 221-225

**Casein kinase II phosphorylation site.**amino acids 102-106, 129-133, 224-228, 316-320, 377-381, 420-424,  
425-429, 478-482, 528-532**N-myristoylation site.**amino acids 10-16, 23-29, 81-87, 135-141, 158-164, 205-211,  
239-245, 240-246, 261-267, 403-409, 442-448, 443-449**Amidation site.**

amino acids 145-149

47/615

**FIGURE 47**

GCCCCGCGCCCGGCGCCGGGCGCCCCGAAGCCGGGAGCCACCGCC**ATG**GGGGCCTGCCTGGGAG  
CCTGCTCCCTGCTCAGCTGCGCGTCCTGCCTCTGCGGCTCTGCCCCCTGCATCCTGTGCAGCT  
GCTGCCCCGCCAGCCGCAACTCCACCGTGAGCCGCCTCATCTTCACGTTCTTCCTCTTCCTGG  
GGGTGCTGGTGTCCATCATTTATGCTGAGCCCGGGCGTGGAGAGTCAGCTCTACAAGCTGCCCT  
GGGTGTGTGAGGAGGGGGCCGGGATCCCCACCGTCCTGCAGGGCCACATCGACTGTGGCTCCC  
TGCTTGGCTACCGCGCTGTCTACCGCATGTGCTTCGCCACGGCGGCCTTCTTCTTCTTCTTTT  
TCACCCTGCTCATGCTCTGCGTGAGCAGCAGCCGGGACCCCCGGGCTGCCATCCAGAATGGGT  
TTTGGTTCTTTAAGTTCCCTGATCCTGGTGGGCCTCACCGTGGGTGCCTTCTACATCCCTGACG  
GCTCCTTCACCAACATCTGGTTCTACTTCGGCGTCGTGGGCTCCTTCCTCTTCATCCTCATCC  
AGTGCTGCTGCTCATCGACTTTGCGCACTCCTGGAACCAGCGGTGGCTGGGCAAGGCCGAGG  
AGTGCGATTCCCGTGCCTGGTACGCAAGGCCTCTTCTTCTTCACTCTCCTCTTCTACTTGCTGT  
CGATCGCGGCCGTGGCGCTGATGTTTCATGTACTACACTGAGCCAGCGGCTGCCACGAGGGCA  
AGGTCTTCATCAGCCTCAACCTCACCTTCTGTGTCTGCGTGTCCATCGCTGCTGTCTGCCCCA  
AGGTCCAGGACGCCCAGCCCACTCGGGTCTGCTGCAGGCCTCGGTTCATCACCTCTACACCA  
TGTTTGTACCTGGTCAGCCCTATCCAGTATCCCTGAACAGAAATGCAACCCCCATTTGCCAA  
CCCAGCTGGGCAACGAGACAGTTGTGGCAGGCCCCGAGGGCTATGAGACCCAGTGGTGGGATG  
CCCCGAGCATTGTGGGCCTCATCATCTTCTCCTGTGCACCCTCTTCATCAGTCTGCGCTCCT  
CAGACCACCGGCAGGTGAACAGCCTGATGCAGACCGAGGAGTGCCACCTATGCTAGACGCCA  
CACAGCAGCAGCAGCAGCAGGTGGCAGCCTGTGAGGGCCGGGCCTTTGACAACGAGCAGGACG  
GCGTCACCTACAGCTACTCCTTCTTCCACTTCTGCCTGGTGCTGGCCTCACTGCACGTCATGA  
TGACGCTCACCAACTGGTACAAGCCCGGTGAGACCCGGAAGATGATCAGCACGTGGACCGCCG  
TGTGGGTGAAGATCTGTGCCAGCTGGGCAGGGCTGCTCCTCTACCTGTGGACCCTGGTAGCCC  
CACTCCTCCTGCGCAACCGCGACTTCAGCT**TG**AGGCGAGCCTCACAGCCTGCCATCTGGTGCCTC  
CTGCCACCTGGTGCCTCTCGGCTCGGTGACAGCCAACCTGCCCCCTCCCCACACCAATCAGCC  
AGGCTGAGCCCCACCCCTGCCCCAGCTCCAGGACCTGCCCCCTGAGCCGGGCCTTCTAGTCGT  
AGTGCCTTCAGGGTCCGAGGAGCATCAGGCTCCTGCAGAGCCCCATCCCCCGCCACACCCAC  
ACGGTGGAGCTGCCTCTTCCTTCCCCTCCTCCCTGTTGCCCATACTCAGCATCTCGGATGAAA  
GGGCTCCCTTGTCCTCAGGCTCCACGGGAGCGGGGCTGCTGGAGAGAGCGGGGAACCTCCCACC  
ACAGTGGGGCATCCGGCACTGAAGCCCTGGTGTTCCTGGTCACGTCCCCCAGGGGACCCCTGCC  
CCCTTCCTGGACTTCGTGCCTTACTGAGTCTCTAAGACTTTTTTCTAATAAACAAGCCAGTGCG  
TGTAATAAAAAA

48/615

**FIGURE 48**

MGACLGACSLSCASCLCGSAPCILCSCCPASRNSTVSRLI FTFFLFLGVLVSIIMLS PGVES  
QLYKLPWVCEE GAGIPTVLQGHIDCGSL LGYRAVYRMCFATAA FFFFFFFTLLMLCVSSSRDPR  
AAIQNGFWFFKFLILVGLTVGAFYIPDGSFTNIWFYFGVVGSFLFILIQLVLLIDFAHSWNQR  
WLGKAEECDSRAWYAGLFFFTLLFYLLSIAAVALMFMYYTEPSGCHEGKVFISLNLTFVCVVS  
IAAVLPKVQDAQPNSGLLQASVITLYTMFVTWSALSSIPEQKCNPHLPTQLGNETVVAGPEGY  
ETQWWDAPSI VGLIIFLLCTLFISLRSSDHRQVNSLMQTEECPPMLDATQQQQQVAACEGRA  
FDNEQDGV TYSYSFFHFCLVLASLHVMMTLTNWYKPGETRKMISTWTAVVWKICASWAGLLLY  
LWTLVAPLLLRNRDFS

**Signal sequence:**

amino acids 1-20

**Transmembrane domains:**amino acids 40-58, 101-116, 134-150, 162-178, 206-223, 240-257,  
272-283, 324-340, 391-406, 428-444

49/615

**FIGURE 49**

GCCGCGCGCTCTCTCCGGGCGCCACACCTGTCTGAGCGGCGAGCGAGCCGGCCCGGGCGG  
 GGCTGCTCGGCGCGGAACAGTGCTCGGCATGGCAGGGATTCCAGGGCTCCTCTCTCTCTCTT  
 CTTTCTGCTCTGTGCTGTTGGGCAAGTGAGCCCTTACAGTGCCCCCTGGAACCCACTTTGGCC  
 TGCATACCGCCTCCCTGTCGTCTTGCCCCAGTCTACCCCTCAATTTAGCCAAGCCAGACTTTGG  
 AGCCGAAGCCAAATTAGAAGTATCTTCTTCATGTGGACCCCAGTGTCTATAAGGGAACCTCCACT  
 GCCCACTTACGAAGAGGCCAAGCAATATCTGTCTTATGAAACGCTCTATGCCAATGGCAGCCG  
 CACAGAGACGCAGGTGGGCATCTACATCCTCAGCAGTAGTGGAGATGGGGCCCAACACCGAGA  
 CTCAGGGTCTTCAGGAAAGTCTCGAAGGAAGCGGCAGATTTATGGCTATGACAGCAGGTTCAG  
 CATTTTTGGGAAGGACTTCCTGCTCAACTACCCTTTCTCAACATCAGTGAAGTTATCCACGGG  
 CTGCACCGGCACCCTGGTGGCAGAGAAGCATGTCCTCACAGCTGCCCACTGCATACACGATGG  
 AAAAACCTATGTGAAAGGAACCCAGAAGCTTCGAGTGGGCTTCCTAAAGCCCAAGTTTAAAGA  
 TGGTGGTCGAGGGGCCAACGACTCCACTTCAGCCATGCCCGAGCAGATGAAATTTAGTGGAT  
 CCGGGTGAAACGCACCCATGTGCCCAAGGGTTGGATCAAGGGCAATGCCAATGACATCGGCAT  
 GGATTATGATTATGCCCTCCTGGAACCTCAAAAAGCCCCACAAGAGAAAATTTATGAAGATTGG  
 GGTGAGCCCTCCTGCTAAGCAGCTGCCAGGGGGCAGAAATTCACTTCTCTGGTTATGACAATGA  
 CCGACCAGGCAATTTGGTGTATCGCTTCTGTGACGTCAAAGACGAGACCTATGACTTGCTCTA  
 CCAGCAATGCGATGCCCAGCCAGGGGGCCAGCGGGTCTGGGGTCTATGTGAGGATGTGGAAGAG  
 ACAGCAGCAGAAGTGGGAGCGAAAAATTATTGGCATTTTTTTCAGGGCACCAGTGGGTGGACAT  
 GAATGGTTCCCCACAGGATTTCAACGTGGCTGTGAGAATCACTCCTCTCAAATATGCCCAGAT  
 TTGCTATTGGATTAAAGGAACTACCTGGATTGTAGGGAGGGGTTGACACAGTGTTCCTCCTG  
 GCAGCAATTAAGGGTCTTCATGTTCTTATTGTTTAGGAGAGGCCAAATTGTTTTTGTATTGGC  
 GTGCACACGTGTGTGTGTGTGTGTGTGTGTGTAAGGTGTCTTATAATCTTTTACCTATTTCT  
 TTACAATTGCAAGATGACTGGCTTTACTATTTTGAAAAGTGGTTTGTGTATCATATCATATATC  
 ATTTAAGCAGTTTGAAGGCATACTTTTGCATAGAAATAAAAAAATACTGATTTGGGGCAATG  
 AGGAATATTTGACAATTAAGTTAATCTTCACGTTTTTGCAAACTTTGATTTTTTATTTTCATCTG  
 AACTTGTTTCAAAGATTTATATTAAATATTTGGCATAACAAGAGATATGAAAAAAAAAAAAAAAA

50/615

**FIGURE 50**

MAGIPGLLFLLFFLLCAVGQVSPYSAPWKPTWPAYRLPVVLPQSTLNLAKPDFGAEAKLEVSS  
SCGPQCHKGTPLPTYEEAKQYLSYETLYANGSRTETQVGIYILSSSGDGAQHRDSGSSGKSRR  
KRQIYGYDSRFSIFGKDFLLNYPFSTSVKLSTGCTGTLVAEKHVLTAAHCIHDGKTYVKGTQK  
LRVGFLKPKFKDGGRGANDSTSAMPEQMKFQWIRVKRTHVPKGWIKGNANDIGMDYDYALLEL  
KKPHKRKFMKIGVSPPAKQLPGGRIHFSGYDNDRPGNLVYRFCDVKDETYDLLYQQCDAQPGA  
SGSGVYVRMWKRQQQKWERKIIGIFSGHQWVDMNGSPQDFNVAVRITPLKYAQICYWIKGNYL  
DCREG

**Signal sequence:**

amino acids 1-19

**N-glycosylation site.**

amino acids 93-97, 207-211

**Glycosaminoglycan attachment site.**

amino acids 109-113, 316-320

**Casein kinase II phosphorylation site.**

amino acids 77-81, 95-99, 108-112, 280-284, 351-355

**N-myristoylation site.**

amino acids 159-165, 162-168, 202-208, 205-211, 314-320, 338-344

**Serine proteases, trypsin family, histidine active site.**

amino acids 171-177

51/615

**FIGURE 51**

GGGAGGGGGCTCCGGGCGCCGCGCAGCAGACCTGCTCCGGCCGCGCGCCTCGCCGCTGTCTCCGGGAGCGGCAG  
CAGTAGCCCCGGGCGGCGAGGGCTGGGGGTTCTCGAGACTCTCAGAGGGGCGCCTCCCATCGGCGCCCACCACC  
CAACCTGTTCTCGCGCGCCACTGCGCTGCGCCCCAGGACCCGCTGCCAACATGGATTTTCTCTGGCGCTGGT  
GCTGGTATCCTCGCTCTACCTGCAGGCGGCGCCGAGTTCGACGGGAGGTGGCCAGGCAATAGTGTCTCATCGAT  
TGGCCTATGTCGTTATGGTGGGAGGATTGACTGCTGCTGGGGCTGGGCTCGCCAGTCTTGGGGACAGTGTCTAGCC  
TGTGTGCCAACACGATGCAACATGGTGAATGTATCGGGCCAAACAGTGCAAGTGTCTCTGGTTATGCTGG  
AAAAACCTGTAATCAAGATCTAAATGAGTGTGGCCTGAAGCCCCGGCCCTGTAAGCACAGGTGCATGAACACTTA  
CGGCAGCTACAAGTGTCTACTGTCTCAACGGATATATGCTCATGCCGATGGTTCTGCTCAAGTGCCCTGACCTG  
CTCCATGGCAAACCTGTCAGTATGGCTGTGATGTTGTTAAAGGACAAATACGGTGCCAGTGCCCATCCCCCTGGCCT  
GCACCTGGCTCCTGATGGGAGGACCTGTGTAGATGTTGATGAATGTGCTACAGGAAGAGCCTCCTGCCCTAGATT  
TAGGCAATGTGTCAACACTTTTGGGAGCTACATCTGCAAGTGTCTATAAGGCTTCGATCTCATGTATATTGGAGG  
CAAATATCAATGTCTGACATAGACGAATGCTCACTTGGTCAGTATCAGTGCAGCAGCTTTGCTCGATGTTATAA  
CGTACGTGGGTCTTACAAGTGCAATGTAAAGAAGGATACCAGGGTGATGGACTGACTTGTGTGTATATCCCAA  
AGTTATGATTGAACCTTCAGGTCCAATTCATGTACCAAAGGAAATGGTACCATTTTAAAGGGTGACACAGGAAA  
TAATAATTGGATTCTCTGATGTTGGAAGTACTTGGTGGCCTCCGAAGACACCATATATTCCTCCTATCATTACCAA  
CAGGCCTACTTCTAAGCCAACAACAAGACCTACACCAAAGCCAACACCAATTCCTACTCCACCACCACCACCACC  
CCTGCCAACAGAGCTCAGAACACCTCTACCACTTACAACCCAGAAAGGCCAACACCACCGGACTGACAACTATAGC  
ACCAGCTGCCAGTACACCTCCAGGAGGGATTACAGTTGACAACAGGGTACAGACAGACCCTCAGAAACCCAGAGG  
AGATGTGTTTCAAGTGTCTGGTACACAGTTGTAATTTGACCATGGACTTTGTGGATGGATCAGGGAGAAAGACAA  
TGACTTGCAGTGGGAACCAATCAGGGACCCAGCAGGTGGACAATATCTGACAGTGTCCGCAGCCAAAGCCCCAGG  
GGGAAAAGCTGCAGCTTGGTGTCTACCTCTCGGCCGCTCATGCATTGAGGGGACCTGTGCCTGTCTTACGGCA  
CAAGGTGACGGGGCTGCACTCTGGCACACTCCAGGTGTTTGTGAGAAAACACGGTGCCACGGAGCAGCCCTGTG  
GGGAAGAAATGGTGGCCATGGCTGGAGGCAACACAGATCACCTTGGCAGGGGCTGACATCAAGAGCGAATCACA  
AAGATGAATTAAAGGTTTGGAAAAAAGATCTATGATGGAAAATTAAAGGAACTGGGATTATTGAGCCTGGAGAAG  
AGAAGACTGAGGGGCAAACCATTTGATGGTTTTCAAGTATATGAAGGGTTGGCACAGAGAGGGTGGCGACCAGCTG  
TTCTCCATATGCACTAAGAATAGAACAAGAGGAACTGGCTTAGACTAGAGTATAAGGGAGCATTCTTGGCAGG  
GGCCATTGTTAGAATACTTCATAAAAAAAGAGTGTGAAAATCTCAGTATCTCTCTCTCTTTCTAAAAAATTAGA  
TAAAAATTTGTCTATTTAAGATGGTTAAAGATGTTCTTACCCAAGGAAAAGTAACAAATTATAGAATTTCCCAA  
AGATGTTTTGATCTACTAGTAGTATGCAGTGAAAATCTTTAGAACTAAATAATTTGGACAAGGCTTAATTTAGG  
CATTTCCCTCTTGACCTCCTAATGGAGAGGGATTGAAAGGGGAAGAGCCCAAAATGCTGAGCTCACTGAAATA  
TCTCTCCCTTATGGCAATCCTAGCAGTATTAAAGAAAAAAGGAACTATTTATTCCAAATGAGAGTATGATGGAC  
AGATATTTTAGTATCTCAGTAATGTCCTAGTGTGGCGGTGGTTTTCAATGTTTCTTCATGGTAAAGGTATAAGCC  
TTTCATTTGTTCAATGGATGATGTTTCAGATTTTTTTTTTTTTTAAAGAGATCCTTCAAGGAACACAGTTCAGAGAG  
ATTTTCATCGGGTGCATTCTCTCTGCTTCGTGTGTGACAAGTTATCTTGGCTGCTGAGAAAGAGTGCCCTGCCCC  
ACACCGGCAGACCTTTCTTTACCTCATCAGTATGATTGAGTTTCTCTTATCAATTGGACTCTCCAGGTTCCAC  
AGAACAGTAATATTTTTGAACAATAGGTACAATAGAAGGTCTTCTGTCTATTAACCTGGTAAAGGCAGGGCTGG  
AGGGGGAAAAATAAATCATTAAGCCTTTGAGTAACGGCAGAATATATGGCTGTAGATCCATTTTAAATGGTTTCATT  
TCCTTTATGGTCAATAACTGCACAGCTGAAGATGAAAGGGGAAAAATAAATGAAAATTTTACTTTTCGATGCCAA  
TGATACATTGCACTAACTGATGGAAGAAGTTATCCAAAGTACTGTATAACATCTTGTATTATTTAATGTTTT  
CTAAAAATAAAAAATGTAGTGGTTTTCCAAATGGCCTAATAAAAAACATTATTTGTAATAAAAAACACTGTTAGTAAT

52/615

**FIGURE 52**

MDPELLALVLVSSLYLQAAAEFDGRWPRQIVSSIGLCRYGGRIDCCWGWARQSWGQCQPVQCPR  
CKHGEICIGPNKCKCHPGYAGKTCNQDLNECGLKPRPCKHRCMNTYGSYKCYCLNGYMLMPDGS  
CSSALTCSMANCQYGC DVVKGQIRCQCPSPGLHLAPDGRTCV DVDECATGRASCPRFRQCVNT  
FGSYICKCHKGF DL MYIGGKYQCHDIDEC SLGQYQCSSFARCYNVRGSYKCKKEGYQGDGLT  
CVYIPKVMIEPSGPIHVPKNGTILKGD TGNNWIPDVGSTWWPPKTPYIPPIITNRPTSKPT  
TRPTPKPTPIPTPPPPPLPTLRTPLPPTT PERPTTGLTTIAPAASTPPGGITVDNRVQTD  
QKPRGDVFSVLVHSCNFDHGLCGWIREKDNDLHWEPIRDPAGGQYLTVSAAKAPGGKAARLVL  
PLGR LMHSGDLCLSFRHKVTGLHSGTLQVFVRKHGAHGAALWGRNGGHGWRQTQITLRGADIK  
SESQR

**Signal sequence:**

amino acids 1-17

**N-glycosylation site.**

amino acids 273-277

**Casein kinase II phosphorylation site.**

amino acids 166-170, 345-349

**Tyrosine kinase phosphorylation site.**

amino acids 199-206

**N-myristoylation site.**amino acids 109-115, 125-131, 147-153, 191-197, 221-227, 236-242,  
421-427, 433-439, 462-468, 476-482**Aspartic acid and asparagine hydroxylation site.**

amino acids 104-116, 186-198, 231-243

**Cell attachment sequence.**

amino acids 382-385

**EGF-like domain cysteine pattern signature.**

amino acids 75-87

53/615

**FIGURE 53**

CGGGCCGCCCCCGGCCCCATTTCGGGCCGGGCCTCGCTGCGGCGGGCGACTGAGCCAGGCTGGG  
CCGCGTCCCTGAGTCCCAGAGTCGGCGCGGCGCGGCAGGGGCAGCCTTCCACCACGGGGAGCC  
CAGCTGTCAGCCGCTCACAGGAAG**ATG**CTGCGTCGGCGGGGCAGCCCTGGCATGGGTGTGCA  
TGTGGGTGCAGCCCTGGGAGCACTGTGGTTCTGCCTCACAGGAGCCCTGGAGGTCCAGGTCCC  
TGAAGACCCAGTGGTGGCACTGGTGGGCACCGATGCCACCCTGTGCTGCTCCTTCTCCCCTGA  
GCCTGGCTTCAGCCTGGCACAGCTCAACCTCATCTGGCAGCTGACAGATACCAAACAGCTGGT  
GCACAGCTTTGCTGAGGGGCCAGGACCAGGGCAGCGCCTATGCCAACCGCACGGCCCTCTTCCC  
GGACCTGCTGGCACAGGGCAACGCATCCCTGAGGCTGCAGCGCGTGCCTGTGGCGGACGAGGG  
CAGCTTCACCTGCTTCGTGAGCATCCGGGATTTTCGGCAGCGCTGCCGTGACCTGCAGGTGGC  
CGTCCCTACTCGAAGCCCAGCATGACCCTGGAGCCCAACAAGGACCTGCGGCCAGGGGACAC  
GGTGACCATCACGTGCTCCAGCTACCAGGGCTACCCTGAGGCTGAGGTGTTCTGGCAGGATGG  
GCAGGGTGTGCCCTGACTGGCAACGTGACCACGTGCGCAGATGGCCAACGAGCAGGGCTTGT  
TGATGTGCACAGCGTCCTGCGGGTGGTGTGGGTGCGAATGGCACCTACAGCTGCCTGGTGCG  
CAACCCCGTGCTGCAGCAGGATGCGCACRGCTCTGTACCATCACAGGGCAGCCTATGACATT  
CCCCCAGAGGCCCTGTGGGTGACCGTGGGGCTGTCTGTCTGTCTCATTGCACTGCTGGTGGC  
CCTGGCTTTCGTGTGCTGGAGAAAGATCAAACAGAGCTGTGAGGAGGAGAATGCAGGAGCTGA  
GGACCAGGATGGGGAGGGAGAAGGCTCCAAGACAGCCCTGCAGCCTCTGAAACACTCTGACAG  
CAAAGAAGATGATGGACAAGAAATAGCC**TGA**CCATGAGGACCAGGGAGCTGCTACCCCTCCCT  
ACAGCTCCTACCCTCTGGCTGCAATGGGGCTGCACTGTGAGCCCTGCCCCAACAGATGCATC  
CTGCTCTGACAGGTGGGCTCCTTCTCCAAAGGATGCGATACACAGACCACTGTGCAGCCTTAT  
TTCTCCAATGGACATGATTCCCAAGTCATCCTGCTGCCTTTTTTCTTATAGACACAATGAACA  
GACCACCCACAACCTTAGTTCTCTAAGTCATCCTGCCTGCTGCCTTATTTACAGTACATACA  
TTTCTTAGGGACACAGTACACTGACCACATCACCACCCTCTTCTTCCAGTGCTGCGTGGACCA  
TCTGGCTGCCTTTTTTCTCCAAAAGATGCAATATTCAGACTGACTGACCCCTGCCTTATTTTC  
ACCAAAGACACGATGCATAGTCACCCCGGCCTTGTTTCTCCAATGGCCGTGATACACTAGTGA  
TCATGTTTCAGCCCTGCTTCCACCTGCATAGAATCTTTTCTTCTCAGACAGGGACAGTGCGGCC  
TCAACATCTCCTGGAGTCTAGAAGCTGTTTCCTTTCCCCTCCTTCCTCCCTGCCCCAAGTGAA  
GACAGGGCAGGGCCAGGAATGCTTTGGGGACACCGAGGGGACTGCCCCCACCACCATGG  
TGCTATTCTGGGGCTGGGGCAGTCTTTTCCTGGCTTGCTCTGGCCAGCTCCTGGCCTCTGGT  
AGAGTGAGACTTCAGACGTTCTGATGCCTTCCGGATGTCATCTCTCCCTGCCCCAGGAATGGA  
AGATGTGAGGACTTCTAATTTAAATGTGGGACTCGGAGGGATTTTGTAACCTGGGGGTATATT  
TTGGGGAAAATAAATGTCTTTGTAAAAAAAAAAAAAAAAAAAAA



54/615

**FIGURE 54**

></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA41386  
><subunit 1 of 1, 316 aa, 1 stop, 1 unknown  
><MW: -1, pI: 4.62, NX(S/T): 4  
MLRRRGSPGMGVHVGAAALGALWFCLTGALEVQVPEDPVVALVGTDATLCCSFSPPEPGFSLAQL  
NLIWQLTDTKQLVHSFAEGQDQGSAYANRTALFPDLLAQGNASLRLQVRVVADEGSFTCFVSI  
RDFGSAAVSLQVAAPYSKPSMTLEPNKDLRPGDVTITCSSYQGYPEAEVFWQDGQGVPLTGN  
VTTSQMANEQGLFDVHSVLRVVLGANGTYSLVRNPVLQQDAHXSVTITGQPMTFPPEALWVT  
VGLSVCLIALLLVALAFVCWRKIKQSCEEENAGAEDQDGEGEKSKTALQPLKHSKEDDGGQEIA

**Important features:****Signal peptide:**

amino acids 1-28

**Transmembrane domain:**

amino acids 251-270

**N-glycosylation site.**

amino acids 91-94, 104-107, 189-192 and 215-218

**Homologous region to Immunoglobulins and MHC**

amino acids 217-234

55/615

**FIGURE 55**

GAGTCTTGACCGCCGCCGGGCTCTTGGTACCTCAGCGCGAGCGCCAGGCGTCCGGCCGCCGTG  
GCT**ATG**TTTCGTGTCCGATTTCCGCAAAGAGTTCTACGAGGTGGTCCAGAGCCAGAGGGTCCCTT  
CTCTTCGTGGCCTCGGACGTGGATGCTCTGTGTGCGTGCAAGATCCTTCAGGCCTTGTTCCAG  
TGTGACCACGTGCAATATACGCTGGTTCAGTTTCTGGGTGGCAAGAAGCTTGAACTGCATTT  
CTTGAGCATAAAGAACAGTTTCATTATTTTTATTCTCATAAACTGTGGAGCTAATGTAGACCTA  
TTGGATATTCTTCAACCTGATGAAGACACTATATTCTTTGTGTGTGACTCCCATAGGCCAGTC  
AATGTCGTCAATGTATACAACGATACCCAGATCAAATTACTCATTAAACAAGATGATGACCTT  
GAAGTTCCCGCCTATGAAGACATCTTCAGGGATGAAGAGGAGGATGAAGAGCATTGAGGAAAT  
GACAGTGATGGGTGAGAGCCTTCTGAGAAGCGCACACGGTTAGAAGAGGAGATAGTGGAGCAA  
ACCATGCGGAGGAGGCGAGCGGCGAGAGTGGGAGGCCCGGAGAAGAGACATCCTCTTTGACTAC  
GAGCAGTATGAATATCATGGGACATCGTCAGCCATGGTGATGTTTGAGCTGGCTTGGATGCTG  
TCCAAGGACCTGAATGACATGCTGTGGTGGGCCATCGTTGGACTAACAGACCAGTGGGTGCAA  
GACAAGATCACTCAAATGAAATACGTGACTGATGTTGGTGTCTGTCAGCGCCACGTTTCCCGC  
CACAACCACCGGAACGAGGATGAGGAGAACACACTCTCCGTGGACTGCACACGGATCTCCTTT  
GAGTATGACCTCCGCTGGTGCTCTACCAGCACTGGTCCCTCCATGACAGCCTGTGCAACACC  
AGCTATACCGCAGCCAGGTTCAAGCTGTGGTCTGTGCATGGACAGAAGCGGCTCCAGGAGTTC  
CTTGCAGACATGGGTCTTCCCTGAAGCAGGTGAAGCAGAAGTTCAGGCCATGGACATCTCC  
TTGAAGGAGAATTTGCGGGAAATGATTGAAGAGTCTGCAAATAAATTTGGGATGAAGGACATG  
CGCGTGCAGACTTTTCAGCATTTCATTTTGGGTTCAAGCACAAAGTTTCTGGCCAGCGACGTGGTC  
TTTGCCACCATGTCTTTGATGGAGAGCCCCGAGAAGGATGGCTCAGGGACAGATCACTTCATC  
CAGGCTCTGGACAGCCTCTCCAGGAGTAACCTGGACAAGCTGTACCATGGCCTGGAACCTCGCC  
AAGAAGCAGCTGCGAGCCACCCAGCAGACCATTGCCAGCTGCCTTTGCACCAACCTCGTCATC  
TCCCAGGGGGCCTTTTCTGTACTGCTCTCTCATGGAGGGCACTCCAGATGTCATGCTGTTCTCT  
AGGCCGGCATCCCTAAGCCTGCTCAGCAAACACCTGCTCAAGTCCTTTGTGTGTTGACAAAG  
AACCGGCGCTGCAAACCTGCTGCCCCCTGGTGATGGCTGCCCCCTGAGCATGGAGCATGGCACA  
GTGACCGTGGTGGGCATCCCCCAGAGACCGACAGCTCGGACAGGAAGAACTTTTTTGGGAGG  
GCGTTTGAGAAGGCAGCGGAAAGCACCAGCTCCCGGATGCTGCACAACCATTTTGACCTCTCA  
GTAATTGAGCTGAAAGCTGAGGATCGGAGCAAGTTTCTGGACGCACTTATTTCCCTCCTGTCC  
**TAG**GAATTTGATTCTTCCAGAATGACCTTCTTATTTATGTAAGTGGCTTTTCAATTTAGATTGTA  
AGTTATGGACATGATTTGAGATGTAGAAGCCATTTTTTATTAAATAAAATGCTTATTTTAGGAAA

56/615

**FIGURE 56**

MFVSDFRKEFYEVVQSQRVLLFVASDVDALCACKILQALFQCDHVQYTLVPVSGWQELETAF  
EHKEQFHYFILINCGANVDLLDILQPDEDTIFVCDSHRPVNVVNVYNDTQIKLLIKQDDLE  
VPAYEDIFRDEEEDEEHSGNDSGSEPSEKRTRLEEEIVEQTMRRRQRREWEARRRDILFDYE  
QYEHGTSSAMVMFELAWMLSKDLNDMLWWAIVGLTDQWVQDKITQMKYVTDVGVLRHVSRH  
NHRNEDEENTLSVDCTRISFEYDLRLVLYQHWSLHDSL CNTSYTAARFKLWSVHGQKRLQEFL  
ADMGLPLKQVKQKFQAMDISLKENLREMIEESANKFGMKDMRVQTF SIHFGFKHKFLASDVVF  
ATMSLMESPEKDGSGTDHFIQALDSLRSNLDKLYHGLELAKKQLRATQQTIASCLCTNLVIS  
QGPFLYCSLMEGTPDVMLFSRPASLSLLSKHLLKSFVCSTKNRRCKLLPLVMAAPLSMEHGT  
TVVGIPPETDSSDRKNFFGRAFEKAAESTSSRMLHNHFDLSVIELKAEDRSKFLDALISLLS

57/615

**FIGURE 57**

CGCCGCCGTTGGGGCTGGAAGTTCCCGCCAGGTCCGTGCCGGGCGAGAGAGATGCTGCCCGGC  
CCGCCTCGGCTTTGAGGCGAGAGAAGTGTCCCAGACCCATTTGCGCTTGCTGACGGCGTTCGAG  
CCCTGGCCAGACATGTCCACAGGGTTCTCCTTCGGGTCCGGGACTCTGGGCTCCACCACCGTG  
GCCGCCGGCGGGACCAGCACAGGCGGCGTTTTCTCCTTCGGAACGGGAACGTCTAGCAACCCT  
TCTGTGGGGCTCAATTTTGGAAATCTTGGAAGTACTCAACTCCAGCAACTACATCTGCTCCT  
TCAAGTGGTTTTTGAACCGGGCTCTTGATCTAAACCTGCCACTGGGTTCACTCTAGGAGGA  
ACAAATACAGGTGCCCTGCACACCAAGAGGCCTCAAGTGGTCACCAAATATGGAACCCTGCAA  
GGAAAACAGATGCATGTGGGGAAGACACCCATCCAAGTCTTTTTAGGAGTCCCTTCTCCAGA  
CCTCCTCTAGGTATCCTCAGGTTTGACCTCCAGAACCCCGGAGCCCTGGAAAGGAATCAGA  
GATGCTACCACCTACCCGCTGGATGGAGTCTCGCTCTGTCGCCAGGCTGGAGTGCAGTGGCA  
CGATCTCGGCTCACTGCAACCTCCGCTCCCGGGTTCAAGCGAGTCTCCTGCCTCAGCCTCTG  
AGTGTCTGGGGCTACAGGTGCCCTGCAGGAGTCTGGGGCCAGCTGGCCTCGATGTACGTACGC  
ACGCGGGAACGGTACAAGTGGCTGCGCTTCAGCGAGGACTGTCTGTACCTGAACGTGTACGCG  
CCGGCGCGCGCGCCCGGGGATCCCCAGCTGCCAGTGATGGTCTGGTTCCCGGGAGGCGCCTTC  
ATCGTGGGCGCTGCTTCTTCGTACGAGGGCTCTGACTTGGCCGCCCGCGAGAAAGTGGTGCTG  
GTGTTTCTGCAGCACAGGCTCGGCATCTTCGGCTTCTGAGCACGGACGACAGCCACGCGCGC  
GGAACTGGGGGCTGCTGGACCAGATGGCGGCTCTGCGCTGGGTGCAGGAGAACATCGCAGCC  
TTCGGGGGAGACCCAGGAAATGTGACCCTGTTTCGGCCAGTCGGCGGGGGCCATGAGCATCTCA  
GGACTGATGATGTACCCCTAGCCTCGGCTCTTCCATCGGGCCATTTCCCAGAGTGGCACC  
GCGTTATTTCAGACTTTTCATCACTAGTAACCCACTGAAAGTGGCCAAGAAGGTTGCCACCTG  
GCTGGATGCAACCACAACAGCACACAGATCCTGGTAAACTGCCTGAGGGCACTATCAGGGACC  
AAGGTGATGCGTGTGTCCAACAAGATGAGATTCTTCCAACCTGAACCTCCAGAGAGACCCGAA  
GAGATTATCTGGTCCATGAGCCCTGTGGTGGATGGTGTGGTGATCCCAGATGACCCTTTGGTG  
CTCCTGACCCAGGGGAAGGTTTTCATCTGTGCCCTACCTTCTAGGTGTCAACAACCTGGAATTC  
AATTGGCTCTTGCCTTATAATATACCAAGGAGCAGGTACCACTTGTGGTGGAGGAGTACCTG  
GACAATGTCAATGAGCATGACTGGAAGATGCTACGAAACCGTATGATGGACATAGTTCAAGAT  
GCCACTTTTCGTGTATGCCACACTGCAGACTGCTCACTACCACCGAGAAACCCCAATGATGGGA  
ATCTGCCCTGCTGGCCACGCTACAACAAGGATGAAAAGTACCTGCAGCTGGATTTTACCACAA  
GAGTGGGCATTGAAGCTCAAGGAGAAGAAGATGGCTTTTTTGGATGAGTCTGTACCAGTCTCAA  
GACCTGAGAAGCAGAGGCAATTCTAAGGGTGGCTATGCAGGAAGGAGCCAAAGAGGGGTTTGC  
CCCCACCATCCAGGCCCTGGGGAGACTAGCCATGGACATACCTGGGGACAAGAGTTCTACCCA  
CCCCAGTTTAGAACTGCAGGAGCTCCCTGCTGCCTCCAGGCCAAAGCTAGAGCTTTTGCCTGT  
TGTGTGGGACCTGCACTGCCCTTTCCAGCCTGACATCCCATGATGCCCCCTACTTCACTGTT  
GACATCCAGTTAGGCCAGGCCCTGTCAACACCACACTGTGCTCAGCTCTCCAGCCTCAGGACA  
ACCTCTTTTTTTTCCCTTCTTCAAATCCTCCCACCTTCAATGTCTCCTTGTGACTCCTTCTTA  
TGGGAGGTCGACCAGACTGCCACTGCCCTGTCACTGCACCCAGCTTGGCATTATACCATCCA  
TCCTGCTCAACCTTGTTCTGTGTTTACATTGGCCTGGAGGCCTAGGGCAGGTTGTGACAT  
GGAGCAAACCTTTTGGTAGTTTGGGATCTTCTCTCCACCCACACTTATCTCCCCCAGGGCCAC  
TCCAAAGTCTATACACAGGGGTGGTCTCTTCAATAAAGAAGTGTTGATTAGAAAAA

58/615

**FIGURE 58**

&lt;/usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA44179

&lt;subunit 1 of 1, 545 aa, 1 stop

&lt;MW: 58934, pI: 9.45, NX(S/T): 4

MSTGFSFGSGTLGSTTVAAGGTSTGGVFSFGTGTSSNPSVGLNFGNLGSTSTPATTSSAPSSGF  
GTGLFGSKPATGFTLGGTNTGALHTKRPQVVTKYGTLLQGMHVGKTPIQVFLGVPFSRPPLG  
ILRFAPPEPPEPWKGIRDATTYPGWSLALSPGWSAVARSRLTATSASRVQASLLPQPLSVWG  
YRCLQESWGQLASMYVSTRERYKWLRFSEDCLYLNVEYAPARAPGDPQLPVMVWFPGGAFIVGA  
ASSYEGSDLAAREKVVLVFLQHRLGIFGFLSTDDSHARGNWGLLDQMAALRWVQENIAAFGGD  
PGNVTLFGQSAGAMSISGLMMSPLASGLFHRAISQSGTALFRLFITSNPLKVAKKVAHLACN  
HNSTQILVNCLRALSGTKVMRVS NKMRFLQLNFQRPDEEIIWSMSPVVDGVVIPDDPLVLLTQ  
GKVSSVPYLLGVNNLEFNWLLPYNITKEQVPLVVEEYLDNVNEHDWKMLRNRMMDIVQDATEV  
YATLQTAHYHRET PMMGICPAGHATTRMKSTCSWILPQEWA

**Important features:****Signal peptide:**

amino acids 1-29

**Carboxylesterases type-B serine active site.**

amino acids 312-327

**Carboxylesterases type-B signature 2.**

amino acids 218-228

**N-glycosylation sites.**

amino acids 318-321, 380-383 and 465-468

59/615

**FIGURE 59**

CGGACGCGTGGGCTGGGCGCTGCAAAGCGTGTCCCGCCGGGTCCCCGAGCGTCCCGCGCCCTC  
GCCCCGCC**ATG**CTCCTGCTGCTGGGGCTGTGCCTGGGGCTGTCCCTGTGTGGGGTTCGCAGG  
AAGAGGCGCAGAGCTGGGGCCACTCTTCGGAGCAGGATGGACTCAGGGTCCCGAGGCAAGTCA  
GACTGTTGCAGAGGCTGAAAACCAAACCTTTGATGACAGAATTCTCAGTGAAGTCTACCATCA  
TTTCCCGTTATGCCTTCACTACGGTTTTCCTGCAGAATGCTGAACAGAGCTTCTGAAGACCAGG  
ACATTGAGTTCCAGATGCAGATTCCAGCTGCAGCTTTCATCACCAACTTCACTATGCTTATTG  
GAGACAAGGTGTATCAGGGCGAAATTACAGAGAGAGAAAAGAAGAGTGGTGATAGGGTAAAAG  
AGAAAAGGAATAAAAACACAGAAGAAAATGGAGAGAAGGGGACTGAAATATTCAGAGCTTCTG  
CAGTGATTCCCAGCAAGGACAAAGCCGCTTTTTCTGAGTTATGAGGAGCTTCTGCAGAGGC  
GCCTGGGCAAGTACGAGCACAGCATCAGCGTGCGGCCCCAGCAGCTGTCCGGGAGGCTGAGCG  
TGGACGTGAATATCCTGGAGAGCGCGGGCATCGCATCCCTGGAGGTGCTGCCGCTTCACAACA  
GCAGGCAGAGGGGCAGTGGGCGCGGGGAAGATGATTCTGGGCCTCCCCCATCTACTGTCATTA  
ACCAAATGAAACATTTGCCAACATAATTTTAAACCTACTGTAGTACAACAAGCCAGGATTG  
CCCAGAATGGAATTTTGGGAGACTTTATCATTAGATATGACGTCAATAGAGAACAGAGCATTG  
GGGACATCCAGGTTCTAAATGGCTATTTTGTGCACTACTTTGCTCCTAAAGACCTTCCTCCTT  
TACCCAAGAATGTGGTATTCGTGCTTGACAGCAGTGCTTCTATGGTGGGAACCAAACCTCCGGC  
AGACCAAGGATGCCCTCTTACAATTCTCCATGACCTCCGACCCCAGGACCGTTTCAGTATCA  
TTGGATTTTCCAACCGGATCAAAGTATGGAAGGACCACTTGATATCAGTCACTCCAGACAGCA  
TCAGGGATGGGAAAGTGTACATTACCATATGTCACCCACTGGAGGCACAGACATCAACGGGG  
CCCTGCAGAGGGCCATCAGGCTCCTCAACAAGTACGTGGCCACAGTGGCATTGGAGACCGGA  
GCGTGTCCCTCATCGTCTTCTGACGGATGGGAAGCCACGGTCCGGGAGACGCACACCCTCA  
AGATCCTCAACAACACCCGAGAGGGCCGCCGAGGCCAAGTCTGCATCTTCACCATTGGCATCG  
GCAACGACGTGGACTTCAGGCTGCTGGAGAACTGTGCTGGAGAACTGTGGCTCACACGGC  
GCGTGCACGAGGAGGAGGACGCAGGCTCGCAGCTCATCGGGTTCTACGATGAAATCAGGACCC  
CGCTCCTCTCTGACATCCGCATCGATTATCCCCCAGCTCAGTGGTGCAGGCCACCAAGACCC  
TGTTCCCCAACTACTTCAACGGCTCGGAGATCATCATTGCGGGGAAGCTGGTGGACAGGAAGC  
TGGATCACCTGCACGTGGAGGTCACCGCCAGCAACAGTAAGAAATTCATCATCCTGAAGACAG  
ATGTGCCTGTGCGGCCTCAGAAGGCAGGGAAAGATGTCACAGGAAGCCCCAGGCCTGGAGGCG  
ATGGAGAGGGGGACACCAACCACATCGAGCGTCTCTGGAGCTACCTCACCACAAAGGAGCTGC  
TGAGCTCCTGGCTGCAAAGTGACGATGAACCGGAGAAGGAGCGGCTGCGGCAGCGGGCCAGG  
CCCTGGCTGTGAGCTACCGCTTCCTCACTCCCTTACCTCCATGAAGCTGAGGGGGCCGGTCC  
CACGCATGGATGGCCTGGAGGAGGCCCACGGCATGTGCGCTGCCATGGGACCCGAACCGGTG  
TGCAGAGCGTTCGAGGAGCTGGCACGCAGCCAGGACCTTTGCTCAAGAAGCCAAACTCCGTCA  
AAAAAAAACAAAACAAAACAAAAAAAAGACATGGGAGAGATGGTGTTTTTCTCTCCACCACC  
TGGGGATACGA**TGA**GAAAGATGGCCACCTGCAAGCCAGGAAGACGGCCCTCACCAGACACCATG  
TCTGCTGGCACCTTGATCTTGACCTCCAGCCTCCAGAACTGTGAGAAATAAATGTGTTTTG  
TTTAAGCTAAAAAAA

60/615

**FIGURE 60**

</usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA44192  
<subunit 1 of 1, 694 aa, 1 stop  
<MW: 77400, pI: 9.54, NX(S/T): 6  
MLLLGLCLGLSLCVGSQEEAQSWGHSSEQDGLRVPRQVRLQLRKTKPLMTEFSVKSTIISR  
YAFTTVSCRMLNRASEDQDIEFQMQUIPAAAFITNFTMLIGDKVYQGEITEREKKSGDRVKEKR  
NKTTEENGEKGTETFRASAVIPSKDKAAFFLSYEELLQRRLGKYEHSISVRPQQLSGRLSVDV  
NILESAGIASLEVLPLHNSRQRGSGRGEDDSGPPPSTVINQNETFANIIIFKPTVVQQARIAQN  
GILGDFIIRYDVNREQSIGDIQVLNGYFVHYFAPKDLPLPKNVFVLDSSASMVGTKLRQTK  
DALFTILHDLRPQDRFSIIGFSNRIKVWKDHLISVTPDSIRDGKVYIHHMSPTGGTDINGALQ  
RAIRLLNKYVAHSGIGDRSVSLIVFLTDGKPTVGETHTLKILNNTREAARGQVCIFTIGIGND  
VDFRLLLEKLSLENCGLTRRVHEEEDAGSQLIGFYDEIRTPLLSDIRIDYPPSSVVQATKTLFP  
NYFNGSEIIIIAGKLVDKLDHLHVEVTASNSKKFIILKTDVPVVRPQKAGKDVTSRPPGGDGE  
GDTNHIERLWSYLTTKELLSSWLQSDDEPEKERLRQRAQALAVSYRFLTPFTSMKLRGPVPRM  
DGLEEAHGMSAAMGPEPVQSVRGAGTQPGPLLKKPNSVKKKQNKTKKRHGRDGVFPLHHLGIR

**Signal sequence.**

amino acids 1-14

**N-glycosylation sites.**

amino acids 97-101, 127-131, 231-235, 421-425, 508-512, 674-678

**Glycosaminoglycan attachment sites.**

amino acids 213-217, 391-395

**N-myristoylation sites.**

amino acids 6-12, 10-16, 212-218, 370-376, 632-638, 638-644

61/615

**FIGURE 61**

CAGGAACCCCTCTCTTTGGGTCTGGATTGGGACCCCTTTCCAGTACCATTTTTTCTAGTGAACC  
ACGAAGGGACGATACCAGAAAAACACCCCTCAACCCAAAGGAAATAGACTACAGCCCCAATTGGC  
TGACTTTGGCTATAGAAAAAAGAAAGGAACGAAAAGAGACAGTTTTTTTTTGGAAAGCTAAGTC  
TTCCCTTTATCGAGTCAAGAAACCCCCCTTCTTGAGCTATTTACAGCTTTTAACAATTGAGT  
AAAGTACGCTCCGGTCACCATCGGTGACAGCCGCCCTGGGTCCCGTCTGGGCAGCGCTCCTGCT  
CTTTCTCCTGATGTGTGAGATCCGTATGGTGGAGCTCACCTTTGACAGAGCTGTGGCCAGCGG  
CTGCCAACGGTGCTGTGACTCTGAGGACCCCTGGATCCTGCCCATGTATCCTCAGCCTCTTC  
CTCCGGCCGCCCCACGCCCTGCCTGAGATCAGACCCTACATTAATATCACCATCCTGAAGGG  
TGACAAAGGGGACCCAGGCCCAATGGGCCTGCCAGGGTACATGGGCAGGGAGGGTCCCCAAGG  
GGAGCCTGGCCCTCAGGGCAGCAAGGGTGACAAGGGGAGATGGGCAGCCCCGGCGCCCGTG  
CCAGAAGCGCTTCTTCGCCCTTCTCAGTGGGCCGCAAGACGGCCCTGCACAGCGCGAGGACTT  
CCAGACGCTGCTCTTCGAAAGGGTCTTTGTGAACCTTGATGGGTGCTTTGACATGGCGACCGG  
CCAGTTTGCTGCTCCCCCTGCGTGGCATCTACTTCTTCAGCCTCAATGTGCACAGCTGGAATTA  
CAAGGAGACGTACGTGCACATTATGCATAACAGAAAGAGGCTGTCTATCCTGTACGCGCAGCC  
CAGCGAGCGCAGCATCATGCAGAGCCAGAGTGTGATGCTGGACCTGGCCTACGGGGACCGCGT  
CTGGGTGCGGCTCTTCAAGCGCCAGCGCGAGAACGCCATCTACAGCAACGACTTCGACACCTA  
CATCACCTTCAGCGGCCACCTCATCAAGGCCGAGGACGACTGAGGGCCTCTGGGCCACCCTCC  
CGGCTGGAGAGCTCAGGTGCTGGTCCCGTCCCTGCAGGGCTCAGTTTGCACTGCTGTGAAGC  
AGGAAGGCCAGGGAGGTCCCCGGGGACCTGGCATTCTGGGGAGACCCTGCTTCTATCTTGGCT  
GCCATCATCCCTCCCAGCCTATTTCTGCTCCTCTCTCTCTCTTGGACCTATTTTAAGAAGCT  
TGCTAACCTAAATATTCTAGAACTTTCCCAGCCTCGTAGCCCAGCACTTCTCAAACCTTGAAA  
TGCATGCGAATCACCCGGGGTTCGTGTAAATGCAGATTCTGACTCAGCAGGTCTGAGTGGGT  
CCAGGATTCTGTGTTTCTCATATGTTCTGGGTGATGCTGATGGGGTCAGTCTATGAACCACA  
CTGGAGCAACAGGTTCTAGGACTTTCTCAATATTCTAGTACTTTCTGAACATTCTGGAATCC  
TCCCCACATTCTAGAATTCTCCCAACATTTTTTTTTTCTTGAGACAGAGTCTTGCTCTGTTGCC  
CAGGCTAGAGTGCAGTGGTGCAATCTCAGTTCACTGCAACCTCTGCCTCCCGGGTTCAGCGA  
TTCTTCTGCCTCAGCCTCCCTAGTGGCTGGGATTACAGGCGCCTGCTACCATGCCTGGCTAAT  
TTTTGTATTTTTTAGTAGAGATGGGGTTTACCATAATTGGCCAGGCTGGTCTTGAACCTCTGAC  
TTCAGGTGACCCACCCGCCCTCGGCCTCTCAAATGTCTGGGATTACAGGTGTGAGCCACCGTGC  
CTGGCCAATTCCAACATTCTTAAATTCTCTCATCCCTCCAGGGCTCCCGTGTCTATGTTCTCT  
TTACCCCTTCCCCCTCTTCTCTTGCTCAGGCCTGCACCACTGCAGCCACCGTTCATTTATTCA  
TTCATTAAACACTGAGCACTCACTCTGTGCTGGGTCCCGGAAGGGTGAGGGGGTCAGACACA  
GGCCCTGCCCTGCCCTCAGTGACTGGCCAGTCCAGCCCAGGCGGGGAGAGATGTGTACATAG  
GTTTTAAAGCAGACCCAGAGCTCATGGGGGCTGTGTTCTGGGTGTTTCAAGGTGCTGCTGGTCC  
TCCATTACCCACTGCTCCCCAAGGCTGGTGGGACGGGGTCCCGGTGGCAGGGGCAGGTATCTC  
CTTCCCGTTCCCTCATCCACCTGCCAGTGCTCATCGTTACAGCAAACCCAGGGGGCCTTGGC  
CAGGTCAAGGGTTCTGTGAGGAGAGGACCCAGGAGTGTGGGGGCATTTGGGGGGTGAAGTGGC  
CCCCGAAGAATGGAACCCACACCCATAGCTCTCCCCACAGCTGATACGGCATCCTGCGAGAAG  
ACCTGCCCTCCTCACTGGGATCCCCCTTCTGCTCCTCCCAGGGCTCTGCCAGGGCCTTGCTC  
AGTCCCTTCCACCAAAGTCATCTGAACCTCCGTTTCCCCAGGGCCTCCAGCTGCCCTCAGACA  
CTGATGTCTGTCCCCAGGTGCTCTCTGCCCCCTCATGCCCCCTCTACCGGCCAGTGCCCCGAC  
TCTCCAGGCTTTATCAAGGTGCTAAGGCCCGGGTGGGCAGCTCCTCGTCTCAGAGCCCTCCTC  
CGGCCTGGTGCTGCCTTTACAAACACCTGCAGGAGAAGGGCCACGGAAGCCCCAGGCTTTAGA  
GCCCTCAGCAGGTCTGGGGAGCTAGAGCAAAGGAGGGACCTCAGGCCTTCCGTTTCTTCTTCC  
AGGGTGGGGTGGCCTGGTGTTCCTTAGCCTTCCAAACCCAGGTGGCCTGCCCTTCTCCCCAG  
AGGGAGGGCGGCCTCCGCCCATTTGGTGCTCATGCAGACTCTGGGGCTGAGGTGCCCCGGGGGT  
GATCTCTGGTGCTCACAGCCGAGGGAGCCGTGGCTCCATGGCCAGATGACGGAAACAGGGTCT  
GACCAAGTGCCAGGAAGACCTGTGCTATAAACCCACCTGCCTGATCCTGCCCTGCCTGACCC  
CGCCACGCCCTGCCGTCCAGCATGATTAAAGAATGCTGTCTCTCTTGAAAAA



62/615

**FIGURE 62**

MVTAALGPVWAAALLFLLMCEIRMVELTFDRAVASGCQRCCDSEDPLDPAHVSSASSSSGRPHA  
LPEIRPYINITILKGDGDPGPMGLPGYMGREGPQGEPPGQSGKDGKMGSPGAPCQKRFFA  
FSVGRKTALHSGEDFQTLLFERVFVNLDGCFDMATGQFAAPLRGIYFFSLNVHSWNYKETVH  
IMHNQKEAVILYAQPSESRIMQSQSVMLDLAYGDRVWVRLFKRQRENAIYSNDFDTYITFSGH  
LIKAEDD

**Important features:****Signal peptide:**

amino acids 1-20

**N-glycosylation site.**

amino acids 72-75

**Clq domain proteins.**

amino acids 144-178, 78-111 and 84-117

63/615

**FIGURE 63**

ATGGGAAGCCAGTAACACTGTGGCCTACTATCTCTTCCGTGGTGCCATCTACATTTTTTGGGAC  
TCGGGAATTATGAGGTAGAGGTGGAGGCGGAGCCGGATGTCAGAGGTCCTGAAATAGTCACCA  
**T**GGGGGAAAATGATCCGCCTGCTGTTGAAGCCCCCTTCTCATTCCGATCGCTTTTTTGGCCTTG  
ATGATTTGAAAATAAGTCCTGTTGCACCAGATGCAGATGCTGTTGCTGCACAGATCCTGTCAC  
TGCTGCCATTGAAGTTTTTTCCAATCATCGTCATTGGGATCATTGCATTGATATTAGCACTGG  
CCATTGGTCTGGGCATCCACTTCGACTGCTCAGGGAAGTACAGATGTCGCTCATCCTTTAAGT  
GTATCGAGCTGATAGCTCGATGTGACGGAGTCTCGGATTGCAAAGACGGGGAGGACGAGTACC  
GCTGTGTCCGGGTGGGTGGTCAGAATGCCGTGCTCCAGGTGTTACAGCTGCTTCGTGGAAGA  
CCATGTGCTCCGATGACTGGAAGGGTCACTACGCAAATGTTGCCTGTGCCCAACTGGGTTTTCC  
CAAGCTATGTGAGTTCAGATAACCTCAGAGTGAGCTCGCTGGAGGGGCAGTTCGGGGAGGAGT  
TTGTGTCCATCGATCACCTCTTGCCAGATGACAAGGTGACTGCATTACACCACTCAGTATATG  
TGAGGGAGGGATGTGCCTCTGGCCACGTGGTTACCTTGCAGTGCACAGCCTGTGGTTCATAGAA  
GGGGCTACAGCTCACGCATCGTGGGTGGAAACATGTCTTGCTCTCGCAGTGGCCCTGGCAGG  
CCAGCCTTCAGTTCAGGGCTACCACCTGTGCGGGGGCTCTGTCATCACGCCCCCTGTGGATCA  
TCACTGCTGCACACTGTGTTTATGACTTGTACCTCCCCAAGTCATGGACCATCCAGGTGGGTCT  
TAGTTTCCCTGTTGGACAATCCAGCCCCATCCCACTTGGTGGAGAAGATTGTCTACCACAGCA  
AGTACAAGCCAAAGAGGCTGGGCAATGACATCGCCCTTATGAAGCTGGCCGGGCCACTCACGT  
TCAATGAAATGATCCAGCCTGTGTGCCTGCCCACTCTGAAGAGAACTTCCCCGATGGAAAAG  
TGTGCTGGACGTCAGGATGGGGGGCCACAGAGGATGGAGGTGACGCCCTCCCTGTCTGAACC  
ACGCGGCCGTCCCTTTGATTTCCAACAAGATCTGCAACCACAGGGACGTGTACGGTGGCATCA  
TCTCCCCCTCCATGCTCTGCGCGGGCTACCTGACGGGTGGCGTGGACAGCTGCCAGGGGGACA  
GCGGGGGGGCCCCCTGGTGTGTCAAGAGAGGAGGCTGTGGAAGTTAGTGGGAGCGACCAGCTTTG  
GCATCGGCTGCGCAGAGGTGAACAAGCCTGGGGTGTACACCCGTGTCACCTCCTTCCTGGACT  
GGATCCACGAGCAGATGGAGAGAGACCTAAAAACCT**TGA**AGAGGAAGGGGACAAGTAGCCACCT  
GAGTTCCTGAGGTGATGAAGACAGCCCGATCCTCCCCCTGGACTCCCGTGTAGGAACCTGCACA  
CGAGCAGACACCCTTGAGCTCTGAGTTCCGGCACCAGTAGCAGGCCCGAAAGAGGCACCCTT  
CCATCTGATTCCAGCACACCTTCAAGCTGCTTTTTTGTTTTTTTGTTTTTTTGGAGGTGGAGTCT  
CGCTCTGTTGCCAGGCTGGAGTGCAGTGGCGAAATCCCTGCTCACTGCAGCCTCCGCTTCCC  
TGGTTCAAGCGATTCTCTTGCCCTCAGCTTCCCCAGTAGCTGGGACCACAGGTGCCCCGCCACCA  
CACCCAACTAATTTTTTGTATTTTTTAGTAGAGACAGGGTTTCACCATGTTGGCCAGGCTGCTCT  
CAAACCCCTGACCTCAAATGATGTGCCTGCTTCAGCCTCCACAGTGCTGGGATTACAGGCAT  
GGGCCACCACGCCTAGCCTCACGCTCCTTTCTGATCTTCACTAAGAACAAAAGAAGCAGCAAC  
TTGCAAGGGCGGCCTTTCCCACTGGTCCATCTGGTTTTCTCTCCAGGGTCTTGCAAAATTCCT  
GACGAGATAAGCAGTTATGTGACCTCACGTGCAAAGCCACCAACAGCCACTCAGAAAAGACGC  
ACCAGCCCAGAAGTGCAGAACTGCAGTCACTGCACGTTTTTCATCTCTAGGGACCAGAACCAAA  
CCCACCCTTTCTACTTCCAAGACTTATTTTACATGTGGGGAGGTTAATCTAGGAATGACTCG  
TTTAAGGCCTATTTTCATGATTTCTTTGTAGCATTGGTGCTTGACGTATTATTGTCCTTTGA  
TTCCAAATAATATGTTTCCTTCCCTCATTGTCTGGCGTGTCTGCGTGGACTGGTGACGTGAAT  
CAAAATCATCCACTGAAA

64/615

**FIGURE 64**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA45234
><subunit 1 of 1, 453 aa, 1 stop
><MW: 49334, pI: 6.32, NX(S/T): 1
MGENDPPAVEAPFSFRSLFGLDDLKISPVAPDADAVAAQILSLLPLKFFPIIVIGIIALILAL
AIGLGIHFDCSGKYRCRSSFKCIELIARCDGVSDCKDGEDEYRCVRVGGQNAVLOVFTAASWK
TMCSDDWKGHYANVACAQLGFPSYVSSDNLRVSSLEGQFREEFVSIDHLLPDDKVLTALHHSVY
VREGCASGHVVTLQCTACGHRRGYSSRIVGGNMSLLSQWPWQASLQFQGYHLCGGSVITPLWI
ITAAHCVDLYLPKSWTIQVGLVSLLDNPAPSHLVEKIVYHSKYKPKRLGNDIALMKLAGPLT
FNEMIQPVCLPNSEENFPDGKVCWTSGWGATEDGGDASPVLNHAAVPLISNKICNHRDVYGGI
ISPSMLCAGYLTGGVDSCQGDSSGGLVCQERRLWKLVGATSFQIGCAEVNKPQVYTRVTSFLD
WIHEQMERDLKT
```

**Signal Peptide:**

amino acids 1-20

**Transmembrane domain:**

amino acids 240-284

65/615

**FIGURE 65**

CGGGCCAGCCTGGGGCGGCCGGCCAGGAACCAACCCGTTAAGGTGTCTTCTCTTTAGGGATGGT  
GAGGTTGGAAAAAGACTCCTGTAACCCCTCCTCCAGGATGAACCAACCTGCCAGAAGACATGGAG  
AACGCTCTCACCGGGAGCCAGAGCTCCCATGCTTCTCTGCGCAATATCCATTCCATCAACCCC  
ACACAACCTCATGGCCAGGATTGAGTCCTATGAAGGAAGGGAAAAGAAAGGCATATCTGATGTC  
AGGAGGACTTTCTGTTTGTGTTGTCACCTTTGACCTCTTATTTCGTAACATTACTGTGGATAATA  
GAGTTAAATGTGAATGGAGGCATTGAGAACACATTAGAGAAGGAGGTGATGCAGTATGACTAC  
TATTCTTCATATTTTGTATATTTCTTCTGGCAGTTTTTTCGATTTAAAGTGTTAATACTTGCA  
TATGCTGTGTGCAGACTGCGCCATTGGTGGGCAATAGCGTTGACAACGGCAGTGACCAGTGCC  
TTTTTACTAGCAAAAAGTGATCCTTTCGAAGCTTTTCTCTCAAGGGGCTTTTGGCTATGTGCTG  
CCCATCATTTTCATTCATCCTTGCCTGGATTGAGACGTGGTTTCTGGATTTCAAAGTGTTACCT  
CAAGAAGCAGAAGAAGAAAACAGACTCCTGATAGTTCAGGATGCTTCAGAGAGGGGCAGCACTT  
ATACCTGGTGGTCTTTCTGATGGTCAGTTTTATTCCCTCCTGAATCCGAAGCAGGATCTGAA  
GAAGCTGAAGAAAACAGGACAGTGAGAAACCACTTTTAGAACTATGAGTACTACTTTTGTTA  
AATGTGAAAAACCCCTCACAGAAAGTCATCGAGGCAAAAAGAGGCAGGCAGTGGAGTCTCCCTG  
TCGACAGTAAAGTTGAAATGGTGACGTCCACTGCTGGCTTTATTGAACAGCTAATAAAGATTT  
ATTTATTGTAATACCTCACAAACGTTGTACCATATCCATGCACATTTAGTTGCCTGCCTGTGG  
CTGGTAAGGTAATGTCATGATTCATCCTCTCTTCAGTGAGACTGAGCCTGATGTGTTAACAAA  
TAGGTGAAGAAAGTCTTGTGCTGTATTCTTAATCAAAAGACTTAATATATTGAAGTAACACTT  
TTTTAGTAAGCAAGATACCTTTTTTATTTCAATTACAGAATGGAATTTTTTTGTTTCATGTCT  
CAGATTTATTTTGTATTTCTTTTTTAACACTCTACATTTCCCTTGTTTTTTAACTCATGCACA  
TGTGCTCTTTGTACAGTTTTTAAAAAGTGTAATAAAATCTGACATGTCAATGTGGCTAGTTTTTA  
TTTTTCTTGTTTTGTCATTATGTGTATGGCCTGAAGTGTTGGACTTGCAAAAGGGGAAGAAAGG  
AATTGCGAATACATGTAAAATGTCACCAGACATTTGTATTATTTTTATCATGAAATCATGTTT  
TTCTCTGATTGTTCTGAAATGTTCTAAATACTCTTATTTTGAATGCACAAAATGACTTAAACC  
ATTCATATCATGTTTCTTTGCGTTCAGCCAATTTCAATTAAAATGAACTAAATTAAAAA

66/615

**FIGURE 66**

MNHLPEDMENALTGSQSSHASLRNIHSINPTQLMARIESYEGREKKGISDVRRTFCLFVTFDL  
LFVTLLEWIIELNVNGGIENTLEKEVMQYDYYSSYFDIFLLAVERFKVLILAYAVCRLRHWWAI  
ALTTAVTSAFLLAKVILSKLFSQGAFGYVLPPIISFILAWIETWFLDFKVLPPQEAEENRLLIV  
QDASERAALIPGGLSDGQFYSPPESEAGSEEAEKQDSEKPLLEL

**Important features of the protein:****Signal peptide:**

amino acids 1-20

**Transmembrane domains:**

amino acids 54-72, 100-118, 130-144, 146-166

**N-myristoylation sites.**

amino acids 14-20, 78-84, 79-85, 202-208, 217-223

67/615

**FIGURE 67**

AATAAAGCTTCCTTAATGTTGTATATGTCTTTGAAGTACATCCGTGCATTTTTTTTTTAGCATC  
CAACCATTCCTCCCTTGTAGTTCTCGCCCCCTCAAATCACCTCTCCCGTAGCCACCCGACT  
AACATCTCAGTCTCTGAAAATGCACAGAGATGCCTGGCTACCTCGCCCTGCCTTCAGCCTCAC  
GGGGCTCAGTCTCTTTTTCTCTTTGGTGCCACCAGGACGGAGCATGGAGGTCACAGTACCTGC  
CACCTCAACGTCTCAATGGCTCTGACGCCCCGCTGCCCTGCACCTTCAACTCCTGCTACAC  
AGTGAACCACAAACAGTTCTCCCTGAACTGGACTTACCAGGAGTGCAACAACCTGCTCTGAGGA  
GATGTTCCCTCCAGTTCCGCATGAAGATCATTAACTGAAGCTGGAGCGGTTTCAAGACCGCGT  
GGAGTTCTCAGGGAACCCCAGCAAGTACGATGTGTGGTGATGCTGAGAAACGTGCAGCCGGA  
GGATGAGGGGATTTACAACCTGCTACATCATGAACCCCCCTGACCGCCACCGTGGCCATGGCAA  
GATCCATCTGCAGGTCTCATGGAAGAGCCCCCTGAGCGGGACTCCACGGTGGCCGTGATTGT  
GGGTGCCCTCCGTGGGGGCTTCTGGCTGTGGTCTCTGGTGCTGATGGTGGTCAAGTGTGT  
GAGGAGAAAAAAGAGCAGAAGCTGAGCACAGATGACCTGAAGACCGAGGAGGAGGGCAAGAC  
GGACGGTGAAGGCAACCCGGATGATGGCGCCAAGTAGTGGTGGCCGGCCCTGCAGCCTCCCG  
TGTCCCGTCTCTCCCTCTCCGCCCTGTACAGTGACCCTGCCTGCTCGCTCTTGGTGTGCTT  
CCCGTGACCTAGGACCCAGGGCCACCTGGGGCTCTGAACCCCCGACTTCGTATCTCCCA  
CCCTGCACCAAGAGTGACCACTCTCTTCATCCGAGAAACCTGCCATGCTCTGGGACGTGTG  
GGCCCTGGGGAGAGGAGAGAAAGGGCTCCACCTGCCAGTCCCTGGGGGAGGCAGGAGGCAC  
ATGTGAGGGTCCCCAGAGAGAAGGGAGTGGGTGGGCAGGGGTAGAGGAGGGGCCGCTGTACC  
TGCCCAGTGCTTGCCCTGGCAGTGGCTTCAGAGAGGACCTGGTGGGGAGGGAGGGCTTTCCTGT  
GCTGACAGCGCTCCCTCAGGAGGGCTTGGCCTGGCACGGCTGTGCTCCTCCCTGCTCCAG  
CCCAGAGCAGCCATCAGGCTGGAGGTGACGATGAGTTCCTGAAACTTGGAGGGGCATGTTAA  
GGGATGACTGTGCATTCCAGGGCACTGACGGAAAGCCAGGGCTGCAGGCAAAGCTGGACATGT  
GCCCTGGCCCAGGAGGCCATGTTGGGCCCTCGTTTTCCATTGCTAGTGGCCTCCTTGGGGCTCC  
TGTTGGCTCCTAATCCCTTAGGACTGTGGATGAGGCCAGACTGGAAGAGCAGCTCCAGGTAGG  
GGGCCATGTTTCCAGCGGGGACCCACCAACAGAGGCCAGTTTCAAAGTCAGCTGAGGGGCTG  
AGGGGTGGGGCTCCATGGTGAATGCAGGTGCTGCAGGCTCTGCCTTCTCCATGGGGTAACCA  
CCCTCGCCTGGGCAGGGGCAGCCAAGGCTGGGAAATGAGGAGGCCATGCACAGGGTGGGGCAG  
CTTTCTTTGGGGCTTCAGTGAGAACTCTCCAGTTGCCCTTGGTGGGGTTTCCACCTGGCTTT  
TGGCTACAGAGAGGGAAGGGAAAGCCTGAGGCCGGCATAAGGGGAGGCCCTTGAACCTGAGCT  
GCCAATGCCAGCCCTGTCCCATCTGCGGCCACGCTACTCGCTCCTCTCCCAACAACCTCCCTTC  
GTGGGGACAAAAGTGACAATTGTAGGCCAGGCACAGTGGCTCACGCCCTGTAATCCAGCACTT  
TGGGAGGCCAAGGCGGGTGGATTACCTCCATCTGTTTAGTAGAAATGGGCAAAACCCCATCTC  
TACTAAAAATACAAGAATTAGCTGGGCGTGGTGGCGTGTGCCTGTAATCCAGCTATTTGGGA  
GGCTGAGGCAGGAGAATCGCTTGAGCCCGGAAGCAGAGGTTGCAGTGAACCTGAGATAGTGAT  
AGTGCCACTGCAATTCAGCCTGGGTGACATAGAGAGACTCCATCTCAAAAAAA

68/615

**FIGURE 68**

&lt;/usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA45415

&lt;subunit 1 of 1, 215 aa, 1 stop

&lt;MW: 24326, pI: 6.32, NX(S/T): 4

MHRDAWLPRPAFSLTGLSLFFSLVPPGRSMEVTVPATLNLNGSDARLPCTFNSCYTVNHKQF  
SLNWTYQECNNCSEEMFLQFRMKIINLKLRFQDRVEFSGNPSKYDVSVMRLRVQPEDEGIYN  
CYIMNPPDRHRGHGKIHLQVLMEEPPERDSTVAVIVGASVGGFLAVVILVLMVVKCVRRKKEQ  
KLSTDDLKTEEEGKTDGEGNPDDGAK

**Important features:****Signal peptide:**

amino acids 1-20

**Transmembrane domain:**

amino acids 161-179

**Immunoglobulin-like fold:**

amino acids 83-127

**N-glycosylation sites.**

amino acids 42-45, 66-69 and 74-77

69/615

**FIGURE 69**

GGCGCCTGGTTCTGCGCGTACTGGCTGTACGGAGCAGGAGCAAGAGGTGCGCGCCAGCCTCCGCCGCCGAGCCTC  
GTTTCGTGTCCCCGCCCTCGCTCCTGCAGCTACTGCTCAGAAACGCTGGGGCGCCCACCCTGGCAGACTAACGAA  
GCAGCTCCCTTCCCACCCCAACTGCAGGTCTAATTTTGGACGCTTTGCCTGCCATTTCTTCCAGGTTGAGGGAGC  
CGCAGAGGCGGAGGCTCGCGTATTCTGTCAGTCAGCACCCACGTGCCCCCGGACGCTCGGTGCTCAGGCCCTTC  
GCGAGCGGGGCTCTCCGTCTGCGGTCCCTTGTGAAGGCTCTGGGCGGCTGCAGAGGCCGGCCGTCCGGTTTGGCT  
CACCTCTCCCAGGAACTTCACACTGGAGAGCCAAAAGGAGTGGAAGAGCCTGTCTTGGAGATTTTCTCGGGGAA  
ATCCTGAGGTCATTCAATATGAAGTGTACCGCGCGGGAGTGGCTCAGAGTAACCACAGTGTCTTTCATGGCTAGA  
GCAATTCAGCCATGGTGGTTCCCAATGCCACTTTATTGGAGAACTTTTGGAAAAATACATGGATGAGGATGGT  
GAGTGGTGGATAGCCAAACAACGAGGGAAAAGGGCCATCACAGACAATGACATGCAGAGTATTTTGGACCTTCAT  
AATAAATTACGAAGTCAGGTGTATCCAACAGCCTCTAATATGGAGTATATGACATGGGATGTAGAGCTGGAAGA  
TCTGCAGAATCCTGGGCTGAAAGTTGCTTGTGGGAACATGGACCTGCAAGCTTGCTTCCATCAATTGGACAGAAT  
TTGGGAGCACACTGGGGAAGATATAGCCCCCGACGTTTTCATGTACAATCGTGGTATGATGAAGTGAAGACTTT  
AGCTACCCATATGAACATGAATGCAACCCATATTGTCCATTAGGTGTTCTGGCCCTGTATGTACACATTATACA  
CAGGTCTGTGGGCAACTAGTAACAGAATCGTGTGTGCCATTAATTTGTGTACATAACATGAACATCTGGGGGAG  
ATATGGCCCAAAGCTGTCTACCTGGTGTGCAATTACTCCCCAAAGGGAAGTGGTGGGGCCATGCCCTTACAAA  
CATGGGCGGCCCTGTTCTGCTTGCCACCTAGTTTTGGAGGGGGCTGTAGAGAAAATCTGTGCTACAAAGAAGGG  
TCAGACAGGTATTATCCCCCTCGAGAAGAGGAAACAAATGAAATAGAACGACAGCAGTCACAAGTCCATGACACC  
CATGTCCGGACAAGATCAGATGATAGTAGCAGAAATGAAGTCATAAGCGCACAGCAAATGTCCCAAATTTGTTTCT  
TGTGAAGTAAGATTAAGAGATCAGTGCAAGGAACAACCTGCAATAGGTACGAATGTCTGCTGGCTGTTTGGAT  
AGTAAAGCTAAAGTTATTGGCAGTGTACATTATGAAATGCAATCCAGCATCTGTAGAGCTGCAATTCATTATGGT  
ATAATAGACAATGATGGTGGCTGGGTAGATATCACTAGACAAGGAAGAAAGCATTATTTTCATCAAGTCCAATAGA  
AATGGTATTCAAACAATTGGCAATATCAGTCTGCTAATTCCTTCACAGTCTCTAAAGTAACAGTTCAGGCTGTG  
ACTTGTGAAACAACCTGTGGAACAGCTCTGTCCATTTTATAAGCCTGCTTCACATTGCCAAGAGTATACTGTCT  
CGTAACTGTATGCAAGCAAATCCACATTATGCTCGTGTAATTGGAACCTGAGTTTATTCTGATCTGTCCAGTATC  
TGCAGAGCAGCAGTACATGCTGGAGTGGTTCGAAATCACGGTGGTTATGTTGATGTAATGCCTGTGGACAAAAGA  
AAGACCTACATTGCTTCTTTTTCAGAAATGGAATCTTCTCAGAAAGTTTACAGAATCCTCCAGGAGGAAAGGCATTC  
AGAGTGTGTTGCTGTTGTGTCGAACTGAATACTTGGGAAGAGGACCATAAAGACTATTCCAAATGCAATATTTCTGA  
ATTTTGTATAAACTGTAACTTACTGTACAGAGTACATCAACTATTTTTCAGCCCAAAAAGGTGCCAAATGCATA  
TAAATCTTGATAAACAAGTCTATAAAATAAAACATGGGACATTAGCTTTGGGAAAAGTAATGAAAATATAATGG  
TTTGTAGAAATCCTGTGTTAAATATTGCTATATTTTCTTAGCAGTTATTTCTACAGTTAATTACATAGTCATGATT  
GTTCTACGTTTCATATATTATATGGTGCTTTGTATATGCCACTAATAAAATGAATCTAAACATTGAATGTGAATG  
GCCCTCAGAAAATCATCTAGTCATTTAAAAATAATCGACTCTAAAACCTGAAAGAAACCTTATCACATTTTCCCC  
AGTTCAATGCTATGCCATTACCAACTCCAAATAATCTCAAATAATTTTCCACTTAATACTGTAAAGTTTTTTTC  
TGTTAATTTAGGCATATAGAATATTAAATCTGATATTGCACTTCTTATTTTATATAAAATAATCCTTTAATATC  
CAAATGAATCTGTTAAATGTTTGATTCTTGGGAATGGCCTTAAAAATAAATGTAATAAAGTCAGAGTGGTGGT  
ATGAAAACATTCTAGTGATCATGTAGTAAATGTAGGGTTAAGCATGGACAGCCAGAGCTTTCTATGTACTGTTA  
AAATTGAGGTCACATATTTTCTTTTGTATCCTGGCAAATACTCCTGCAGGCCAGGAAGTATAATAGCAAAAAGTT  
GAACAAAGATGAACTAATGTATTACATTACCATTGCCACTGATTTTTTTTAAATGGTAAATGACCTTGTATATAA  
ATATTGCCATATCATGGTACCTATAATGGTGATATATTTGTTTCTATGAAAATGTATTGTGCTTTGATACTAAA  
AATCTGTAAATGTTAGTTTTTGGTAATTTTTTTTCTGCTGGTGGATTACATATTAATTTTTTCTGCTGGTGGGA  
TAAACATTAATAATCATGTTTCAAAAAAAAAAAAAA



70/615

**FIGURE 70**

&lt;/usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA45417

&lt;subunit 1 of 1, 500 aa, 1 stop

&lt;MW: 56888, pI: 8.53, NX(S/T): 2

MKCTAREWLRVTTVLFMARAI PAMVVPNATLLEKLLLEKYMDEDGEWWIAKQRGKRAITDNDMQ  
SILDLHNKLR SQVYPTASNMEYMTWDVELERSAESWAESCLWEHGPASLLPSIGQNLGAHWGR  
YRPPTFHVQSWYDEVKDFSYPYEHECNPYCPFRCSGPVCTHYTQVWATSNRIGCAINLCHNM  
NIWGQIWPKAVYLVLCNYS PKGNWWGHAPYKHGRPCSACPPSFSGGGCRENL CYKEGSDRYYP  
EEETNEIERQQSQVHDTHVRTRSDDSSRNEVISAQQMSQIVSCEVRLRDQCKGTTTCNRYECPA  
GCLDSKAKVIGSVHYEMQSSICRAAIHYGIIDNDGGWVDITRQGRKH YFIKSNRNGIQTIGKY  
QSANSFTVSKVTVQAVTCETTVEQLCPFHKPASHCPRVYCPRNCMQANPHYARVIGTRVYSDL  
SSICRAAVHAGVVRNHGGYVDVMPVDKRKTYIASFQNGIFSESLQNPPGGKA FRVFAVV

**Important features:****Signal peptide:**

amino acids 1-20

**Extracellular proteins SCP/Tpx-1/Ag5/PR-1/Sc7 protein**

amino acids 165-186, 196-218, 134-146, 96-108 and 58-77

**N-glycosylation site**

amino acids 28-31

71/615

**FIGURE 71**

CAGCCCCGCGCGCCGCGGAGTCTGAGCCGCGGCTGCCGGACGGGACGGGACCGGCTAGGC  
TGGGCGCGCCCCCGGGCCCCGCGTGGGCATGGGGCGCACTGGCCCCGGGCGCTGCTGCTGCCT  
CTGCTGGCCCACTGGCTCCTGCGCGCCGCCCGGAGCTGGCCCCCGCGCCCTTCACGCTGCCC  
CTCCGGGTGGCCGCGGCCACGAACCGCGTAGTTGCGCCACCCCGGGACCCGGGACCCCTGCC  
GAGCGCCACGCCGACGGCTTGGCGCTCGCCCTGGAGCCTGCCCTGGCGTCCCCCGCGGGCGCC  
GCCAACTTCTTGGCCATGGTAGACAACCTGCAGGGGGACTCTGGCCGCGGCTACTACCTGGAG  
ATGCTGATCGGGACCCCCCGCAGAAGCTACAGATTCTCGTTGACACTGGAAGCAGTAACTTT  
GCCGTGGCAGGAACCCCCGCACTCCTACATAGACACGTACTTTGACACAGAGAGGTCTAGCACA  
TACCGCTCCAAGGGCTTTGACGTACAGTGAAGTACACACAAGGAAGCTGGACGGGCTTCGTT  
GGGGAAGACCTCGTCACCATCCCCAAAGGCTTCAATACTTCTTTTCTTGTCAACATTGCCACT  
ATTTTTGAATCAGAGAATTCTTTTTGCTGGGATTAAATGGAATGGAATACTTGGCCTAGCT  
TATGCCACACTTGCCAAGCCATCAAGTTCTCTGGAGACCTTCTTCGACTCCCTGGTGACACAA  
GCAAACATCCCCAACGTTTTCTCCATGCAGATGTGTGGAGCCGGCTTGCCCGTTGCTGGATCT  
GGGACCAACGGAGGTAGTCTTGTCTTGGGTGGAATTGAACCAAGTTTGTATAAAGGAGACATC  
TGGTATACCCCTATTAAGGAAGAGTGGTACTACCAGATAGAAATTCTGAAATTGGAATTGGA  
GGCCAAAGCCTTAATCTGGACTGCAGAGAGTATAACGCAGACAAGGCCATCGTGGACAGTGGC  
ACCACGCTGCTGCGCCTGCCCCAGAAGGTGTTTGATGCGGTGGTGGAAGCTGTGGCCCGCGCA  
TCTCTGATTCCAGAATTCTCTGATGGTTTTCTGGACTGGGTCCCAGCTGGCGTGCTGGACGAAT  
TCGGAAACACCTTGGTCTTACTTCCCTAAAATCTCCATCTACCTGAGAGACGAGAACTCCAGC  
AGGTCATTCCGTATCACAACTCCTGCCTCAGCTTTACATTACAGCCCATGATGGGGGCCGGCCTG  
AATTATGAATGTTACCGATTTCGGCATTTCCCCATCCACAAATGCGCTGGTGATCGGTGCCACG  
GTGATGGAGGGCTTCTACGTCTCTTCGACAGAGCCAGAAGAGGGTGGGCTTCGACGCGAGC  
CCCTGTGCAGAAATTGCAGGTGCTGCAGTGTCTGAAATTTCCGGGCCTTTCTCAACAGAGGAT  
GTAGCCAGCAACTGTGTCCCCGCTCAGTCTTTGAGCGAGCCCATTTTGTGGATTGTGTCTAT  
GCGCTCATGAGCGTCTGTGGAGCCATCCTCCTTGTCTTAATCGTCCTGCTGCTGCTGCCGTT  
CGGTGTCAGCGTCGCCCCCGTGACCCTGAGGTCGTCAATGATGAGTCCTCTCTGGTCAGACAT  
CGCTGGAAATGAATAGCCAGGCCTGACCTCAAGCAACCATGAACTCAGCTATTAAGAAAATCA  
CATTTCCAGGGCAGCAGCCGGGATCGATGGTGGCGCTTTCTCCTGTGCCACCCGCTCTTCAAT  
CTCTGTTCTGCTCCCAGATGCCTTCTAGATTCACTGTCTTTTGATTCTTGATTTTCAAGCTTT  
CAAATCCTCCCTACTTCCAAGAAAAATAATTAAAAAAAACCTTCATTCTAA

72/615

**FIGURE 72**

&gt;&lt;/usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA45493

&gt;&lt;subunit 1 of 1, 518 aa, 1 stop

&gt;&lt;MW: 56180, pI: 5.08, NX(S/T): 2

MGALARALLPLLAQWLLRAAPELAPAPFTLPLRVAAATNRVVAPTPGPGTPAERHADGLALA  
LEPALASPAGAAANFLAMVDNLQGDSEGRGYYLEMLIGTPPQKLQILVDTGSSNFAVAGTPHSYI  
DTYFDTERSSTYRSKGFVDVTVKYTQGSWTGFVGEDLVTIPKGFNTSFLVNIATIFESENFFLP  
GIKWNGILGLAYATLAKPSSSLETFFDSLVTQANIPNVFSMQMCGAGLPVAGSGTNGGSLVLG  
GIEPSLYKGDWYTPIKEEWYYQIEILKLEIGGQSLNLDREYNADKAIVDSGTTLLRLPQKV  
FDAVVEAVARASLIPEFSDGFWTGSQACWTNSETPWSYFPKISYLRDENSSRSFRITILPQ  
LYIQPMMGAGLNYECYRFGISPSTNALVIGATVMEGFYVIFDRAQKRVGFAASPCAIEIAGAAV  
SEISGPFSTEDVASNCVPAQSLSEPIWVSYALMSVCGAILLVLLVLLLPPFCQRRPRDPE  
VVNDESSLVRHRWK

**Important features:****Signal peptide:**

amino acids 1-20

**Transmembrane domain:**

amino acids 466-494

**N-glycosylation sites.**

amino acids 170-173 and 366-369

**Leucine zipper pattern.**

amino acids 10-31 and 197-118

**Eukaryotic and viral aspartyl proteases**

amino acids 109-118, 252-261 and 298-310

73/615

**FIGURE 73**

CGCCGCGGCGAGAGCGCGCCAGCCCCGCGCGATGCCGCGCGCCAGGACGCCTCCTCCCGCTGCTGGCCCCGGC  
CGGCGGCCCTGACTGCGCTGCTGCTGCTGCTGCTGGGCCATGGCGGCGGCGGGCGCTGGGGCGCCCGGGCCAGG  
AGGCGGCGGCGGCGGCGGCGGACGGGCCCCCGCGGCAGACGGCGAGGACGGACAGGACCCGCACAGCAAGCACC  
TGTACACGCGCGACATGTTACGCACGGGATCCAGAGCGCGCGCACCTTCGTCACTGTTCTTCGCGCCCTGGTGTG  
GACACTGCCAGCGGCTGCAGCCGACTTGAATGACCTGGGAGACAAATACAACAGCATGGAAGATGCCAAAGTCT  
ATGTGGCTAAAGTGGACTGCACGGCCCACTCCGACGTGTGCTCCGCCAGGGGTGCGAGGATACCCACCTTAA  
AGCTTTTCAAGCCAGGCCAAGAAGCTGTGAAGTACCAGGGTCTCGGGACTTCCAGACACTGGAAAAGTGGATGC  
TGCAGACACTGAACGAGGAGCCAGTGACACCAGAGCCGGAAGTGAACCGCCAGTGGCCCCGAGCTCAAGCAAG  
GGCTGTATGAGCTCTCAGCAAGCAACTTTGAGCTGCACGTTGCACAAGGCGACCACTTTATCAAGTTCTTCGCTC  
CGTGGTGTGGTCACTGCAAAGCCCTGGCTCCAACTGGGAGCAGCTGGCTCTGGGCCCTGAACATTCCGAAACTG  
TCAAGATTGGCAAGGTTGATTGTACACAGCACTATGAACCTGCTCCGGAACAGGTTCTGGCTATCCCACTC  
TTCTCTGGTTCGAGATGGGAAAAAGGTGGATCAGTACAAGGGGAAAGCGGGATTTGGAGTCACTGAGGGAGTACG  
TGGAGTCGCGAGCTGCAGCGCACAGAGACTGGAGCGACGGAGACCGTCACGCCCTCAGAGGCCCGGTGCTGGCAG  
CTGAGCCCGAGGCTGACAAGGGCACTGTGTTGGCACTCACTGAAAATAACTTCGATGACACCATGCGAGAAGGAA  
TAACCTTCATCAAGTTTTATGCTCCATGGTGTGGTCATTGTAAGACTCTGGCTCTACTTTGGGAGGAACTCTCTA  
AAAAGGAATTCCCTGGTCTGGCGGGGGTCAAGATCGCGGAAGTAGACTGCACTGCTGAACGGAATATCTGCAGCA  
AGTATTCGGTACGAGGCTACCCACGTTATTGCTTTCCGAGGAGGGAAGAAAGTCAGTGAGCACAGTGGAGGCA  
GAGACCTTGACTCGTTACACCGCTTTGTCTGAGCCAAGCGAAAGACGAACCTTTAGGAACACAGTTGGAGGTCAC  
CTCTCTGCCAGCTCCCGCACCTTGGCTTTAGGAGTTCACTCCACAGAGGCCACTGGGTTCCCACTGGTGGCT  
GTTTCAGAAAGCAGAACATACTAAGCGTGAGGTATCTTCTTTGTGTGTGTGTTTTCCAAAGCCACACACTCTACAG  
ATTCTTTATTAAGTTAAGTTTCTCTAAGTAAATGTGTAACCTCATGGTCACTGTGTAAACATTTTCAGTGGCGATA  
TATCCCTTTGACCTTCTCTGATGAAATTTACATGGTTTCCTTTGAGACTAAAATAGCGTTGAGGGAATGAAA  
TTGCTGGACTATTTGTGGCTCCTGAGTTGAGTGATTTTGGTGAAAGAAAGCACATCCAAAGCATAGTTTACCTGC  
CCACGAGTTCTGGAAGGTGGCCTTGTGGCAGTATTGACGTTCTCTGATCTTAAGGTACAGTTGACTCAATAC  
TGTGTTGGTCCGTAGCATGGAGCAGATTGAAATGCAAAAACCCACACCTCTGGAAGATACCTTCACGGCCGCTGC  
TGGAGCTTCTGTTGCTGTGAATACTTCTCTCAGTGTGAGAGGTTAGCCGTGATGAAAGCAGCGTTACTTCTGACC  
GTGCTGAGTAAGAGAATGCTGATGCCATAACTTTATGTGTCGATACTTGTCAAATCAGTTACTGTTACGGGGAT  
CCTTCTGTTTCTCACGGGGTGAAACATGTCTTTAGTTTCTCATGTAAACACGAAGCCAGAGCCACATGAACGTG  
TGGATGTCTTCTTAGAAAGGTAGGCATGGAAAATTCACGAGGCTCATTCTCAGTATCTCATTAACTCATTGA  
AAGATTCCAGTTGTATTTGTACCTGGGGTGACAAGACCAGACAGGCTTTCCAGGCCCTGGGTATCCAGGGAGGC  
TCTGCAGCCCTGCTGAAGGGCCCTAACTAGAGTTCTAGAGTTTCTGATTCTGTTTCTCAGTAGTCTTTTAGAGG  
CTTGCTATACTTGGTCTGCTTCAAGGAGGTCGACCTTCTAATGTATGAAGAATGGGATGCATTTGATCTCAAGAC  
CAAAGACAGATGTCACTGGGCTGCTCTGCCCTGGTGTGCACGGCTGTGGCAGCTGTTGATGCCAGTGTCTCTA  
ACTCATGCTGTCTTGTGATTAAACACCTCTATCTCCCTTGGGAATAAGCACATAACAGGCTTAAGCTCAAGATA  
GATAGGTGTTGTCTTTTACCATCGAGCTACTTCCCATATAAACCACCTTTGCATCCAACACTCTTCACCACCT  
CCCATACGCAAGGGGATGTGGATACTTGGCCCAAAGTAAGTGGTGGTAGGAATCTTAGAAACAAGACCACTTATA  
CTGCTGTCTGAGGCAGAAGATAACAGCAGCATCTCGACCAGCCTCTGCCTTAAAGGAAATCTTTATTAATCACG  
TATGGTTTACAGATAATTCTTTTTTAAAAAACCACCTCCTAGAGAAGCACAACTGTCAAGAGTCTTGTACA  
CACAACCTCAGCTTTGCATCAGAGTCTTGTATTCCAAGAAAATCAAAGTGGTACAATTTGTTTGTACTAT  
GATACTTTCTAAATAAACTCTTTTTTTTTAA

74/615

**FIGURE 74**

&gt;&lt;/usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA46776

&gt;&lt;subunit 1 of 1, 432 aa, 1 stop

&gt;&lt;MW: 47629, pI: 5.90, NX(S/T): 0

MPARPGRLLPLLARPAALTALLLLLLLGHGGGGRWGARAQEAAAAAADGPPAADGEDGQDPHSK  
HLYTADMFTHGIQSAAHFVMFFAPWCGHCQRLQPTWNDLGDKYNSMEDAKVYVAKVDCTAHS  
VCSAQGVRGYPTLKLKFKPGQEAVKYQGPRDFQTLNWMQLTLNEEPVTPEPEVEPPSAPELKQ  
GLYELSASNFEHVAQGDHFIKFFAPWCGHCKALAPTWEQLALGLEHSETVKIGKVDCTQHYE  
LCSGNQVRGYPTLLWFRDGKKVDQYKGRDLESLEYVESQLQRTETGATETVTPSEAPVLAA  
EPEADKGTVLALTENNFDITIAEGITFIKFYAPWCGHCKTLAPTWEELSKKEFPGLAGVKIAE  
VDCTAERNICSKYSVRGYPTLLLFRGGKKVSEHSGGRDLDSLHRFVLSQAKDEL

**Signal sequence:**

amino acids 1-32

75/615

**FIGURE 75A**

CGGACGCGTGGGCGGACGCGTGGGCAAAAGAACTCGGAGTGCCAAAGCTAAATAAGTTAGCTGAGAAAACGCACG  
CAGTTTGCAGCGCCTGCGCCGGGTGCGCCAACCTACGCAAAAGACCAAGCGGGCTCCGCGCGGACCGGCCGCGGGG  
TAGGGACCCGGCTTTGGCCTTCAGGCTCCCTAGCAGCGGGGAAAAGGAATTGCTGCCCGGAGTTTCTGCGGAGGT  
GGAGGGAGATCAGGAAACGGCTTCTTCTCACTTCGCCGCTGGTGAGTGTGCGGGAGATTGGCAAACGCCTAGG  
AAAGGACTGGGGAAAATAGCCCTGGGAAAGTGGAGAAGGTGATCAGGAGGCCGGTCCACTACGGCAGTTTATCTG  
TCTGATCAGAGCCAGACGCGACGCGTCCACTTCGAGTTCTTCCAGGTGTGGGACCGCAGGACAGACGCGCGA  
TCCCGCCGCCCTCCGTACCAGCACTCCAGGAGAGTCAGCCTCGCTCCCCAACGTCGAGGGCGCTCTGGCCACGA  
AAAGTCTCTGTCCACTGTGATTCTCAATTCTTGCTTGGTTTTTTTCTCCAGAGAACTTTTGGGTGGAGATATTA  
ACTTTTTTCTTTTTTTTTTCTTGGTGGAGCTGCTCTAGGGAGGGGGAGGAGGAGGAGAAAGTGAATGTGC  
TGGAGAAGAGCGAGCCCTCCTTGTCTTCCGGAGTCCCATCCATTAAGCCATCACTTCTGGAAGATTAAAGTTGT  
CGGACATGGTGACAGCTGAGAGGAGAGGAGGATTTCTGCCAGGTGGAGAGTCTTACCCTGTGTGGGTGCATG  
TGTGCGCCCGCAGCGGCGCGGGGCGCGTGGTTCTCCGCGTGGAGTCTCACCTGGGACCTGAGTGAATGGCTCCCA  
GGGGCTGTGCGGGGCATCCGCTCCGCTTCTCCACAGGCCTGTGTCTGTCTGGAAAGATGCTAGCAATGGGG  
CGCTGGCAGGATTCTGGATCCTCTGCCTCCTCACTTATGGTTACCTGTCTGGGGCCAGGCCTTAGAAGAGGAGG  
AAGAAGGGGCCCTTACTAGCTCAAGCTGGAGAGAACTAGAGCCAGCACAACCTCCACCTCCAGCCCCATCTCA  
TTTTCATCCTAGCGGATGATCAGGGATTTAGAGATGTGGGTTACCACGGATCTGAGATTAACACCTACTCTTG  
ACAAGCTCGCTCCGAAGGAGTTAAACTGGAGAACTACTATGTCCAGCCTATTTGCACACCATCCAGGAGTCAGT  
TTATTACTGGAAGATATCAGATACACACCGGACTTCAACATTCTATCATAAGACCTACCCAACCAACTGTTTAC  
CTCTGGACAATGCCACCTACCTCAGAACTGAAGGAGGTTGGATATTCAACGCATATGGTCGAAAATGGCACT  
TGGGTTTTTAACAGAAAAGATGCATGCCACCAGAAGAGGATTTGATACCTTTTTTGGTTCCTTTTGGGAAGTG  
GGGATTACTATACACTACAAATGTGACAGTCTGGGATGTGTGGCTATGACTTGTATGAAAACGACAATGCTG  
CCTGGGACTATGACAATGGCATATACTCCACACAGATGTACACTCAGAGAGTACAGCAAATCTTAGCTTCCCAT  
ACCCCAAAAGCCTATATTTTTATATACCTGCCCTATCAAGCTGTTTCACTTACCACCTGCAAGCTCTGGCAGGTATT  
TCGAACACTACCGATCCATTATCAACATAAACAGGAGAAGATATGCTGCCATGCTTTCCTGCTTAGATGAAGCAA  
TCAACAACGTGACATTGGCTCTAAAGACTTATGGTTTCTATAACAACAGCATTATCATTTACTCTTCAGATAATG  
GTGGCCAGCTACGGCAGGAGGGAGTAAGTGGCCTCTCAGAGGTAGCAAAGGAACATATTGGGAAGGAGGGATCC  
GGGCTGTAGGCTTTGTGCATAGCCACTTCTGAAAACAAGGGAACAGTGTGTAAGGAACCTGTGCACATCACTG  
ACTGGTACCCCACTCTCATTTCACTGGCTGAAGGACAGATTGATGAGGACATTCAACTAGATGGCTATGATATCT  
GGGAGACCATAAGTGAGGGTCTTCGCTCACCCCGAGTAGATATTTTGATAACATTGACCCCTATACACCAAGGC  
AAAAAATGGCTCCTGGGCAGCAGGCTATGGGATCTGGAACACTGCAATCCAGTCAGCCATCAGAGTGCAGCACTG  
GAAATTGCTTACAGGAAATCCTGGCTACAGCGACTGGGTCCCCCTCAGTCTTTCAGCAACCTGGGACCGAACC  
GTGGCACAATGAACGGATCACCTTGTCAACTGGCAAAAGTGTATGGCTTTTCAACATCACAGCCGACCCATATGA  
GAGGGTGGACCTATCTAACAGGTATCCAGGAATCGTGAAGAAGCTCCTACGGAGGCTCTCACAGTTCAACAAAAC  
TGCACTGCCGCTCAGGTATCCCCCAAGACCCAGAAAGTAAACCTAGGCTCAATGGAGGGGTCTGGGGACCATG  
GTATAAAGAGGAAACCAAGAAAAGAACCAAGCAAAATCAGGCTGAGAAAAGCAAAAGCAAAAGCAAAAGCAAA  
GAAGAAGAAACAGCAGAAAGCAGTCTCAGGTAAACAGCAAAATTTGGCTCGATAATATCGCTGGCCTAAGCGTCA  
GGCTTGTTCATGCTGTGCCACTCCAGAGACTTCTGCCACCTGGCCGCCACACTGAAAACGTCTCTGCTCAGTG  
CCAAGGTGCTACTCTTGCAAGCCACACTTAGAGAGAGTGGAGATGTTTATTTCTCTCGCTCCTTTAGAAAACGTG  
GTGAGTCTGAGTTCCTGCTGTGCTTCACTGCAACTGACCAAAACACTGCTTTGAATTATAGGAGGAGAACAATA  
ACCTACCATCCGCAAGCATGCTAATTGATGGAAGTTACAGGCTAGCATGATTAAACTACCTTTGATAAATTAC  
AGTCAAAGATTGTGTCACCTCAAAGGCCCTTGAAGAATATATTTCTTGGTGAATTTTGTATGTCTGTATATGA  
CACTTGGGTTTTTAATTAATTCTATTTTATATATAAATATATGTTTCTTTCTCTGTAAGAGCTGTTTTCT  
CACATGTGAACAGCTTGACCTCATTTTACCATGCGTGAGGGAATGGCAAATAAGAATGTTTGAGCACACTGCCC  
ACAAATGAATGTAATATTTTCTAAACACTTTACTAGAAGAACATTTTCACTATAAAAAACCTAATTTATTTTACA  
GAAAAATATTTTGTGTTTTTATAAAAAGTTATGCAAATGACTTTTATTTTATTTCTCTGCATACCATTAGAAGA  
ATTTTATTTTCAATTTCTTCAAATTATCAAGCACTGTAATACTATAAATTAATGTAATACTGTGTGAATTCAGACTA  
TAAAAACATCATTCAGAAAACCTTTATAATCGTCATTGTTCAATCAAGATTTTGAATGTAATAAGATGAATATAT  
ATTACTTGAATATCAATGTTTGTGTCAGAGTTGAGACAACTTTATTTGTTTCTATCATAACTATTTATGTATCTT  
AATTATTAATGATTTTACTTTATGGCACTAGAAAATTTACTGTGGCTTTTCTGATCTAACTTCTAGCTAAAATT  
GTATCATTTGGTCTTAAAAAATAAAATCTTTACTAATAGGCAATTGAAGGAATGGTTTGTAAACAACACAGTAA  
TATATATGATTTTACAGATAGATGCTTCCCTTGGCTATGACATGGAGAAAAGATTTTCCCATATAATAAATACTAA  
TATTTATATTAGGTTGGTGCAAAACTAGTTGCGGTTTTTCCCATTAAGTAATAACCTTACTCTTATACAAAGT  
GGACACTGTGGGGAGATACAGAGAAATGGAAGATACGGATCCTGCCTGGAGTAGGTAACCTTGCTTGGAAACCC  
ACATGCAAAAGCTCATGAGGAGAATTAAGGAGTATTATCAGTAATGAAGTTTATCATGGGTTCATCAATGAGCATA  
GATTGGTGTGGATCCTGTAGACCTGGTGTTTTTCTTTGAAGTGCCCTCTCCTAATGCAGAGGCCCTTGAAGCTTAC

76/615

**FIGURE 75B**

[illegible]

77/615

**FIGURE 76**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA48296
><subunit 1 of 1, 515 aa, 1 stop
><MW: 56885, pI: 6.49, NX(S/T): 5
MAPRGCAGHPPPPSPQACVCPGKMLAMGALAGFWILCLLTGYLSWGQALEEEEEEGALLAQAGEKLEPSTTSTSQ
PHLIFILADDQGFRDVGYPYHGSEIKTPTLDKLAAGVKLENYYVQPICTPSRSQFITGKYQIHTGLQHSIIRPTQP
NCLPLDNATLPQKLKEVGYSTHMGVKGWHLGFNRKECMPTRRGFDTFFGSLLGSGDYTHYKCDSPGMCQYDLYEN
DNAAWDYDNGIYSTQMYTORVQQILASHNPTKPIFLYTAYQAVHSPLOAPGRYFEHYRSIININRRRYAAMLSCV
DEAINNVTLALKTYGFYNNSIIYYSSDNGGQPTAGGSNWPLRGSKGTYWEGGIRAVGFVHSPLLKNKGTVCVELV
HITDWYPTLISLAEGQIDEDIQLDGYDIWETISEGLRSPRVDILHNIDPYTPRQKMAPGQQAMGSGTLQSSQPSE
CSTGNCLQEILATATGSPLSLSATWDRTGGTMNGSPCQLAKVYGFSTSQPTHMRGWTYLTGIQES
```

**Important Features:****Signal Peptide:**

amino acids 1-37

**Sulfatases signature 1.**

amino acids 120-132

**Sulfatases signature 2.**

amino acids 168-177

**Tyrosine kinase phosphorylation site.**

amino acids 163-169

**N-glycosylation sites.**

amino acids 157-160, 306-309 and 318-321



78/615

**FIGURE 77**

AAAAAGCTCACTAAAGTTTCTATTAGAGCGAATACGGTAGATTTCCATCCCCTTTTGAAGAACAGTACTGTGGA  
GCTATTTAAGAGATAAAAAACGAAATATCCTTTCTGGGAGTTCAAGATTGTGCAGTAATTGGTTAGGACTCTGAGC  
GCCGCTGTTACCAATCGGGGAGAGAAAAGCGGAGATCCTGCTCGCCTTGCACGCGCCTGAAGCACAAAGCAGAT  
AGCTAGGAATGAACCATCCCTGGGAGTATGTGGAACAACGGGAGGAGCTCTGACTTCCCAACTGTCCCATTCTAT  
GGGCGAAGGAACGTCTCTGACTTCAGTGGTTAAGGGCAGAATTGAAAATAATTCTGGAGGAAGATAAGAATGAT  
TCCTGCGCGACTGCACCGGGACTACAAAGGGCTTGTCTGCTGGGAATCCTCCTGGGGACTCTGTGGGAGACCGG  
ATGCACCCAGATACGCTATTCTAGTTCGGGAAGAGCTGGAGAAAGGCTCTAGGGTGGGCGACATCTCCAGGGACCT  
GGGGCTGGAGCCCCGGGAGCTCGCGGAGCGCGGAGTCCGCATCATCCCAGAGGTAGGACGCGAGCTTTTCGCCCT  
GAATCCGCGCAGCGGCAGCTTGGTCCAGCGCGGGCAGGATAGACCGGGAGGAGCTCTGTATGGGGGCCATCAAGTG  
TCAATTAAATCTAGACATTCTGATGGAGGATAAAGTGAAAATATATGGAGTAGAAGTAGAAGTAAGGGACATTAA  
CGACAATGCGCCTTACTTTCTGTGAAAGTGAATTAGAAAATAAAATTAGTGAAAATGCAGCCACTGAGATGCGGTT  
CCCTCTACCCACGCTGGGATCCGGATATCGGGAAGAACTCTCTGCAGAGCTACGAGCTCAGCCCCGAACACTCA  
CTTCTCCCTCATCGTGCAAAATGGAGCCGACGGTAGTAAGTACCCGAATTGGTGCTGAAACGCGCCCTGGACCG  
CGAAGAAAAGGCTGCTCACCACCTGGTCTTACGGCTCCGACGGGGGCGACCCGCTGCGCACAGGCACCGCGCG  
CATCCGCGTGATGGTTCTGGATGCGAACGACAACGCACCCAGCGTTTGCTCAGCCCCGAGTACCGCGCGAGCGTTCC  
GGAGAATCTGGCCTTGGGCACGCAGCTGCTTGTAGTCAACGCTACCGACCCTGACGAAGGAGTCAATGCGGAAGT  
GAGGTATTCTTCCGGTATGTGGACGACAAGGCGGCCCAAGTTTTCAAAGTAGATTGTAATTCAGGGACAATATC  
AACAATAGGGGAGTTGGACCACGAGGAGTCAGGATTCTACCAGATGGAAGTGCAAGCAATGGATAATGCAGGATA  
TTCTGCGCGAGCCAAAGTCTGATCACTGTTCTGGACGTGAACGACAATGCCCCAGAAGTGGTCTCACCCTCTCT  
CGCCAGCTCGGTTCCCGAAAACCTCTCCAGAGGGACATTAATTGCCCTTTTAAATGTAAATGACCAAGATTCTGA  
GGAAAACGGACAGGTGATCTGTTTCATCCAAGGAAATCTGCCCTTTAAATTAGAAAAATCTTACGGAAATTACTA  
TAGTTTAGTCAAGACATAGTCTTGGATAGGGAACAGGTTCTTAGCTACAACATCACAGTGACCGCCACTGACCG  
GGGAACCCCGCCCCATCCACGGAACCTCATATCTCGCTGAACGTGGCAGACACCAACGACAACCCGCGGCTCTT  
CCCTCAGGCCTCCTATTCCGCTTATATCCCAGAGAACAATCCCAGAGGAGTTTCCCTCGTCTCTGTGACCGCCCA  
CGACCCCGACTGTGAAGAGAACGCCAGATCACTTATCCCTGGCTGAGAACACCATCCAAGGGGCAAGCCTATC  
GTCCTACGTGTCCATCAACTCCGACACTGGGGTACTGTATGCGCTGAGCTCCTTCGACTACGAGCAGTTCCGAGA  
CTTGCAAGTGAAAGTGATGGCGCGGGACAACGGGCGACCCGCCCTCAGCAGCAACGTGTCTGTGAGCCTGTTCTG  
GCTGGACCAGAACGACAATGCGCCGAGATCCTGTACCCCGCCCTCCCCACGGACGGTTCCTGCGTGGAGCT  
GGCTCCCCGCTCCGAGAGCCCGGCTACCTGGTGACCAAGGTGGTGGCGGTGGACAGAGACTCCGGCCAGAACGC  
CTGGCTGTCTACCGTCTGCTCAAGGCCAGCGAGCCGGGACTCTTCTCGGTGGGTCTGCACACGGGCGAGGTGCG  
CACGGCGCGAGCCCTGCTGGACAGAGACGCGCTCAAGCAGAGCCCTCGTAGTGGCCGCTCCAGGACCAACGGCCAGCC  
CCCTCTCTCCGCCACTGTACGCTCACCGTGGCCGTGGCCGACAGCATCCCCAAGTCTGGCGGACCTCGGCAG  
CCTCGAGTCTCCAGCTAACTCTGAAACCTCAGACCTCACTCTGTACCTGGTGGTAGCGGTGGCCGCGGTCTCCTG  
CGTCTTCTGCGCCTTCGTCTATCTTGTCTGCTGGCGCTCAGGCTGCGGCGCTGGCACAAGTCACGCCTGTCTCAGGC  
TTCAGGAGGCGGCTTGACAGGAGCGCCGGCGTCCGACTTTGTGGGCGTGGACGGGGTGCAGGCTTTCCTGCAGAC  
CTATTCACGAGGTTTCCCTCACCACGGACTCGCGGAAGAGTCACTGATCTTCCCCAGCCCCAACTATGCAGA  
CATGCTCGTCAGCCAGGAGAGCTTTGAAAAAAGCGAGCCCTTTTGCTGTGAGGTGATTCGGTATTTTCTAAAGA  
CAGTCATGGGTTAATTGAGGTGAGTTTATATCAATCTTCTTTCTTTTTTTTTTAAATTGCTCTGTCTCCCAAGC  
TGGAGTGCAGCGGTACGATCATAGCTCACTGCGGCCTCAAACCTCCTAGGCTCAAGCAATTATCCACCTTTGCCT  
CCGGTGTAAACAGGGACTACAGGTGCAAGCCACCTACTGTCTGCCTATCTATCTATCTATCTATCTATCTAT  
CTATCTATCTATCTATCTATCTATCTTCTTGTACAGACGGGAGTCTCACGCCTGTAATCCCAGTACTTTGGGAGGC  
CGAGGCGGGTGGATCACCTGAGGTTGGGAGTTTGAGACCAGCCTGACCAACATGGAGAAACCCGCTCTATACTAA  
AAAAATACAAAATTAGCCGGGCGTGGTGGTGCATGTCTGTAATCCCAGCTACTTGGGAGGCTGAGTCAGGAGAAT  
TGCTTTAACCTGGGAGGTGGAGGTTGCAATGAGCTGAGATTGTGCCATTGCACTCCAGCCTGGGCAACAAGAGTG  
AAACTCTATCTCA

79/615

**FIGURE 78**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA48306
><subunit 1 of 1, 916 aa, 1 stop
><MW: 100204, pI: 4.92, NX(S/T): 4
MIPARLHRDYKGLVLLGILLGLTWETGCTQIRYSVP EELEKGSRVGDISRDLGLEPRELAERGVRIIPRGRTQLF
ALNPRSGSLVTAGRIDREELCMGAIKCQLNLDILMEDKVKIYGVEVEVRDINDNAPYFRESELEIKISENAATEM
RFPLPHAWDPDIGKNSLQSYELSPNTHFSLIVQNGADGSKYPELV LKRALDREEKAAHHLVLTASDGGDPVRTGT
ARIRVMVLDANDNAPAFAPQPEYRASVPENLALGTQLLVVNATDPDEGVNAEVRYSFYVDDKAAQVFKLDCNSGT
ISTIGELDHEESGFYQMEVQAMDNAGYSARAKVLITVLDVNDNAPEVVLTSLASSVPENSPRGTLIALLNVDQD
SEENGQVICFIQGNLPFKLEKSYGNYYSLVTDIVLDREQVPSYNIITVTATDRGTPPLSTETHISLNVADTNDNPP
VFPQASY SAYIPENNPRGVSLSVSVTAHDPDCEENAQITYSLAENTIQGASLSSYVSINSDTGVLYALSSFDYEQF
RDLQVKVMARDNGHPPLSSNVSLSLFVLDQNDNAPEILYPALPTDGSTGVELAPRSAEPGYLVTKVAVDRDSGQ
NAWLSYRLKASEPGLF SVGLHTGEVRTARALLDRDALKQSLVVAVQDHGQPFPLSATVTLTVAVADSI PQVLADL
GSLESPANSETSDLTLYLVVAVAAVSCVFLAFVILL LALRLRRWHKSRLLQASGGGLTGAPASHFVGVDGVQAF L
QTY SHEVSLTTDSRKSHLIFPQPNYADMLVSVQESFEKSEPLLLSGDSVFSKDSHGLIEVS LYQIFFLFFFNCSVS
QAGVQRYDHSSLRPQT PRLKQLSHLCLRCNRDYRCKPPTVCLSIYLSIYLSIYLSIYLLLSCTDGS LTPVIPVLW
EAEAGGSPEVGS LRPA
```

**Signal sequence:**

amino acids 1-30

**Transmembrane domains:**

amino acids 693-711, 809-823, 869-888

80/615

**FIGURE 79**

AGCCGCTGCCCCGGGCGGGCGCCGCGGGCAGCCATGAGTCCCCGCTCGTGCCTGCGTTTCGCTGCGCCTCCTC  
GTCTTCGCCGTCTTCTCAGCCGCGCGAGCAACTGGCTGTACCTGGCCAAGCTGTCTCGGTGGGGAGCATCTCA  
GAGGAGGAGACGTGCGAGAACTCAAGGGCCTGATCCAGAGGCAGGTGCAGATGTGCAAGCGGAACCTGGAAGTC  
ATGGACTCGGTGCGCCGCGGTGCCAGCTGGCCATTGAGGAGTGCCAGTACCAGTTCCGGAACCGGCGCTGGAAC  
TGCTCCACACTCGACTCCTTGCCCGTCTTCGGCAAGTGCGTACGCAAGGGACTCGGGAGGCGGCTTCGTGTAC  
GCCATCTCTTCGGCAGGTGTGGCCTTTCAGTGACGCGGGCGTGACGAGTGGGGAGCTGGAGAAGTGCGGCTGT  
GACAGGACAGTGATGGGGTCAGCCACAGGGCTTCCAGTGGTCAGGATGCTCTGACAACATCGCCTACGGTGTG  
GCCTTCTCACAGTCGTTTGTGGATGTGCGGGAGAGAAGCAAGGGGGCCTCGTCCAGCAGAGCCCTCATGAACCTC  
CACAACAATGAGGCCGGCAGGAAGGCCATCCTGACACACATGCGGGTGGAATGCAAGTGCCACGGGGTGTCAGGC  
TCCTGTGAGGTAAAGACGTGCTGGCGAGCCGTGCCGCCCTTCCGCCAGGTGGGTACGCACTGAAGGAGAAGTTT  
GATGGTGCCACTGAGGTGGAGCCACGCGCGTGGGCTCCTCCAGGGCACTGGTACCACGCAACGCACAGTTCAAG  
CCGCACACAGATGAGGACCTGGTGTACTTGGAGCCTAGCCCCGACTTCTGTGAGCAGGACATGCGCAGCGGCGTG  
CTGGGCACGAGGGGCCGCACATGCAACAAGACGTCCAAGGCCATCGACGGCTGTGAGCTGCTGTGCTGTGGCCGC  
GGCTTCCACACGGCGCAGGTGGAGCTGGCTGAACGCTGCAGCTGCAAATTCCACTGGTGCTTCGTCAAGTGC  
CGGCAGTGCCAGCGGCTCGTGGAGTTGCACACGTGCCGATGACCGCCTGCCTAGCCCTGCGCCGGCAACCACCTA  
GTGGCCAGGGAAGGCCGATAATTAAACAGTCTCCACCACTACCCCAAGAGATACTGGTTGTATTTTTTGT  
CTGGTTTGGTTTTTGGGTCTCATGTTATTTATTGCCGAAACCAGGCAGGCAACCCCAAGGGCACCAACCAGGGC  
CTCCCCAAAGCCTGGGCCTTTGTGGCTGCCACTGACCAAGGGACCTTGCTCGTGCCGCTGGCTGCCCCGATGTG  
GCTGCCACTGACCACTCAGTTGTTATCTGTGTCCGTTTTTCTACTTGCAGACCTAAGGTGGAGTAACAAGGAGTA  
TTACCACCACATGGCTACTGACCGTGTATCGGGGAAGAGGGGGCCTTATGGCAGGGAATAAGGTACCGACTTG  
ATGGAAGTCACACCTCTGGAAAAAAGAACTCTTAACCTCTCCAGCACACATACATGGACTCCTGGCAGCTTGA  
GCCTAGAAGCCATGTCTCTCAAATGCCCTGAGAAAGGGAACAAGCAGATACCAGGTCAAGGGCACAGGTTTCATT  
TCAGCCCTTACATGGACAGCTAGAGGTTTCGATATCTGTGGGTCTTCCAGGCAAGAAGAGGGAGATGAGAGCAAG  
AGACGACTGAAGTCCCACCTAGAACCCAGCCTGCCCCAGCCTGCCCCCTGGGAAGAGGAACTTAACCACTCCCC  
AGACCCACCTAGGCAGGCATATAGGCTGCCATCCTGGACCAGGGATCCCGGCTGTGCCTTTGCAGTCATGCCCCGA  
GTCACCTTTCACAGCGCTGTTCCCTCCATGAAACTGAAAAACACACACACACACACACACACACACACACACAC  
ACACACACACGGACACACACACACACCTGCGAGAGAGAGGGAGGAAAGGGCTGTGCCTTTGCAGTCATGCCCGAG  
TCACCTTTCACAGCACTGTTCTC

81/615

**FIGURE 80**

</usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA48328  
<subunit 1 of 1, 351 aa, 1 stop  
<MW: 39052, pI: 8.97, NX(S/T): 2  
MSPRSCLRLRLLVFAVFSAAASNWLYLAKLSSVGSISEEETCEKLKGLIQRVQMCKRNLEVMDSVRRGAQLAI  
EECQYQFRNRWNCSTLDSLPLVFGKVVTQGTREAAFVYAISSAGVAFVTRACSSGELEKCGCDRTVHGVSPQGF  
QWSGCSDNIAYGVAFSQSFSVDVRERSKGASSSRALMNLHNNEAGRKAILTHMRVECKCHGVSGSCEVKTWCWRAVP  
PFRQVGHALKEKFDGATEVEPRRVGSSRALVPRNAQFKPHTDEDLVYLEPSPDFCEQDMRSGVLGTRGRTCNKTS  
KAIDGCELLCCGRGFHTAQVELAERCSCFHWCCFVKCRQCQRLVELHTCR

**Important features:****Signal peptide:**

amino acids 1-22

**N-glycosylation sites.**

amino acids 88-91 and 297-300

**Wnt-1 family signature.**

amino acids 206-215

**Homologous region to Wnt-1 family proteins**

amino acids 183-235, 305-350, 97-138, 53-92 and 150 -174

82/615

**FIGURE 81**

CCGAGCCGGGCGCGCAGCGACGGAGCTGGGGCCGGCCTGGGACCATGGGCGTGAGTGCAATCTACGGATCAGTCT  
CTGATGGTGGGTGCTTAACCTCAGTGGGGACTCCAAGATTTCCATGAAGAAAATCAGTTGTCTTCATTCAAGAAT  
TGGGGTCTGGCTCAGAATTCCTGCAGCTGGTGAAAATCTGTTTTCTAGAAGAGGTTAATTAATGCCTGCAGTCT  
GACATGTTCCCGATTTGAGGTGAAACCATGAAGAGAAAATAGAATACTTAATAATGCTTTTCCGCAACCGCTTCT  
TGCTGCTGCTGGCCCTGGCTGCGCTGCTGGCCTTTGTGAGCCTCAGCCTGCAGTTCTTCCACCTGATCCCGGTGT  
CGACTCCTAAGAATGGAATGAGTAGCAAGAGTCGAAAGAGAATCATGCCCGACCCGTGTGACGGAGCCCCCTGTGA  
CAGACCCCTTTATGAAGCTCTTTTGTACTGCAACATCCCCAGTGTGGCCGAGCGCAGCATGGAAGGTGATGCCC  
CGCATCATTTTAAGCTGGTCTCAGTGCATGTGTTTCATTGCGCACGGAGACAGGTACCCACTGTATGTCATTCCCA  
AAACAAAGCGACCAAGAAATGACTGCACTCTGGTGGCTAACAGGAAACCGTATCACCCAAAACCTGGAAGCTTTCA  
TTAGTCACATGTCAAAAGGATCCGGAGCCTCTTTGAAAGCCCCCTGAACTCCTTGCCCTCTTACCCAAATCACC  
CATTGTGTGAGATGGGAGAGCTCACACAGACAGGAGTTGTGCAGCATTTCGAGAACGGTCAGCTGCTGAGGGATA  
TCTATCTAAAGAAACACAAACTCCTGCCCAATGATTGGTCTGCAGACCAGCTCTATTTAGAGACCACTGGGAAAA  
GCCGGACCCCTACAAAGTGGGCTGGCCTTGCTTTATGGCTTTCTCCAGATTTTGACTGGAAGAAGATTTATTTCA  
GGCACCAGCCAAAGTGGCTGTTCTGCTCTGGAAGCTGCTATTGCCCGGTAAGAAACCAAGTATCTGGAAAAGGAGC  
AGCGTCGTCAGTACCTCCTACGTTTGAAAAACAGCCAGCTGGAGAAGACCTACGGGGAGATGGCCAAGATCGTGG  
ATGTCCCCACCAAGCAGCTTAGAGCTGCCAACCCCATAGACTCCATGCTCTGCCACTTCTGCCACAATGTCAGCT  
TTCCCTGTACCAGAAATGGCTGTGTTGACATGGAGCACTTCAAGGTAATTAAGACCCATCAGATCGAGGATGAAA  
GGGAAAGACGGGAGAAGAAATTGTACTTCGGGTATTCTCTCTGGGTGCCACCCCATCCTGAACCAAACCATCG  
GCCGGATGCAGCGTGCCACCGAGGGCAGGAAAGAGAGCTCTTTGCCCTCTACTCTGCTCATGATGTCAGTCTGT  
CACCAGTTCTCAGTGCCCTTGGGCCTTTTCAAGGCCAGGTTCCCAAGGTTTGAGCCAGGTTGATCTTTGAGCTTT  
GGCAAGACAGAGAAAAGCCAGTGAACATTCCTGCGGATTTTACAATGGCGTCGATGTCACATTCACACACCT  
CTTTCTGCCAAGACCACCAAGCGTTCTCCCAAGCCCATGTGCCCGCTTGAAAACCTTGGTCCGCTTTGTGAAAA  
GGGACATGTTTGTAGCCCTGGGTGGCAGTGGTACAAATTATTATGATGCATGTCACAGGGAAGGATTCTAAAGG  
TATGCAGTACAGCAGTATAGAATCCATGCCAATACAGAGCATAGGGAAAGGTCCACTTCTAGTTTTGTCTGTTAC  
TAAGGGTAGAAGATTATTGCTTTTTAAAGGCTAAATATTGTTTGTGGGAACCACAGATGGTTGGGGTTGAACAGT  
AAGCACATTGCTGCAATGTGGTACGTGAATTGCTTGGTACAAAATGGCCAGTTACAGAGGAATAGAAGGTACTT  
TATCATAGCCAGACTTCGCTTAGAATGCCAGAATAATATAGTTCAAGACCTGAAGTTGCCAATCCAAGTTTGCAC  
TCTTCTGGCCTGCCCATGTTACTATGTGATGGAACCAGCACACCTCAACCAAATTTTTTAAATCTTAGACATT  
TTTACCTTGTCTTGTAAAGAATTTCTTGAAGTGATTTATCTAAAATAAAGGTTGGCAAACCTTTTTCTGTAAAGG  
GCCAGATTGTAAATATTTAGACTGTGTGGACCAAAAGGCCACATACAGTCTCTGTCATAACTACTCAACTCTGT  
TTCTGAAGCAGGAAAGCCACCACAGACAGTACATAAAGGAATATGTGTAGCTGGGTCCAGGCCAGACAAAACA  
GATGGTGACCAGACTTGGCCCCCTGGGCTGTAGTTTGCTGACCCCTCATCTAAAAAATAGGCTATACTACAATTGC  
ACTTCCAGCACTTTGAGAACGAGTTGAATACCAAGAATTATTCAATGGTTCCCTCCAGTAACTTCTGCTAGAAACA  
CAGAATTTGGTCTGTATCTGACACTAGAACAAAACCTTGAGGGTAATAAACATTGAATTAGAATGAATCATAGAA  
AACTGATTAGAAGAATACTTGATGTTTATGATGATTGTGGTACAAGATAGTTTTAAGTATGTTCTAAATATTTGT  
CTGCTGTAGTCTATTTGCTGTATATGCTGAAATTTTTGTATGCCATTTAGTATTTTTATAGTTTAGGAAAATATT  
TTCTAAGACCAGTTTTTAGATGACTCTTATTCCTGTAGTAATATTCAATTTGCTGTACCTGCTTGGTGGTTAGAAG  
GAGGCTAGAAGATGAATTCAGGCACCTTCTTCCAATAAACTAATTATGGCTCATTCCCTTTGACAAGCTGTAGA  
ACTGGATTCATTTTAAACATTTTCATCAGTTTCAAATGGTAAATTCGTATTGATTTTTAAATGCGTTTTTTGGA  
AGAATTTGCTATTAGGTAGTTTACAGATCTTTATAAGGTGTTTTATATATTAGAAGCAATTATAATTACATCTG  
TGATTTCTGAACTAATGGTGCTAATTAGAGAAATGGAAAGTGAAAGTGAGATTCTGTGTGTCATCGGCATTCC  
AACTTTTTCTTTTGTTTTTGTCCAGTGTGCAATTTGAATATGCTGTTTCTATAAATAAATTTTTTAAGAATAA

83/615

**FIGURE 82**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA48329
><subunit 1 of 1, 480 aa, 1 stop
><MW: 55240, pI: 9.30, NX(S/T): 2
MLFRNRFLLLLALAAALLAFVSLSLQFFHLIPVSTPKNGMSSKSRKRIMPDVPTEPPVTDVPVYEALLYCNIPSVAE
RSMEGHAPHHFKLVSVHVFIRHGDRYPLYVIPKTKRPEIDCTLVANRKPYHPKLEAFISHMSKSGSGASFESPLNS
LPLYPNHPLCEMGELTQTGVVQHLQNGQLLRDIYLLKKHKLLPNDWSADQLYLETTGKSRTLQSGLALLYGFLPDF
DWKKIYFRHQPSALFCSGSCYCPVRNQYLEKEQRRQYLLRLKNSQLEKTYGEMAKIVDVPTKQLRAANPIDSMC
HFCHNVSFPCTRNGCVDMEHFKVIKTHQIEDERERREKKLYFGYSLLGAHPILNQTIGRMQRATEGRKEELFALY
SAHDVTLSPVLSALGLSEARFPRFAARLIFELWQDREKPSSEHSVRILYNGVDVTFHTSFQDHHKRSFKPMCPLE
NLVRFVKRDMFVALGGSGTNYDACHREGF
```

**Signal sequence:**  
amino acids 1-18

84/615

**FIGURE 83**

TCTCGCAGATAGTAAATAATCTCGGAAAGGCGAGAAAGAAGCTGTCTCCATCTTGTCTGTATCCGCTGCTCTTGT  
GACGTTGTGGAGATGGGGAGCGTCTGGGGCTGTGCTCCATGGCGAGCTGGATAACCATGTTTGTGTGGAAGTGCC  
CCGTTGTTGCTATGCCGATGCTGTCTAGTGGAAACAACCTCACTGTAAGTATGATCTATGCACCTTTCTTG  
CTTGTTGGAGTATGTAGCTTGTGTAATGTTGATACCAGGAATGGAAGAACAACCTGAATAAGATTCTGGATT  
TGTGAGAAATGAGAAAGGTGTTGTCCCTTGTAAACATTTTGGTTGGCTATAAAGCTGTATATCGTTTGTGCTTTGGT  
TTGGCTATGTTCTATCTTCTCTCTCTTACTAATGATCAAAGTGAAGAGTAGCAGTGATCCTAGAGCTGCAGTG  
CACAATGGATTTTGGTTCTTTAAATTTGCTGCAGCAATTGCAATTATTATTGGGGCATTCTTCATTCCAGAAGGA  
ACTTTTACAACTGTGTGGTTTATGTAGGCATGGCAGGTGCCCTTTGTTTCATCCTCATACAACCTAGTCTTACTT  
ATTGATTTTGACATTGATGGAATGAATCGTGGGTTGAAAAATGGAAGAAGGGAACCTCGAGATGTTGGTATGCA  
GCCTTGTATCAGCTACAGCTCTGAATTATCTGCTGTCTTTAGTTGCTATCGTCTGTTCTTTGTCTACTACACT  
CATCCAGCCAGTTGTTTCAAGAAACAAGGCGTTTCATCAGTGTCAACATGCTCCTCTGCGTTGGTGCTTCTGTAAATG  
TCTATACTGCCAAAAATCCAAGAATCACAACCAAGATCTGGTTTGTACAGTCTTCAGTAATTACAGTCTACACA  
ATGTATTTGACATGGTCAGCTATGACCAATGAACCAGAAACAATTGCAACCCAAGTCTACTAAGCATAATTGGC  
TACAATACAAAGCACTGTCCCAAGGAAGGGCAGTCAGTCCAGTGGTGGCATGCTCAAGGAATTATAGGACTA  
ATTCCTCTTTTGTGTGTGTTATTTTATCCAGCATCCGTACTTCAACAATAGTCAGGTTAATAAACTGACTCTA  
ACAAGTGATGAATCTACATTAATAGAAGATGGTGGAGCTAGAAGTGATGGATCACTGGAGGATGGGGACGATGTT  
CACCGAGCTGTAGATAATGAAAGGGATGGTGTCACTTACAGTTATTCCTTCTTTCACTTCATGCTTTTCTGGCT  
TCACCTTATATCATGATGACCTTACCAACTGGTCCAGGTATGAACCTCTCGTGAGATGAAAAGTCAGTGGACA  
GCTGTCTGGGTGAAAATCTCTTCCAGTTGGATTGGCATCGTGTGTATGTTTGGACACTCGTGGCACCACCTTGT  
CTTACAAATCGTGATTTTGTGACTGAGTGAGACTTCTAGCATGAAAGTCCCACCTTTGATTATTGCTTATTGAAAC  
AGTATTTCCAACTTTTGTAAAGTTGTGTATGTTTTGCTTCCCATGTAACCTTCTCCAGTGTCTGGCATGAATTA  
GATTTTACTGCTTGTCAATTTTGTATTTTCTTACCAAGTGCAATGATATGTGAAGTAGAATGAATTGCAGAGGAA  
AGTTTTATGAATATGGTGATGAGTTAGTAAAGTGGCCATTATTGGGCTTATTCTCTGCTCTATAGTTGTGAAT  
GAAGAGTAAAAACAAATTTGTTTGACTATTTTAAATTTATATTAGACCTTAAGCTGTTTTAGCAAGCATTAAAGC  
AAATGTATGGCTGCCCTTTGAAATATTTGATGTGTTGCCCTGGCAGGATACTGCAAAGAACATGGTTATTTTAAA  
ATTTATAAACAAAGTCACCTTAAATGCCAGTTGTCTGAAAAATCTTATAAGGTTTTACCCTTGATACGGAATTTACA  
CAGGTAGGGAGTGTTTAGTGGACAATAGTGTAGGTTATGGATGGAGCTGTCGGTACTAAATTGAATAACGAGTAA  
ATAATCTTACTTGGGTAGAGATGGCCTTTGCCAACAAAGTGAACCTGTTTTGGTTGTTTTAACTCATGAAGTATG  
GGTTCAGTGGAAATGTTTGGAACTCTGAAGGATTTAGACAAGGTTTTGAAAAGGATAATCATGGGTAGAAAGGAA  
GTGTTTTGAAAGTCACCTTTGAAAGTTAGTTTTGGGCCACGACGGTAGCTCACCTTGGTAAATCCAGCACTTTG  
GGAGCTTAAGTGGGTAGATTACTTGAAGCCAGGAATTCAGACCAAGCTTGGCACATGGTGAACCTGTTCTATAAAA  
ATAATCTGGCTTTGAGCATATGCTGTGGTCCAGCACTGAGAGGCTAGTGAAGATTGCTGAGCCCAGAGCCAAAG  
GTTGCAGTGAGCAAGTCACGTCACTGCACTCTAGCTGGCACAGAGTAAGCCAAAAAATATATATATTGAAAT  
CAAGGAGGCCAAAATTTGACAGGGAAGCAAGTAACTGAAAACCACTAGGCTTTAGTAGGTACTTATATAAAATC  
TAGTCCAGTTCTCTCATTTAAAAAATGAAGACACTGAAATACAGACTTAAATAGCTCAGATAGCTAATTAGGAA  
ATTTCAAGTTGGCCAATAATAGCATTCTCTGACATTTAAAAATAATTTCTATTCAAAATACATGCATATTGAT  
TTACACCTCATACTGTGATAATTAATGTGATGTGGATTGCTGGTGTCCAGCATGACCCATAAACAGGTGAGAAGA  
ATGATGGAATGTTTTAGAATAAACTCCTGCTTATAGTATACTACACAGTTCAAAGATGTTTAAATGCTTTTGT  
ATTTACTGCCATGTAATTGAAATATATAGATTATTGTAACCTTTCAACCTGAAAATCAAGCAGTATGAGAGTTTA  
GTTATTTGTATGTGTCACTAGTGTCTAATGAAGCTTTTAAATCTACAATTTCTTCTTTAAAAATATTTATTAAT  
GTGAATGGAATATAACAATTGAGCTTAATTTCCCAACCTTATTCTGTGTGTAGACATTGATTCCACAATTTTGA  
ATGGCTGTGTTTACCTCTAAATAAATGAATTGAGAGAAAAA

85/615

**FIGURE 84**

MGSVLGLCSMASWIPCLCGSAPCLLCRCCPSGNNSTVTRLIYALFLLVGVCVACVMLIPGMEEQLNKIPGFCENE  
KGVVPCNILVGYKAVYRLCFGLAMFYLLSLLMIKVKSSSDPRAAVHNGFWFFKFAAAIATIIIGAFFIPEGTFTT  
VWFYVGMAGAFCFILIQVLVLLIDFAHSWNEWVEKMEEGNSRCWYAALLSATALNYLLSLVAIVLFFVYYTHPAS  
CSENKAFISVNMLLCVGASVMSILPKIQESQPRSGLLQSSVITVYTMYLTSAMTNEPETNCNPSLLSIIGYNTT  
STVPKEGQSVQWWHAQGIIGLILFLLCVFYSSIRTSNNSQVNKLTLTSDESTLIEDGGARSDGSLEDGDDVHRAV  
DNERDGVITYSYSFFHFMLFLASLYIMMTLTNWSRYEPSREMKSQWTAVWVKISSSWIGIVLYVWTLVAPLVLTNRDFD



86/615

**FIGURE 85**

AACAAAGTTCAGTGACTGAGAGGGCTGAGCGGAGGCTGCTGAAGGGGAGAAAGGAGTGAGGAGCTGCTGGGCAGA  
GAGGGACTGTCCGGCTCCCAGATGCTGGGCCTCCTGGGGAGCACAGCCCTCGTGGGATGGATCACAGGTGCTGCT  
GTGGCGGTCCGTGCTGCTGCTGCTGCTGGCCACCTGCCCTTTCCACGGACGGCAGGACTGTGACGTGGAGAGG  
AACCGTACAGCTGCAGGGGGAAACCGAGTCCGCCGGGCCAGCCTTGGCCCTTCCGGCGGCGGGGCCACCTGGGA  
ATCTTTCACCATCACCGTCATCCTGGCCACGTATCTCATGTGCCGAATGTGGGCCTCCACCACCACCACCC  
CGCCACACCCCTCACCACTCCACCACCACCACACCCACCGCCACCATCCCCGCCACGCTCGCTGAGGCTGC  
TGTCGCCGGTGCCTGTGGACAGCAGCTGCCCCTGCCCTCCCATCTGTTCCCAGGACAAGTGGACCCCATGTTTCC  
ATGTGGAAGGATGCATCTCTGGGGTGAACGAGGGGAACAATAGACTGGGGCTTGCTCCAGCTGCATTTGCATGGC  
ATGCCCCAGTGTAATATGGCAGCAGAGAATGGAGGAACACTGGGTCTGCAGTGCTGAAGGGTTTGGGGAGTGGAG  
AGCAAGGGTGTCTTTGGGGCTGGACAGCCCGTCTTGTGACAGTGACTCCAGTGAGCCCCAGAAATGACAAGC  
GTGTCTTGGCAGAGCCAGCACACAAGTGGATGTGAAGTGCCCGTCTTGACCTCCTCATCAGGCTGCTGCAGGCCT  
CTGGCGGGCAGGGCACTGGGAGAGGCCCTGAGAATGTCTTTTGGTTTGGAGAAGGCAGTGTGAGGCTGCACAGT  
CAATTCATCGGTGCCTTAGTCCAAGAAAATAAAAAACCACTAAGAAGCTTTAAAAAAAAAAAAAAAAAAAAA

87/615

**FIGURE 86**

MLGLLGSTALVGWITGA AVAVLLLLLLLLLATCLFHGRQDCDVERNRTAAGGNRVRRAPWPFRRRGHLGIFHHHRH  
PGHVSHVPNVGLHHHHHP RHTPHHLHHHHHPHRHHPRHAR

88/615

**FIGURE 87**

CCCACGCGTCCGTCTAGTCCCCGGGCCAACTCGGACAGTTTGCTCATTATTGCAACGGTCAAGGCTGGCTTGT  
GCCAGAACGGCGCGCGCGCGCGCACGCACACACGGGGGAACTTTTTTAAAAATGAAAGGCTAGAAGA  
GCTCAGCGCGCGCGCGCGCGCTGCGCGAGGGCTCCGGAGCTGACTCGCCGAGGCAGGAAATCCCTCCGGTCCGGA  
GCCCCGCCCCGGCTCGGCGCCCCGCTGGGATGGTGCAGCGCTCGCCGCGGGGCCGAGAGCTGCTGCACTGAAG  
GCCGGCGACGATGGCAGCGCGCCCGTGGCCGTGTCCCCGCGCGCCCTCCTGCTCGCCCTGGCCGGTGTCTCT  
GCTCGCGCCCTGCGAGGCCCGAGGGGTGAGCTTATGGAAACCAAGGAAGAGCTGATGAAGTTGTCACTGCCCTCTGT  
TCGGAGTGGGGACCTCTGGATCCAGTGAAGAGCTTCGACTCCAAGAATCATCCAGAAGTGTGAATATTCGACT  
ACAACGGGAAAGCAAAGAAGTATCATATACTGGAAAGAAATGAAGGTCTCATTGCCAGCAGTTTCACGGAAAC  
CCACTATCTGCAAGACGGTACTGATGTCTCCCTCGCTCGAAATTACACGGGTCACTGTTACTACCATGGACATGT  
ACGGGATATTCTGATTAGCAGTCACTCTCAGCACGTGTTCTGGTCTCAGGGGACTTATTGTGTTGAAAATGA  
AAGCTATGTCTTAGAACCAATGAAAAGTGAACCAACAGATACAACTCTTCCAGCGAAGAAGCTGAAAAGCGT  
CCGGGGATCATGTGGATCACATCAACACACCAAACTCGCTGCAAAGAATGTGTTCCACCACTCTCAGAC  
ATGGGCAAGAAGGCATAAAAGAGAGACCCTCAAGGCACTAAGTATGTGGAGCTGGTGTCTGTCAGACAACCG  
AGAGTTTCAGAGGCAAGGAAAAGATCTGAAAAAGTTAAGCAGCGATTAATAGAGATTGCTAATCACGTTGACAA  
GTTTTACAGACCACTGAACATTCGGATCGTGTGGTAGGCGTGGAAAGTGTGAATGACATGGACAAATGCTCTGT  
AAGTCAGGACCCATTACCAAGCCTCCATGAATTTCTGGACTGGAGGAAGATGAAGCTTCTACCTCGCAAATCCCA  
TGACAATGCGCAGCTTGTCACTGGGGTTTATTTCCAAAGGGACCACTCGGCATGGCCCCAATCATGAGCATGTG  
CACGGCAGACCACTCTGGGGGAATTTGTATGGACCATTGACACAATCCCCTTGGTGCAGCCGTGACCCTGGCACA  
TGAGCTGGGCCACAATTTCCGGGATGAATCATGACACACTGGACAGGGGCTGTAGCTGTCAAATGGCGGTTGAGAA  
AGGAGGCTGCATCATGAACGCTTCCACCGGGTACCCATTTCCCATGGTGTTCAGCAGTTGCAGCAGGAAGGACTT  
GGAGACCAAGCTGGAGAAAGGAATGGGGGTGTGCCTGTTAACTGCGGAAGTCAAGGAGTCTTTCCGGGGGCA  
GAAGTGTGGGAACAGATTGTGGAAGAAGGAGAGAGTGTGACTGTGGGGAGCCAGAGGAATGTATGAATCGCTG  
CTGCAATGCCACCACCTGTACCCTGAAGCCGGACGCTGTGTGCGCACATGGGCTGTGCTGTGAAGACTGCCAGCT  
GAAGCCTGCAGGAACAGCGTGCAGGGACTCCAGCAACTCCTGTGACCTCCAGAGTTCTGCACAGGGGCCAGCCC  
TCACTGCCCAGCCAATGTGTACCTGCAGCATGGGCACCTCATGTGAGGATGTGGACGGCTACTGCTACAATGGCAT  
CTGCCAGACTCACGAGCAGCAGTGTGTACGCTCTGGGGACCAAGTGTAAACCTGCCCTGGGATCTGCTTTGA  
GAGAGTCAATTTGCAAGTGATCCTTATGGCAACTGTGGCAAAGTCTCGAAGAGTTCCTTTGCCAAATGCCGAGAT  
GAGAGATGCTAAATGTGAAAAATCCAGTGTCAAGGAGGTGCCAGCCGGCCAGTCAATGGTACCAATGCCGTTTC  
CATAGAAACAAACATCCCTCTGCAGCAAGGAGGCCGATTCTGTGCCGGGGACCCAGTGTACTTTGGCGCATGA  
CATGCCGGACCCAGGGCTTGTGCTTGCAGGCACAAAGTGTGCAGATGGAAAAATCTGCCTGAATCGTCAATGTCA  
AAATATTAGTGTCTTTGGGGTTTACGAGTGTGCAATGCACTGCCACGGCAGAGGGGTGTGCAACAACAGGAAGAA  
CTGCCACTGCGAGGCCCACTGGGCACCTCCCTTCTGTGACAAGTTTGGCTTTGGAGGAAGCACAGACAGCGGCC  
CATCCGGCAAGCAGAAGCAAGGCAGGAAGCTGCAGAGTCCAACAGGGAGCGCGGCCAGGGCCAGGAGCCCGTGGG  
ATCGCAGGAGCATGCGTCTACTGCCTCACTGACACTCATCTGAGCCCTCCCATGACATGGAGACCGTGACCAGTG  
CTGCTGCAGAGGAGGTCAACGCTCCCCAAGGCCTCCTGTGACTGGCAGCATTGACTCTGTGGCTTTGCCATCGTT  
TCCATGACAACAGACACAACACAGTTCTCGGGCTCAGGAGGGGAAGTCCAGCCTACCAGGCACGTCTGCAGAAA  
CAGTGAAGGAAGGGCAGCGACTTCTGGTTGAGCTTCTGTAAACATGGACATGCTTCAGTGTCTCTCTGAG  
AGAGTAGCAGGTTACCACTCTGGCAGGGCCCCAGCCCTGCAGCAAGGAGGAAGAGGACTCAAAAGTCTGGCCTTTC  
ACTGAGCCTCCACAGCAGTGGGGGAGAAGCAAGGGTTGGGCCAGTGTCCCTTTCCCCAGTGACACCTCAGCCT  
TGGCAGCCCTGATGACTGGTCTCTGGCTGCACTTAATGCTCTGATATGGCTTTTAGCATTATATATGAAAAT  
AGCAGGGTTTTAGTTTTAATTTATCAGAGACCTGCCACCCATTCCATCTCCATCCAAGCAAATGAATGGCAA  
TGAAACAACTGGAGAAGAAGGTAGGAGAAAGGGCGGTGAACCTCTGGCTCTTTGCTGTGGACATGCGTGACCAGC  
AGTACTCAGGTTTGGGGTTTGCAGAAAGCCAGGGAACCCACAGAGTCAACCAACCTTCATTTAACAAGTAAGAA  
TGTTAAAAAGTGAACAATGTAAGAGCTAACTCCATCCCCGTGGCCATTACTGCATAAAATAGAGTGCATTT  
GAAAT

89/615

**FIGURE 88**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA49624
><subunit 1 of 1, 735 aa, 1 stop
><MW: 80177, pI: 7.08, NX(S/T): 5
MAARPLPVSPARALLALAGALLAPCEARGVSLWNQGRADEVVVSASVRSGLWIPVKSFDSKNHPEVLNIRLQRE
SKELIINLERNEGLIASSETETHYLQDGTDVSLARNYTGHCIYHGHVVRGYSDSAVSLSTCSGLRGLIVFENESYV
LEPMKSATNRYKLFPAKKLKSVRGSCGSHHNTPNLAANKVFPSPQWARRHKRETLKATKYVELVIVADNREFQ
RQGDLEKVKQRLIEIANHVDFYRPLNIRIVLVGVEVWMDMDKCSVSQDPFTSLHEFLDWRKMKLLPRKSHDNA
QLVSGVYFQGTIGMAPIMSMCTADQSGGIVMDHSDNPLGAAVTLAHELGHNFGMNHDTLDRGCSCQMAVEKGGC
IMNASTGYPPFPMVFSSCSRKDLETSLKGMGVCLFNLPEVRESFGGQKCGNRFVEEGEECDCEPEECMNRCCNA
TTCTLKPDCAHGLCCEDCQLKPAGTACRDSSNSCDLPEFCTGASPHCPANVYLHDGHSCQDVGVCYNGICQT
HEQQCVTLWGPGAKPAPGICFERVNSAGDPYGNCCKVSKSSFAKCEMRDAKCGKIQCQGGASRPVIGTNAVSIET
NIPLOQGGRIICRGTHVYLGDDMPDGLVLAGTKCADGKICLNRCQNISVFGVHECAMQCHGRGVCNNRKNCHC
EAHWAPPFCDFGFGGSTDSGPTRQAEARQEAESNRERGGQGEFVGSGEHASTASLTLLI
```

**Signal peptide:**  
amino acids 1-28

90/615

**FIGURE 89**

CTGCTGCATCCGGGTGTCTGGAGGCTGTGGCCGTTTTGTTTTCTTGGCTAAAATCGGGGGAGTGAGGCGGGCCGG  
CGCGGCGCGACACCGGGCTCCGGAACCACTGCACGACGGGGCTGGACTGACCTGAAAAAAATGCTCTGGATTTCTA  
GAGGGCTTGAGATGCTCAGAATGCATTGACTGGGGGGAAAAGCGCAATACTATTGCTTCCATTGCTGCTGGTGTA  
CTATTTTTTACAGGCTGGTGGATTATCATAGATGCAGCTGTTATTTATCCCACCATGAAAGATTTCAACCACTCA  
TACCATGCCTGTGGTGTTATAGCAACCATAGCCTTCCTAATGATTAATGCAGTATCGAATGGACAAGTCCGAGGT  
GATAGTTACAGTGAAGGTTGTCTGGGTCAAACAGGTGCTCGCATTTGGCTTTTCGTTGGTTTCATGTTGGCCTTT  
GGATCTCTGATTGCATCTATGTGGATTCTTTTTGGAGGTTATGTTGCTAAAGAAAAAGACATAGTATACCCTGGA  
ATTGCTGTATTTTTCCAGAATGCCTTCATCTTTTTTGGAGGGCTGGTTTTTAAGTTTGGCCGCACTGAAGACTTA  
TGGCAGTGAACACATCTGATTTCCACAGCACAACAGCCCTGCATGGGTTTGTGTTTTTTTTACTGCTCACTCC  
CAACCTTTTTGTAATGCCATTTTCTAACTTATTTCTGAGTGTAGTCTCAGCTTAAAGTTGTGTAATACTAAAATC  
ACGAGAACACCTAAACAACAACCAAAAATCTATTGTGGTATGCACTTGATTAACCTATAAAATGTTAGAGGAAAC  
TTTCACATGAATAATTTTGTCAAATTTTATCATGGTATAATTTGTAAAAATAAAAAGAAATTACAAAAGAAATT  
ATGGATTTGTCAATGTAAGTATTTGTCTATCTGAGGTCCAAAACCAATGAAAGTGTCTGAAGATTTAATGT  
GTTTATTCAAATGTGGTCTCTTCTGTGTCAAATGTTAAATGAAATATAAACATTTTTTAGTTTTTAAATATTCC  
GTGGTCAAAATTTCTTCTCACTATAATTGGTATTTACTTTTACCAAAAATTTCTGTGAACATGTAATGTAAGTGGC  
TTTTGAGGGTCTCCCAAGGGGTGAGTGGACGTGTTGGAAGAGAGAAGCACCATGGTCCAGCCACCAGGCTCCCTG  
TGTCCCTTCCATGGGAAGGTCTTCCGCTGTGCCTCTCATTCCAAGGGCAGGAAGATGTGACTCAGCCATGACACG  
TGGTTCTGGTGGGATGCACAGTCACTCCACATCCACCACTG

91/615

**FIGURE 90**

MSGFLEGLRCSECIDWGEKRNTIASIAAGVLFFTGWIIIDA AVIYPTMKDFNHSYHACGVIATIAFLMINAVSN  
GQVRGDSYSEGCLGQTGARIWLFVGFMLAFGSLIASMWILFGGYVAKEKDIVYPGIAVFFQNAFIFFGGLVFKFG  
RTEDLWQ

92/615

**FIGURE 91**

CGACGCCGGCGTGATGGCTTCCGCTGGTGTGCTCCTGGCTGTGCTGCTGCTGGCCGCTCCTCTGCAAAGTTTA  
CTTGGGACTATTCTCTGGCAGCTCCCCGAATCCTTTCTCCGAAGATGTCAAACGGCCCCCAGCGCCCCCTGGTAAC  
TGACAAGGAGGCCAGGAAGAAGGTTCTCAAACAAGCTTTTTTCAGCCAACCAAGTGCCGGGAGAAGCTGGATGTGGT  
GGTAATTGGCAGTGGCTTTGGGGGCTGGCTGCAGCTGCAATTCTAGCTAAAGCTGGCAAGCGAGTCTGGTGTGCT  
GGAACAACATACCAAGGCAGGGGGCTGCTGTACATACCTTTGGAAAGAATGGCCTTGAATTTGACACAGGAATCCA  
TTACATTGGGCGTATGGAAGAGGGCAGCATTGGCCGTTTATCTTGGACCAGATCACTGAAGGGCAGCTGGACTG  
GGCTCCCCCTGTCTCTCTTTTACATCATGGTACTGGAAGGGGCCAATGGCCGAAAGGAGTACCCCATGTACAG  
TGGAGAGAAAGCCTACATTCAAGGGCCTCAAGGAGAAGTTTCCACAGGAGGAAGCTATCATTGACAAGTATATAAA  
GCTGGTTAAGGTGGTATCCAGTGGAGCCCCCTCATGCCATCCTGTTGAAATTCCTCCCATTGCCCGTGGTTCAGCT  
CCTCGACAGGTGTGGGCTGTGACTCGTTTCTCCATTCCCTTCAAGCATCCACCCAGAGCCTGGCTGAGGTCTT  
GCAGCAGCTGGGGGCTCCTCTGAGCTCCAGGCAGTACTCAGCTACATCTTCCCCACTTACGGTGTCACCCCCAA  
CCACAGTGCCTTTTCCATGCACGCCCTGCTGGTCAACCACTACATGAAAGGAGGCTTTTATCCCCGAGGGGGTTC  
CAGTGAATTTGCCCTTCCACACCATCCCTGTGATTACAGCGGGCTGGGGGCGCTGTCCTCACAAAGGCCACTGTGCA  
AGTGTGTGCTGGACTCAGCTGGGAAAGCCTGTGGTGTGCTGAGTGAAGAAGGGGCATGAGCTGGTGAACATCTA  
TTGCCCATCGTGGTCTCCAACGCAGGACTGTTCAACACCTATGAACACCTACTGCCGGGGAACGCCCGCTGCCT  
GCCAGGTGTGAAGCAGCAACTGGGGACGGTGGCGGCCGGCTTAGGCATGACCTCTGTTTTTCATCTGCCTGCGAGG  
CACCAAGGAAGACCTGCATCTGCCGTCCACCAACTACTATGTTACTATGACACGGACATGGACCAGGCGATGGA  
GCGCTACGTCTCCATGCCAGGGAAGAGGCTGCGGAACACATCCCTCTTCTCTTCTCGCTTTCCCATCAGCCAA  
AGATCCGACCTGGGAGGACCGATTCCAGGCCGGTCCACCATGATCATGCTCATACCCACTGCCCTACGAGTGGTT  
TGAGGAGTGGCAGGCGGAGCTGAAGGGGAAAGCGGGGCAGTGACTATGAGACCTTCAAAAACCTCCTTGTGGAAGC  
CTCTATGTGCTAGTGGTCTGAAACTGTTCCACAGCTGGAGGGGAAGGTGGAGAGTGTGACTGCAGGATCCCCACT  
CACCAACAGTTCTATCTGGCTGCTCCCCGAGGTGCCTGCTACGGGGCTGACCATGACCTGGGCGCCTGCACCC  
TTGTGTGATGGCCTCCTTGAAGGGCCAGAGCCCCATCCCCAACCTCTATCTGACAGGCCAGGATATCTTACCTG  
TGGACTGGTGGGGGCCCTGCAAGGTGCCCTGCTGTGCAGCAGCGCCATCCTGAAGCGGAACCTGTACTCAGACCT  
TAAGAATCTTGATTCTAGGATCCGGGCACAGAAGAAAAAGAATTAGTTCATCAGGGAGGAGTCAGAGGAATTTG  
CCCAATGGCTGGGGCATCTCCCTTGACTTACCCATAATGTCTTTCTGCATTAGTTCCTTGCACGTATAAAGCACT  
CTAATTTGGTTCTGATGCCTGAAGAGAGGCCCTAGTTTAAATCACAAATCCGAATCTGGGGCAATGGAATCACTGC  
TTCCAGCTGGGGCAGGTGAGATCTTTACGCCTTTTATAACATGCCATCCCTACTAATAGGATATTGACTTGGATA  
GCTTGATGTCTCATGACGAGCGGCGCTCTGCATCCCTCACCCATGCCTCCTAATCAGTGATCAAAGCGAATATT  
CCATCTGTGGATAGAACCCCTGGCAGTGTGTGCTCAGCTCAACCTGGTGGGTTCAAGTCTGTCTGAGGCTTCTGCT  
CTCATTCAATTTAGTGTCTACGCTGCACAGTTCTACACTGTCAAGGGGAAAGGGAGACTAATGAGGCTTAACTCAA  
ACCTGGGCGTGGTTTTGGTTGCCATTCCATAGGTTTGGAGAGCTCTAGATCTCTTTGTGCTGGGTTCACTGGCT  
CTTCAGGGGACAGGAAATGCCGTGTGTCTGGCCAGTGTGGTTCTGGAGCTTTGGGGTAACAGCAGGATCCATCAGT  
TAGTAGGTTGCATGTGATGATCATATCCAATTCATATGGAAGTCCCGGCTGTCTTCTTATCATCGGGGTG  
GCAGCTGGTTCTCAATGTGCCAGCAGGGACTCAGTACCTGAGCCTCAATCAAGCCTTATCCACCAAAATACACAGG  
GAAGGGTGATGCAGGGAAGGGTGACATCAGGAGTCAGGGCATGGACTGGTAAGATGAATACTTTGCTGGGCTGAA  
GCAGGCTGCAGGGCATTTCCAGCCAAGGGCACAGCAGGGGACAGTGCAGGGAGGTGTGGGGTAAGGGAGGGAAGTC  
ACATCAGAAAAGGGAAAGCCACGGAATGTGTGAAGCCCAGAAATGGCATTTGAGTTAATTAGCATGTGAG  
GGTTAGACAGGTAGGTGAATGCAAGCTCAAGGTTTGGAAAAATGACTTTTCACTTATGTCTTTGGTATCAGACAT  
ACGAAAGGTCTCTTTGTAGTTCGTGTTAATGTAACATTAATAAATTTATTGATTCCATTGCTTTAAAAA

93/615

**FIGURE 92**

MWLPLVLLLAVLLLAVLCKVYLGLFSGSSPNPFSEDKRPPAPLVTDKARKKVLKQAFSANQVPEKLDVVVIGS  
GFGGLAAAAILAKAGKRVLVLEQHTKAGGCCHTFGKNGLEFDTGIHYIGRMEEGSIGRFILDQITEGQLDWAPLS  
SPFDIMVLEGPNRKEYPMYSGEKAYIQGLKEKFPQEEAIDKYIKLVKVVSSGAPHAILLKFLPLPVVQLLDRC  
GLLTRFSPFLQASTQSLAEVLQQLGASSELQAVLSYIFPTYGVTPNHSAFSMHALLVNHMYKGGFYPRGGSSEIA  
FHTIPVIQRAGGAVLTAKATVQSVLLDSAGKACGVSVKKGHELVNIYCPIVVSNAGLFNTYEHLLPGNARCLPGVK  
QQLGTVRPGLGMTSVFICLRGTEKEDLHLPSTNYYVYYDTMDQAMERYVSMFREEAAEHIPLLFFAFPSAKDPTW  
EDRFPRSTMIIMLIPTAYEWFEWQAEKKGKRGSDYETFKNSFVEASMSVVLKLFPPQLEGKVESVTAGSPLTNQF  
YLAAPRGACYGADHDLGRLHPCVMASLRAQSPINLYLTGQDIFTCLVGLALQGALLCSSAILKRNLVSDLNLD  
SRIRAQKKKN



95/615

**FIGURE 94**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA50911
><subunit 1 of 1, 348 aa, 1 stop
><MW: 39711, pI: 8.70, NX(S/T): 1
MAATLGPLGSWQQWRRCLSDGSRMLLLLLLLGSGQGPPQVGAGQTFEYLKREHSLSKPYQGVGTGSSSIWNLM
GNAMVMTQYIRLTPDMQSKQALWNRVPCFLRDWELQVHFKIHGQGGKKNLHGDGLAIWYTKDRMQPGPVFGNMDK
FVGLGVFVDTPNEEKQQERVFPYISAMVNNGSLSYDHERDGRPTLGGCTAIVRNLYDFTFLVIRYVKRHLTIM
MDIDGKHEWRDCIEVPGVRLPRGYFGTSSITGDLSDNHDVISLKLFEFTVERTPEEEKLHRDVELPSVDNMKLP
EMTAPLPPLSGLALFLIVFFSLVFSVFAIVIGIILYNKWQEQSRKRFY
```

**Signal sequence:**

amino acids 1-38

**Transmembrane domain:**

amino acids 310-329

94/615

**FIGURE 93**

GGGAAAGATGCGGCGGACTCTGGGACCCCTTGGGTCTGGCAGCAGTGGCGGCGATGTTTGTCCGGCTCGGGATGG  
GTCCAGGATGTTACTCCTTCTTTTGTGGGGTCTGGGCAGGGGCCACAGCAAGTCGGGGCGGGTCAAACGTT  
CGAGTACTTGAAACGGGAGCACTCGCTGTGGAAGCCCTACCAGGGTGTGGGCACAGGCAGTTCCTCACTGTGGAA  
TCTGATGGGCAATGCCATGGTGATGACCCAGTATATCCGCCTTACCCAGATATGCAAAGTAAACAGGGTGCCTT  
GTGGAACCGGGTGCCATGTTTCTGAGAGACTGGGAGTTGCAGGTGCACTTCAAATCCATGGACAAGGAAAGAA  
GAATCTGCATGGGGATGGCTTGGCAATCTGGTACACAAAGGATCGGATGCAGCCAGGGCCTGTGTTTGGAAACAT  
GGACAAATTTGTGGGGCTGGGAGTATTTGTAGACACCTACCCCAATGAGGAGAAGCAGCAAGAGCGGGTATTCCC  
CTACATCTCAGCCATGGTGAACAACGGCTCCCTCAGCTATGATCATGAGCGGGATGGCGGCCCTACAGAGCTGGG  
AGGCTGCACAGCCATTGTCCGCAATCTTCATTACGACACCTTCCCTGGTGATTTCGTACGTCAAGAGGCATTTGAC  
GATAATGATGGATATTGATGGCAAGCATGAGTGGAGGGACTGCATTGAAGTGCCCGGAGTCCGCCTGCCCCGCGG  
CTACTACTTCGGCACCTCCTCCATCACTGGGGATCTCTCAGATAATCATGATGTCATTTCCCTGAAGTTGTTTGA  
ACTGACAGTGGAGAGAACCCCAAGAGGAAAAGCTCCATCGAGATGTGTTCTTGCCCTCAGTGGACAATATGAA  
GCTGCCTGAGATGACAGCTCCACTGCCGCCCCCTGAGTGGCCTGGCCCTCTTCCCTCATCGTCTTTTTCTCCCTGGT  
GTTTTCTGTATTTGCCATAGTCATTTGGTATCATACTCTACAACAAATGGCAGGAACAGAGCCGAAAGCGCTTCTA  
CTGAGCCCTCCTGCTGCCACCCTTTTGTGACTGTCACCCATGAGGTATGGAAGGAGCAGGCCTGGCCTGAGCA  
TGCAGCCTGGAGAGTGTCTTGTCTCTAGCAGCTGGTTGGGGACTATATTCTGTCACTGGAGTTTGAATGCAGG  
GACCCCGCATTTCCCATGGTTGTGCATGGGGACATCTAACTCTGGTCTGGGAAGCCACCCACCCAGGGCAATGCT  
GCTGTGATGTGCCCTTCCCTGCAGTCCCTCCATGTGGGAGCAGAGGTGTGAAGAGAATTTACGTGGTTGTGATGC  
CAAATCACAGAACAGAATTTCTAGCCCCAGGCTGCCGTGTTGTTGACTCAGAAGGCCCTTCTACTTCAGTTTT  
GAATCCACAAAGAATTAAAACTGGTAACACCACAGGCTTTCTGACCATCCATTGCTTGGGTTTTGCATTTGACC  
CAACCTCTGCCTACCTGAGGAGCTTTCTTTGGAAACCAGGATGGAACCTTCTCCCTGCCTTACCTTCCCTTTCA  
CTCCATTCAATTGTCCTCTCTGTGTGAACCTGAGCTGGGAAGGCATTTGGATGCCTCTCTGTTGGGGCTGGGG  
CTGCAGAACACACCTGCGTTTCACTGGCCTTCATTAGGTGGCCCTAGGGAGATGGCTTTCTGCTTTGGATCACTG  
TTCCCTAGCATGGGTCTTGGGTCTATTGGCATGTCCATGGCCTTCCCAATCAAGTCTTTCAGGCCCTCAGTGAA  
GTTTGGCTAAAGGTTGGTGTAAAAATCAAGAGAAGCCTGGAAGACATCATGGATGCCATGGATTAGCTGTGCAAC  
TGACCAGCTCCAGGTTTGATCAAACCAAAGCAACATTTGTGATGTGGTCTGACCATGTGGAGATGTTTCTGGAC  
TTGCTAGAGCCTGCTTAGCTGCATGTTTTGTAGTTACGATTTTTGGAATCCCACTTTGAGTGCTGAAAGTGTAAG  
GAAGCTTTCTTCTTACACCTTGGGCTTGGATATTGCCAGAGAAGAAATTTGGCTTTTTTTTTCTTAATGGACAA  
GAGACAGTTGCTGTTCTCATGTTCCAAGTCTGAGAGCAACAGACCCTCATCATCTGTGCCTGGAAGAGTTCACTG  
TCATTGAGCAGCACAGCCTGAGTGCTGGCCTCTGTCAACCTTATTCCACTGCCTTATTTGACAAGGGGTTACAT  
GCTGCTCACCTTACTGCCCTGGGATTAAATCAGTTACAGGCCAGAGTCTCCTTGGAGGGCCTGGAACCTCTGAGTC  
CTCCTATGAACCTCTGTAGCCTAAATGAAATTTCTTAAATCACCGATGGAACCAAAAAAAAAAAAAAGGGCG  
GCCGCGACTCTAGAGTCGACCTGCAGTAGGGATAACAGGGTAATAAGCTTGGCCGCCATGG

**FIGURE 95**

CCTGTGTTAAGCTGAGGTTTCCCTAGATCTCGTATATCCCCAACACATACCTCCACGCACACATCCCCAAGA  
 ACCTCGAGCTCACACCAACAGACACACGCGCGCATACACACTCGCTCTCGTTGTCCATCTCCCTCCCGGGGAG  
 CCGGCGCGCGCTCCCACCTTTGCCGCACACTCCGGCGAGCCGAGCCCGCAGCGCTCCAGGATTCTGCGGCTCGGA  
 ACTCGGATTGCAGCTCTGAACCCCCATGGTGGTTTTTTAAACACTTCTTTTCTCTCTCTCTCGTTTTGATTGC  
 ACCGTTTCCATCTGGGGCTAGAGGAGCAAGGCAGACGCTTCCAGCCAGCCCTTGTGGCTTGGCATCGTCCCA  
 TCTGGCTTATAAAAGTTTGTCTGAGCGCAGTCCAGAGGGCTGCGTCTGCTCCCTCGGCTGGCAGAAGGGGTG  
 ACGCTGGGCAGCGGCGAGGAGCGCGCCGCTGCCTCTGGCGGGCTTTGGGCTTGAGGGGCAAGGTGAAGAGCGCAC  
 CGGCCGTGGGGTTTACCGAGCTGGATTTGTATGTTGCACCATGCGCTTCTTGATCGGGGCTGTGATTCTTCCCCT  
 CTTGGGGCTGCTGCTCTCCCTCCCCGCGGGGCGGATGTGAAGGCTCGGAGCTGCGGAGAGTCCGCCAGGCGTA  
 CGGTGCCAAGGGATTACGCTTGGCGGCATCCCCTACCAGGAGATCGCAGGGGAAACATTAAGAATCTGTCTCTCA  
 GGAATATACATGCTGCACCAGAAATGGAAGACAAGTTAAGCCAACAAGCAAACTCGAATTTGAAAACCTGT  
 GGAAGAGACAAGCCATTTTGTGCGCACCACCTTTTGTGTCCAGGCATAAGAAATTTGACGAATTTTCCGAGAGT  
 CCTGGAGAATGCAGAAAAGTCACTAAATGATATGTTTGTACGGACCTATGGCATGCTGTACATGCAGAATTCAGA  
 AGTCTTCCAGGACCTCTTTCACAGAGCTGAAAAGGTACTACACTGGGGGTAATGTGAATCTGGAGGAAATGCTCAA  
 TGACTTTTGGGCTCGGCTCCTGGAACGGATGTTTACGTGATAAACCTTCAGTATCACTTCAGTGAAGACTACCT  
 GGAATGTGTGAGCAAATACACTGACAGCTCAAGCCATTTGGAGAGCTGCCCCGGAACATGAAGATTACAGGTTAC  
 CCGCGCCTTCATTGCTGCCAGGACCTTTGTCCAGGGGCTGACTGTGGGCAGAGAAGTTGCAAAACCGAGTTTCCAA  
 GGTCAGGCCCAACCCAGGGGTGTATCCGTGCCCTCATGAAGATGCTGTACTGCCCATACTGTGCGGGGCTTCCCAC  
 TGTGAGGCCCTGCAACAACACTACTGTCTCAACGTATGAAGGGCTGCTTGGCAAATCAGGCTGACCTCGACACAGA  
 GTGGAATCTGTTTATAGATGCAATGCTCTTGGTGGCAGGCGCATGGAGGGGCGATTCAACATTTAGTTCGGTCTAT  
 GGACCCGATAGATGTCAAGATTTCTGAAGCCATTATGAACATGCAAGAAAACGAGCATGAGGTGTCTGCAAAAGGT  
 CTTTCAGGGATGTGGTCAGCCCAAACCTGCTCCAGCCCTCAGATCTGCCCGCTCAGCTCCTGAAAATTTTAAATAC  
 ACGTTTCAGGCCCTACAATCTCTGAGGAAAGACCAACAACTGCTGCAGGCACAAGCTTGGACCGGCTGGTCACAGA  
 CATAAAGAGAAATTGAAGCTCTCTAAAAAGGTCTGGTCAGCATTACCTTACACTATCTGCAAGGACGAGAGCGT  
 GACAGCGGCGACGTCCAACGAGGAGGAATGCTGGAACGGGCACAGCAAAGCCAGATCTTGCTGAGATCATGAA  
 TGATGGGCTCACCAACCAGATCAACAATCCCGAGGTGGATGTGGACATCACTCGGCTGACACTTTCATCAGACA  
 GCAGATTATGGCTCTCCGTGTGATGACCAACAACTAAAAAACGCCTACAATGGCAATGATGTCAATTTCCAGGA  
 CACAAGTGATGAATCCAGTGGCTCAGGGAGTGGCAGTGGGTGCATGGATGACGTGTGTCCACGGAGTTTGAGTT  
 TGTCAACAGAGAGGCCCCCGCAGTGGATCCCGAGCGGAGAGAGGTGGACTCTTCTGCAGCCGAGCGTGGCCACTC  
 CTTGCTCTCCTGGTCTCTCACTTGCATTTGCTCTGGCAGTGCAGAGACTGTGCAGATATCTTGGGTTTTTGGTCA  
 GATGAAACTGCATTTTAGCTATCTGAATGGCCAACCTCACTTCTTTTCTTACACTCTGGACAATGGACCATGCCA  
 CAAAAACTTACCGTTTTCTATGAGAAGAGAGCAGTAATGCAATCTGCCTCCCTTTTTGTTTTCCCAAAGAGTACC  
 GGGTGCCAGACTGAACGTCTTCTCTTCTTCTCAGCTATCTGTGGGGACCTTGTATTCTAGAGAGAATTTCTTA  
 CTCAAATTTTTCTGATCCAGGAGATTTTTCTTACCTTCATTTGCTTTTATGCTGCAGAAGTAAAGGAATCTCACGTT  
 GTGAGGGTTTTTTTTTTCTCATTTAAAAAT

97/615

**FIGURE 96**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA50914
><subunit 1 of 1, 555 aa, 1 stop
><MW: 62736, pI: 5.36, NX(S/T): 0
MPSWIGAVILPLLGLLLSLPAGADV KARSCEV RQAYGAKGFS LADIPYQEIAGEHLRICPQEYTCCTTEMEDKL
SQQSKLEFENLVEETSHFVRTTFVSRHKKFDEFFRELLENAEKSLNDMFVRTYGM LYMQNSEVFQDLFTELKRY
TGGNVNLEEMLNDFWARLLERMFQLINPQYHFSE DYECVSKYTDQLKPF GDVPRKLKIQVTRAFIAARTFVQGL
TVGREVANRVSKVSPTPGCIRALMKMLYCPYCRGLPTVRPCNNYCLNVMKGCLANQADLDTEWNLFI DAMLLVAE
RLEGPFNIESVMDPIDVKISEAIMNMQENSMQVS AKVFQGCQPKPAPALRSARSAPENFNTRFRPYNPEERPTT
AAGTSLDRLVTDIKEK LKLSKKVWSALPYTICKDES VTAGTSNEEECWNGH SKARYLPEIMNDGLTNQINNPEVD
VDITRPDTFIRQQIMALRVMTNKLKNAYNGNDVNFQDTSDESSGSGSGSGCMDDVCPTFEFEFVTTEAPAVDPDRR
EVDSSAAQRGHSLLSWSLTCIVLALQRLCR
```

**Signal peptide:**  
amino acids 1-23

98/615

**FIGURE 97**

GGCGGCGTCCGTGAGGGGCTCCTTTGGGCAGGGGTAGTGTGTTGGTGTCCCTGTCTTGCGTGATATTGACAACTG  
AAGCTTTCCTGCACCACTGGACTTAAGGAAGAGTGTACTCGTAGGCGGACAGCTTTAGTGGCCGGCCGGCCGCTC  
TCATCCCCCGTAAGGAGCAGAGTCCTTTGTACTGACCAAGATGAGCAACATCTACATCCAGGAGCCTCCCACGAA  
TGGGAAGGTTTTATTGAAAACCTACAGCTGGAGATATTGACATAGAGTTGTGGTCCAAAGAAGCTCCTAAAGCTTG  
CAGAAATTTTATCCAACCTTTGTTTGAAGCTTATTATGACAATAACCATTTTTTCATAGAGTTGTGCCTGGTTTCAT  
AGTCCAAGGCGGAGATCCTACTGGCACAGGGAGTGGTGGAGAGTCTATCTATGGAGCGCCATTCAAAGATGAATT  
TCATTACGGTTGCGTTTTAATCGGAGAGGACTGGTTGCCATGGCAAATGCTGGTTCTCATGATAATGGCAGCCA  
GTTTTTCTTCACACTGGGTGCGAGCAGATGAACCTTAACAATAAGCATACCATCTTTGGAAAGGTTACAGGGGATAC  
AGTATATAACATGTTGCGACTGTGAGAAGTAGACATTGATGATGACGAAAGACCACATAATCCACACAAAATAAA  
AAGCTGTGAGGTTTTGTTTAATCCTTTTGATGACATCATTTCCAAGGGAAAATTAAAAGGCTGAAAAAGAGAAACC  
AGAGGAGGAAGTAAAGAAATTGAAACCCAAAGGCACAAAAAATTTTAGTTTACTTTTCATTGGAGAGGAAGCTGA  
GGAAGAAGAGGAGGAGTAAATCGAGTTAGTCAGAGCATGAAGGGCAAAGCAAAGTAGTCATGACTTGCTTAA  
GGATGATCCACATCTCAGTTCTGTTCCAGTTGTAGAAAGTGAAAAAGGTGATGCACCAGATTTAGTTGATGATGG  
AGAAGATGAAAGTGCAGAGCATGATGAATATATTGATGGTGATGAAAAGAACCTGATGAGAGAAAGAATTGCCAA  
AAAATTAAAAAAGGACACAAGTGCGAATGTTAAATCAGCTGGAGAAGGAGAAGTGGAGAAGAAATCAGTCAGCCG  
CAGTGAAGAGCTCAGAAAAGAAGCAAGACAATTAAACCGGGAACCTCTAGCAGCAAAACAAAAAAGTAGAAAA  
TGCAGCAAAACAAGCAGAAAAAAGAAGTGAAGAGGAAGAAGCCCTCCAGATGGTGCTGTTGCCGAATACAGAAG  
AGAAAAGCAAAGTATGAAGCTTTGAGGAAGCAACAGTCAAAGAAGGGAACTTCCCGGGAAGATCAGACCCTTGC  
ACTGCTGAACCAAGTTTAAATCTAACTCACTCAAGCAATTGCTGAAACACCTGAAAATGACATTCCTGAAACAGA  
AGTAGAAGATGATGAAGGATGGATGTACATGTACTTCAGTTTGAGGATAAAAGCAGAAAAGTGAAAGATGCAAG  
CATGCAAGACTCAGATACATTTGAAATCTATGATCCTCGGAATCCAGTGAATAAAAGAAGGAGGGAAGAAAGCAA  
AAAGCTGATGAGAGAGAAAAAAGAAAGATATAAATGAGAATAATGATAACCAGAACTTGCTGGAAATGTGCCT  
ACAATGGCCTTGTAACAGCCATTGTTCCCAACAGCATCACTTAGGGGTGTGAAAAGAAGTATTTTTGAACCTGTT  
GTCTGGTTTTGAAAAACAATTATCTTGTGTTTGCAAATGTTGGAATGATGTAAGCAAATGCTTTTGGTTACTGGTA  
CATGTGTTTTTCCTAGCTGACCTTTTATATTGCTAAATCTGAAATAAAATAACTTTCCTTCCACAAAAA  
AAAAAAAAAAAAAAAAAAAA

99/615

**FIGURE 98**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA50919
><subunit 1 of 1, 472 aa, 1 stop
><MW: 53847, pI: 5.75, NX(S/T): 2
MSNIYIQEPPTNGKVLLKTTAGDIDIELWSKEAPKACRNFIQLCLEAYYDNTIFHRVVPGFIVQGGDPTGTGSGG
ESIYGAPFKDEFHSRLRFNRRGLVAMANAGSHDNGSQFFFTLGRADELNNKHTIFGKVTGDTVYNMLRLSEVDID
DDEPHNPHKIKSCEVLFPFDDIIPREIKRLKKEKPEEEVKKLKPKGTKNFSLLSFGEAEAEAEAEAEVNRVSQSM
KGKSKSSHDLLKDDPHLSSVPVVESEKGDAPDLVDDGEDESAEHDEYIDGDEKNLMRERIAKKLKKDTSANVKSA
GEGEVEKKSVSRSEELRKEARQLKRELLAAKQKKVENAAKQAEKRSEEEAEPPDGAVAEYRREKQKYEALRKQQS
KKGTSREDQTLALLNQFKSKLTQAIATPENDIPETEVEDDEGWMSHVLQFEDKSRKVKDASMQSDTFEIIDPR
NPVNKRREESKMLMREKKERR
```

**Important features:****Signal peptide:**

amino acids 1-21

**N-glycosylation sites.**

amino acids 109-112 and 201-204

**Cyclophilin-type peptidyl-prolyl cis-trans isomerase signature.**

amino acids 49-66

**Homologous region to Cyclophilin-type peptidyl-prolyl cis-trans isomerase**

amino acids 96-140, 49-89 and 22-51

100/615

**FIGURE 99**

CTTTTCTGAGGAACCACAGCAATGAATGGCTTTGCATCCTTGCTTCGAAGAAACCAATTTATCCTCCTGGTACTA  
TTTCTTTTGCAAATTCAGAGTCTGGGTCTGGATATTGATAGCCGTCTACCGCTGAAGTCTGTGCCACACACACA  
ATTTACACAGGACCCAAAGGAGATGATGGTGAAAAAGGAGATCCAGGAGAAGAGGGAAAGCATGGCAAAGTGGGA  
CGCATGGGGCCGAAAGGAATTAAAGGAGAACTGGGTGATATGGGAGATCAGGGCAATATTGGCAAGACTGGGCCC  
ATTGGGAAGAAGGGTGACAAAGGGGAAAAAGGTTTGCTTGGAATACCTGGAGAAAAAGGCAAAGCAGGTACTGTC  
TGTGATTGTGGAAGATACCGGAAATTTGTTGGACAACCTGGATATTAGTATTGCTCGGCTCAAGACATCTATGAAG  
TTTGTCAAGAATGTGATAGCAGGGATTAGGGAACTGAAGAGAAATTCTACTACATCGTGCAGGAAGAGAAGAAC  
TACAGGGAATCCCTAACCCACTGCAGGATTCGGGGTGGAATGCTAGCCATGCCCAAGGATGAAGCTGCCAACACA  
CTCATCGCTGACTATGTTGCCAAGAGTGGCTTCTTTGGGTGTTTATTGGCGTGAATGACCTTGAAAGGGAGGGA  
CAGTACATGTCCACAGACAACACTCCACTGCAGAACTATAGCAACTGGAATGAGGGGGAACCCAGCGACCCCTAT  
GGTCATGAGGACTGTGTGGAGATGCTGAGCTCTGGCAGATGGAATGACACAGAGTGCCATCTTACCATGTACTTT  
GTCTGTGAGTTCATCAAGAAGAAAAAGTAACTTCCCTCATCCTACGTATTTGCTATTTTCTGTGACCGTCATTA  
CAGTTATTGTTATCCATCCTTTTTTCTGATTGTACTACATTTGATCTGAGTCAACATAGCTAGAAAATGCTAA  
ACTGAGGTATGGAGCCTCCATCATCAAAAAAAAAAAAAAAAAA

101/615

**FIGURE 100**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA50980
><subunit 1 of 1, 277 aa, 1 stop
><MW: 30645, pI: 7.47, NX(S/T): 2
MNGFASILLRRNQFILLVLFLLQIQLGLDIDSRPTAEVCATHTISPGPKGDDGEKGDPEGEGKHGKVGRMGPKGI
KGELGDMGDQGNIGKTGPIGKKGDKGEKGLLGIPGEKGKAGTVCDGGRYRKFFVGQLDISIARLKTSMKFVKNVIA
GIRETEEFYIIVQEEKNYRESLTHCRIRGGMLAMPKDEAANTLIADYVAKSGFFRVFIGVNDLEREGQYMSTDN
TPLQNYNSNWNNEGEPSPDPYGHEDCVEMLSGRWNDTECHLTMYFVCEFIKKKK
```

**Signal peptide:**  
amino acids 1-25



102/615

**FIGURE 101**

GCAACCTCAGCTTCTAGTATCCAGACTCCAGCGCCGCCCGGGCGCGGACCCCAACCCCGACCCAGAGCTTCTCC  
AGCGGGCGGGCGCAGCGAGCAGGGCTCCCCGCCTTAACCTTCTCCGCGGGGCCAGCCACCTTCGGGAGTCCGGGTT  
GCCACCTGCAAACCTCTCCGCCCTTGACACCTGCCACCCCTGAGCCAGCGCGGGGCCCGGAGCGAGTCAATGGCCA  
ACGCGGGGCTGCAGCTGTTGGGCTTCATTCTCGCCTTCTTGGGATGGATCGGCGCCATCGTCAGCACTGCCCTGC  
CCCAGTGAGGATTTACTCCTATGCCGGCGACAACATCGTGACCGCCAGGCCATGTACGAGGGGCTGTGGATGT  
CCTGCGTGTGCGAGAGCACCGGGCAGATCCAGTGCAAAGTCTTTGACTCCTTGCTGAATCTGAGCAGCACATTGC  
AAGCAACCCGTGCCCTTGATGGTGGTGGCATCCTCTGGGAGTGATAGCAATCTTTGTGGCCACCGTTGGCATGA  
AGTGTATGAAGTGCTTGAAGACGATGAGGTGCAGAAGATGAGGATGGCTGTCTATTGGGGTGCGATATTTCTTC  
TTGCAGGTCTGGCTATTTTAGTTGCCACAGCATGGTATGGCAATAGAATCGTTCAAGAATCTATGACCCCTATGA  
CCCCAGTCAATGCCAGGTACGAATTTGGTCAGGCTCTCTTCACTGGCTGGGCTGCTGCTTCTCTGCTTCTGCTG  
GAGGTGCCCTACTTTGCTGTTCTGTCCCGGAAAAACAACCTCTTACCCAACACCAAGGCCCTATCCAAAACCTG  
CACCTTCCAGCGGGAAAGACTACGTGTGACCACAGAGGCAAAAGGAGAAAATCATGTTGAAACAAACCGAAAATGG  
ACATTGAGATACTATCATTAAACATTAGGACCTTAGAATTTTGGGTATTGTAATCTGAAGTATGGTATTACAAAAC  
AAACAAACAAACAAAAAACCCTATGTGTTAAATACTCAGTGCTAAACATGGCTTAATCTTATTTTATCTTCTTTC  
CTCAATATAGGAGGGGAAGATTTTCCATTGTATTACTGCTTCCATTGAGTAATCATACTCAAATGGGGGAAGG  
GGTGCTCCTTAAATATATATAGATATGTATATATACATGTTTTCTATTAAAAATAGACAGTAAAATACTATTCT  
CATTATGTTGATACTAGCATACTTAAATATCTCTAAATAGGTAAATGTATTTAATTCCATATTGATGAAGATG  
TTTATTGGTATATTTTCTTTTCGTCCTTATATACATATGTAACAGTCAAATATCATTACTCTTCTTCATTAGC  
TTTGGGTGCCCTTGGCCACAAGACCTAGCCTAATTTACCAAGGATGAATTCTTTCAATTCCTCATGCGTGCCCTTT  
TCATATACTTATTTTATTTTACCATAATCTTATAGCACTTGCATCGTTATTAAGCCCTTATTTGTTTTGTGTT  
TCATTGGTCTCTATCTCCTGAATCTAACACATTTCTAGCCTACATTTTAGTTTTCTAAAGCCAAGAAGAAATTTAT  
TACAAATCAGAACTTTGGAGGCAAATCTTTCTGCATGACCAAAGTGATAAATTCCTGTGACCTTCCCACACAAT  
CCCTGTACTCTGACCCATAGCACTCTTGTGTTGCTTTGAAAATATTTGTCCAATTGAGTAGCTGCATGCTGTTCCC  
CCAGGTGTTGTAACACAACCTTATTTGATTGAATTTTAAAGTACTTATTCATAGTTTTATATCCCCCTAAACTAC  
CTTTTTGTTCCCCATTCTTAATTGTATTGTTTTCCCAAGTGAATTATCATGCGTTTTATATCTTCTTAATAAG  
GTGTGGTCTGTTTGTCTGAACAAAGTGCTAGACTTTCTGGAGTGATAATCTGGTGACAAATATTCTCTCTGTAGC  
TGTAAGCAAGTCACTTAATCTTTCTACCTCTTTTTCTATCTGCCAAATTGAGATAATGATACTTAACCAGTTAG  
AAGAGGTAGTGTGAATATTAATTAGTTTTATATTACTCTTATTCTTTGAACATGAACATAGCCTATGTAGTGTCTT  
TATTTGCTCAGCTGGCTGAGACACTGAAGAAGTCACTGAACAAAACCTACACACGTACCTTCATGTGATTCACTG  
CCTTCCCTCTCTTACCAGTCTATTTCCACTGAACAAAACCTACACACATAACCTTCATGTGGTTCACTGCTTCTCT  
CTCTCTACCAGTCTATTTCCACTGAACAAAACCTACGCACATAACCTTCATGTGGCTCAGTGCTTCTCTCTCTA  
CCAGTCTATTTCCATTCTTTTCACTGTGTCTGACATGTTTGTGCTCTGTTCCATTTTAACAACTGCTCTTACTTT  
TCCAGTCTGTACAGAATGCTATTTCACTTGAGCAAGATGATGTAATGGAAAGGGTGTGGCACTGGTGTCTGGAG  
ACCTGGATTTGAGTCTTGGTGCTATCAATCACCGTCTGTGTTTGGCAAGGCATTTGGCTGCTGTAAGCTTATTG  
CTTCATCTGTAAGCGGTGGTTTGTAAATTCCTGATCTTCCACCTCACAGTGATGTTGTGGGGATCCAGTGAGATA  
GAATACATGTAAGTGTGGTTTTGTAAATTTAAAAAGTGCTATACTAAGGGAAAGAATTGAGGAATTAACGCATAC  
GTTTTGGTGTGCTTTTCAATGTTTGAATAAAAAAATGTTAAG

103/615

**FIGURE 102**

></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA52185  
><subunit 1 of 1, 211 aa, 1 stop  
><MW: 22744, pI: 8.51, NX(S/T): 1  
MANAGLQLLGFI LAF LGWIGAIVSTALPQWRIYSYAGDNIVTAQAMYEGLWMSCVVSQSTGQIQCKVFDSLNLSS  
TLQATRALMVVGILLGVIAIFVATVGMKCMKCLEDDEVQKMRMAVIGGAIFLLAGLAILVATAWYGNRIVQEFYD  
PMTFVNARYEFGQALFTGWAAASLCLLGALLCCSCPRKTTSYPTPRPYPKPAPSSGKDYV

**Important features:****Signal peptide:**

amino acids 1-21

**Transmembrane domains:**

amino acids 82-102, 118-142 and 161-187

**N-glycosylation site.**

amino acids 72-75

**PMP-22 / EMP / MP20 family proteins .**

amino acids 70-111

**ABC-2 type transport system integral membrane protein**

amino acids 119-133

104/615

**FIGURE 103**

CCCACGCGTCCGCGGACGCGTGGGCTGGACCCAGGTCTGGAGCGAATTCCAGCCTGCAGGGCTGATAAGCGAGG  
CATTAGTGAGATTGAGAGAGACTTTACCCCGCGTGGTGGTTGGAGGGCGCGCAGTAGAGCAGCAGCACAGGCGC  
GGGTCCCGGGAGGCGCGCTCTGCTCGCGCCGAGATGTTGGAATCTCCTTCACGAAACCGACTCGGCTGTGGCCACC  
GCGCGCCGCCCCGCGTGGCTGTGCGCTGGGGCGCTGGTGTGGCGGGTGGCTTCTTCTCCTCGGCTTCTCTTC  
GGGTGGTTTATAAAATCCTCCAATGAAGCTACTAACATTACTCCAAAGCATAATATGAAAGCATTMTTGGATGAA  
TTGAAAGCTGAGAACATCAAGAAGTTCTTACATAATTTTACACAGATACCACATTTAGCAGGAACAGAACAAAAC  
TTTCAGCTTGCAAAGCAAATTCATCCAGTGGAAAGAATTTGGCCTGGATTCTGTTGAGCTAGCTCATTATGAT  
GTCTGTGTGCTTACCCAAATAAGACTCATCCAACTACATCTCAATAATTAATGAAGATGGAAATGAGATTTTC  
AACACATCATTATTTGAACCACCTCCTCCAGGATATGAAAATGTTTCGGATATTTGTAACCTTTCAGTGCTTTTC  
TCTCCTCAAGGAATGCCAGAGGGCGATCTAGTGTATGTTAACTATGCACGAACTGAAGACTTCTTTAAATTGGAA  
CGGGACATGAAAATCAATTGCTCTGGGAAAATTGTAATTGCCAGATATGGGAAAAGTTTTAGAGGAAATAAGGTT  
AAAAATGCCAGCTGGCAGGGGCCAAAGGAGTCATTCTCTACTCCGACCCTGCTGACTACTTTGCTCCTGGGGTG  
AAGTCTTATCCAGACGGTTGGAATCTTCTGGAGGTGGTGTCCAGCGTGGAAATATCCTAAATCTGAATGGTGCA  
GGAGACCTCTCACACCAGGTTACCCAGCAAATGAATATGCTTATAGGCGTGGAAATTCAGAGGGCTGTGGTCTT  
CCAAGTATTCCTGTTTCATCCAATTGGATACTATGATGCACAGAAGCTCCTAGAAAAATGGGTGGCTCAGCACCA  
CCAGATAGCAGCTGGAGAGGAAGTCTCAAAGTGCCCTACAATGTTGGACCTGGCTTTACTGGAACTTTTCTACA  
CAAAAAGTCAAGATGCACATCCACTCTACCAATGAAGTGACGAGAATTTACAATGTGATAGGTACTCTCAGAGGA  
GCAGTGGAAACCAGACAGATATGTCAATCTGGGAGGTACCCGGGACTCATGGGTGTTTGGTGGTATTGACCCTCAG  
AGTGGAGCAGCTGTTGTTTCATGAAATTGTGAGGAGCTTTGGAACACTGAAAAGGAAGGGTGGAGACCTAGAAGA  
ACAATTTTGTGTTGCAAGCTGGGATGCAGAAGAATTTGGTCTTCTTGGTTCTACTGAGTGGGCAGAGGAGAATTC  
AGACTCCTTCAAGAGCGTGGCGTGGCTTATATTAATGCTGACTCATCTATAGAAGGAACTACACTCTGAGAGTT  
GATTGTACACCGCTGATGTACAGCTTGGTACACAACCTAACAAAAGAGCTGAAAAGCCCTGATGAAGGCTTTGAA  
GGCAAATCTCTTTATGAAAGTTGGACTAAAAAAGTCTTCCCCAGAGTTTCAGTGGCATGCCAGGATAAGCAAA  
TTGGGATCTGAAAATGATTTGAGGTGTTCTTCCAACGACTTGAATTTGCTTCAGGCAGAGCACGGTATACTAAA  
AATTGGGAAACAAACAAATTCAGCGGCTATCCACTGTATCACAGTGTCTATGAAACATATGAGTTGGTGGAAAAG  
TTTTATGATCCAATGTTTAAATATCACCTCACTGTGGCCAGGTTTCGAGGAGGGATGGTGTGTTGAGCTAGCCAAT  
TCCATAGTGTCTCCCTTTGATTGTGAGATTATGCTGTAGTTTAAAGAAAGTATGCTGACAAAATCTACAGTATT  
TCTATGAAACATCCACAGGAAATGAAGACATACAGTGTATCATTTGATTCACTTTTTTCTGCAGTAAAGAATTTT  
ACAGAAATTGCTTCCAAGTTCAGTGAGAGACTCCAGGACTTTGACAAAAGCAACCCATAGTATTAAGAATGATG  
AATGATCAACTCATGTTTCTGGAAAAGAGCATTATTGATCCATTAGGGTTACCAGACAGGCTTTTATAGGCAT  
GTCATCTATGCTCCAAGCAGCCACAACAAGTATGCAGGGGAGTCATTCCAGGAATTTATGATGCTCTGTTTGAT  
ATTGAAAGCAAAGTGGACCTTCCAAGGCCTGGGGAGAAGTGAAGAGACAGATTTATGTTGCAGCCTTCACAGTG  
CAGGCAGCTGCAGAGACTTTGAGTGAAGTAGCTTAAGAGGATTTTTTAGAGAATCCGTATTGAATTTGTGTGGTA  
TGTCACTCAGAAAGAATCGTAATGGGTATATTGATAAATTTTAAATTTGGTATATTTGAAATAAAGTTGAATATT  
ATATATAA

105/615

**FIGURE 104**

>>/usr/seqdb2/sst/DNA/Dnaseqs.full/ss.DNA52756  
><subunit 1 of 1, 750 aa, 1 stop  
><MW: 84305, pI: 6.93, NX(S/T): 10  
MWNLLHETDSAVATARRPRWLCAGALVLAGGFLLGFLGFWFIKSSNEATNITPKHNMKAFLDELKAENIKKFLH  
NFTQIPHLAGTEQNFQQLAKQIQSQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPPPG  
YENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVARYGKVFRGNKVKNQAQLAGAKGV  
ILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNIILNLNGAGDPLTPGYPANAYAYRRGIAEAVGLPSIPVHPIGYY  
DAQKLEKMGGSAPPDSSWRGSLKVPYNVGPFTGNFSTQKVKMHIHSTNEVTRIYNVIGTLRGAVEPDRYVILG  
GHRDSWVFGGIDPQSGAAVVHEIVRSFGLTKKEGWRPRRTILFASWDAEEFGLLGSTEWAEENSRLQERGVAYI  
NADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEGKSLEYESWTKKSPSPEFSGMPRISKLGSGNDFEVFF  
QRLGIASGRARYTKNWETNKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDY  
AVVLRKYADKIYSISMKHPQEMKTYSVSFDLSFSAVKNFTEIASKFSERLQDFDKSNPIVLRMMNDQLMFLERAF  
IDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFTVQAAAETLSEVA

**Signal sequence:**  
amino acids 1-40

**N-glycosylation sites.**

amino acids 76-80, 121-125, 140-144, 153-157, 195-199, 336-340, 459-463,  
476-480, 638-642

**Tyrosine kinase phosphorylation sites.**

amino acids 363-372, 605-613, 606-613, 617-626

**N-myristoylation sites.**

amino acids 85-91, 168-174, 252-258, 256-262, 282-288, 335-341, 360-366,  
427-433, 529-535, 707-713

106/615

**FIGURE 105**

TGAAGAGTAATAGTTGGAATCAAAAGAGTCAACGCAATGAAGTGTATTTACTGCTGCGTTTTATGTTGGGAATT  
CCTCTCCTATGGCCTTGTCTTGGAGCAACAGAAAACCTCTCAAACAAAGAAAGTCAAGCAGCCAGTGGCATCTCAT  
TTGAGAGTGAAGCGTGGCTGGGTGTGGAACCAATTTTTGTACCAGAGGAAATGAATACGACTAGTCATCACATC  
GGCCAGCTAAGATCTGATTTAGACAATGGAAACAATTCTTTCCAGTACAAGCTTTTGGGAGCTGGAGCTGGAAGT  
ACTTTTATCATTGATGAAAGAACAGGTGACATATATGCCATACAGAAGCTTGATAGAGAGGAGCGATCCCTCTAC  
ATCCTAAGAGCCCAGGTAAATAGACATCGCTACTGGAAGGGCTGTGGAACCTGAGTCTGAGTTTGTTCATCAAAGTT  
TCGGATATCAATGACAATGAACCAAATTCCTAGATGAACCTTATGAGGCCATTGTACCAGAGATGTCTCCAGAA  
GGAACATTAGTTATCCAGGTGACAGCAAGTGATGCTGACGATCCCTCAAGTGGTAATAATGCTCGTCTCCTCTAC  
AGCTTACTTCAAGGCCAGCCATATTTTTCTGTTGAACCAACAACAGGAGTCATAAGAATATCTTCTAAATGGAT  
AGAGAAGTGAAGATGAGTATTGGGTAATCATTCAAGCCAAGGACATGATTGGTCAGCCAGGAGCGTTGTCTGGA  
ACAACAAGTGTATTAAATTAACCTTTTCTAGATGTTAATGACAATAAGCCTATATTTAAAGAAAGTTTATACCGCTTG  
ACTGTCTCTGAATCTGCACCCACTGGGACTTCTATAGGAACAATCATGGCATATGATAATGACATAGGAGAGAAT  
GCAGAAATGGATTACAGCATTGAAGAGGATGATTCGCAACATTTGACATTATTACTAATCATGAACTCAAGAA  
GGAATAGTTATATTTAAAAAGAAAGTGGATTTTGGCACCAGAACCTACCGGTATTAGAGCAAAAGTTAAAAAC  
CATCATGTTCTGAGCAGCTCATGAAGTACCACACTGAGGCTTCCACCCTTTCATTAAAGATCCAGGTGGAAGAT  
GTTGATGAGCCTCCTCTTTCTCCTTCCATATTATGATTTGAAGTTTGAAGAAACCCACAGGGATCATT  
GTAGGCGTGGTGTCTGCCACAGACCCAGACAATAGGAAATCTCCTATCAGGTATTCTATTACTAGGAGCAAAAGTG  
TTCAATATCAATGATAATGGTACAATCACTACAAGTAACTCACTGGATCGTGAAATCAGTCTTGGTACAACCTA  
AGTATTACAGCCACAGAAAAATACAATATAGAACAGATCTCTCGATCCCACTGTATGTGCAAGTTCTTAACATC  
AATGATCATGCTCCTGAGTTCTCTCAATACTATGAGACTTATGTTTGTGAAATGCAGGCTCTGGTCAGGTAATT  
CAGACTATCAGTGCAGTGGATAGAGATGAATCCATAGAAGAGCACCATTTTTACTTTAATCTATCTGTAGAAGAC  
ACTAACAATTCAAGTTTTACAATCATAGATAATCAAGATAACACAGCTGTCTATTTTGACTAATAGAAGTGGTTTT  
AACCTTCAAGAAGAACCTGTCTTCTACATCTCCATCTTAATTGCCGACAATGGAATCCCGTCACTTACAAGTACA  
AACACCCTTACCATCCATGTCTGTGACTGTGGTGACAGTGGGAGCACACAGACCTGCCAGTACCAGGAGCTTGTG  
CTTTCCATGGGATTCAAGACAGAAGTTATCATTGCTATTCTCATTTGCATTATGATCATATTTGGGTTTTATTTTT  
TTGACTTTGGGTTTTAAACAACGGAGAAAACAGATTCTATTTCTGAGAAAAGTGAAGATTTTCAGAGAGAATATA  
TTCCAATATGATGATGAAGGGGGTGGAGAAGAAGATACAGAGGCCTTTGATATAGCAGAGCTGAGGAGTAGTACC  
ATAATGCGGGAACGCAAGACTCGGAAAACCAAGCGCTGAGATCAGGAGCCTATACAGGCAGTCTTTGCAAGTT  
GGCCCCGACAGTGCCATATTTCAGGAAATTCATTCTGGAAGCTCGAAGAAGCTAATACTGATCCGTGTGCCCT  
CCTTTTGATTCCCTCCAGACCTACGCTTTTGAGGGAACAGGGTCATTAGCTGGATCCCTGAGCTCCTTAGAATCA  
GCAGTCTCTGATCAGGATGAAAGCTATGATTACCTTAATGAGTTGGGACCTCGCTTTAAAGATTAGCATGCATG  
TTTGGTCTGCAGTGCAGTCAAATAATTAGGGCTTTTTACCATCAAAATTTTTAAAGTGCTAATGTGTATTCTGA  
ACCCAATGGTAGTCTTAAAGAGTTTGTGCCCTGGCTCTATGGCGGGGAAGCCCTAGTCTATGGAGTTTTCTGA  
TTTCCCTGGAGTAAATACTCCATGGTTATTTTAAGCTACCTACATGCTGTCTTGAACAGAGATGTGGGGAGAAA  
TGTAACAATCAGCTCACAGGCATCAATACAACCAGATTTGAAGTAAATAATGTAGGAAGATATTTAAAGTAGA  
TGAGAGGACACAAGATGTAGTCGATCCTTATGCGATTATATCATTATTTACTTAGGAAAGAGTAAAAATACCAA  
CGAGAAAATTTAAAGGAGCAAAAATTTGCAAGTCAAATAGAAATGTACAAATCGAGATAACATTTACATTTCTAT  
CATATTGACATGAAATGAAAATGTATAGTCAGAGAAATTTTCATGAATTATTCCATGAAGTATTGTTTCCTTT  
ATTTAAA

107/615

**FIGURE 106**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA53906
><subunit 1 of 1, 772 aa, 1 stop
><MW: 87002, pI: 4.64, NX(S/T): 8
MNCYLLLRFMLGIPLLWPCLGATENSQTKVKQPVRSRLRVKRGWVWNQFFVPEEMNTTSHHIGQLRSDLDNGNN
SFQYKLLGAGAGSTFIIDERTGDIYAIQKLDREERSLYILRAQVIDIATGRAVEPESEFVIKVS DINDNEPKFLD
EPYEAIVPEMSPEGT LVIQVTASDADDPSSGNNARLLYSLLQGQPYFSVEPTTG VIRISSKMDRELQDEYWV IIQ
AKDMIGQPGALSGTTSVLIKLSDVNDNKPIFKESLYRLTVSESAPTGT SIGTIMAYDNDIGENAEMDYSIEEDDS
QTFDIITNHETQEGIVILKKKVD FEHQNHYGIRAKVKNHHVPEQLMKYHTEASTTFIKIQVEDVDEPPLFLLPY Y
VFEVFEETPQGSFVGVSATDPDNRKSPIRYSITRSKVFNINDNGTITTSNSLDREISAWYNLSITATEKYNIEQ
ISSIPLYVQVLNINDHAPEFSQYYETYVCENAGSGQVIQTISAVDRDESEEHFFYFNLSVEDTNNSSFTIIDNQ
DNTAVILTNRGTGNLQEEP VFYISILIADNGIPSLTSTNTLTIHVCD CGDSGSTQTCQYQELVLSMGFKTEV IIA
ILICIMII FGFIFLT LGLKQRRKQILFPEKSEDFRENIFQYDDEGGGEEDTEAFDIAELRSSTIMRERKTRK TTS
AEIRSLYRQSLQVGPDSAI FRKFILEKLEEANTDPCAPPFDSLQTYAFEGTGS LAGSLSSLES AVSDQDES YDYL
NELGPRFKRLACMFGSAVQSNN
```

**Important features:****Signal peptide:**

amino acids 1-21

**Transmembrane domain:**

amino acids 597-617

**N-glycosylation sites.**

amino acids 57-60, 74-77, 419-423, 437-440, 508-511, 515-518, 516-519 and 534-537

**Cadherins extracellular repeated domain signature.**

amino acids 136-146 and 244-254

108/615

**FIGURE 107**

ATCTGGTTGAACTACTTAAGCTTAATTTGTTAAACTCCGGTAAGTACCTAGCCCACATGATTTGACTCAGAGATT  
CTCTTTTGTCCACAGACAGTCATCTCAGGGGCAGAAAGAAAAGAGCTCCCAAATGCTATATCTATTCCAGGGGCTC  
TCAAGAACAATCGGAATATCATCCTGATTTAGAAAATTTGGATGAAGATGGATATACTCAATTACACTTCGACTCT  
CAAAGCAATACCAGGATAGCTGTTGTTTCAGAGAAAGGATCGTGTGCTGCATCTCCTCCTGGCGCCTCATTGCT  
GTAATTTTGGGAATCCTATGCTTGGTAATACTGGTGATAGCTGTGGTCCTGGGTACCATGGGGGTTCTTTCCAGC  
CCTTGTCTCTTAATTTGGATTATATATGAGAAGAGCTGTTATCTATTGAGCATGTCAATAATTCCTGGGATGGA  
AGTAAAAGACAATGCTGGCAACTGGGCTCTAATCTCCTAAAGATAGACAGCTCAAATGAATTGGGATTTATAGTA  
AAACAAGTGTCTTCCCAACCTGATAATTCATTTTGGATAGGCCTTTCTCGGCCCCAGACTGAGGTACCATGGCTC  
TGGGAGGATGGATCAACATTCTCTTAACCTTATTTGAGATCAGAACCACAGCTACCCAAGAAAACCCATCTCCA  
AATTGTGTATGGATTACGCTGTGAGTCAATTTATGACCAACTGTGTAGTGTGCCCTCATATAGTATTTGTGAGAAG  
AAGTTTTCAATGTAAGAGGAAGGGTGGAGAAGGAGAGAGAAATATGTGAGGTAGTAAGGAGGACAGAAAACAGAA  
CAGAAAAGAGTAACAGCTGAGGTCAAGATAAATGCAGAAAATGTTTAGAGAGCTTGGCCAACCTGTAATCTTAAC  
AAGAAATTGAAGGGAGAGGCTGTGATTTCTGTATTTCTGACCTACAGGTAGGCTAGTATTATTTTCTAGTTAG  
TAGATCCCTAGACATGGAATCAGGGCAGCCAAGCTTGAGTTTTTATTTTTTATTTTATTTTATTTTATTTTATTTT  
GTCTCACTTTGTTTACCAGGCTGGAGTGCAGTGGCACAATCTCGACTCACTGCAGCTATCTCTCGCCTCAGCCCC  
TCAAGTAGCTGGGACTACAGGTGCATGCCACCATGCCAGGCTAATTTTTGTTGTTTTTGTAGAGACTGGGTTTT  
GCCATGTTGACCAAGCTGGTCTCTAATCCTGGGCTTAAGTGATCTGCCCGCCTTGGCCTCCCAAGTGCTGGGA  
TTACAGATGTGAGCCACCACACCTGGCCCCAAGCTTGAATTTTCAATCTGCCATTGACTTGGCATTACCTTGGG  
TAAGCCATAAGCGAATCTTAATTTCTGGCTCTATCAGAGTTGTTTCATGCTCAACAATGCCATTGAAGTGCACGG  
TGTGTTGCCACGATTTGACCCTCAACTTCTAGCAGTATATCAGTTATGAAGTGAAGGTGAAATATATTTCTGAAT  
AGCTAAATGAAGAAATGGGAAAAATCTTCACCACAGTCAGAGCAATTTTATTATTTTATCAGTATGATCATAA  
TTATGATTATCATCTTAGTAAAAAGCAGGAACCTCTACTTTTTCTTTATCAATTAATAGCTCAGAGAGTACATC  
TGCCATATCTCTAATAGAATCTTTTTTTTTTTTTTTTTTTTTTTTGTAGACAGAGTTTCGCTCTTGTGCCCAGGCTG  
GAGTGCAACGGCAGCATCTCGGCTCACCAGCAACCTCCGCCCCCTGGGTTCAAGCAATCTCCTGCCTCAGCCTCC  
CAAGTAGCTGGGATTACAGTCAGGCACCACACCCGGCTAATTTTGTATTTTATTTTATTTTATTTTATTTTATTTT  
CCATGTCCGTCAGGGTAGTCCCGAATCTGACCTCAAGTGATCTGCCTGCCTCGGCCTCCCAAGTGCTGGGATT  
ACAGGCGTGAGCCACTGCACCCAGCCTAGAATCTTGTATAATATGTAATTGTAGGGAACTGCTCTCATAGGAAA  
GTTTTCTGCTTTTAAATAACAAAATACATAAAAATACATAAAATCTGATGATGAATATAAAAAAGTAACCAACC  
TCATTGGAACAAGTATTAACATTTTGAATATGTTTTATTAGTTTTGTGATGTACTGTTTACAAATTTTACCAT  
TTTTTTCAGTAATTACTGTAAATGGTATTATTGGAATGAACTATATTTCTCATGTGCTGATTTGTCTTATTT  
TTTTCATACTTTCCCACTGGTGCTATTTTTATTTTCAATGGATATTTCTGTATTACTAGGGAGGCATTTACAGTC  
CTCTAATGTTGATTAATATGTGAAAAGAAATTGTACCAATTTTACTAAATTATGCAGTTTAAATGGATGATTTT  
ATGTTATGTGGATTTCAATTTCAATAAAAAAACTCTTATCAAAAAAAATTTTATTTTATTTTATTTTATTTTATTTT

109/615

**FIGURE 108**

</usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA53912  
<subunit 1 of 1, 201 aa, 1 stop  
<MW: 22563, pI: 4.87, NX(S/T): 1  
MEYHPDLENLDEDGYTQLHFDSQSNTRIAVVSEKGSAAASPPWRLIAVILGILCLVILVIAVVLGTMGVLSSPCP  
PNWIIYEKSCYLFMSLSNSWDGSKRQCWQLGSNLLKIDSSNELGFIVKQVSSQPDNSFWIGLSRPQTEVPWLWED  
GSTFSSNLFQIRTTATQENPSPNCVWIHVSVIYDQLCSVPSYSICEKKFSM

**Important features:****Type II transmembrane domain:**

amino acids 45-65

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 197-200

**N-myristoylation sites.**

amino acids 35-40 and 151-156

**Homologous region to LDL receptor**

amino acids 34-67 and 70-200.



110/615

**FIGURE 109**

CTGCAAGTTGTTAACGCCTAACACACAAGTATGTTAGGCTTCCACCAAAGTCCTCAATATACCTGAATACGCACA  
ATATCTTAACTCTTCATATTTGGTTTGGGGATCTGCTTTGAGGTCCCATCTTCATTTAAAAAAAATACAGAGAC  
CTACCTACCCGTACGCATACATACATATGTGTATATATATGTAACTAGACAAAGATCGCAGATCATAAAGCAAG  
CTCTGCTTTAGTTTCCAAGAAGATTACAAAGAATTTAGAGATGATTTGTCAAGATCCCTGTGATTCATGCCCT  
TTGGGTTACGGTGTCTCAGTGATGCAGCCCTACCCTTTGGTTTGGGGACATTATGATTTGTGTAAGACTCAGAT  
TTACACGGAAGAAGGGAAAGTTTGGGATTACATGGCCCTGCCAGCCGGAATCCACGGACATGACAAAATATCTGAA  
AGTGAACCTCGATCCTCCGGATATTACCTGTGGAGACCCCTCTGAGACGTTCTGTGCAATGGGCAATCCCTACAT  
GTGCAATAATGAGTGTGATGCGAGTACCCTGAGCTGGCACACCCCTGAGCTGATGTTGATTTGAAGGAAG  
ACATCCCTCCACATTTTGGCAGTCTGCCACTTGAAGGAGTATCCCAAGCCTCTCCAGGTTAACATCACTCTGTCT  
TTGGAGCAAAACCATTGAGCTAACAGACAACATAGTTATTACCTTTGAATCTGGGCGTCCAGACCAATGATCCT  
GGAGAAGTCTCTCGATTATGGACGAACATGGCAGCCCTATCAGTATTATGCCACAGACTGCTTAGATGCTTTTCA  
CATGGATCCTAAATCCGTGAAGGATTTATCACAGCATACGGTCTTAGAAATCATTGACAGAGAAGTACTCAAC  
AGGGTATACAACAAATAGCAAAATAATCCACTTTGAAATCAAAGACAGGTTCCGCGCTTTTGGTGGACCTCGCCT  
ACGCAATATGGCTTCCCTCTACGGACAGCTGGATACAACCAAGAACTCAGAGATTTCTTACAGTCAACAGACCT  
GAGGATAAGGCTGTTAAGACCAGCCGTGGGGAATATTTGTAGATGAGCTACACTTGGCAGCTACTTTTACGC  
GATCTCAGACATAAAGGTGCGAGGAAGGTGCAAGTGTAACTCCATGCCACTGTATGTGTATGACAACAGCAA  
ATTGACATGCGAATGTGAGCACAACACTACAGGTCCAGACTGTGGGAAATGCAAGAAGAATTATCAGGGCCGACC  
TTGGAGTCCAGGCTCCTATCTCCCCATCCCCAAAGGCACTGCAAAATACCTGTATCCCCAGTATTTCCAGTATTGG  
TACGAATGTCTGCGACAACGAGCTCCTGCACTGCCAGAACGGAGGGACGTGCCACAACAACGTGCGCTGCCTGTG  
CCCGGCCGCATACACGGGCATCCTCTGCGAGAAGCTGCGGTGCGAGGAGGCTGGCAGCTGCGGCTCCGACTCTGG  
CCAGGGCGCGCCCCCGCACGGCACCCCGAGCGCTGCTGCTGACCACGCTGCTGGGAACCGCCAGCCCCCTGGT  
GTTCTAGGTGTCACCTCCAGCCACACCGGACGGGCTGTGCCGTGGGGAAGCAGACACAACCCAAACATTTGCTA  
CTAACATAGGAAACACACACATACAGACACCCCACTCAGACAGTGTACAACTAAGAAGGCCTAACTGAACATA  
GCCATATTTATCACCCGTGGACAGCACATCCGAGTCAAGACTGTTAATTTCTGACTCCAGAGGAGTTGGCAGCTG  
TTGATATTATCACTGCAAAATCACATTGCCAGCTGCAGAGCATATTGTGGATTGGAAAGGCTGCGACAGCCCCCA  
AACAGGAAAGACAAAAAACAACAAATCAACCGACCTAAAAACATTGGCTACTCTAGCGTGGTGCGCCCTAGTAC  
GACTCCGCCCAGTGTGTGGACCAACCAATAGCATTCTTTGCTGTGAGGTGCATTGTGGGCATAAGGAAATCTGT  
TACAAGCTGCCATATTGGCCTGCTTCCGTCCCTGAATCCCTTCCAACCTGTGCTTTAGTGAACGTTGCTCTGTAA  
CCCTCGTTGGTTGAAAGATTTCTTTGTCTGATGTTAGTGATGCACATGTGAACAGCCCCCTCTAAAGCGCAAG  
CCAGTCATACCCCTGTATATCTTAGCAGCACTGAGTCCAGTGCGAGCACACCCCACTATAAAGAGTGGCTATA  
GGAAAAAGAAAGTGATCTATCCTTTTGTATTCAAATGAAGTTATTTTCTTGAACACTACTGTAATATGTAGATT  
TTTTGTATTATTGCCAATTTGTGTTACCAGACAATCTGTTAATGTATCTAATTCGAATCAGCAAAGACTGACATT  
TTATTTTGTCTCTTTCTGTTTGTGTTCACTGTGCAGAGATTTCTCTGTAAGGGCAACGAACGTGCTGGCA  
TCAAAGAATATCAGTTTACATATATAACAAGTGAATAAGATTCCACCAAAGGACATTCTAAATGTTTTCTTGTT  
GCTTTAACACTGGAAGATTTAAAGAATAAAAACTCCTGCATAAACGATTTAGGAATTTGTATTGCAATTTCTTA  
AGATGAAAGGAACAGCCACCAAGCAGTTTCACTCACTTTACTGATTTCTGTGTGGACTGAGTACATTCAGCTG  
ACGAATTTAGTTCCAGGAAGATGGATTGATGTTCACTAGCTTGGACAACCTCTGCAAAATATGAGACTATTTCC  
ACTTGGGAAAAATTACAACAGCAAAAAAAAAAAAAAAAAAAAAA

111/615

**FIGURE 110**

MYLSRSLSIHALWVTVSSVMQPYPLVWGHYDLCKTQIYTEEGKVWDYMACQPESTDMTKYLKVKLDPPDITCGDP  
PETFCAMGNPYMCNNECDASTPELAHPPELMFD FEGRHPSTFWQSATWKEYPKPLQVNITLSWSKTIELTDNIVI  
TFESGRPDQMIKESLDYGRWQPYQYYATDCLDAFHMDPKSVKDLSQHTVLEIICTEEYSTGYTTNSKIIHFEI  
KDRFALFAGPRLRNMASLYGQLDTTKKLRDFFTVDLRIRLLRPVGEIFVDELHLARYFYAISDIKVRGRCKCN  
LHATVCVYDNSKLTCECEHNTTGPDGKCKKNYQGRPWSPGSLPIPKGTANTCIPSISSIGTNVCDNELLHCQN  
GGTCHNNVRCLCPAAYTGILCEKLRCEEAGSCGSDSGQAPPHTPALLLLTLLGTASPLVF

112/615

**FIGURE 111**

GCGTGCCGTCAGCTCGCCGGGACCCGCGGCCTCGCCCTCGCCCTCCGCCCTGCGCCTGCACCGCGTAGACCGAC  
CCCCCCTCCAGCGCGCCACCCGGTAGAGGACCCCGCCCGTGCCCGACCGGTCCCCGCCTTTTTGTAAACT  
TAAAGCGGGCGCAGCATTAAACGCTTCCCGCCCCGGTGACCTCTCAGGGGTCTCCCGCCAAAGGTGCTCCGCCGC  
TAAGGAACATGGCGAAGGTGGAGCAGGTCTGAGCCTCGAGCCGCAGCAGAGCTCAAATTCGAGGTCCCTTCA  
CCGATGTTGTCACCACCAACCTAAAGCTTGGCAACCCGACAGACCGAAATGTGTGTTTTAAGGTGAAGACTACAG  
CACCACGTAGGTACTGTGTGAGGCCCAACAGCGGAATCATCGATGCAGGGGCTCAATTAATGTATCTGTGATGT  
TACAGCCTTTGATTATGATCCCAATGAGAAAAGTAAACACAAGTTTATGGTTCAGTCTATGTTTGCTCCAACTG  
ACACTTCAGATATGGAAGCAGTATGGAAGGAGGCAAAACCGGAAGACCTTATGGATTCAAACCTTAGATGTGTGT  
TTGAATTGCCAGCAGAGAATGATAAACCATGATGTAGAAATAAATAAAATTATATCCACAACCTGCATCAAAGA  
CAGAAACACCAATAGTGTCTAAGTCTCTGAGTTCTTCTTTGGATGACACCGAAGTTAAGAAGGTTATGGAAGAAT  
GTAAGAGGCTGCAAGGTGAAGTTCAGAGGCTACGGGAGGAGAACAGCAGTTCAAGGAAGAAGATGGACTGCGGA  
TGAGGAAGACAGTGCAGAGCAACAGCCCCATTTACGATTAGCCCCAACTGGGAAGGAAGAAGGCCCTTAGCACC  
GGCTCTTGGCTCTGGTGGTTTTGTCTTTATCGTTGGTGAATTATTGGGAAGATTGCCTTGTAAGGTTAGCATG  
CACAGGATGGTAAATTGGATTGGTGGATCCACCATATCATGGGATTTAAATTTATCATAACCATGTGTAAAAAGA  
AATTAATGTATGATGACATCTCACAGGTCTTGCCCTTTAAATTACCCCTCCCTGCACACACATACACAGATACACA  
CACACAAATATAATGTAACGATCTTTAGAAAGTTAAAAATGTATAGTAACTGATTGAGGGGGAAAAAGAATGAT  
CTTTATTAATGACAAGGGAAACCATGAGTAATGCCACAATGGCATATTGTAAATGTCATTTTAAACATTGGTAGG  
CCTTGGTACATGATGCTGGATTACCTCTCTTAAATGACACCCCTTCCTCGCCTGTTGGTGTCTGGCCCTTGGGGAG  
CTGGAGCCCAGCATGCTGGGGAGTCCGCTCAGCTCCACACAGTAGTCCCCACGTGGCCCACTCCCGGCCAGGCT  
GCTTTCGCTGTCTCAGTCTGTCTCAAGCCATCAGCTCCTTGGGACTGATGAACAGAGTCAGAAGCCCCAAAGGAA  
TTGCACTGTGGCAGCATCAGACGTACTCGTCATAAGTGAGAGGCGTGTGTTGACTGATTGACCCAGCGCTTTGGA  
AATAAATGGCAGTGCTTTGTTCACTTAAAGGGACCAAGCTAAATTTGTATTGGTTCATGTAGTGAAGTCAAACCTG  
TTATTAGAGATGTTTAAATGCATATTTAACTTATTTAATGTATTTTCATCTCATGTTTTCTATTGTACAAGAGT  
ACAGTTAATGCTGCGTGCTGCTGAACCTCTGTTGGGTGAAGTGGTATTGCTGCTGGAGGGCTGTGGGCTCCTCTGT  
CTCTGGAGAGTCTGGTCATGTGGAGGTGGGGTTTTATTGGGATGCTGGAGAAGAGTGCCAGGAAGTGTTTTTTCT  
GGGTCAGTAAATAACAACCTGTCATAGGGAGGGAAATTCAGTAGTGACAGTCAACTCTAGGTTACCTTTTTTAA  
TGAAGAGTAGTCAGTCTTCTAGATTGTTCTTATACCACCTCTCAACCATTACTCACACTTCAGCGCCAGGTCC  
AAGTCTGAGCCTGACCTCCCCTTGGGGACCTAGCCTGGAGTCAGGACAAATGGATCGGGCTGCAGAGGGTTAGAA  
GCGAGGGCACCAGCAGTTGTGGGTGGGGAGCAAGGAAGAGAGAACTCTTCAGCGAATCCTTCTAGTACTAGTT  
GAGAGTTTGAAGTGTGAATTAATTTTATGCCATAAAAGACCAACCCAGTTCTGTTGACTATGTAGCATCTTGAAA  
AGAAAAATTATAATAAAGCCCCAAAATTAAGAAAA

113/615

**FIGURE 112**

</usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA53977  
<subunit 1 of 1, 243 aa, 1 stop  
<MW: 27228, pI: 7.43, NX(S/T): 2  
MAKVEQVLSLEPQHLEKFRGPFTDVVTNLKLGNPTRNVCFKVKTAPRRYCVRPNSGIIDAGASINVSVMLQP  
FDYDENEKSKHKFMVQSMFAPTDTSMEAVWKEAKPEDLMSKLRVCFELPAENDKPHDVEINKIISTTASKTET  
PIVSKSLSSSLDDTEVKKVMEECKRLQGEVQRLREENKQFKEEDGLRMRKTVQSNPISALAPTGKEEGLSTRLL  
ALVVLEFFIVGVIIGKIAL

**Important features:****Transmembrane domain:**

amino acids 224-239

**N-glycosylation site.**

amino acids 68-71

**N-myristoylation site.**

amino acids 59-64, 64-69 and 235-240

114/615

**FIGURE 113**

CCCACGCGTCCGGGTGACCTGGGCCGAGCCCTCCCGGTGCGCTAAGATTGCTGAGGAGGCGGCGGGTAGCTGGCA  
GGCGCCGACTTCCGAAGGCCGCCGTCCGGGCGAGGTGTCCTCATGACTTCTCTTGTGGACCATGTCCGTGATCTT  
TTTTGCCTGCGTGGTACGGGTAAGGGATGGACTGCCCTCTCAGCCTCTACTGATTTTTACCACACCCAAGATTT  
TTTGGAATGGAGGAGACGGCTCAAGAGTTTAGCCTTGCGACTGGCCAGTATCCAGGTCGAGGTTCTGCAGAAGG  
TTGTGACTTTAGTATACATTTTTCTTCTTTGCGGGACGTGGCCTGCATGGCTATCTGCTCCTGCCAGTGTCCAGC  
AGCCATGGCCTTCTGCTTCCTGGAGACCCTGTGGTGGGAATTCACAGCTTCCTATGACACTACCTGCATTGGCCT  
AGCCTCCAGGCCATACGCTTTTCTTGAGTTTGACAGCATCATTCAGAAAGTGAAGTGGCATTTTAACTATGTAAG  
TTCCTCTCAGATGGAGTGCAGCTTGAAAAAATTCAGGAGGAGCTCAAGTTGCAGCCTCCAGCGGTTCTCACTCT  
GGAGGACACAGATGTGGCAAATGGGGTGATGAATGGTCACACACCGATGCACCTGGAGCCTGCTCCTAATTTCCG  
AATGGAACCAAGTGACAGCCCTGGGTATCCTCTCCCTCATTCTCAACATCATGTGTGCTGCCCTGAATCTCATTCTG  
AGGAGTTCACCTTGACAGAACATTCTTTACAGGATCCAAGGAGCTGGTTCTGCTGCTGGACCAAACCTCGTGAGC  
CAGCCACCCCTGACCCAAATGAGGAGAGCTCTGATTCTCCCATCCGGGAGCAGTGATGTCAAACCTTCTGCTGCTG  
GGGAAATCTCATCAGCAGGGAGCCTGTGGAAAAGGGCATGTCAGTGAAATCTGGGAATGGCTGGATTCCGGAAACA  
TCTGCCCATGTGTATTGATGGCAGAGCTGTTGCCCACAAGCGCCTTTATTTAGGGTAAATTAACAAATCCATT  
CTATTCTCTGACCCATGCTTAGTACATATGACCTTTAACCTTACATTTATATGATTCTGGGGTTGCTTCAGAA  
GTGTTATTTTCATGAATCATTATATGATTTGATCCCCCAGGATTCTATTTTGTTTAATGGGCTTTTCTACTAAAA  
GCATAAAATACTGAGGCTGATTTAGTCAGGGCAAACCATTTACTTTACATATTCGTTTTCAATACTTGCTGTTC  
ATGTTACACAAGCTTCTTACGGTTTCTTGTAACAATAAATATTTTGAGTAAATAATGGGTACATTTTAACAAAC  
TCAGTAGTACAACCTAACTTGTATAAAAGTGTGTAATAATGTATAGCCATTTATATCCTATGTATAAATTAAT  
GAGGTGGCTTCAGAAATGGCAGAATAAATCTAAAGTGTTTATTAAAAAAG

115/615

**FIGURE 114**

MSVIFFACVVRVRDGLPLSASTDFYHTQDFLEWRRRLKSLALRLAQYPGRGSAEGCDFSIHFSSFGDVACMAICS  
CQCPAAMAFCFLET LW EFTASYDTTCIGLASRPYAFLEFDSIIQVKWHFNYVSSSQMECSLEKIQEELKLQPP  
AVLTLEDTDVANGVMNGHTPMHLEPAPNFRMEPVTALGILSLILNIMCAALNLIRGVHLAEHSLQDPRSWFCWLDQTS

116/615

**FIGURE 115**

CTCAGCGGCGCTTCCTCGTAGCGAGCCTAGTGGCGGGTGTTCGATTGAAACGTGAGCGCGACCCGACCTTAAAG  
AGTGGGGAGCAAAGGGAGGACAGAGCCCTTTAAACGAGGCGGGTGGTGCCTGCCCTTTAAGGGCGGGCGTCC  
GGACGACTGTATCTGAGCCCCAGACTGCCCCGAGTTTCTGTGCGAGGCTGCGAGGAAAGGCCCTAGGCTGGGTC  
TGGGTGCTTGGCGGGCGGCGGCTTCCTCCCCGCTCGTCTCCCCGGGCCAGAGGCACCTCGGCTTCAGTCATGCT  
GAGCAGAGTATCGAAGCACCTGACTACGAAGTGCTATCCGTGCGAGAACAGCTATTCCACGAGAGGATCCGCGAG  
TGTATTATATCAACACTTCTGTTTGAACACTGTACATCCTCTGCCACATCTTCTGACCCGCTTCAAGAAAGCCT  
GCTGAGTTTACCACAGTGGATGATGAAGATGCCACCGTCAACAAGATTGCGCTCGAGCTGTGCACCTTTACCCTG  
GCAATTGCCCTGGGTGCTGTCTGCTCCTGCCCTTCTCCATCATCAGCAATGAGGTGCTGCTCTCCCTGCCCTCGG  
AACTACTACATCCAGTGGCTCAACGGCTCCCTCATCCATGGCCTCTGGAACCTTGTTCCTTCCCCAACCTG  
TCCCTCATCTTCTCATGCCCTTTGCATATTTCTTCACTGAGTCTGAGGGCTTTGCTGGCTCCAGAAAGGGTGTCT  
CTGGGCGGGTCTATGAGACAGTGGTGATGTTGATGCTCCTCACTCTGCTGGTGCTAGGTATGTTGGGTGGCA  
TCAGCCATTGTGGACAAGACAAGGCCAACAGAGAGTCACTCTATGACTTTTGGGAGTACTATCTCCCTACCTC  
TACTCATGCATCTCCTTCTTGGGGTCTGCTGCTCCTGGTGTGTACTCCACTGGGTCTCGCCCGCATGTTCTCC  
GTCACCTGGGAAGCTGCTAGTCAAGCCCCGGCTGCTGGAAGACCTGGAGGAGCAGCTGTACTGCTCAGCCTTTGAG  
GAGGCAGCCCTGACCCGCGAGGATCTGTAATCCTACTTCTGCTGGCTGCCCTTTAGACATGGAGCTGCTACACAGA  
CAGGTCTGGCTCTGCAGACACAGAGGGTCTGCTGGAGAAGAGGCGGAAGGCTTCAGCCTGGCAACGGAACCTG  
GGCTACCCCTGGCTATGCTGTGCTTGTGCTGCTGCTGACGGGCTGTCTGTGCTCATTGTGGCCATCCACATCCTG  
GAGCTGCTCATCGATGAGGCTGCCATGCCCCGAGGCTGCGAGGGTACCTCCTTAGGCCAGGTCTCCTTCTCCAAG  
CTGGGCTCCTTTGGTGCCGTCAATCAGGTTGTACTCATCTTTTACCTAATGGTGTCTCCTCAGTTGTGGGCTTCTAT  
AGCTCTCCACTCTTCCGGAGCCTGCGGCCCAGATGGCACGACACTGCCATGACGCAGATAATTGGGAAGTGTGTC  
TGTCTCCTGGTCTTAAGCTCAGCACTTCTGTCTTCTCTCGAACCTTGGGGCTCACTCGCTTGACCTGCTGGGT  
GACTTTGGACGCTTCAACTGGCTGGGCAATTTCTACATTGTGTTTCTCTACAACGCAGCCTTTGCAGGCCTCACC  
ACACTCTGTCTGGTGAAGACCTTCACTGCAGCTGTGCGGGCAGAGCTGATCCGGGCTTTGGGCTGGACAGACTG  
CCGCTGCCCCGTCTCCGGTTTCCCCCAGGCATCTAGGAAGACCCAGCACCAGTCACTCCAGCTGGGGGTGGGAAG  
GAAAAAAGTGGACACTGCCATCTGCTGCCTAGGCCTGGAGGGAAGCCCAAGGCTACTTGGACCTCAGGACCTGGA  
ATCTGAGAGGGTGGGTGGCAGAGGGGAGCAGAGCCATCTGCACTATTGCATAATCTGAGCCAGAGTTTGGGACCA  
GGACCTCCTGCTTTTCCATACTTAAGTGTGGCTCAGCATGGGGTAGGGCTGGGTGACTGGGTCTAGCCCCTGAT  
CCCAAATCTGTTTACACATCAATCTGCCTCACTGCTGTTCTGGGCCATCCCATAGCCATGTTTACATGATTTGA  
TGTGCAATAGGGTGGGTAGGGGCAGGGAAGGACTGGGCCAGGGCAGGCTCGGGAGATAGATTGTCTCCCTTGC  
CTCTGGCCCAGCAGAGCCTAAGCACTGTGCTATCCTGGAGGGGCTTTGGACCACCTGAAAGACCAAGGGGATAGG  
GAGGAGGAGGCTTCAGCCATCAGCAATAAAGTTGATCCAGGGAAAAAA

117/615

**FIGURE 116**

MEAPDYEVL SVREQLFHERIRECIISTLLFATLYILCHIFLTRFKKPAEFTTVDDATV NKIALELCTFTLAIA  
LGAVLLLPFSIISNEVLLSLPRNYIIQWLNGSLIHGLWNLVLFPNLSLIFLMPFAYFFTESEGFAGSRKGV LGR  
VYETVVMMLMLLTLLVLGMVWVASAIVDKNKANRESLYDFWEYYLPYLYSCISFLGVLLLLLVCTPLGLARMF SVTG  
KLLVKPRLEEDLEEQLYCSAFEEAALTRRICNPTSCWLPLDMELLHRQVLALQTRVLLKRRKASAWQRNLGYP  
LAMLCLLVLTGLSVLIVAIHILELLIDEAAMP RGMQGTSLGQVSFSKLGSFGAVIQVVLIFYLMVSSVVG FYSSP  
LFRSLRPRWHD TMTQIIIGNCVCLLVLSALPVFSRTLGLTRFDLLGDFGRFNWLGNFYIVFLYNAAFAGLT TLC  
LVKTFTA AVRAELIRAFGLDRLPLPVSGFPQASRKTQHQ



118/615

**FIGURE 117**

[illegible]

119/615

**FIGURE 118**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA54002
><subunit 1 of 1, 544 aa, 1. stop
><MW: 60268, pI: 9.53, NX(S/T): 3
MLLP LLLSSLLGGSQAMDGRFWIRVQESVMVPEGLCISVPCSF SYPRQDWTGSTPAYGYWFKAVTETTKGAPVAT
NHQSREVE MSTRGRFQLTGDPAGKNC SLVIRDAQM QDESQYFFRVERGSYVTYNFMNDGFFLKVTVLSFTPRPQD
HNTDLTCHVDFSRKGVSAQRTVRLRVAYAPRDLVISISRDNTPALEPQPQGNVPYLEAQKGQFLRLCAADSQPP
ATLSWVLQNRVLSSSHPWGPRPLGLELPGVKAGDSGRYTCRAENRLGSQQRALDLSVQYPPENLRVMVSQANRTV
LENLGNGTSLPVLEGQSLCLVCVTHSSPPARLSWTQRGQVLSPSQPSDPGVLELPRVQVEHEGEFTCHARHPLGS
QHVSLSLSVHYKKGLISTAFSNGAFLGIGITALLFLCLALIIMKILPKRRTQTETPRPRFSRHSTILDYINNVPT
AGPLAQKR NQKATPNSPRTPPPPGAPSPESKKNQKKQYQLPSFPEPKSSTQAPESQESQEELHYATLNFPGVRPR
PEARMPKGTQADYAEVKFQ
```

**Important features:****Signal peptide:**

amino acids 1-15

**Transmembrane domain:**

amino acids 399-418

**N-glycosylation site.**

amino acids 100-103, 297-300 and 306-309

**Immunoglobulins and major histocompatibility complex proteins signature.**

amino acids 365-371

120/615

**FIGURE 119**

CTCGCGCAGGGATCGTCCC**ATG**CGCGGGGCTCGGAGCCGCGACCCTTGGGGGGCCTCCGGGATTGCTACCTTTT  
TGGCTCCTTGCTCGTCAACTGCTCTTCTCACGGGCTGTGCGCTTCAATCTGGACGTGATGGGTGCCTTGCGCAA  
GGAGGGCGAGCCAGGCAGCCTCTTCGGCTTCTCTGTGGCCCTGCACCGGCAGTTGCAGCCCCGACCCAGAGCTG  
GCTGCTGGTGGGTGCTCCCCAGGCCCTGGCTCTTCTGGGCAGCAGGCCGAATCGACTGGAGGCCCTCTCGCTTG  
CCCCTTGAGCCTGGAGGAGACTGACTGCTACAGAGTGGACATCGACCAGGGAGCTGATATGCAAAAGGAAAGCAA  
GGAGAACCAGTGTTTGGGAGTCAGTGTTCGGAGCCAGGGGCTGGGGCAAGATTGTTACCTGTGCACACCGATA  
TGAGGCAAGGCAGCGAGTGGACCAGATCCTGGAGACGCGGGATATGATTGGTCTGCTTTGTGCTCAGCCAGGA  
CCTGGCCATCCGGGATGAGTTGGATGTTGGGGAATGGAAGTTCTGTGAGGGACGCCCCAAGGCCATGAACAATT  
TGGGTTCTGCCAGCAGGGCACAGCTGCCGCCCTTCTCCCCTGATAGCCACTACCTCCTCTTTGGGGCCCCAGGAAC  
CTATAATTGGAAGGGCACGGCCAGGGTGGAGCTCTGTGCACAGGGCTCAGCGGACCTGGCACACCTGGACGACGG  
TCCCCTACGAGGCGGGGGGAGAGAAGGAGCAGGACCCCCGCTCATCCCGTCCCTGCCAACAGCTACTTTGGCTT  
CTCTATTGACTCGGGGAAAGGTCTGGTGGCTGCAGAAGAGCTGAGCTTTGTGGCTGGAGCCCCCGGCCAACCA  
CAAGGGTGCTGTGGTTCATCTGCGCAAGGACAGCGCCAGTCCCTGGTGGCCGAGGTTATGCTGTCTGGGGAGCG  
CCTGACCTCCGGCTTTGGCTACTCACTGGCTGTGGCTGACCTCAACAGTGATGGCTGGCCAGACCTGATAGTGGG  
TGCCCCTACTTCTTTGAGCGCCAAAGAAGAGCTGGGGGTGCTGTGTATGTGTAATTGAACAGGGGGGTCACTG  
GGCTGGGATCTCCCTCTCCGGCTCTGCGGCTCCCTGACTCCATGTTTCGGGATCAGCCTGGCTGTCTGGGGGA  
CCTCAACCAAGATGGCTTTCCAGATATTGCAGTGGGTGCCCCCTTTGATGGTGATGGGAAAGTCTTCATCTACCA  
TGGGAGCAGCCTGGGGGTGTGCGCAACCTTCACAGGTGCTGGAGGGCGAGGCTGTGGGCATCAAGAGCTTCGG  
CTACTCCCTGTGAGGCAGCTTGATATGGATGGGAACCAATACCCTGACCTGCTGGTGGGCTCCCTGGCTGACAC  
CGCAGTGCTCTTCAGGGCCAGACCCATCTCCATGTCTCCATGAGGTCTCTATTGCTCCACGAAGCATCGACCT  
GGAGCAGCCCCAAGTGTGCTGGCGGCCACTCGGTCTGTGTGGACCTAAGGGTCTGTTTCAGCTACATTGCAGTCCC  
CAGCAGCTATAGCCCTACTGTGGCCCTGGACTATGTGTTAGATGCGGACACAGACCGGAGGCTCCGGGGCCAGGT  
TCCCGTGTGACGTTCCCTGAGCCGTAACCTGGAAGAACCAGCAGCAGGCTCCGGGCACCGTGTGGCTGAAGCA  
CCAGCATGACCGAGTCTGTGGAGACGCCATGTTCCAGCTCCAGGAAAATGTCAAAGACAAGCTTCGGGCCATTGT  
AGTGACCTTGTCTACAGTCTCCAGACCCCTCGGCTCCGGCGACAGGCTCCTGGCCAGGGGCTGCCTCCAGTGGC  
CCCCATCCTCAATGCCACAGCCAGCCAGCAGCCAGCGGGCAGAGATCCACTTCCTGAAGCAAGGCTGTGGTGAAGA  
CAAGATCTGCCAGAGCAATCTGCAGCTGGTCCACGCCCCGCTTCTGTACCCGGGTGAGCGACACGGAATTCCAACC  
TCTGCCCCATGGATGTGGATGGAACAACAGCCCTGTTTGCAGTGAAGTGGGCAGCCAGTCAATTGGCCTGGAGCTGAT  
GGTCACCAACCTGCCATCGGACCCAGCCAGCCAGGCTGATGGGGATGATGCCATGAAGCCCAGCTCCTGGT  
CATGCTTCTGACTCACTGCACTACTCAGGGGTCCGGGCCCTGGACCTGCGGAGAAGCCACTGTGCTGTCCA  
TGAGAATGCCTCCCATGTTGAGTGTGAGCTGGGGAAACCCATGAAGAGAGGTGCCAGGTCACTTCTACCTCAT  
CCTTAGCACCTCCGGGATCAGCATTGAGACCACGGAAGTGGAGGTAGAGCTGCTGTTGGCCACGATCAGTGAGCA  
GGAGCTGCATCCAGTCTCTGCAGAGCCCGTGTCTTCAATTGAGCTGCCACTGTCCATTGCAGGAATGGCCATTCC  
CCAGCAACTCTTCTCTCTGGTGTGGTGGAGGGGCGAGAGGCCATGCAGTCTGAGCGGGATGTGGGCAGCAAGGT  
CAAGTATGAGGTACCGGTTTCCAACCAAGGCCAGTCCCTCAGAACCCTGGGCTCTGCCTTCCCTCAACATCATGTG  
GCCTCATGAGATTGCCAATGGGAAGTGGTTGCTGTACCCAATGCAGGTTGAGCTGGAGGGCGGCGAGGGGCTGG  
GCAGAAAGGGCTTTGCTCTCCAGGCCAACATCCTCCACCTGGATGTGGACAGTAGGGATAGGAGGCGGCGGGA  
GCTGGAGCCACCTGAGCAGCAGGAGCCTGGTGGAGCGGCAGGAGCCAGCATGTCTGGTGGCCAGTGTCTCTGC  
TGAGAAGAAGAAAACATCACCTGGACTGCGCCCGGGGCACGGCCAACTGTGTGGTGTTCAGCTGCCACTCTA  
CAGCTTTGACCGCGCGGCTGTGCTGCATGTCTGGGGCCGTCTCTGGAACAGCACCTTTCTGGAGGAGTACTCAGC  
TGTGAAGTCCCTGGAAGTGATTGTCCGGGCCAACATCACAGTGAAGTCCCTCCATAAAGAACTTGATGCTCCGAGA  
TGCTCCACAGTGATCCAGTGATGGTATACTTGGACCCCATGGCTGTGGTGGCAGAAGGAGTGCCCTGGTGGGT  
CATCCTCCTGGCTGTACTGGCTGGGCTGCTGGTGTAGCACTGCTGGTGTCTCCTGTGGAAGATGGGATTCTT  
CAAACGGGCGAAGCACCCCGAGGGCCACCGTGCCCCAGTACCATGCGGTGAAGATTCTCGGGAAGACCGACAGCA  
GTTCAAGGAGGAGAAGACGGGCACCATCCTGAGGAACAAGTGGGGCAGCCCCGGCGGGAGGGCCCCGATGCACA  
CCCCATCCTGGCTGCTGACGGGCTATCCCGAGCTGGGCCCGATGGGCATCCAGGGCCAGGCACCGCC**TAGG**TTCC  
CATGTCCAGCCTGGCCTGTGGCTGCCCTCCATCCCTTCCCCAGAGATGGCTCCTTGGGATGAAGAGGGTAGAGT  
GGGCTGCTGGTGTGCGATCAAGATTGGCAGGATCGGCTTCCCTCAGGGGCACAGACCTCTCCACCCACAAGAAC  
TCCTCCACCCAACTTCCCTTAGAGTGCTGTGAGATGAGAGTGGGTAAATCAGGGACAGGGCCATGGGGTAGGG  
TGAGAAGGGCAGGGGTGCTGATGCAAGGTGGGGAGAAGGGATCCTAATCCCTTCCCTCTCCATTACCCCTGT  
GTAACAGGACCCCAAGGACCTGCCCTCCCGGAAGTGCCCTAACCTAGAGGGTCCGGGAGGAGGTTGTGTCACTGA  
CTCAGGCTGCTCCTTCTCTAGTTCCCTCTCATCTGACCTTAGTTTGTGCTGCCATCAGTCTAGTGGTTTTCGTGGT  
TTCGTCTATTTATTAAAAAATATTTGAGAACAACAAAAA

121/615

**FIGURE 120**

></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA55737  
><subunit 1 of 1, 1141 aa, 1 stop  
><MW: 124671, pI: 5.82, NX(S/T): 5  
MAGARSRDPWGASGICYLFGSLLVELLFSRAVAFNLDVMGALRKEGEPGSLFGFSVALHRQLQPRPQSWLLVGAP  
QALALPGQQANRTGGGLFACPLSLEETDCYRVDDIDQGADMQKESKENQWLGVSVRSQGPGGKIIVTCAHRYEARQRV  
DQILETRDMIGRCFVLSQDLAIRDELDDGGGEWKFCGRPQGHEQFGFCQQGTAAAFSPDSHYLLFGAPGTYNWKGT  
ARVELCAQGSADLAHLDDGPYEAGGEKEQDPRLTPVPANSYFGFSIDSGKGLVRAEELS FVAGAPRANHKGAVVI  
LRKDSASRLVPEVMLSGERLTSFGFYS LAVADLNSDGWPD LIVGAPYFFERQEELGGAVYVYLNQGGHWAGISPL  
RLCGSPDSMFGISLAVLGDINQDGFDPDIAGVAPFDGDGKVFIYHGSSSLGVVAKPSQVLEGEAVGIKSFYSLSGS  
LDMDGNQYPDLLVGSILADTAVLFRARPILHVSHEVSIAPRSIDLEQPNACAGGHSVCVDLRVCFYSYIAVPSSYSPT  
VALDYVLDADTDRLRGQVPRVTFLSRNLEEPKHQASGTVWLKHQHDRVCGDAMFQLQENVKDKLRAIVVTLSYS  
LQTPRLRRQAPGQGLPPVAPIILNAHQPSQRAEIHFLKQCGGEDKICQSNLQLVHARFCTRVSDTEFQPLPMDVD  
GTTALFALSGQPVIGLELMVTNLPSPDPAQPQADGDDAHEAQLLVMLPDSLHYS GVRALDPAEKPLCLSNENASHV  
ECELGNPMKRGAQVT FYLILSTSGIS IETTELEVELLATISEQELHPVSARARVFIELPLSIAGMAIPQQLFFS  
GVVRGERAMQSERDVGSKVKYEVTVSNQGQSLRTLGS AFLNIMWPHEIANGKWLLYPMQVELEGGQGPQKGLCS  
PRPNILHLDVDSRDRRRRELEPPEQQEPGERQEPMSWWPVSSAEKKKNITLDCARGTANCVVFSCLY SFDRAA  
VLHVWGRWLWNSTFLEEYS AVKSLEIVIVRANITVKSSIKNLMRLDASTVI PVMVYLDPM AVVAEGVPWWVILLAVL  
AGLLVLALLVLLWKMGFFKRAKHPEATVPQYHAVKIPREDRQQFKEEKTGTILRNNWGS PRREGPD AHPILAAD  
GHPELGPDPGHPGPGTA

**Important features:****Signal peptide:**

amino acids 1-33

**Transmembrane domain:**

amino acids 1040-1062

**N-glycosylation sites.**

amino acids 86-89, 746-749, 949-952, 985-988 and 1005-1008

**Integrins alpha chain proteins.**amino acids 1064-1071, 384-408, 1041-1071, 317-346, 443-465, 385-407, 215-224,  
634-647, 85-99, 322-346, 470-479, 442-466, 379-408 and 1031-1047

122/615

**FIGURE 121**

GGCACGAGGCGGCGGGGCGAGTCGCGGGGATGCGCCCGGGAGCCACAGCCTGAGGCCCTCAGGTCTCTGCAGGTGTC  
GTGGAGGAACCTAGCACCTGCCATCCTCTTCCCCAATTTGCCACTTCCAGCAGCTTTAGCCCATGAGGAGGATGT  
GACCGGGGACTGAGTCAGGAGCCCTCTGGAAGCATGGAGACTGTGGTGATTGTTGCCATAGGTGTGCTGGCCACCA  
TCTTTCTGGCTTCGTTTGCAGCCTTGGTGCTGGTTTGCAGGCAGCGCTACTGCCGGCCGCGAGACCTGCTGCAGC  
GCTATGATTCTAAGCCCATTTGTGGACCTCATTGGTGCCATGGAGACCCAGTCTGAGCCCTCTGAGTTAGAAGTGG  
ACGATGTCGTTATCACCAACCCCCACATTGAGGCCATTCTGGAGAATGAAGACTGGATCGAAGATGCCTCGGGTC  
TCATGTCCCACTGCATTGCCATCTTGAAGATTTGTCACTCTGACAGAGAAGCTTGTGGCATGACAATGGGCT  
CTGGGGCCAAGATGAAGACTTCAGCCAGTGTGACGACATCATTGTGGTGGCCAAGCGGATCAGCCCCAGGGTGG  
ATGATGTTGTGAAGTCGATGTACCTCCGTTGGACCCAACTCCTGGACGCACGGACGACTGCCCTGCTCCTGT  
CTGTCAGTCACCTGGTGCTGGTGACAAGGAATGCCTGCCATCTGACGGGAGGCCTGGACTGGATTGACCAGTCTC  
TGTCGGCTGCTGAGGAGCATTGGAAGTCCTTCGAGAAGCAGCCCTAGCTTCTGAGCCAGATAAAGGCCTCCCAG  
GCCCTGAAGGCTTCCTGCAGGAGCAGTCTGCAATTTAGTGCCTACAGGCCAGCAGCTAGCCATGAAGGCCCTGC  
CGCCATCCCTGGATGGCTCAGCTTAGCCTTCTACTTTTTCTATAGAGTTAGTTGTTCTCCACGGCTGGAGAGTT  
CAGCTGTGTGTGCATAGTAAAGCAGGAGATCCCGTCAGTTTATGCCTCTTTTGCAGTTGCAAACGTGGGCTGGT  
GAGTGGCAGTCTAATACTACAGTTAGGGGAGATGCCATTCACCTCTGCAAGAGGAGTATTGAAAACGTGGTGGAC  
TGTCAGCTTTATTTAGCTCACCTAGTGTTCAGAAAAATTGAGCCACCGTCTAAGAAATCAAGAGGTTTCACAT  
TAAATTAGAATTTCTGGCCTCTCTCGATCGGTCAGAATGTGTGGCAATTCTGATCTGCATTTTCAGAAGAGGAC  
AATCAATTGAACTAAGTAGGGGTTTCTTCTTTGGCAAGACTTGTAATCTCTCACCTGGCCTGTTTCATTTATT  
TGTATTATCTGCCTGGTCCCTGAGGCGTCTGGGTCTCTCCTCTCCCTTGAGGTTTGGGTTTGAAGCTGAGGAAC  
TACAAAGTTGATGATTTCTTTTTATCTTTATGCCTGCAATTTTACCTAGCTACCACTAGGTGGATAGTAAATTT  
ATACTTATGTTTCCCTCAAAAAAAAAAAAAAA

123/615

**FIGURE 122**

METVVIVAIGVLATIFLASFAALVLVCRQRYCRPRDLLQRYDSKPIVDLIGAMETQSEPSELELDDVVITNPHIE  
AILENEDWIEDASGLMSHCIAILKICHTLTEKLVAMTMGSGAKMKTSASVSDIIVVAKRISPRVDDVVKSMYPPL  
DPKLLDARTTALLLSVSHLVLVTRNACHLTGGLDWIDQSLSAEEHLEVLREAALASEPDKGLPGPEGFLQEQSAI

124/615

**FIGURE 123**

CCCTTACATCCTCCTAGGACCCGGTCGGTAGTCGTCGCCCCAGCCCGCCGGGGGCGCAGCGCCCCGAGCCGCGGCC  
CTCGAGACGGGACCGAGAGCATCATGGGGCAGCACTGTCCCGCGCTCCGCCTCCGTGCTGCTTCTGCTGCTGCTCC  
TGCGCCGGGCGGAGCAGCCCTGCGGGGCGGAGCTCACCTTCGAGCTGCCGGACAACGCCAAGCAGTGCTTCCACG  
AGGAGGTGGAGCAGGGCGTGAAGTTCTCCCTGGATTACCAGGTCATCACTGGAGGCCACTACGATGTTGACTGCT  
ATGTAGAGGACCCCGAGGGGAACACCATCTACAGAGAAACGAAGAAGCAGTACGACAGCTTCACGTACCGGGCTG  
AAGTCAAGGGCGTTTATCAGTTTGGCTTCAGTAATGAGTTTTCCACCTTCTCTCACAAGACCGTCTACTTTGACT  
TTCAGTGGGCGATGAGCCTCCCATTTCTCCAGACATGGGGAACAGGGTCACAGCTCTCACCCAGATGGAGTCCG  
CCTGCGTGACCATCCATGAGGCTCTGAAAACGGTGATTGACTCCAGACGCATTACCGGCTGCGGGAGGCCCCAGG  
ACCGGGCCCGAGCGGAAGACCTTAATAGCCGAGTCTCTTACTGGTCTGTTGGCGAGACGATTGCCCTGTTCTGTTG  
TCAGCTTCAGTCAGGTGCTACTGTTGAAAAGCTTCTTCACAGAAAAACGACCCATCAGCAGGGCAGTCCACTCCT  
AGCCCCGGGCATCCTGCTCTAGGGCCCCCTCAGCCCCAGGCTGGAGCAGCTCTCCTAGGTCACAGCCTGCTGGGCT  
GGGTGCGGTAGCCCAGGGTGGAGGCAGAACGATGCTGCTGTGGTAGCCCTTTGCCTTTTCATGCCCATGCTTGATT  
CTTGACCTCAGCAGCTGAAGGTCTCAGAGACCAGTAATCAGAAGGCATCCGACTGCATTAAGTGTGCAGCGCTG  
AAAAGACATTTACAACTAGGCCAGGGATTAGCCACTGTGGGAGGGTGGACAGGCAATGGTTTCAGTGGCCTGGCTG  
TTGGCAGGAACTCCAAGTGCCAGGCCTCTTGGGCAGCTTAGGGCCCTGCCTCTGTTTCATGATGCATGGGTGAT  
TTGTCTTGGGTGTCCTATCCCATATGGAGAAGAAAGGGGCTCTAAGTTCTGGCTCTTCTTTCTTTGGGGTTCTCT  
GTACCTGAGGAAACCAGGCCCTGGGTGACTTTGCAGATCTGCTCACCTCGGTGAGCAACAGTGTGAGCCATGCA  
AGCAGGACAGAATGGTGACTGGGTGCCCTTGGTGAGCTGTGTATTTCTAGGAGGTAGAAAACGTGGGAAACTG  
TGGCTAATAAAAACTAAGTGTGAGCGTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

125/615

**FIGURE 124**

&lt;/usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA56052

&lt;subunit 1 of 1, 217 aa, 1 stop

&lt;MW: 24777, pI: 5.55, NX(S/T): 0

MGSTVPRSASVLLLLLLLLRRAEQPCGAELTFELPDNAKQCFHEEVEQGVKFSLDYQVITG

GHYDVDCYVEDPQGNTIYRETKKQYDSFTYRAEVKGVYQFCFSNEFSTFSHKTVYFDFQV

GDEPPILPDMGNRVTALTQMESACVTIHEALKTVIDSQTHYRLREAQDRARAEDLNSRVS

YWSVGETIALFVVSFSQVLLKSFTEKRPISRVAHS

**Important features:****Signal peptide:**

amino acids: 1-23

**Transmembrane domain:**

amino acids: 187-201

**N-myristoylation sites:**

amino acids: 26-32, 48-54, 131-137

**Tyrosine kinase phosphorylation site:**

amino acids: 82-91

**Glycosyl hydrolases family 25 proteins:**

amino acids: 53-61



126/615

**FIGURE 125**

GGCACGAGGCGCTGTCCACCCGGGGGCGTGGGAGTGAGGTACCAGATTGAGCCCATTTGGCCCCGACGCCTCTGT  
TCTCGGAATCCGGGTGCTGCGGATTGAGGTCCCGGTTCCCTAACGGACTGCAAGATGGAGGAAGGCGGGAACCTAG  
GAGGCCTGATTAAGATGGTCCATCTACTGGTCTTGTCAGGTGCCTGGGGCATGCAATGTGGGTGACCTTCGTCT  
CAGGCTTCCTGCTTTTCCGAAGCCTTCCCCGACATACCTTCGGACTAGTGCAGAGCAAACCTTCCCCTTCTACT  
TCCACATCTCCATGGGCTGTGCCTTCATCAACCTCTGCATCTTGGCTTCACAGCATGCTTGGGCTCAGCTCACAT  
TCTGGGAGGCCAGCCAGCTTTACCTGCTGTTCTTGAGCCTTACGCTGGCCACTGTCAACGCCCGCTGGCTGGAAC  
CCCGCACCACAGCTGCCATGTGGGCCCTGCAAACCGTGGAGAAGGAGCGAGGCCTGGGTGGGGAGGTACCAGGCA  
GCCACCAGGGTCCCGATCCCTACCGCCAGCTGCGAGAGAAGGACCCCAAGTACAGTGCTCTCCGCCAGAATTTCT  
TCCGCTACCATGGGCTGTCTCTCTTTGCAATCTGGGCTGCGTCCTGAGCAATGGGCTCTGTCTCGCTGGCCTTG  
CCCTGGAAATAAGGAGCCTCTAGCATGGGCCCTGCATGCTAATAAATGCTTCTCAGAAATGAAAAAAAAAAAAA  
AAAAAA

127/615

**FIGURE 126**

&lt;/usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA56107

&lt;subunit 1 of 1, 231 aa, 1 stop

&lt;NX(S/T): 0

MEEGGNIGGLIKMVHLLVLSGAWGMQMWVTFVSGFLLFRSLPRHTFGLVQSKLFPFYFHISMGCAFINLCILASQ  
HAWAQLTFWEASQLYLLFLSLTLATVNARWLEPRTTAAMWALQTVEKERGLGGEVPGSHQGPDPYRQLREKDPKY  
SALRQNFFRYHGLSSLCLNLCVLSNGLCLAGLALEIRSL**Signal peptide:**

amino acids 1-24

**Transmembrane domain:**

amino acids 86-103, 60-75

**Casein kinase II phosphorylation site.**

amino acids 82-86

**Tyrosine kinase phosphorylation site.**

amino acids 144-151

**N-myristoylation site.**

amino acids 4-10, 5-11, 47-53, 170-176, 176-182

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 54-65

**G-protein coupled receptors proteins.**

amino acids 44-85

128/615

**FIGURE 127**

GCTTCATTTCTCCCGACTCAGCTTCCCACCCTGGGCTTTCCGAGGTGCTTTCGCCGCTGTCCCCACCCTGCAGC  
CATGATCTCCTTAACGGACACGCAGAAAATTGGAATGGGATTAACAGGATTTGGAGTGTTCCTGTTCTTTGG  
AATGATTCTCTTTTTTGACAAAGCACTACTGGCTATTGGAAATGTTTTATTTGTAGCCGGCTTGGCTTTTGTAAAT  
TGGTTTAGAAAAGAACATTCAGATTCTTCTTCCAAAAACATAAAATGAAAGCTACAGGTTTTTTCTGGGTGGTGT  
ATTTGTAGTCCTTATTGGTTGGCCTTTGATAGGCATGATCTTCGAAATTTATGGATTTTTCTCTTGTTCAGGGG  
CTTCTTTCCTGTCGTTGTTGGCTTTATTAGAAGAGTGCCAGTCCTTGGATCCCTCCTAAATTTACCTGGAATTAG  
ATCATTGTAGATAAAGTTGGAGAAAGCAACAATATGGTATTAACAACAAGTGAATTTGAAGACTCATTTAAAATA  
TTGTGTTATTTATAAAGTCATTTGAAGAATATTCAGCACAAAATTAATTTACATGAAATAGCTTGTAAATGTTCTT  
TACAGGAGTTTAAAACGTATAGCCTACAAAGTACCAGCAGCAAATTAGCAAAGAAGCAGTGAACACAGGCTTCTA  
CTCAAGTGAAGTAAAGAAGAAGTCAGCAAGCAAAC TGAGAGAGGTGAAATCCATGTTAATGATGCTTAAGAACTC  
TTGAAGGCTATTTGTGTTGTTTTTCCACAATGTGCGAAACTCAGCCATCCTTAGAGAACTGTGGTGCCTGTTTCT  
TTTCTTTTTATTTTGAAGGCTCAGGAGCATCCATAGGCATTTGCTTTTTTAGAAGTGTCCACTGCAATGGCAAAA  
TATTTCCAGTTGCACTGTATCTCTGGAAGTGATGCATGAATTCGATTGGATTGTGTCATTTTAAAGTATTAAAC  
CAAGGAAACCCCAATTTTGATGTATGGATTACTTTTTTTTGNGCNCAGGGCC

129/615

**FIGURE 128**

MISLTDTQKIGMGLTGFGVFFLFFGMILFFDKALLAIGNVLFVAGLAFVIGLERTFRFFFQKHMKATGFFLGGV  
FVVLIGWPLIGMIFEIYGFFLLFRGFFPVVVGFIIRVPVLGSLNLPGIRSFVDKVGESNNMV

**Important features:**

**Transmembrane domains:**

amino acids 12-30 (typeII), 33-52, 69-89 and 93-109

**N-myristoylation sites.**

amino acids 11-16, 51-56 and 116-121

**Aminoacyl-transfer RNA synthetases class-II protein.**

amino acids 49-59

130/615

**FIGURE 129**

AATTCAGATTTTAAGCCCATTCTGCAGTGGGAATTTTCATGAACTAGCAAGAGGACACCATCTTCTTGTATTATACA  
AGAAAGGAGTGTAACCTATCACACACAGGGGGAAAAATGCTCTTTTGGGTGCTAGGCCTCCTAATCCTCTGTGGTT  
TTCTGTGGACTCGTAAAGGAAAACTAAAGATTGAAGACATCACTGATAAGTACATTTTTATCACTGGATGTGACT  
CGGGCTTTGGAACTTTGGCAGCCAGAACTTTTGATAAAAAGGGATTTTCATGTAATCGCTGCCTGTCTGACTGAAT  
CAGGATCAACAGCTTTTAAAGGCAGAAACCTCAGAGAGACTTCGTACTGTGCTTCTGGATGTGACCGACCCAGAGA  
ATGTCAAGAGGACTGCCCAGTGGGTGAAGAACCAAGTTGGGGAGAAAGGTCTCTGGGGTCTGATCAATAATGCTG  
GTGTTCCCGGCGTGCTGGCTCCCACTGACTGGCTGACACTAGAGGACTACAGAGAACCTATTGAAGTGAACCTGT  
TTGGACTCATCAGTGTGACACTAAATATGCTTCCTTTGGTCAAGAAAGCTCAAGGGAGAGTTATTAATGTCTCCA  
GTGTTGGAGGTCGCCTTGCAATCGTTGGAGGGGGCTATACTCCATCCAAATATGCAGTGGAGGTTTCAATGACA  
GCTTAAGACGGGACATGAAAGCTTTTGGTGTGCACGTCTCATGCATTGAACCAGGATTTGTTCAAAACAAACTTGG  
CAGATCCAGTAAAGGTAATTGAAAAAACTCGCCATTTGGGAGCAGCTGTCTCCAGACATCAAACAACAATATG  
GAGAAGGTTACATTGAAAAAGTCTAGACAACTGAAAGGCAATAAATCCTATGTGAACATGGACCTCTCTCCGG  
TGGTAGAGTGCATGGACCACGCTCTAACAAGTCTCTTCCTAAGACTCATTATGCCGCTGGAAAAGATGCCAAAA  
TTTTCTGGATACCTCTGTCTCACATGCCAGCAGCTTTGCAAGACTTTTTATTGTTGAAACAGAAAGCAGAGCTGG  
CTAATCCCAAGGCAGTGTGACTCAGCTAACCACAAATGTCTCCTCCAGGCTATGAAATTGGCCGATTTCAAGAAC  
ACATCTCCTTTTCAACCCCATTCCTTATCTGCTCCAACCTGGACTCATTTAGATCGTGCTTATTTGGATTGCAA  
AGGGAGTCCCACCATCGCTGGTGGTATCCCAGGCTCCCTGCTCAAGTTTTCTTTGAAAAGGAGGGCTGGAATGGT  
ACATCACATAGGCAAGTCCTGCCCTGTATTTAGGCTTTGCTGCTTGGTGTGATGTAAGGGAAATTGAAAGACTT  
GCCCATTCAAAATGATCTTTACCGTGGCCTGCCCCATGCTTATGGTCCCCAGCATTACAGTAACTTGTGAATGT  
TAAGTATCATCTCTTATCTAAATATTTAAAGATAAGTCAACCCAAAAA  
AAA

131/615

**FIGURE 130**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA56406
><subunit 1 of 1, 319 aa, 1 stop
><MW: 35227, pI: 8.97, NX(S/T): 3
MLFWVLGLLILCGFLWTRKGLKIEDITDKYIFITGCDSGFGNLAARTFDKKG FHVIAACLTESGSTALK AETSE
RLRTVLLDVTDPENVKRTAQWVKNOVGEKGLWGLINNAGVPGVLAPTDWLTLEDYREPIEVNLFGLISVTLNMLP
LVKKAQGRVINVSSVGGRLAIVGGGYTPSKYAVEGFNDSLRRDMKAFGVHVS CIEPGLFKTNLADPVKVIEKKLA
IWEQLSPDIKQQYGE GYIEKSLDKLKG NKS YVNMDLSPVVECDHALTSLFPKTHYAAGKDAKIFWIPLSHMPAA
LQDFLLLKQKAELANPKAV
```

**Important features of the protein:****Signal peptide:**

amino acids 1-17

**Transmembrane domain:**

amino acids 136-152

**N-glycosylation sites.**

amino acids 161-163, 187-190 and 253-256

**Glycosaminoglycan attachment site.**

amino acids 39-42

**N-myristoylation sites.**

amino acids 36-41, 42-47, 108-113, 166-171, 198-203 and 207-212

132/615

**FIGURE 131**

AGACAGTACCTCCTCCCTAGGACTACACAAGGACTGAACCAGAAGGAAGAGGACAGAGCAAAGCCATGAACATCA  
TCCTAGAAATCCTTCTGCTTCTGATCACCATCATCTACTCCTACTTGGAGTCGTTGGTGAAGTTTTTCATTCCCTC  
AGAGGAGAAAAATCTGTGGCTGGGGAGATTGTTCTATTACTGGAGCTGGGCATGGAATAGGCAGGCAGACTACTT  
ATGAATTTGCAAAACGACAGAGCATATTGGTTCTGTGGGATATTAATAAGCGCGGTGTGGAGGAACTGCAGCTG  
AGTGCCGAAAACTAGGCGTCACTGCGCATGCGTATGTGGTAGACTGCAGCAACAGAGAAGAGATCTATCGCTCTC  
TAAATCAGGTGAAGAAAGAAGTGGGTGATGTAACAATCGTGGTGAATAATGCTGGGACAGTATATCCAGCCGATC  
TTCTCAGCACCAAGGATGAAGAGATTACCAAGACATTTGAGGTCAACATCCTAGGACATTTTTGGATCACAAAAG  
CACTTCTTCCATCGATGATGGAGAGAAATCATGGCCACATCGTCACAGTGGCTTCAGTGTGCGGCCACGAAGGGA  
TTCCTTACCTCATCCCATATTGTTCCAGCAAATTTGCCGCTGTTGGCTTTCACAGAGGTCTGACATCAGAACTTC  
AGGCCTTGGGAAAACTGGTATCAAAACCTCATGTCTCTGCCAGTTTTTGTGAATACTGGGTTACCCAAAAATC  
CAAGCACAAAGATTATGGCCTGTATTGGAGACAGATGAAGTCGTAAGAAGTCTGATAGATGGAATACTTACCAATA  
AGAAAAATGATTTTTGTTCCATCGTATATCAATATCTTTCTGAGACTACAGAAGTTTTCTTCTGAACGCGCCTCAG  
CGATTTTAAATCGTATGCAGAATATTCAATTTGAAGCAGTGGTTGGCCACAAAATCAAAATGAAATGAATGAATAATA  
AGCTCCAGCCAGAGATGTATGCATGATAATGATATGAATAGTTTCGAATCAATGCTGCAAAGCTTTATTTACAT  
TTTTTCAGTCCTGATAATATTAAAAACATTGGTTTGGCACTAGCAGCAGTCAAACGAACAAGATTAATTACCTGT  
CTTCCTGTTTCTCAAGAATATTTACGTAGTTTTTTCATAGGTCTGTTTTTCTTTTCATGCCTCTTAAAAACTTCTG  
TGCTTACATAAACATACTTAAAAGGTTTTCTTTAAGATATTTATTTTTCCATTTAAAGGTGGACAAAAGCTACC  
TCCCTAAAAGTAAATACAAAGAGAAGTTATTTACACAGGGAAGGTTTAAAGACTGTTCAAGTAGCATTTCCAATCTG  
TAGCCATGCCACAGAATATCAACAAGAACACAGAATGAGTGCACAGCTAAGAGATCAAGTTTCAGCAGGCAGCTT  
TATCTCAACCTGGACATATTTTAAGATTCAGCATTGAAAGATTTCCCTAGCCTCTTCCTTTTTTCATTAGCCCAA  
AACGGTGCAACTCTATTCTGGACTTTATTACTTGATTCTGTCTTCTGTATAACTCTGAAGTCCACCAAAAGTGGA  
CCCTCTATATTTCTCCCTTTTATAGTCTTATAAGATACATTATGAAAGGTGACCGACTCTATTTTAAATCTCA  
GAATTTTAAGTTCTAGCCCATGATAACCTTTTTCTTTGTAATTTATGCTTTTCATATATCCTTGGTCCCAGAGAT  
GTTTAGACAATTTTAGGCTCAAAAATTAAGCTAACACAGGAAAAGGAAGTGTACTGGCTATTACATAAGAAACA  
ATGGACCCAAGAGAAGAA

133/615

**FIGURE 132**

&lt;/usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA56409

&lt;subunit 1 of 1, 300 aa, 1 stop

&lt;MW: 33655, pI: 9.31, NX(S/T): 1

MNIILEIILLITIIYSYLESIVKFFIPQRRKSVAGEIVLITGAGHGIGRQTTYEFAKRQSILVLWDINKRGVEE  
TAAECRKLGVTAHAYVVDCSNREEIYRSLNQVKEVGDTVIVVNNAGTVYPADLLSTKDEEITKTFEVNIGHFW  
ITKALLPSMMERNHGHIPTVASVCGHEGIPYLI PYCSSKFAAVGFHRGLTSELQALGKTGIKTSCLCPVFNVTGF  
TKNPSTRLWPVLETDEVVRSLIDGILTNNKMIFVPSYINIFLRLQKFLPERASAILNRMONIQFEAVVGHKIKMK

**Important features:****Signal peptide:**

amino acids 1-19

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 30-33 and 58-61

**Short-chain alcohol dehydrogenase family protein**

amino acids 165-202, 37-49, 112-122 and 210-219



134/615

**FIGURE 133**

CTGAGGCGGCGGTAGCATGGAGGGGGAGAGTACGTCGGCGGTGCTCTCGGGCTTTGTGCTCGGGCGCACTCGCTTT  
CCAGCACCTCAACACGGACTCGGACACGGAAGGTTTTCTTCTTGGGGAAGTAAAGGTGAAGCCAAGAACAGCAT  
TACTGATTCCTCAATGGATGATGTTGAAGTTGTTTATACAATTGACATTCAGAAATATATTCATGCTATCAGCT  
TTTTAGCTTTTATAATTCTTCAGGCGAAGTAAATGAGCAAGCACTGAAGAAAATATTATCAAATGTCAAAAAGAA  
TGTGGTAGGTTGGTACAAATCCGTCGTCATTTCAGATCAGATCATGACGTTTAGAGAGAGGCTGCTTCACAAAAA  
CTTGCAGGAGCATTTTTCAAACCAAGACCTTGTTTTCTGCTATTAACACCAAGTATAATAACAGAAAGCTGCTC  
TACTCATCGACTGGAACATTCCCTTATATAAACCTCAAAAAGGACTTTTTTCACAGGGTACCTTTAGTGTTGCCAA  
TCTGGGCATGTCTGAACAACCTGGGTTATAAACTGTATCAGGTTCCCTGTATGTCCACTGGTTTTAGCCGAGCAGT  
ACAAACACACAGCTCTAAATTTTTGAAGAAGATGGATCCTTAAAGGAGGTACATAAGATAAATGAAATGTATGC  
TTCATTACAAGAGGAATTAAGAGTATATGCAAAAAAGTGGAAGACAGTGAACAAGCAGTAGATAAACTAGTAA  
GGATGTAAACAGATTAAACGAGAAATTGAGAAAAGGAGAGGAGCACAGATTCAGGCAGCAAGAGAGAAGAACAT  
CCAAAAGACCTCAGGAGAACATTTTTCTTGTGTCAGGCATTACGGACCTTTTTTCCAAATTCTGAATTTCTTCA  
TTCATGTGTTATGTCTTTAAAAAATAGACATGTTTCTAAAAGTAGCTGTAACCTACAACCACCATCTCGATGTAGT  
AGACAATCTGACCTTAATGGTAGAACACACTGACATTCCTGAAGCTAGTCCAGCTAGTACACCACAAATCATTAA  
GCATAAAGCCTTAGACTTAGATGACAGATGGCAATTCAGAGATCTCGGTTGTTAGATACACAAGACAAACGATC  
TAAAGCAAATACTGGTAGTAGTAACCAAGATAAAGCATCCAAAATGAGCAGCCCAGAAACAGATGAAGAAATTGA  
AAAGATGAAGGGTTTTGGTGAATATTCACGGTCTCCTACATTTGATCCTTTTAACTTACAAGGAGATTTTTTT  
ATTTGGCTGATGGGTAAAGCCAAACATTTCTATTGTTTTTACTATGTTGAGCTACTTGCAGTAAGTTTCATTTGTT  
TTTACTATGTTACCTGTTTGCAGTAATACACAGATAACTCTTAGTGCATTTACTTCACAAAGTACTTTTTCAA  
CATCAGATGCTTTTATTTCCAAACCTTTTTTTCACCTTTCACTAAGTTGTTGAGGGGAAGGCTTACACAGACACA  
TTCTTTAGAATTGGAAAAGTGAGACCAGGCACAGTGGCTCACACCTGTAATCCCAGCACTTAGGGAAGACAAGTC  
AGGAGGATTGATTGAAGCTAGGAGTTAGAGACCAGCCTGGGCAACGTATTGAGACCATGTCTATTAATAAATAAA  
ATGGAAAAGCAAGAATAGCCTTATTTTCAAATATGGAAAAGAAATTTATATGAAAATTTATCTGAGTCATTAAAA  
TTCTCCTTAAGTGATACTTTTTTAGAAGTACATTATGGCTAGAGTTGCCAGATAAAATGCTGGATATCATGCAAT  
AAATTTGCAAAACATCATCTAAATTTAAAAAAAAAAAAAAAAAAAAA

135/615

**FIGURE 134**

MEGESTSAVLSGFVLGALAFQHLNTDSDTEGFLGGEVKGEAKNSITDSQMDDVEVVYTTIDIQKYIPCYQLFSFYN  
SSGEVNEQALKKILSNVKKNVVGWYKFRRHSDQIMTFRERLLHKNLQEHFSNQDLVFLLLTPSIITESCSTHRLE  
HSLYKPQKGLFHRVPLVVANLGMSEQLGYKTVSGSCMSTGFSRAVQTHSSKFFEEEDGSLKEVHKINEMYASLQEE  
LKSICKKVEDSEQAVDKLVKDVNRLKREIEKRRGAQIQAAAREKNIQKDPQENIFLCQALRTFFPNSEFLHSCVMS  
LKNRHVSKSSCNYNHHLDVVDNLTLMEHTDIPEASPASTPQIIKHKALDDDRWQFKRSRLDQTQDKRSKANTG  
SSNQDKASKMSSPETDEEIEKMKGFGEYSRSPTF

136/615

**FIGURE 135**

GGCACAGCCGCGCGGGCGGAGGGCAGAGTCAGCCGAGCCGAGTCCAGCCGGACGAGCGGACCAGCGCAGGGCAGCC  
CAAGCAGCGCGCAGCGAACGCCCCGCCGCCGCCACACCCTCTGCGGTCCCCGCGGCGCCTGCCACCCCTCCCTCC  
TTCCCCGCGTCCCCGCTCGCCGGCCAGTCAGCTTGCCGGGTTGCTGCCCGCGGAAACCCGAGGTACCCAGCC  
CGCGCCTCTGCTTCCCTGGGCGCGCGCCGCCCTCCACGCCCTCCTTCTCCCTGGCCCGGCGCCTGGCACCCGGG  
ACCGTTGCCTGACGCGAGGCCAGCTCTACTTTTCGCCCCGCGTCTCCTCCGCTGCTCGCCTCTTCCACCACT  
CCAACCTCCTTCTCCCTCCAGCTCCACTCGCTAGTCCCCGACTCCGCCAGCCCTCGGCCCGCTGCCGTAGCGCCGC  
TTCCCGTCCGGTCCCAAAGGTGGGAACGCTCCGCCCGGCCCGCACCATGGCACGGTTTGGCTTGGCCGCGCTT  
CTCTGCACCTGGCAGTGCTCAGCGCCGCGCTGCTGGCTGCCGAGCTCAAGTCGAAAAGTTGCTCGGAAGTGCGA  
CGTCTTTACGTGTCCAAAGGCTTCAACAAGAACGATGCCCCCTCCACGAGATCAACGGTGATCATTGAAGATC  
TGTCGCCAGGGTTCTACCTGCTGCTCTCAAGAGATGGAGGAGAAGTACAGCCTGCAAAGTAAAGATGATTTCAA  
AGTGTGGTCAGCGAACAGTGCAATCATTGCAAGCTGTCTTTGCTTACGTTACAAGAAGTTGATGAATCTTC  
AAAGAACTACTTGAAAATGCAGAGAAATCCCTGAATGATATGTTTGTGAAGACATATGGCCATTTATACATGCAA  
AATTTCTGAGCTATTTAAAGATCTCTTCGTAGAGTTGAAACGTTACTACGTGGTGGGAAATGTGAACCTGGAAGAA  
ATGCTAAATGACTTCTGGGCTCGCCTCCTGGAGCGGATGTTCCGCCCTGGTGAACCTCCAGTACCCTTTACAGAT  
GAGTATCTGGAATGTGTGAGCAAGTATACGGAGCAGCTGAAGCCCTTCGGAGATGTCCCTCGCAAATGAAGCTC  
CAGGTTACTCGTGCTTTTGTAGCAGCCCGTACTTTGCTCAAGGCTTAGCGGTTGCGGGAGATGTGCTGAGCAAG  
GTCTCCGTGGTAAACCCACAGCCAGTGTACCCATGCCCTGTTGAAGATGATCTACTGCTCCCACTGCCGGGT  
CTCGTGACTGTGAAGCCATGTTACAACACTACTGCTCAAACATCATGAGAGGCTGTTTGGCCAACCAAGGGGATCTC  
GATTTTGAATGGAACAATTTCATAGATGCTATGCTGATGGTGGCAGAGAGGCTAGAGGGTCTTTCAACATTGAA  
TCGGTCATGGATCCCATCGATGTGAAGATTTCTGATGCTATTATGAACATGCAGGATAAATAGTGTTCAGTGTCT  
CAGAAGGTTTTCCAGGGATGTGGACCCCCAAGCCCCCTCCAGCTGGACGAATTTCTCGTTCCATCTCTGAAAGT  
GCCTTCAGTGCTCGCTTCAGACCACATCACCCCGAGGAACGCCCAACCACAGCAGCTGGCACTAGTTTGGACCGA  
CTGGTTACTGATGTCAAGGAGAACTGAAACAGGCCAAGAAATTTCTGGTCTCCCTTCCGAGCAACGTTTGCAAC  
GATGAGAGGATGGCTGCAGGAAACGGCAATGAGGATGACTGTTGGAATGGGAAAGGCAAAAGCAGGTACCTGTTT  
GCAGTGACAGGAAATGGATTAGCCAACCAGGGCAACAACCCAGAGGTCCAGGTTGACACCAGCAAACCAGACATA  
CTGATCCTTCGTCAAATCATGGCTCTTCGAGTGATGACCAGCAAGATGAAGAATGCATACAATGGGAACGACGTG  
GACTTCTTTGATATCAGTGATGAAAGTAGTGGAGAAGGAAGTGGAAAGTGGCTGTGAGTATCAGCAGTGCCCTTCA  
GAGTTTGACTACAATGCCACTGACCATGCTGGGAAGAGTGCCAATGAGAAAGCCGACAGTGCTGGTGTCCGTCTCT  
GGGGCACAGGCCTACCTCCTCACTGTCTCTGCATCTTGTCTGCTGTTATGCAGAGAGAGTGGAGATTAATTCTCA  
AACTCTGAGAAAAAGTGTTTCATCAAAAAGTTAAAAGGCACCAAGTTATCACTTTTCTACCATCCTAGTGACTTTGC  
TTTTTAAATGAATGGACAACAATGTACAGTTTTTACTATGTGGCCACTGGTTTAAAGAAGTGCTGACTTTGTTTTTC  
TCATTGAGTTTTGGGAGGAAAAGGGACTGTGCATTGAGTTGGTTCTGCTCCCCAAACCATGTTAAACGTGGCT  
AACAGTGATAGGTACAGAACTATAGTTAGTTGTGCATTTGTGATTTTATCACTCTATTATTTGTTGTATGTTTTT  
TTCTCATTTGTTTTGTGGGTTTTTTTTTCCAACCTGTGATCTCGCCTTGTCTTACAAGCAAACCAAGGGTCCCTT  
CTTGGCACGTAACATGTACGTATTTCTGAAATATTAAATAGCTGTACAGAAGCAGGTTTTATTATCATGTATC  
TTATTTAAAGAAAAAGCCCAAAAGC

137/615

**FIGURE 136**

MARFGLPALLCTLAVLSAALLAELKSKSCSEVRRLYVSKGFNKNDAPLHEINGDHLKICPQGSTCCSQEMEKEY  
SLQSKDDFKSVVSEQCNHLQAVFASRYKKFDEFFKELLENAEKSLNDMFVKTYGHLYMQNSSELFKDLFVELKRY  
VVGNVNLEEMLNDFWARLLERMFLVNSQYHFTDEYLECVSKYTEQLKPFQGDVPRKLLQVTRAFVAARTFAQGL  
AVAGDVVSKVSVVNPTAQCTHALLKMIYCSHCRLVTVKPCYNYCSNIMRGCLANQGDLD FEWNNFIDAMLMAE  
RLEGPFNIESVMDPIDVKISDAIMNMQDNSVQVSQVQCGPPLPAGRISRSISESAFSARFRPHHPEERPT  
TAAGTSLDRLVTDVKEKLQAKKFWSSLPSNVCNDERMAAGNGNEDDCWNGKGKSRYLFAVTGNGLANQGNNEV  
QVDTSKPDILILRQIMALRVMTSKMKNAYNGNDVDFDISDESSGEGSGSGCEYQQCPSEFDYNATDHAGKSANE  
KADSAGVRPGAQAYLLTVFCILFLVMQREWR

138/615

**FIGURE 137**

GC GGGGCTGTTGACGGCGCTGCGATGGCTGCCTGCGAGGGCAGGAGAAGCGGAGCTCTCGGTTCTCTCAGTCGGA  
CTTCCTGACGCCGCCAGTGGGCGGGGCCCCCTTGGGCGCTCGCCACCACTGTAGTCATGTACCCACCGCCGCCGCC  
GCCGCCTCATCGGGACTTCATCTCGGTGACGCTGAGCTTTGGCGAGAGCTATGACAACAGCAAGAGTTGGCGGCG  
GCGCTCGTGCTGGAGGAAATGGAAGCAACTGTCGAGATTGCAGCGGAATATGATTCTCTTCTCTCTGCTTTCT  
GCTTTTCTGTGGACTCCTCTTCTACATCAACTTGGCTGACCATTGGAAAGCTCTGGCTTTCAGGCTAGAGGAAGA  
GCAGAAGATGAGGCCAGAAATTGCTGGGTTAAAACCAGCAAATCCACCCGCTTACCAGCTCCTCAGAAGGCGGA  
CACCGACCTGAGAATTACCTGAGATTTGTCACAGAAGACACAAAGACACATCCAGCGGGGACCACCTCACCT  
GCAGATTAGACCCCAAGCCAAGACCTGAAGGATGGGACCCAGGAGGAGGCCACAAAAGGCAAGAAGCCCTGT  
GGATCCCCGCCCCGAAGGAGATCCGCAGAGGACAGTCATCAGCTGGAGGGGAGCGGTGATCGAGCCTGAGCAGGG  
CACCGAGCTCCCTTCAAGAAGAGCAGAAGTGCCACCAAGCCTCCCTGCCACCGGCCAGGACACAGGGCACACC  
AGTGCATCTGAATATCGCCAGAAGGGCGTGATTGACGCTCTTCTGTCATGCATGGAAAGGATAACCGCAAGTTTGC  
ATGGGGCCATGACGAGCTGAAGCCTGTGTCCAGGTCTTTCAGTGAGTGGTTTGGCTCGGTCTCACACTGATCGA  
CGCGCTGGACACCATGTGGATCTTGGGTCTGAGGAAAGAATTTGAGGAAGCCAGGAAGTGGGTGTGGAAGAAGTT  
ACACTTTGAAAAGGACGTGGACGTCAACCTGTTTGAGAGCACGATCCGCATCTTGGGGGGGCTCCTGAGTGCCCTA  
CCACCTGTCTGGGGACAGCCTCTTCTGAGGAAAGCTGAGGATTTTGGAAATCGGCTAATGCTGCCTCAGAAC  
ACCATCCAAGATTCTTACTCGGATGTGAACATCGGTACTGGAGTTGCCACCCGCCACGGTGGACCTCCGACAG  
CACTGTGGCCGAGGTGACCAGCATTACGCTGGAGTTCCGGGAGCTCTCCCGTCTCACAGGGGATAAGAAGTTTCA  
GGAGGCAGTGGAGAAGGTGACACAGCACATCCACGGCCTGTCTGGGAAGAAGGATGGGCTGGTGCCCATGTTTAT  
CAATACCCACAGTGGCCTCTTACCCACCTGGGCGTATTACGCTGGGCGCCAGGGCCGACAGCTACTATGAGTA  
CCTGCTGAAGCAGTGGATCCAGGGCGGGAAGCAGGAGACACAGCTGCTGGAAGACTACGTGGAAGCCATCGAGGG  
TGTCAGAACGCACTGCTGCGGCACTCCGAGCCCAGTAAGCTCACCTTTGTGGGGGAGCTTGCCACCGCCGCTT  
CAGTGCCAAGATGGACCACCTGGTGTGCTTCTGCCAGGGACGCTGGCTCTGGGCGTCTACCACGGCCTGCCCGC  
CAGCCACATGGAGCTGGCCCAGGAGCTCATGGAGACTTGTACAGATGAACCGGCAGATGGAGACGGGGCTGAG  
TCCCGAGATCGTGCACTTCAACCTTTACCCCGAGCCGGGCGCTCGGGACGTGGAGGTCAAGCCAGCAGACAGGCA  
CAACCTGCTGCGGCCAGAGACCGTGGAGAGCCTGTTCTACCTGTACCGCGTCACAGGGGACCGCAAATACAGGA  
CTGGGGCTGGGAGATTCTGCAGAGCTTCAGCCGATTACACAGGGTCCCCTCGGGTGGCTATTCTTCCATCAACAA  
TGTCAGGATCCTCAGAAGCCCCAGCCTAGGGACAAGATGGAGAGCTTCTTCTGGGGGAGACGCTCAAGTATCT  
GTTCTTGCTCTTCTCGATGACCCAAACCTGCTCAGCCTGGACGCCTACGTGTTCAACACCGAAGCCCCACCTCT  
GCCTATCTGGACCCCTGCCATAGGTTGGATGGCTGCTGGTGTGGGGACTTCGGGTGGGCAGAGGCACCTTGCTGGG  
TCTGTGGCATTTCCTCAAGGGCCACGTAGCACCGGCAACCGCCAAGTGGCCAGGCTCTGAACTGGCTCTGGGCT  
CCTCTCTGCTCTGCTTTAATCAGGACACCGTGAGGACAAGTGAGGCCGTGAGTCTTGGTGTGATGCGGGGTGGG  
CTGGGCCGCTGGAGCCTCCGCTGCTTCTCCAGAAGACACGAATCATGACTCACGATTGCTGAAGCCTGAGCAG  
GTCTCTGTGGGCCGACAGAGGGGGGCTTCGAGGTGCTCCCTGGTACTGGGGTGACCGAGTGGACAGCCAGGGT  
GCAGCTCTGCCCCGGCTCGTGAAGCCTCAGATGTCCCAATCCAAGGGTCTGGAGGGGCTGCCGTGACTCCAGAG  
GCCTGAGGCTCCAGGGCTGGCTCTGGTGTGTTTACAAGCTGGACTCAGGGATCCTCCTGGCCGCCCGCAGGGGGCT  
TGGAGGGCTGGACGGCAAGTCCGTCTAGCTCACGGGCCCTCCAGTGGAATGGGTCTTTTTCGGTGGAGATAAAAG  
TTGATTGCTCTAACCGCAA

139/615

**FIGURE 138**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA56529
><subunit 1 of 1, 699 aa, 1 stop
><MW: 79553, pI: 7.83, NX(S/T): 0
MAACEGRRSGALGSSQSDFLTTPVGGAPWAVATTVMYPPPPPPPHRDFISVTLSTFGESYDNSKSWRRRSCWRKW
KQLSRLQRNMILFLIAFLLCGLLFYINLADHWKALAFRLSEEQKMRPEIAGLKPANPPVLPAPQKADTDPENLP
EISSQKTQRHIQRGPPHLQIRPPSQDLKDGTOEEATKROEAPVDPRPEGDPQRTVISWRGAVIEPEQGTELPSTR
AEVPTKPPPLPPARTQGTPTVHLNRYQKGVIDVFLHAWKGYRKFAWGHDELKPVSRSEWFGGLGLTLIDALDTMWI
LGLRKEFEEARKWVSKKLHFEKDVDVNLFEFTIRILGGLLSAYHLSGDSLFLRKAEDFGNRLMPAFRTPSKIPYS
DVNIGTGVAPPRWTSSTVAEVTSIQLEFRELRLTGDKKFQEAVERKVTQHIHGLSGKKDGLVPMFINTHSGLF
THLGVFTLGRADSYEYLLKQWIQGGKQETQLLEDYVEAIEGVRTLLRHSEPSKLTFFVGEAHGRFSAKMDHL
VCFPLPGTLALGVYHGLPASHMELAQELMETCYQMNRMQMETGLSPEIVHFNLYPQPGRRDVEVKPADRNLLRPET
VESLFYLYRVGTDRKYQDWGWEILQSFSRFTTRVPSGGYSSINNVDQPKPEPRDKMESFFLGETLKYLFLLFSDD
PNLLSLDAYVFNTEAHPLPIWTPA
```

**Important features of the protein:**

**Transmembrane domain:**

amino acids 21-40 and 84-105 (type II)

140/615

**FIGURE 139**

CTCGCCCTCAAATGGGAACGCTGGCCTGGGACTAAAGCATAGACCACCAGGCTGAGTATCCTGACCTGAGTCATC  
CCCAGGGATCAGGAGCCTCCAGCAGGGAACCTTCCATTATATTCTTCAAGCAACTTACAGCTGCACCGACAGTTG  
CGATGAAAGTTCTAATCTCTTCCCTCCTCCTGTTGCTGCCACTAATGCTGATGTCCATGGTCTCTAGCAGCCTGA  
ATCCAGGGGTCGCCAGAGGCCACAGGGACCGAGGCCAGGCTTCTAGGAGATGGCTCCAGGAAGGCGGCCAAGAAT  
GTGAGTGCAAAGATTGGTTCTGAGAGCCCCGAGAAGAAAATTCATGACAGTGTCTGGGCTGCCAAGAAGCAGT  
GCCCCGTGTGATCATTTCAAGGGCAATGTGAAGAAAACAAGACACCAAAGGCACCACAGAAAGCCAAACAAGCATT  
CCAGAGCCTGCCAGCAATTTCTCAAACAATGTCAGCTAAGAAGCTTTGCTCTGCCTTTGTAGGAGCTCTGAGCGC  
CCTCTTCCAATTAAACATTCTCAGCCAAGAAGACAGTGAGCACACCTACCAGACACTCTTCTTCTCCACCTC  
ACTCTCCCCTGTACCCACCCCTAAATCATTCAGTGCTCTCAAAAAGCATGTTTTTCAAGATCATTTTGTTTGT  
TGCTCTCTCTAGTGTCTTCTTCTCTCGTCAGTCTTAGCCTGTGCCCTCCCCCTTACCCAGGCTTAGGCTTAATTAC  
CTGAAAGATTCCAGGAACTGTAGCTTCCTAGCTAGTGTCAATTAACCTTAAATGCAATCAGGAAAGTAGCAAAC  
AGAAGTCAATAAATATTTTTAAATGTCAAAAAAAAAAAAAAAAAA

141/615

**FIGURE 140**

MKVLISLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAPRRKFMTVSGLPKKQC  
PCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL



142/615

**FIGURE 141**

AATGGCTGTCTTAGTACTTCGCCTGACAGTTGTCCTGGGACTGCTTGTCTTATTCCTGACCTGCTATGCAGACGA  
CAAACCAGACAAGCCAGACGACAAGCCAGACGACTCGGGCAAAGACCCAAAGCCAGACTTCCCCAAATTCCTAAG  
CCTCCTGGGCACAGAGATCATTGAGAATGCAGTCGAGTTCATCCTCCGCTCCATGTCCAGGAGCACAGGATTTAT  
GGAATTTGATGATAATGAAGGAAAACATTCATCAAAGTGAACATCCTCAGGACACACCCATGTGGCTCCTGGACAA  
TCCAAGAGCAGCCAAATCCTGCTTTTCCAGTTTGGCTCCACAAGTCCTCCAGGACAGAGCCCTCAAAGCAACTCC  
CAACGAGTTCTCAGGATTCAGGCTCTGGCTTCAACCAAACAGAACTCATTTTGAACACCCTGACTGCATTTTTC  
TTTTAGAAAGTTAGAATAAATATGGCGCTTTGGGATCACATAGTTGATGGAGAGGAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAA

143/615

**FIGURE 142**

MAVLVLRITVVLGLLVFLTCYADDKPKPDDKPDGKDPKDFPKFLSLLGTEIIENAVEFILRSMRSTGFM  
EFDDNEGKHSSK

144/615

**FIGURE 143**

GGACGCCAGCGCCTGCAGAGGCTGAGCAGGGGAAAAAGCCAGTGCCCCAGCGGAAGCACAGCTCAGAGCTGGTCTG  
CCATGGACATCCTGGTCCCCTCCTGCAGCTGCTGGTGTGCTTCTTACCCTGCCCTGCACCTCATGGCTCTGC  
TGGGCTGCTGGCAGCCCCTGTGCAAAAGCTACTTCCCCTACCTGATGGCCGTGCTGACTCCCAAGAGCAACCGCA  
AGATGGAGAGCAAGAAACGGGAGCTCTTCAGCCAGATAAAGGGGCTTACAGGAGCCTCCGGGAAAGTGGCCCTAC  
TGGAGCTGGGCTGCGGAACCGGAGCCAACCTTTCAGTTCTACCCACCGGGCTGCAGGGTCACCTGCCTAGACCCAA  
ATCCCCACTTTGAGAAGTTCTTGACAAAGAGCATGGCTGAGAACAGGCACCTCCAATATGAGCGGTTTGTGGTGG  
CTCCTGGAGAGGACATGAGACAGCTGGCTGATGGCTCCATGGATGTGGTGGTCTGCACTCTGGTGTCTGTGCTCTG  
TGCAGAGCCCAAGGAAGTCTCTGCAGGAGGTCCGGAGAGTACTGAGACCGGGAGGTGTGCTCTTTTTCTGGGAGC  
ATGTGGCAGAACCATATGGAAGCTGGGCCTTCATGTGGCAGCAAGTTTTTCGAGCCACCTGGAAACACATTGGGG  
ATGGCTGCTGCCTCACCAGAGAGACCTGGAAGGATCTTGAGAACGCCAGTTCTCCGAAATCCAAATGGAACGAC  
AGCCCCCTCCCTTGAAGTGGCTACCTGTTGGGCCCCACATCATGGGAAAGGCTGTCAAACAATCTTCCCAAGCT  
CCAAGGCACTCATTTGCTCCTTCCCCAGCCTCCAATTAGAACAAGCCACCCACCAGCCTATCTATCTTCCACTGA  
GAGGGACCTAGCAGAAATGAGAGAAGACATTATGTACCACCTACTAGTCCCTCTCTCCCCAACCTCTGCCAGGGC  
AATCTCTAACTTCAATCCCGCCTTCGACAGTGAAAAAGCTCTACTTCTACGCTGACCCAGGGAGGAAACACTAGG  
ACCTGTGTGATCCTCAACTGCAAGTTTCTGGACTAGTCTCCAACGTTTGCCTCCCAATGTTGTCCCTTTCCTT  
CGTTCCCATGGTAAAGCTCCTCTCGCTTTCCTCCTGAGGCTACACCCATGCGTCTCTAGGAACCTGGTCACAAAAG  
TCATGGTGCCTGCATCCCTGCCAAGCCCCCTGACCTCTCTCCCCACTACCACCTTCTTCCCTGAGCTGGGGGCA  
CCAGGGAGAATCAGAGATGCTGGGGATGCCAGAGCAAGACTCAAAGAGGCAGAGGTTTGTCTCAAATATTTTT  
TAATAAATAGACGAAACCACG